An O
antioxidant O
property O
was O
tested O
with O
the O
oil O
obtained O
by O
means O
of O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
assay O
; O
the O
oil O
presented O
interesting O
radical O
scavenging O
activity O
. O

A O
selective O
and O
structurally O
novel O
mGlu O
( O
2 O
/ O
3 O
) O
receptor O
agonist O
, O
2 B
- I
amino I
- I
4 I
- I
fluorobicyclo I
[ I
3 I
. I
1 I
. I
0 I
] I
hexane I
- I
2 I
, I
6 I
- I
dicarboxylic I
acid I
( O
LY459477 B
) O
was O
tritiated O
and O
the O
distribution O
of O
mGlu O
( O
2 O
) O
and O
mGlu O
( O
3 O
) O
receptors O
was O
studied O
in O
transgenic O
mice O
lacking O
either O
mGlu O
( O
2 O
) O
, O
mGlu O
( O
3 O
) O
or O
both O
receptors O
. O

Trans B
- I
3 I
( I
10 I
) I
- I
caren I
- I
4 I
- I
ol I
( O
22 O
. O
3 O
% O
) O
, O
artemisia B
ketone I
( O
18 O
. O
6 O
% O
) O
, O
1 B
, I
8 I
- I
cineole I
( O
14 O
. O
9 O
% O
) O
, O
delta B
- I
selinene I
( O
13 O
. O
0 O
% O
) O
and O
alpha B
- I
pinene I
( O
8 O
. O
2 O
% O
) O
were O
the O
major O
compounds O
. O

A O
new O
chromone B
, O
5 B
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
hydroxymethyl I
) I
- I
6 I
, I
8 I
- I
dimethyl I
- I
chromen I
- I
4 I
- I
one I
, O
named O
melachromone B
, O
together O
with O
12 O
known O
compounds O
, O
including O
chromones B
, O
anthraquinone B
, O
flavonoids B
, O
flavonoid B
glycosides I
, O
benzene B
derivatives O
, O
ellagic B
acids I
and O
terpenes B
, O
were O
isolated O
from O
the O
leaves O
of O
Melaleuca O
cajuputi O
Powell O
. O

( O
1 O
) O
and O
3 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
6 I
) I
- I
[ I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
2 I
) I
] I
- I
beta I
- I
D I
- I
glucopyranosyl I
, I
28 I
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
( I
1 I
- I
- I
> I
6 I
) I
- I
beta I
- I
D I
- I
glucopyranosyl I
16 I
- I
deoxybarringtogenol I
C I
( O
2 O
) O
, O
respectively O
, O
based O
on O
the O
analysis O
on O
their O
spectral O
data O
including O
NMR O
and O
HR O
- O
ESI O
- O
MS O
. O

( O
Euphorbiaceae O
) O
were O
investigated O
for O
its O
diterpenoids B
and O
afforded O
three O
new O
five O
- O
membered O
ring O
, O
pentacyclic B
myrisinane I
polyester I
comprised O
of O
3 B
, I
5 I
, I
10 I
- I
O I
- I
triacetyl I
- I
8 I
- I
O I
- I
isobutanoyl I
- I
14 I
- I
O I
- I
benzoylcyclomyrsinol I
( O
1 O
) O
, O
3 B
, I
5 I
, I
10 I
, I
14 I
- I
O I
- I
tetraacetyl I
- I
8 I
- I
O I
- I
( I
2 I
' I
- I
methyl I
butanoyl I
) I
- I
cyclomyrsinol I
( O
2 O
) O
and O
3 B
, I

( O
Euphorbiaceae O
) O
were O
investigated O
for O
its O
diterpenoids B
and O
afforded O
three O
new O
five O
- O
membered O
ring O
, O
pentacyclic B
myrisinane I
polyester I
comprised O
of O
3 B
, I
5 I
, I
10 I
- I
O I
- I
triacetyl I
- I
8 I
- I
O I
- I
isobutanoyl I
- I
14 I
- I
O I
- I
benzoylcyclomyrsinol I
( O
1 O
) O
, O
3 B
, I
5 I
, I
10 I
, I
14 I
- I
O I
- I
tetraacetyl I
- I
8 I
- I
O I
- I
( I
2 I
' I
- I
methyl I
butanoyl I
) I
- I
cyclomyrsinol I
( O
2 O
) O
and O
3 B
, I

The O
structure O
of O
the O
new O
metabolite O
was O
characterised O
as O
4 B
- I
( I
4 I
- I
hydroxy I
- I
phenyl I
) I
- I
3H I
- I
pyran I
- I
2 I
, I
6 I
- I
dione I
using O
1D O
and O
2D O
NMR O
spectroscopy O
. O

From O
the O
chloroform B
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane B
diterpenoid I
, O
xantoquinone B
( O
5 B
alpha I
, I
6 I
alpha I
- I
dimethoxy I
- I
7 I
, I
11 I
, I
14 I
- I
trioxoabieta I
- I
8 I
, I
12 I
- I
diene I
) O
and O
one O
known O
oleanene B
triterpenoid I
namely O
1 B
beta I
, I
3 I
beta I
- I
dihydroxy I
- I
12 I
- I
oleanene I
were O
isolated O
. O

From O
the O
chloroform B
extract O
of O
aerial O
part O
of O
Salvia O
xanthocheila O
Boiss O
. O
one O
new O
abietane B
diterpenoid I
, O
xantoquinone B
( O
5 B
alpha I
, I
6 I
alpha I
- I
dimethoxy I
- I
7 I
, I
11 I
, I
14 I
- I
trioxoabieta I
- I
8 I
, I
12 I
- I
diene I
) O
and O
one O
known O
oleanene B
triterpenoid I
namely O
1 B
beta I
, I
3 I
beta I
- I
dihydroxy I
- I
12 I
- I
oleanene I
were O
isolated O
. O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

Two O
lupeol B
- O
type O
pentacyclic B
triterpenoids I
characterised O
as O
lup B
- I
20 I
( I
29 I
) I
- I
en I
- I
3 I
beta I
- I
ol I
- I
27 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
A I
) O
and O
lup B
- I
12 I
, I
20 I
( I
29 I
) I
- I
dien I
- I
3 I
beta I
- I
ol I
- I
26 I
- I
oic I
acid I
( O
moruslupenoic B
acid I
B I
) O
and O
lanst B
- I
5 I
, I
24 I
- I
dien I
- I
3 I
beta I
- I
yl I
acetate I
( O
moruslanosteryl B
acetate I
) O
along O
with O
the O
known O
triterpenoidal O

phytoconstituents O
alpha B
- I
amyrin I
acetate I
, O
beta B
- I
amyrin I
- I
beta I
- I
D I
- I
glucopyranoside I
and O
betulinic B
acid I
have O
been O
isolated O
from O
the O
stem O
bark O
of O
Morus O
alba O
L O
. O

The O
new O
product O
was O
identified O
as O
2 B
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
. O

Its O
derivatives O
, O
2 B
alpha I
, I
3 I
alpha I
- I
diacetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
, O
2 B
alpha I
, I
3 I
alpha I
- I
di I
- I
O I
- I
carbonyl I
- I
2 I
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
and O
2 B
alpha I
, I
3 I
alpha I
- I
dipropionyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
4 O
) O
were O
obtained O
by O
semisynthesis O
. O

Its O
derivatives O
, O
2 B
alpha I
, I
3 I
alpha I
- I
diacetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
, O
2 B
alpha I
, I
3 I
alpha I
- I
di I
- I
O I
- I
carbonyl I
- I
2 I
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
and O
2 B
alpha I
, I
3 I
alpha I
- I
dipropionyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
4 O
) O
were O
obtained O
by O
semisynthesis O
. O

Its O
derivatives O
, O
2 B
alpha I
, I
3 I
alpha I
- I
diacetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
2 O
) O
, O
2 B
alpha I
, I
3 I
alpha I
- I
di I
- I
O I
- I
carbonyl I
- I
2 I
alpha I
, I
3 I
alpha I
- I
dihydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
3 O
) O
and O
2 B
alpha I
, I
3 I
alpha I
- I
dipropionyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
4 O
) O
were O
obtained O
by O
semisynthesis O
. O

The O
known O
compounds O
were O
identified O
as O
3 B
beta I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
aleuritolic B
acid I
( O
5 O
) O
( O
McPhail O
, O
A O
. O
T O
. O
, O
McPhail O
, O
D O
. O
R O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
& O
A O
. O
W O
. O
, O
Nicholas O
, O
A O
. O
W O
. O
( O
1989 O
) O
. O
Identity O
of O
maprounic B
acid I
with O
aleuritolic B
acid I
. O
Revision O
of O
the O
structure O
of O
maprounic B
acid I
: O
X O
- O
ray O
crystal O
structure O
of O
p B
- I
bromobenzyl I

acetylmaprounate I
. O
Journal O
Natural O
Products O
, O
52 O
, O
212 O
) O
, O
3 B
alpha I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
isoaleuritolic B
acid I
( O
6 O
) O
, O
3 B
alpha I
- I
acetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
acetate I
or O
aleuritolic B
acid I
acetate I
( O
7 O
) O
( O
Chaudhuri O
, O
S O
. O
K O
. O
, O
Fullas O
, O
F O
. O
, O
Brown O
, O
D O
. O
M O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
, O
Cai O
, O
L O
. O
, O
. O
. O
. O

acetylmaprounate I
. O
Journal O
Natural O
Products O
, O
52 O
, O
212 O
) O
, O
3 B
alpha I
- I
hydroxytaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
or O
isoaleuritolic B
acid I
( O
6 O
) O
, O
3 B
alpha I
- I
acetyltaraxer I
- I
14 I
- I
en I
- I
28 I
- I
oic I
acid I
acetate I
or O
aleuritolic B
acid I
acetate I
( O
7 O
) O
( O
Chaudhuri O
, O
S O
. O
K O
. O
, O
Fullas O
, O
F O
. O
, O
Brown O
, O
D O
. O
M O
. O
, O
Wani O
, O
M O
. O
C O
. O
, O
Wall O
, O
M O
. O
E O
. O
, O
Cai O
, O
L O
. O
, O
. O
. O
. O

Kinghorn O
, O
A O
. O
D O
. O
( O
1995 O
) O
. O
Isolation O
and O
structural O
elucidation O
of O
pentacyclic O
triterpenoids O
from O
Maprounea O
africana O
. O
Journal O
of O
Natural O
Products O
, O
58 O
, O
1 O
- O
9 O
) O
, O
3 B
- I
oxo I
- I
taraxer I
- I
14 I
- I
ene I
or O
taraxerone B
( O
8 O
) O
beta B
- I
sitosterol I
( O
9 O
) O
and O
stigmasterol B
( O
10 O
) O
( O
Kamboj O
& O
Saluja O
, O
2011 O
) O
, O
together O
with O
fatty O
acids O
. O

A O
new O
acylated B
flavonoid I
, O
3 B
- I
O I
- I
rhamnocitrin I
- I
6 I
- I
O I
- I
benzoyl I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
1 O
) O
, O
together O
with O
five O
known O
flavonoids B
, O
rhamnocitrin B
( O
2 O
) O
, O
pratensein B
( O
3 O
) O
, O
( B
3R I
) I
- I
7 I
, I
3 I
' I
- I
dihydroxy I
- I
2 I
' I
, I
4 I
' I
- I
dimethoxyisoflavan I
( O
4 O
) O
, O
( B
3R I
) I
- I
7 I
, I
2 I
' I
- I
dihydroxy I
- I
3 I
' I
, I
4 I
' I
- I

A O
new O
acylated B
flavonoid I
, O
3 B
- I
O I
- I
rhamnocitrin I
- I
6 I
- I
O I
- I
benzoyl I
- I
beta I
- I
D I
- I
glucopyranoside I
( O
1 O
) O
, O
together O
with O
five O
known O
flavonoids B
, O
rhamnocitrin B
( O
2 O
) O
, O
pratensein B
( O
3 O
) O
, O
( B
3R I
) I
- I
7 I
, I
3 I
' I
- I
dihydroxy I
- I
2 I
' I
, I
4 I
' I
- I
dimethoxyisoflavan I
( O
4 O
) O
, O
( B
3R I
) I
- I
7 I
, I
2 I
' I
- I
dihydroxy I
- I
3 I
' I
, I
4 I
' I
- I

dimethoxyisoflavan I
( O
5 O
) O
and O
isoliquiritigenin B
( O
6 O
) O
, O
was O
isolated O
from O
Oxytropis O
ochrocephala O
Bunge O
. O

We O
have O
previously O
shown O
that O
epidermal O
growth O
factor O
( O
EGF O
) O
downregulates O
E O
- O
cadherin O
and O
induces O
ovarian O
cancer O
cell O
invasion O
through O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
/ O
p38 O
MAPK O
- O
mediated O
upregulation O
of O
the O
E O
- O
cadherin O
transcriptional O
repressor O
Snail O
. O

EGF O
- O
induced O
Egr O
- O
1 O
expression O
required O
the O
activation O
of O
the O
ERK1 O
/ O
2 O
and O
PI3K O
/ O
Akt O
signaling O
pathways O
and O
was O
unrelated O
to O
EGF O
- O
induced O
H B
( I
2 I
) I
O I
( I
2 I
) I
production O
and O
activation O
of O
the O
p38 O
MAPK O
pathway O
. O

Our O
results O
also O
demonstrate O
that O
EGF O
activates O
two O
independent O
signaling O
pathways O
, O
which O
are O
the O
H B
( I
2 I
) I
O I
( I
2 I
) I
/ O
p38 O
MAPK O
- O
mediated O
upregulation O
of O
Snail O
expression O
and O
the O
Egr O
- O
1 O
- O
mediated O
upregulation O
of O
Slug O
expression O
. O

Effect O
of O
water O
extracts O
from O
edible O
myrtaceae O
plants O
on O
uptake O
of O
2 B
- I
( I
n I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
) I
- I
2 I
- I
deoxyglucose I
in O
TNF O
- O
alpha O
- O
treated O
FL83B O
mouse O
hepatocytes O
. O

The O
fluorescent O
dye O
2 B
- I
( I
n I
- I
( I
7 I
- I
nitrobenz I
- I
2 I
- I
oxa I
- I
1 I
, I
3 I
- I
diazol I
- I
4 I
- I
yl I
) I
amino I
) I
- I
2 I
- I
deoxyglucose I
was O
used O
to O
estimate O
the O
uptake O
ability O
of O
the O
cells O
. O

Mouse O
hippocampal O
synaptosomes O
were O
preloaded O
with O
[ B
( I
3 I
) I
H I
] I
D I
- I
gamma I
- I
aminobutyric I
acid I
( O
[ B
( I
3 I
) I
H I
] I
GABA I
) O
and O
then O
exposed O
in O
superfusion O
to O
12 O
mM O
KCl B
. O

The O
K B
( I
+ I
) I
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N B
, I
N I
' I
- I
dibenzyhydryl I
- I
ethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
[ O
( B
l I
) I
- I
AP4 I
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

The O
K B
( I
+ I
) I
- O
evoked O
[ B
( I
3 I
) I
H I
] I
GABA I
release O
was O
inhibited O
by O
the O
mGlu7 O
allosteric O
agonist O
N B
, I
N I
' I
- I
dibenzyhydryl I
- I
ethane I
- I
1 I
, I
2 I
- I
diamine I
dihydrochloride I
( O
AMN082 B
, O
0 O
. O
001 O
- O
10 O
mu O
M O
) O
, O
as O
well O
as O
by O
the O
group O
III O
mGlu O
receptor O
agonist O
l B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
[ O
( B
l I
) I
- I
AP4 I
, O
0 O
. O
01 O
- O
1 O
mM O
] O
. O

The O
mGlu8 O
receptor O
agonist O
( B
S I
) I
- I
3 I
, I
4 I
- I
dicarboxyphenylglyci I
[ O
( B
S I
) I
- I
3 I
, I
4 I
- I
DCPG I
, O
10 O
- O
100 O
nM O
] O
was O
ineffective O
. O

The O
mGlu8 O
receptor O
agonist O
( B
S I
) I
- I
3 I
, I
4 I
- I
dicarboxyphenylglyci I
[ O
( B
S I
) I
- I
3 I
, I
4 I
- I
DCPG I
, O
10 O
- O
100 O
nM O
] O
was O
ineffective O
. O

AMN082 B
and O
( B
l I
) I
- I
AP4 I
- O
induced O
effects O
were O
recovered O
by O
the O
mGlu7 O
negative O
allosteric O
modulator O
( O
NAM O
) O
6 B
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
5 I
- I
methyl I
- I
3 I
- I
( I
4 I
- I
pyridinyl I
) I
- I
isoxazolo I
[ I
4 I
, I
5 I
- I
c I
] I
pyridin I
- I
4 I
( I
5H I
) I
- I
one I
hydrochloride I
( O
MMPIP B
) O
. O

AMN082 B
- O
inhibitory O
effect O
was O
additive O
to O
that O
caused O
by O
( B
- I
) I
baclofen I
, O
but O
insensitive O
to O
the O
GABA B
( O
B O
) O
antagonist O
3 B
- I
[ I
[ I
( I
3 I
, I
4 I
- I
Dichlorophenyl I
) I
methyl I
] I
amino I
] I
propyl I
] I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP52432 B
) O
. O

Using O
pharmacologic O
and O
molecular O
approaches O
that O
suppress O
the O
prolyl B
- O
hydroxylase O
( O
PHD O
) O
- O
mediated O
inhibition O
of O
HIF1 O
alpha O
, O
we O
show O
that O
DCA B
inhibits O
HIF1 O
alpha O
by O
both O
a O
PHD O
- O
dependent O
mechanism O
( O
that O
involves O
a O
DCA B
- O
induced O
increase O
in O
the O
production O
of O
mitochondria O
- O
derived O
alpha B
- I
ketoglutarate I
) O
and O
a O
PHD O
- O
independent O
mechanism O
, O
involving O
activation O
of O
p53 O
via O
mitochondrial O
- O
derived O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
as O
well O
as O
activation O
of O
GSK3 O
beta O
. O

Their O
structures O
were O
elucidated O
as O
5 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
1H I
- I
pyrrole I
- I
2 I
- I
carbaldehyde I
( O
1 O
) O
and O
6 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
3 I
- I
pyridinol I
( O
2 O
) O
by O
various O
spectroscopic O
means O
including O
HR O
- O
ESI O
- O
MS O
, O
IR O
, O
1D O
and O
2D O
NMR O
. O

Their O
structures O
were O
elucidated O
as O
5 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
1H I
- I
pyrrole I
- I
2 I
- I
carbaldehyde I
( O
1 O
) O
and O
6 B
- I
[ I
( I
alpha I
- I
D I
- I
galactopyranosyloxy I
) I
methyl I
] I
- I
3 I
- I
pyridinol I
( O
2 O
) O
by O
various O
spectroscopic O
means O
including O
HR O
- O
ESI O
- O
MS O
, O
IR O
, O
1D O
and O
2D O
NMR O
. O

A O
new O
bromophenol B
, O
2 B
, I
3 I
, I
6 I
- I
tribromo I
- I
4 I
, I
5 I
- I
dihydroxybenzyl I
methyl I
sulphoxide I
, O
was O
isolated O
from O
the O
EtOH B
extract O
of O
the O
marine O
alga O
Symphyocladia O
latiuscula O
. O

The O
antioxidant O
activity O
of O
the O
oil O
was O
evaluated O
in O
terms O
of O
their O
free O
- O
radical O
scavenging O
activity O
against O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
. O

A O
new O
caryolane B
sesquiterpene I
, O
1 B
beta I
- I
methoxycaryol I
- I
9 I
- I
one I
( O
1 O
) O
, O
along O
with O
eight O
known O
compounds O
( O
2 O
- O
9 O
) O
, O
was O
isolated O
from O
the O
whole O
plant O
of O
Heteropappus O
altaicus O
. O

This O
study O
discloses O
strong O
in O
vitro O
antileishmanial O
activity O
of O
2 B
- I
methyl I
- I
5 I
- I
( I
3 I
' I
- I
methyl I
- I
but I
- I
2 I
' I
- I
enyloxy I
) I
- I
[ I
1 I
, I
4 I
] I
naphthoquinone I
( O
1 O
) O
, O
a O
prenyloxy B
- I
naphthoquinone I
isolated O
and O
characterised O
from O
roots O
of O
the O
plant O
Plumbago O
zeylanica O
( O
family O
- O
Plumbaginaceae O
) O
. O

The O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
comprises O
6 O
mol O
of O
amino B
acids I
, O
including O
2 O
mol O
of O
serine B
and O
1 O
mol O
each O
of O
ornithine B
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxy I
- I
N I
- I
delta I
- I
formylornithine I
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxyornithine I
, O
and O
cyclic B
N I
- I
hydroxyornithine I
. O

The O
structure O
of O
tsukubachelin B
B I
( O
1 O
) O
comprises O
6 O
mol O
of O
amino B
acids I
, O
including O
2 O
mol O
of O
serine B
and O
1 O
mol O
each O
of O
ornithine B
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxy I
- I
N I
- I
delta I
- I
formylornithine I
, O
N B
- I
alpha I
- I
methyl I
- I
N I
- I
delta I
- I
hydroxyornithine I
, O
and O
cyclic B
N I
- I
hydroxyornithine I
. O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

To O
investigate O
new O
neuroprotective O
mechanisms O
associated O
with O
I O
( O
2 O
) O
- O
imidazoline B
receptors O
, O
the O
effects O
of O
selective O
( O
2 B
- I
styryl I
- I
2 I
- I
imidazoline I
( O
LSL B
61122 I
) O
, O
2 B
- I
( I
2 I
- I
benzofuranyl I
) I
- I
2 I
- I
imidazoline I
( O
2 B
- I
BFI I
) O
, O
2 B
- I
( I
4 I
, I
5 I
- I
dihydroimidazol I
- I
2 I
- I
yl I
) I
quinoline I
hydrochloride I
( O
BU B
- I
224 I
) O
) O
and O
non O
- O
selective O
( O
idazoxan B
) O
I O
( O
2 O
) O
- O
drugs O
on O

The O
optimized O
preparation O
of O
Poly B
- I
( I
lactide I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
nanospheres O
containing O
ubiquinone O
( O
UQ O
) O
for O
cosmetic O
products O
was O
pursued O
. O

Here O
, O
we O
used O
two O
compounds O
, O
Compound O
44 O
[ O
6 B
, I
6 I
- I
dimethyl I
- I
3 I
- I
( I
3 I
- I
hydroxypropyl I
) I
thio I
- I
1 I
- I
( I
thiazol I
- I
2 I
- I
yl I
) I
- I
6 I
, I
7 I
- I
dihydro I
- I
2 I
- I
benzothiophen I
- I
4 I
( I
5H I
) I
- I
one I
] O
and O
Compound O
6 O
[ O
methyl B
3 I
, I
5 I
- I
diphenylpyridazine I
- I
4 I
- I
carboxylate I
] O
, O
with O
functional O
activity O
as O
potentiators O
of O
gamma B
- I
aminobutyric I
acid I
at O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
, O
to O

Here O
, O
we O
used O
two O
compounds O
, O
Compound O
44 O
[ O
6 B
, I
6 I
- I
dimethyl I
- I
3 I
- I
( I
3 I
- I
hydroxypropyl I
) I
thio I
- I
1 I
- I
( I
thiazol I
- I
2 I
- I
yl I
) I
- I
6 I
, I
7 I
- I
dihydro I
- I
2 I
- I
benzothiophen I
- I
4 I
( I
5H I
) I
- I
one I
] O
and O
Compound O
6 O
[ O
methyl B
3 I
, I
5 I
- I
diphenylpyridazine I
- I
4 I
- I
carboxylate I
] O
, O
with O
functional O
activity O
as O
potentiators O
of O
gamma B
- I
aminobutyric I
acid I
at O
GABA B
( O
A O
) O
alpha O
5 O
receptors O
, O
to O

The O
free O
- O
radical O
scavenging O
activity O
of O
the O
extracts O
was O
also O
determined O
by O
the O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picryhydrazyl I
( O
DPPH B
) O
assay O
. O

Density O
functional O
theory O
study O
on O
the O
reaction O
mechanism O
of O
synthesizing O
1 B
, I
3 I
- I
dimethyl I
- I
2 I
- I
imidazolidinone I
by O
urea B
method O
. O

We O
report O
a O
first O
- O
principles O
density O
functional O
theory O
investigation O
on O
tailoring O
the O
fundamental O
reaction O
mechanism O
of O
synthesizing O
1 B
, I
3 I
- I
dimethyl I
- I
2 I
- I
imidazolidinone I
( O
DMI B
) O
through O
the O
urea B
method O
with O
water O
serving O
as O
both O
solvent O
and O
catalyst O
. O

Anti O
- O
inflammatory O
trends O
of O
1 B
, I
3 I
- I
diphenyl I
- I
2 I
- I
propen I
- I
1 I
- I
one I
derivatives O
. O

Chalcones B
( O
1 B
, I
3 I
- I
Diphenyl I
- I
2 I
- I
propen I
- I
1 I
- I
one I
) O
are O
constituted O
by O
a O
three O
carbon B
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
system O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide B
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide B
cleavage O
from O
beta B
- I
nicotinamide I
adenine I
dinucleotide I
( O
beta B
- I
NAD I
+ O
or O
NAD B
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 B
' I
- I
O I
- I
acetyl I
- I
ADP I
- I
ribose I
( O
2 B
' I
- I
O I
- I
AADPR I
) O
. O

We O
have O
extended O
our O
study O
on O
structure O
/ O
activity O
relationship O
studies O
of O
insect O
peptide O
alloferon B
( O
H B
- I
His I
- I
Gly I
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
) O
by O
evaluating O
the O
antiviral O
effects O
of O
new O
alloferon B
analogues O
. O

We O
synthesized O
18 O
alloferon B
analogues O
: O
12 O
peptides O
with O
sequences O
shortened O
from O
N B
- O
or O
C B
- O
terminus O
and O
6 O
N B
- O
terminally O
modified O
analogues O
H O
- O
X O
( O
1 O
) O
- O
Gly B
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
, O
where O
X O
( O
1 O
) O
= O
Phe B
( O
13 O
) O
, O
Tyr B
( O
14 O
) O
, O
Trp B
( O
15 O
) O
, O
Phg O
( O
16 O
) O
, O
Phe B
( I
p I
- I
Cl I
) I
( O
17 O
) O
, O
and O
Phe B
( I
p I
- I
OMe I
) I
( O
18 O
) O

The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O
anti O
- O
BP B
- I
7 I
, I
8 I
- I
dihydrodiol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
can O
be O
detoxified O
by O
glutathione B
conjugate O
formation O
catalyzed O
by O
glutathione B
S B
- O
transferases O
. O

Up O
to O
100 O
mu O
M O
Pb B
( I
NO I
( I
3 I
) I
) I
( I
2 I
) I
had O
no O
effect O
on O
cellular O
viability O
and O
proliferation O
. O

Disposition O
and O
metabolism O
of O
[ B
( I
1 I
) I
4 I
C I
] I
PTZ601 I
in O
healthy O
volunteers O
. O

Ultrasound O
promoted O
one O
- O
pot O
synthesis O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
in O
aqueous O
media O
: O
a O
complementary O
' O
green O
chemistry O
' O
tool O
to O
organic O
synthesis O
. O

A O
green O
and O
simple O
approach O
to O
assembling O
of O
2 B
- I
amino I
- I
4 I
, I
8 I
- I
dihydropyrano I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
3 I
- I
carbonitrile I
scaffolds O
via O
three O
- O
component O
reaction O
of O
kojic B
acid I
, O
malononitrile B
, O
and O
aromatic B
aldehydes I
in O
aqueous O
media O
under O
ultrasound O
irradiation O
is O
described O
. O

Adult O
ovariectomised O
rats O
were O
divided O
into O
six O
groups O
and O
injected O
either O
with O
vehicle O
or O
a O
single O
dose O
of O
oestradiol B
, O
a O
selective O
ER O
alpha O
agonist O
- O
PPT B
[ O
4 B
, I
4 I
' I
, I
4 I
' I
' I
- I
( I
4 I
- I
propyl I
- I
[ I
1H I
] I
- I
pyrazole I
- I
1 I
, I
3 I
, I
5 I
- I
triyl I
) I
trisphenol I
] O
, O
a O
selective O
ER O
beta O
agonist O
- O
DPN B
[ O
2 B
, I
3 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
propionitrile I
] O
, O
a O
selective O
ER O
alpha O
antagonist O
- O
MPP B
[ O
1 B
, I

Adult O
ovariectomised O
rats O
were O
divided O
into O
six O
groups O
and O
injected O
either O
with O
vehicle O
or O
a O
single O
dose O
of O
oestradiol B
, O
a O
selective O
ER O
alpha O
agonist O
- O
PPT B
[ O
4 B
, I
4 I
' I
, I
4 I
' I
' I
- I
( I
4 I
- I
propyl I
- I
[ I
1H I
] I
- I
pyrazole I
- I
1 I
, I
3 I
, I
5 I
- I
triyl I
) I
trisphenol I
] O
, O
a O
selective O
ER O
beta O
agonist O
- O
DPN B
[ O
2 B
, I
3 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
propionitrile I
] O
, O
a O
selective O
ER O
alpha O
antagonist O
- O
MPP B
[ O
1 B
, I

3 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
4 I
- I
methyl I
- I
5 I
- I
[ I
4 I
- I
( I
2 I
- I
piperidinylethoxy I
) I
phenol I
] O
- O
1H B
- I
pyrazole I
dihydrochloride I
] O
or O
a O
selective O
ER O
beta O
antagonist O
- O
PHTPP B
( O
4 B
- I
[ I
2 I
- I
phenyl I
- I
5 I
, I
7 I
- I
bis I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
] I
phenol I
) O
. O

The O
growth O
of O
sphere O
- O
like O
trimanganese B
tetraoxide I
( O
Mn B
( I
3 I
) I
O I
( I
4 I
) I
) O
nanoparticles O
on O
silk O
fiber O
was O
achieved O
by O
sequential O
dipping O
in O
an O
alternating O
bath O
of O
potassium B
hydroxide I
and O
manganese B
( I
II I
) I
nitrate I
under O
ultrasound O
irradiation O
. O

Ultraviolet O
B O
activated O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
affects O
the O
level O
of O
fibroblast O
growth O
factor O
- O
23 O
in O
human O
. O

Several O
studies O
suggest O
that O
dietary O
phosphate B
, O
serum O
phosphate B
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
[ O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
] O
are O
candidate O
regulators O
of O
FGF O
- O
23 O
. O

While O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
increased O
by O
75 O
% O
( O
49 O
. O
9 O
pg O
/ O
mL O
to O
64 O
. O
4 O
pg O
/ O
mL O
, O
p O
< O
0 O
. O
001 O
) O
then O
both O
level O
decreased O
after O
4 O
weeks O
of O
withdrawal O
. O

UVB O
exposure O
effectively O
increased O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
with O
delayed O
stimulatory O
effect O
on O
FGF O
- O
23 O
. O

This O
result O
could O
support O
the O
regulatory O
loop O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
and O
FGF O
- O
23 O
in O
human O
, O
FGF O
- O
23 O
regulation O
by O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

This O
result O
could O
support O
the O
regulatory O
loop O
of O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
and O
FGF O
- O
23 O
in O
human O
, O
FGF O
- O
23 O
regulation O
by O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
. O

The O
effectiveness O
of O
D B
- I
cycloserine I
( O
DCS B
) O
, O
an O
N B
- I
methyl I
- I
D I
- I
aspartate I
glutamate I
receptor O
partial O
agonist O
, O
and O
valproic B
acid I
( O
VPA B
) O
, O
a O
histone O
deacetylase O
inhibitor O
, O
in O
facilitating O
the O
extinction O
of O
fear O
- O
conditioned O
memory O
has O
been O
explored O
in O
humans O
and O
animals O
. O

It O
has O
recently O
been O
reported O
that O
iron B
oxide I
nanoparticles O
( O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
, O
30 O
nm O
) O
have O
the O
ability O
to O
translocate O
directly O
from O
the O
olfactory O
nerve O
to O
the O
brain O
. O

Therefore O
, O
it O
is O
critical O
to O
evaluate O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
and O
their O
potential O
to O
confer O
striatum O
and O
hippocampus O
neurotoxicity O
. O

This O
study O
focuses O
on O
the O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
on O
the O
striatum O
and O
hippocampus O
, O
including O
oxidative O
injury O
and O
the O
accumulation O
and O
retention O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

This O
study O
focuses O
on O
the O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
on O
the O
striatum O
and O
hippocampus O
, O
including O
oxidative O
injury O
and O
the O
accumulation O
and O
retention O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

This O
study O
also O
explores O
the O
molecular O
mechanism O
of O
oxidative O
damage O
in O
dopaminergic O
neurons O
; O
we O
were O
able O
to O
assess O
the O
neurotoxic O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
by O
incubating O
dopaminergic O
neurons O
with O
radioactive O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

This O
study O
also O
explores O
the O
molecular O
mechanism O
of O
oxidative O
damage O
in O
dopaminergic O
neurons O
; O
we O
were O
able O
to O
assess O
the O
neurotoxic O
effects O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
by O
incubating O
dopaminergic O
neurons O
with O
radioactive O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
. O

A O
regional O
distribution O
of O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
was O
observed O
in O
rat O
brains O
after O
the O
particles O
were O
intranasally O
instilled O
for O
seven O
days O
. O

Over O
half O
of O
the O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
were O
retained O
in O
the O
striata O
for O
a O
minimum O
of O
14 O
days O
, O
and O
may O
have O
induced O
oxidative O
damage O
to O
the O
region O
. O

These O
in O
vitro O
studies O
demonstrate O
that O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
may O
decrease O
neuron O
viability O
, O
trigger O
oxidative O
stress O
, O
and O
activate O
JNK O
- O
and O
p53 O
- O
mediated O
pathways O
to O
regulate O
the O
cell O
cycle O
and O
apoptosis O
. O

These O
results O
also O
suggest O
that O
environmental O
exposure O
to O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
- O
NPs O
may O
play O
a O
role O
in O
the O
development O
of O
neurodegenerative O
diseases O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

The O
cytotoxic O
activity O
of O
the O
drugs O
was O
determined O
by O
the O
MTT B
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
diphenyltetrazolium I
bromide I
) O
test O
. O

This O
study O
introduces O
GS967 B
( O
6 B
- I
[ I
4 I
- I
( I
trifluoromethoxy I
) I
phenyl I
] I
- I
3 I
- I
( I
trifluoromethyl I
) I
- I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
4 I
, I
3 I
- I
a I
] I
pyridine I
) O
, O
a O
potent O
and O
selective O
inhibitor O
of O
late O
I O
( O
Na B
) O
, O
and O
demonstrates O
its O
effectiveness O
to O
suppress O
ventricular O
arrhythmias O
. O

In O
contrast O
, O
oils O
had O
the O
lowest O
syringic B
, I
p I
- I
cumaric I
, I
chlorogenic I
and I
ferulic I
acids I
. O

Volatile O
compounds O
identified O
by O
GC O
- O
MS O
analysis O
showed O
that O
the O
content O
of O
the O
important O
meaty O
flavour O
compounds O
( O
such O
as O
2 B
- I
methyl I
- I
3 I
- I
furanthiol I
, O
bis B
( I
2 I
- I
methyl I
- I
3 I
- I
furyl I
) I
disulfide I
) O
of O
MSPC O
were O
dramatically O
higher O
than O
that O
of O
MRPs O
from O
uncross O
- O
linking O
peptides O
. O

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

The O
formation O
of O
supramolecular O
inclusion O
complexes O
between O
rutin B
and O
four O
cyclodextrins O
, O
namely O
beta B
- I
cyclodextrin I
( O
beta B
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
alpha I
- I
cyclodextrin I
( O
HP B
- I
alpha I
- I
CD I
) O
, O
( B
2 I
- I
hydroxypropyl I
) I
- I
beta I
- I
cyclodextrin I
( O
HP B
- I
beta I
- I
CD I
) O
and O
( B
2 I
- I
hydroxypropyl I
) I
- I
gamma I
- I
cyclodextrin I
( O
HP B
- I
gamma I
- I

Direct O
- O
acting O
CB1 O
agonists O
, O
including O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
, O
WIN B
55 I
, I
212 I
[ O
R B
- I
( I
1 I
) I
- I
[ I
2 I
, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
] O
, O
AM2389 B
[ O
9 B
beta I
- I
hydroxy I
- I
3 I
- I
( I
1 I
- I
hexyl I

- I
cyclobut I
- I
1 I
- I
yl I
) I
- I
hexahydrocannabinol I
] O
, O
and O
AM4054 B
[ O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
] O
, O
produced O
dose O
- O
dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED O
( O
50 O
) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O

- I
cyclobut I
- I
1 I
- I
yl I
) I
- I
hexahydrocannabinol I
] O
, O
and O
AM4054 B
[ O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
] O
, O
produced O
dose O
- O
dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature O
, O
with O
slightly O
lower O
ED O
( O
50 O
) O
values O
for O
diuresis O
than O
for O
hypothermia O
. O

The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded O
, O
on O
average O
, O
26 O
- O
32 O
g O
/ O
kg O
urine O
; O
comparable O
effects O
were O
obtained O
with O
10 O
mg O
/ O
kg O
furosemide B
and O
3 O
. O
0 O
mg O
/ O
kg O
trans B
- I
( I
- I
) I
- I
3 I
, I
4 I
- I
dichloro I
- I
N I
- I
methyl I
- I
N I
- I
[ I
2 I
- I
( I
1 I
- I
pyrrolidinyl I
) I
cyclohexyl I
] I
benzeneacetamide I
( O
U50 B
- I
488 I
) O
. O

Methanandamide B
( O
10 O
. O
0 O
mg O
/ O
kg O
) O
had O
lesser O
effect O
than O
other O
CB O
agonists O
, O
and O
the O
CB2 O
agonist O
AM1241 B
[ O
1 B
- I
( I
methylpiperidin I
- I
2 I
- I
ylmethyl I
) I
- I
3 I
- I
( I
2 I
- I
iodo I
- I
5 I
- I
nitrobenzoyl I
) I
indole I
] O
, O
the O
anandamide B
transport O
inhibitor O
AM404 B
, O
and O
the O
CB O
antagonist O
rimonabant B
did O
not O
have O
diuretic O
effects O
. O

Role O
of O
carbonyl B
reducing O
enzymes O
in O
the O
phase O
I O
biotransformation O
of O
the O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
nabumetone B
in O
vitro O
. O

Nabumetone B
is O
a O
clinically O
used O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
its O
biotransformation O
includes O
major O
active O
metabolite O
6 B
- I
methoxy I
- I
2 I
- I
naphtylacetic I
acid I
and O
another O
three O
phase O
I O
as O
well O
as O
corresponding O
phase O
II O
metabolites O
which O
are O
regarded O
as O
inactive O
. O

Metabolism O
of O
triethylenetetramine B
and O
1 B
, I
12 I
- I
diamino I
- I
3 I
, I
6 I
, I
9 I
- I
triazadodecane I
by O
the O
spermidine B
/ O
spermine B
- O
N O
( O
1 O
) O
- O
acetyltransferase O
and O
thialysine B
acetyltransferase O
. O

By O
contrast O
, O
1 B
, I
12 I
- I
diamino I
- I
3 I
, I
6 I
, I
9 I
- I
triazadodecane I
( O
SpmTrien B
) O
, O
a O
charge O
- O
deficient O
spermine B
analog O
, O
was O
an O
extremely O
poor O
substrate O
of O
human O
recombinant O
SSAT2 O
and O
was O
metabolized O
by O
SSAT1 O
in O
HEPG2 O
cells O
and O
in O
wild O
- O
type O
primary O
hepatocytes O
. O

Here O
we O
report O
novel O
ASK1 O
inhibitor O
scaffold O
, O
namely O
5 B
- I
( I
5 I
- I
Phenyl I
- I
furan I
- I
2 I
- I
ylmethylene I
) I
- I
2 I
- I
thioxo I
- I
thiazolidin I
- I
4 I
- I
one I
, O
that O
has O
been O
identified O
using O
virtual O
screening O
and O
biochemical O
tests O
. O

It O
was O
revealed O
that O
the O
most O
active O
compounds O
4 B
- I
( I
( I
5Z I
) I
- I
5 I
- I
{ I
[ I
5 I
- I
( I
4 I
- I
bromophenyl I
) I
- I
2 I
- I
furyl I
] I
methylene I
} I
- I
4 I
- I
oxo I
- I
2 I
- I
thioxo I
- I
1 I
, I
3 I
- I
thiazolidin I
- I
3 I
- I
yl I
) I
butanoic I
acid I
and O
6 B
- I
( I
( I
5Z I
) I
- I
5 I
- I
{ I
[ I
5 I
- I
( I
4 I
- I
bromophenyl I
) I
- I
2 I
- I
furyl I
] I
methylene I
} I
- I
4 I
- I
oxo I
- I
2 I
- I
thioxo I
- I
1 I
, I
3 I
- I

Structure O
- O
activity O
relationships O
of O
33 O
derivatives O
of O
5 B
- I
( I
5 I
- I
Phenyl I
- I
furan I
- I
2 I
- I
ylmethylene I
) I
- I
2 I
- I
thioxo I
- I
thiazolidin I
- I
4 I
- I
one I
have O
been O
studied O
and O
binding O
mode O
of O
this O
chemical O
class O
has O
been O
predicted O
. O

Differential O
cell O
- O
protective O
function O
of O
two O
resveratrol B
( B
trans I
- I
3 I
, I
5 I
, I
4 I
' I
- I
trihydroxystilbene I
) I
glucosides I
against O
oxidative O
stress O
. O

Resveratrol B
( O
trans B
- I
3 I
, I
5 I
, I
4 I
' I
- I
trihydroxystilbene I
; O
RSV B
) O
, O
a O
natural O
polyphenol B
, O
exerts O
a O
beneficial O
effect O
on O
health O
and O
diseases O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

In O
this O
study O
, O
we O
compared O
the O
effects O
of O
RSV B
and O
two O
glycosyl B
RSVs I
, O
resveratrol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
3G B
- I
RSV I
; O
polydatin B
/ O
piceid B
) O
and O
resveratrol B
- I
4 I
' I
- I
O I
- I
beta I
- I
d I
- I
glucoside I
( O
4 B
' I
G I
- I
RSV I
) O
, O
at O
the O
cellular O
level O
. O

In O
oxygen O
radical O
absorbance O
capacity O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
assays O
, O
the O
antioxidant O
activity O
of O
3G B
- I
RSV I
was O
comparable O
to O
that O
of O
RSV B
, O
whereas O
the O
radical O
- O
scavenging O
efficiency O
of O
4 B
' I
G I
- I
RSV I
was O
less O
than O
50 O
% O
of O
that O
of O
RSV B
. O

Then O
, O
the O
effect O
of O
UVA O
- O
irradiation O
over O
NCTC2544 O
cells O
treated O
with O
increasing O
concentrations O
of O
15 O
compounds O
including O
photoallergens O
( O
benzophenone B
, O
4 B
- I
ter I
- I
butyl I
- I
4 I
- I
methoxy I
- I
dibenzoylmethane I
, I
2 I
- I
ethylexyl I
- I
p I
- I
methoxycinnamate I
, O
ketoprofen B
, O
6 B
- I
methylcumarin I
) O
; O
photoirritant O
and O
photoallergen O
( O
4 B
- I
aminobenzoic I
acid I
, O
chlorpromazine B
, O
promethazine B
) O
; O
photoirritants O
( O
acridine B
, O

The O
purpose O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiovascular O
profile O
of O
INO B
- I
8875 I
, O
a O
highly O
selective O
A O
( O
1 O
) O
R O
agonist O
, O
and O
to O
compare O
its O
properties O
with O
N B
- I
[ I
3 I
( I
R I
) I
- I
tetrahydrofuranyl I
] I
- I
6 I
- I
aminopurine I
riboside I
( O
CVT B
- I
510 I
) O
, O
which O
has O
already O
been O
shown O
to O
induce O
negative O
dromotropic O
effects O
with O
minimal O
cardiovascular O
side O
effects O
in O
animals O
and O
in O
clinical O
studies O
. O

Based O
on O
mild O
local O
irritation O
after O
topical O
application O
of O
1 O
. O
0 O
% O
sodium B
metaphosphate I
[ O
( B
NaPO I
( I
3 I
) I
) I
6 I
* I
H2O I
] O
to O
intact O
skin O
of O
sensitive O
volunteers O
, O
a O
do O
not O
use O
concentration O
of O
8 O
, O
000 O
mg O
PO4 B
/ O
L O
can O
be O
assigned O
. O

Given O
the O
lack O
of O
eye O
irritation O
in O
rabbits O
after O
direct O
instillation O
of O
0 O
. O
2 O
% O
( B
NaPO I
( I
3 I
) I
) I
6 I
* I
H2O I
, O
an O
acute O
ocular O
contact O
limit O
of O
50 O
mg O
PO4 B
/ O
L O
serves O
as O
the O
overall O
do O
not O
use O
level O
. O

Further O
biotransformation O
of O
DCA B
leads O
to O
the O
production O
of O
6 B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
6OH B
- I
DCA I
) O
and O
N B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
NOH B
- I
DCA I
) O
. O

Further O
biotransformation O
of O
DCA B
leads O
to O
the O
production O
of O
6 B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
6OH B
- I
DCA I
) O
and O
N B
- I
hydroxy I
- I
3 I
, I
4 I
- I
dichloroaniline I
( O
NOH B
- I
DCA I
) O
. O

Metabolism O
and O
quantification O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
, O
a O
new O
TSPO O
positron O
emission O
tomography O
radioligand O
. O

[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
[ O
N B
, I
N I
- I
diethyl I
- I
2 I
- I
( I
2 I
- I
( I
4 I
- I
( I
2 I
[ I
( I
18 I
) I
F I
] I
- I
fluoroethoxy I
) I
phenyl I
) I
5 I
, I
7dimethylpyrazolo I
[ I
1 I
, I
5a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
acetamide I
] O
is O
a O
new O
radioligand O
currently O
used O
for O
imaging O
the O
18 O
- O
kDa O
translocator O
protein O
in O
animal O
models O
of O
neuroinflammation O
and O
recently O
in O
humans O
. O

[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
[ O
N B
, I
N I
- I
diethyl I
- I
2 I
- I
( I
2 I
- I
( I
4 I
- I
( I
2 I
[ I
( I
18 I
) I
F I
] I
- I
fluoroethoxy I
) I
phenyl I
) I
5 I
, I
7dimethylpyrazolo I
[ I
1 I
, I
5a I
] I
pyrimidin I
- I
3 I
- I
yl I
) I
acetamide I
] O
is O
a O
new O
radioligand O
currently O
used O
for O
imaging O
the O
18 O
- O
kDa O
translocator O
protein O
in O
animal O
models O
of O
neuroinflammation O
and O
recently O
in O
humans O
. O

The O
biodistribution O
by O
positron O
emission O
tomography O
( O
PET O
) O
in O
baboons O
and O
the O
in O
vitro O
and O
in O
vivo O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
were O
investigated O
in O
rats O
, O
baboons O
, O
and O
humans O
. O

The O
liver O
was O
a O
major O
route O
of O
elimination O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
, O
and O
urine O
was O
a O
route O
of O
excretion O
for O
radiometabolites O
. O

O B
- O
deethylation O
led O
to O
a O
nonradioactive O
compound O
and O
[ B
( I
18 I
) I
F I
] I
fluoroacetic I
acid I
. O

Finally O
an O
easy O
, O
rapid O
, O
and O
accurate O
method O
- O
- O
indispensable O
for O
PET O
quantitative O
clinical O
studies O
- O
- O
for O
quantifying O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
by O
solid O
- O
phase O
extraction O
was O
developed O
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

In O
vivo O
, O
an O
extensive O
metabolism O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
was O
observed O
in O
rats O
and O
baboons O
, O
identified O
as O
[ B
( I
18 I
) I
F I
] I
deethyl I
, O
[ B
( I
18 I
) I
F I
] I
hydroxyl I
, O
and O
[ B
( I
18 I
) I
F I
] I
carboxylic I
acid I
derivatives O
of O
[ B
( I
18 I
) I
F I
] I
DPA I
- I
714 I
. O

As O
a O
proof O
of O
concept O
, O
we O
employed O
a O
Protein O
Kinase O
A O
( O
PKA O
) O
- O
dependent O
switch O
and O
coupled O
it O
to O
a O
lipid O
phosphatase O
to O
manipulate O
the O
level O
of O
phosphatidylinositol B
4 I
, I
5 I
- I
bisphosphate I
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
in O
living O
cells O
. O

PKA O
activation O
results O
in O
rapid O
degradation O
of O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
. O

Conversely O
, O
when O
PKA O
is O
inhibited O
, O
dephosphorylation O
of O
the O
switch O
leads O
to O
the O
replenishment O
of O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
. O

The O
present O
work O
first O
describes O
the O
synthesis O
and O
characterization O
of O
five O
new O
O B
- I
2 I
, I
O I
- I
3 I
permethylated I
O I
- I
6 I
alkylthio I
- I
and I
perfluoroalkyl I
- I
propanethio I
- I
amphiphilic I
beta I
- I
cyclodextrins I
. O

Improved O
preparation O
of O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
- I
bromophosphonoacetat I
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

We O
have O
established O
an O
efficient O
method O
for O
preparing O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
bromophosphonoacetat I
, O
which O
we O
developed O
for O
the O
stereoselective O
synthesis O
of O
( B
E I
) I
- I
alpha I
- I
bromoacrylates I
. O

This O
improved O
method O
enables O
the O
reagent O
to O
be O
prepared O
reproducibly O
in O
one O
step O
from O
methyl B
bis I
( I
2 I
, I
2 I
, I
2 I
- I
trifluoroethoxy I
) I
phosphonoacetate I
. O

Buspirone B
and O
its O
major O
metabolites O
1 B
- I
( I
2 I
- I
pyrimidinyl I
) I
piperazine I
and O
6 B
' I
- I
hydroxybuspirone I
were O
determined O
using O
a O
newly O
validated O
UPLC O
- O
MS O
/ O
MS O
method O
. O

Single O
dose O
and O
7 O
- O
day O
AC O
administration O
at O
0 O
. O
125mg O
/ O
kg O
had O
no O
effect O
on O
CYP3A O
activity O
since O
no O
change O
in O
the O
formation O
of O
1 B
- I
( I
2 I
- I
pyrimidinyl I
) I
piperazine I
and O
6 B
' I
- I
hydroxybuspirone I
. O

Furthermore O
, O
antibodies O
to O
DNA O
show O
localized O
binding O
to O
these O
microstructures O
, O
which O
also O
react O
positively O
with O
DNA O
intercalating O
stains O
propidium B
iodide I
( O
PI O
) O
and O
4 B
' I
, I
6 I
' I
- I
diamidino I
- I
2 I
- I
phenylindole I
dihydrochloride I
( O
DAPI B
) O
. O

In O
this O
article O
, O
we O
checked O
the O
effect O
of O
2 B
, I
3 I
- I
dimercaptosuccinic I
acid I
- O
coated O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
nanoparticles O
on O
gene O
expression O
of O
mouse O
macrophage O
RAW264 O
. O
7 O
cells O
and O
found O
that O
the O
transcription O
of O
several O
important O
genes O
related O
to O
intracellular O
iron B
homeostasis O
were O
significantly O
changed O
. O

The O
effect O
of O
LPV B
, O
RTV B
, O
and O
LPV B
/ O
r O
on O
cellular O
viability O
and O
the O
disposition O
of O
[ B
( I
3 I
) I
H I
] I
taurocholic I
acid I
( O
TCA B
) O
and O
[ B
( I
14 I
) I
C I
] I
chenodeoxycholic I
acid I
( O
CDCA B
) O
was O
determined O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
( O
SCRH O
) O
and O
suspended O
rat O
hepatocytes O
. O

The O
effect O
of O
LPV B
, O
RTV B
, O
and O
LPV B
/ O
r O
on O
cellular O
viability O
and O
the O
disposition O
of O
[ B
( I
3 I
) I
H I
] I
taurocholic I
acid I
( O
TCA B
) O
and O
[ B
( I
14 I
) I
C I
] I
chenodeoxycholic I
acid I
( O
CDCA B
) O
was O
determined O
in O
sandwich O
- O
cultured O
rat O
hepatocytes O
( O
SCRH O
) O
and O
suspended O
rat O
hepatocytes O
. O

The O
complete O
and O
reversible O
charge O
- O
selective O
sequestration O
of O
fluorophores O
by O
a O
weak O
polyelectrolyte O
brush O
, O
poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethylmethacrylate I
) I
( O
PDMAEMA B
) O
was O
demonstrated O
using O
fluorescence O
correlation O
spectroscopy O
( O
FCS O
) O
. O

Blood O
pressure O
was O
increased O
in O
rats O
exposed O
to O
IH O
, O
and O
treatment O
with O
the O
PDK O
- O
1 O
inhibitor O
OSU B
- I
03012 I
[ O
2 B
- I
amino I
- I
N I
- I
{ I
4 I
- I
[ I
5 I
- I
( I
2 I
- I
phenanthrenyl I
) I
- I
3 I
- I
( I
trifluoromethyl I
) I
- I
1H I
- I
pyrazol I
- I
1 I
- I
yl I
] I
- I
phenyl I
} I
- I
acetamide I
] O
( O
33 O
mg O
/ O
day O
) O
lowered O
blood O
pressure O
in O
IH O
but O
not O
sham O
group O
rats O
. O

A O
novel O
nickel B
( I
II I
) I
hexaaza I
macrocyclic O
complex O
, O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
ClO I
( I
4 I
) I
) I
( I
2 I
) I
( O
1 O
) O
, O
containing O
chiral O
pendant O
groups O
was O
synthesized O
by O
an O
efficient O
one O
- O
pot O
template O
condensation O
and O
characterized O
( O
L O
( O
R O
, O
R O
) O
= O
1 B
, I
8 I
- I
di I
( I
( I
R I
) I
- I
alpha I
- I
methylnaphthyl I
) I
- I
1 I
, I
3 I
, I
6 I
, I
8 I
, I
10 I
, I
13 I
- I
hexaazacyclotetradec I
) O
. O

A O
novel O
nickel B
( I
II I
) I
hexaaza I
macrocyclic O
complex O
, O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
ClO I
( I
4 I
) I
) I
( I
2 I
) I
( O
1 O
) O
, O
containing O
chiral O
pendant O
groups O
was O
synthesized O
by O
an O
efficient O
one O
- O
pot O
template O
condensation O
and O
characterized O
( O
L O
( O
R O
, O
R O
) O
= O
1 B
, I
8 I
- I
di I
( I
( I
R I
) I
- I
alpha I
- I
methylnaphthyl I
) I
- I
1 I
, I
3 I
, I
6 I
, I
8 I
, I
10 I
, I
13 I
- I
hexaazacyclotetradec I
) O
. O

Open O
framework O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
3 I
) I
[ I
C I
( I
6 I
) I
H I
( I
3 I
) I
( I
COO I
) I
( I
3 I
) I
] I
( I
2 I
) I
( O
2 O
) O
was O
constructed O
from O
the O
self O
- O
assembly O
of O
compound O
1 O
with O
deprotonated O
1 B
, I
3 I
, I
5 I
- I
benzenetricarboxylic I
acid I
, O
BTC B
( I
3 I
- I
) I
. O

Open O
framework O
[ B
Ni I
( I
L I
( I
R I
, I
R I
) I
) I
] I
( I
3 I
) I
[ I
C I
( I
6 I
) I
H I
( I
3 I
) I
( I
COO I
) I
( I
3 I
) I
] I
( I
2 I
) I
( O
2 O
) O
was O
constructed O
from O
the O
self O
- O
assembly O
of O
compound O
1 O
with O
deprotonated O
1 B
, I
3 I
, I
5 I
- I
benzenetricarboxylic I
acid I
, O
BTC B
( I
3 I
- I
) I
. O

Chiral O
discrimination O
of O
rac B
- I
1 I
, I
1 I
' I
- I
bi I
- I
2 I
- I
naphthol I
and O
rac B
- I
2 I
, I
2 I
, I
2 I
- I
trifluoro I
- I
1 I
- I
( I
9 I
- I
anthryl I
) I
ethanol I
was O
performed O
to O
determine O
the O
chiral O
recognition O
ability O
of O
the O
chiral O
complex O
( O
1 O
) O
and O
its O
self O
- O
assembled O
framework O
( O
2 O
) O
. O

Chiral O
discrimination O
of O
rac B
- I
1 I
, I
1 I
' I
- I
bi I
- I
2 I
- I
naphthol I
and O
rac B
- I
2 I
, I
2 I
, I
2 I
- I
trifluoro I
- I
1 I
- I
( I
9 I
- I
anthryl I
) I
ethanol I
was O
performed O
to O
determine O
the O
chiral O
recognition O
ability O
of O
the O
chiral O
complex O
( O
1 O
) O
and O
its O
self O
- O
assembled O
framework O
( O
2 O
) O
. O

In O
other O
groups O
, O
each O
atrium O
was O
incubated O
with O
selective O
adenosine B
A O
( O
1 O
) O
antagonist O
( O
8 B
- I
cyclopentyl I
- I
1 I
, I
3 I
- I
dipropylxanthine I
( O
DPCPX B
) O
, O
10 O
( O
- O
4 O
) O
M O
) O
or O
selective O
adenosine B
A O
( O
2a O
) O
receptor O
antagonist O
( O
8 B
- I
( I
3 I
- I
chlorostyryl I
) I
caffeine I
, O
10 O
( O
- O
5 O
) O
M O
) O
before O
amitriptyline B
administration O
. O

In O
other O
groups O
, O
each O
atrium O
was O
incubated O
with O
selective O
adenosine B
A O
( O
1 O
) O
antagonist O
( O
8 B
- I
cyclopentyl I
- I
1 I
, I
3 I
- I
dipropylxanthine I
( O
DPCPX B
) O
, O
10 O
( O
- O
4 O
) O
M O
) O
or O
selective O
adenosine B
A O
( O
2a O
) O
receptor O
antagonist O
( O
8 B
- I
( I
3 I
- I
chlorostyryl I
) I
caffeine I
, O
10 O
( O
- O
5 O
) O
M O
) O
before O
amitriptyline B
administration O
. O

Androgen B
receptor O
CAG O
repeat O
length O
modifies O
the O
effect O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
on O
receptor O
activity O
in O
human O
prostate O
cells O
. O

Increased O
incidence O
of O
prostate O
cancer O
has O
been O
reported O
in O
men O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

A O
simple O
GC O
- O
MS O
method O
for O
the O
screening O
of O
betulinic B
, I
corosolic I
, I
maslinic I
, I
oleanolic I
and I
ursolic I
acid I
contents O
in O
commercial O
botanicals O
used O
as O
food O
supplement O
ingredients O
. O

A O
simple O
GC O
- O
MS O
method O
for O
the O
simultaneous O
determination O
of O
betulinic B
, I
corosolic I
, I
maslinic I
, I
oleanolic I
and I
ursolic I
acids I
was O
developed O
and O
applied O
to O
38 O
different O
commercial O
plant O
extracts O
sold O
as O
ingredients O
for O
dietary O
supplements O
. O

Lastly O
, O
the O
1 B
, I
1 I
' I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
assay O
showed O
that O
the O
gallic B
acid I
had O
retained O
its O
antioxidant O
activity O
after O
incorporation O
in O
zein O
electrospun O
fibres O
. O

The O
reaction O
of O
enaminones B
with O
3 B
- I
amino I
- I
2 I
- I
cyanopent I
- I
2 I
- I
enedinitrile I
can O
lead O
to O
an O
array O
of O
12 O
possible O
products O
, O
depending O
on O
the O
reaction O
pathway O
and O
tautomerization O
. O

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

To O
assess O
the O
influence O
of O
Zn B
( I
2 I
+ I
) I
, O
Cu B
( I
2 I
+ I
) I
, O
Fe B
( I
3 I
+ I
) I
, O
Al B
( I
3 I
+ I
) I
, O
Ti B
( I
IV I
) I
, O
and O
Sn B
( I
IV I
) I
on O
incorporation O
of O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
into O
pendant O
- O
arm O
macrocyclic O
chelators O
, O
the O
( B
68 I
) I
Ga I
labeling O
of O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
triacetic I
acid I
( O
NOTA B
) O
, O
1 B
, I
4 I
, I
7 I
, I
10 I
- I
tetraazacyclododecan I
- I

1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
( O
DOTA B
) O
, O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
tris I
[ I
methyl I
( I
2 I
- I
carboxyethyl I
) I
phosphinic I
acid I
] I
) I
( O
TRAP B
) O
, O
and O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
- I
[ I
methyl I
( I
2 I
- I
carboxyethyl I
) I
phosphinic I
acid I
] I
- I
4 I
, I
7 I
- I
bis I
[ I
methyl I
( I
2 I
- I
hydroxymethyl I
) I
phosphinic I

1 I
, I
4 I
, I
7 I
, I
10 I
- I
tetraacetic I
acid I
( O
DOTA B
) O
, O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
, I
4 I
, I
7 I
- I
tris I
[ I
methyl I
( I
2 I
- I
carboxyethyl I
) I
phosphinic I
acid I
] I
) I
( O
TRAP B
) O
, O
and O
1 B
, I
4 I
, I
7 I
- I
triazacyclononane I
- I
1 I
- I
[ I
methyl I
( I
2 I
- I
carboxyethyl I
) I
phosphinic I
acid I
] I
- I
4 I
, I
7 I
- I
bis I
[ I
methyl I
( I
2 I
- I
hydroxymethyl I
) I
phosphinic I

acid I
] I
( O
NOPO B
) O
, O
as O
well O
as O
their O
peptide O
conjugates O
, O
was O
investigated O
in O
the O
presence O
of O
varying O
concentrations O
of O
these O
metal O
ions O
. O

The O
latter O
are O
able O
to O
rapidly O
exchange O
coordinated O
Zn B
( I
II I
) I
with O
( B
68 I
) I
Ga I
( I
3 I
+ I
) I
, O
as O
confirmed O
by O
mass O
spectrometry O
and O
( B
31 I
) I
P I
NMR O
spectroscopy O
. O

Supporting O
functional O
significance O
of O
this O
interaction O
, O
both O
the O
Rev1 O
pathway O
and O
Rad5 O
are O
required O
for O
translesion O
synthesis O
and O
mutagenesis O
of O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenine I
. O

Inhibition O
of O
vitellogenin O
gene O
induction O
by O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
is O
mediated O
by O
aryl B
hydrocarbon I
receptor O
2 O
( O
AHR2 O
) O
in O
zebrafish O
( O
Danio O
rerio O
) O
. O

Pre O
- O
treatment O
with O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
) O
or O
1 B
, I
2 I
, I
3 I
, I
7 I
, I
8 I
- I
pentachlorodibenzo I
- I
p I
- I
dioxin I
inhibited O
the O
EE2 B
induction O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
> O
95 O
% O
( O
p O
< O
= O
0 O
. O
05 O
) O
. O

Pre O
- O
treatment O
with O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
) O
or O
1 B
, I
2 I
, I
3 I
, I
7 I
, I
8 I
- I
pentachlorodibenzo I
- I
p I
- I
dioxin I
inhibited O
the O
EE2 B
induction O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
> O
95 O
% O
( O
p O
< O
= O
0 O
. O
05 O
) O
. O

Pre O
- O
treatment O
with O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
) O
or O
1 B
, I
2 I
, I
3 I
, I
7 I
, I
8 I
- I
pentachlorodibenzo I
- I
p I
- I
dioxin I
inhibited O
the O
EE2 B
induction O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
> O
95 O
% O
( O
p O
< O
= O
0 O
. O
05 O
) O
. O

In O
comparison O
, O
a O
splice O
- O
blocking O
AHR2 O
morpholino O
used O
to O
down O
- O
regulate O
ahr2 O
expression O
significantly O
reduced O
the O
inhibition O
of O
vtg1 O
, O
vtg2 O
and O
vtg3 O
by O
400 O
pptr O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
( O
20 O
. O
7 O
- O
27 O
. O
4 O
% O
rescue O
) O
. O

These O
studies O
demonstrate O
that O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
directly O
inhibits O
the O
vitellogenin O
pathway O
in O
vivo O
through O
activation O
of O
the O
AHR2 O
. O

In O
vitro O
exposure O
of O
precision O
- O
cut O
lung O
slices O
to O
2 B
- I
( I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
) I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
( O
NSC B
710305 I
, O
Phortress B
) O
increases O
inflammatory O
cytokine O
content O
and O
tissue O
damage O
. O

The O
anticancer O
drug O
( O
2 B
- I
[ I
4 I
- I
amino I
- I
3 I
- I
methylphenyl I
] I
- I
5 I
- I
fluorobenzothiazole I
lysylamide I
dihydrochloride I
) O
( O
NSC B
710305 I
, O
Phortress B
) O
is O
a O
metabolically O
activated O
prodrug O
that O
causes O
DNA O
adduct O
formation O
and O
subsequent O
toxicity O
. O

Emodin B
- I
6 I
- I
O I
- I
beta I
- I
D I
- I
glucoside I
inhibits O
HMGB1 O
- O
induced O
inflammatory O
responses O
in O
vitro O
and O
in O
vivo O
. O

Emodin B
- I
6 I
- I
O I
- I
beta I
- I
D I
- I
glucoside I
( O
EG O
) O
is O
a O
new O
active O
compound O
from O
Reynoutria O
japonica O
, O
and O
its O
biologic O
activities O
have O
not O
been O
previously O
investigated O
. O

In O
Ca B
( I
2 I
+ I
) I
- O
free O
medium O
, O
treatment O
with O
the O
endoplasmic O
reticulum O
Ca B
( I
2 I
+ I
) I
pump O
inhibitor O
thapsigargin B
( O
TG O
) O
or O
2 B
, I
5 I
- I
di I
- I
tert I
- I
butylhydroquinone I
( O
BHQ B
) O
inhibited O
carvacrol B
- O
induced O
[ O
Ca B
( I
2 I
+ I
) I
] O
( O
i O
) O
rise O
. O

Carvacrol B
decreased O
cell O
viability O
, O
which O
was O
not O
reversed O
when O
cytosolic O
Ca B
( I
2 I
+ I
) I
was O
chelated O
with O
BAPTA B
- I
AM I
( O
1 B
, I
2 I
- I
bis I
( I
2 I
- I
aminophenoxy I
) I
ethane I
- I
N I
, I
N I
, I
N I
' I
, I
N I
' I
- I
tetraacetic I
acid I
- I
acetoxymethyl I
ester I
) O
. O

The O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
hydroxylated O
metabolites O
5 B
- I
OH I
- I
BDE I
- I
47 I
and O
6 B
- I
OH I
- I
BDE I
- I
47 I
stimulate O
estradiol B
secretion O
in O
the O
ovary O
by O
activating O
aromatase O
expression O
. O

Enhanced O
bile B
acid I
synthesis O
in O
these O
animals O
was O
also O
confirmed O
by O
a O
2 O
- O
fold O
increase O
in O
plasma O
marker O
7 B
alpha I
- I
hydroxy I
- I
4 I
- I
cholesten I
- I
3 I
- I
one I
. O

The O
polycyclic B
aromatic I
hydrocarbon I
( O
PAH B
) O
benzo B
[ I
a I
] I
pyrene I
( O
BP O
) O
is O
metabolized O
into O
a O
complex O
pattern O
of O
BP O
derivatives O
, O
among O
which O
the O
ultimate O
carcinogen O
( B
+ I
) I
- I
anti I
- I
BP I
- I
7 I
, I
8 I
- I
diol I
- I
9 I
, I
10 I
- I
epoxide I
( O
BPDE B
) O
is O
formed O
to O
certain O
extents O
. O

Design O
, O
synthesis O
and O
anticancer O
activity O
of O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxamide I
. O

A O
series O
of O
novel O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxamide I
, O
three O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthene I
- I
3 I
, I
11 I
- I
dimethanamine I
derivatives O
and O
their O
intermediates O
14 B
- I
aryl I
- I
14H I
- I
dibenzo I
[ I

A O
series O
of O
novel O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxamide I
, O
three O
N B
( I
3 I
) I
, I
N I
( I
11 I
) I
- I
bis I
( I
2 I
- I
hydroxyethyl I
) I
- I
14 I
- I
aryl I
- I
14H I
- I
dibenzo I
[ I
a I
, I
j I
] I
xanthene I
- I
3 I
, I
11 I
- I
dimethanamine I
derivatives O
and O
their O
intermediates O
14 B
- I
aryl I
- I
14H I
- I
dibenzo I
[ I

a I
, I
j I
] I
xanthenes I
- I
3 I
, I
11 I
- I
dicarboxylic I
acid I
, O
were O
synthesized O
, O
and O
the O
structures O
of O
which O
were O
characterized O
by O
( B
1 I
) I
H I
- O
NMR O
, O
( B
13 I
) I
C I
- O
NMR O
, O
high O
resolution O
( O
HR O
) O
- O
MS O
, O
and O
IR O
spectra O
. O

The O
carboxamide B
derivatives O
6c O
and O
6e O
exhibitted O
good O
inhibition O
on O
NB4 O
cancer O
cells O
, O
and O
the O
IC O
( O
50 O
) O
values O
of O
which O
were O
0 O
. O
82 O
micro O
M O
and O
0 O
. O
96 O
micro O
M O
, O
respectively O
, O
much O
lower O
than O
5 O
. O
01 O
micro O
M O
of O
the O
positive O
control O
As B
( I
2 I
) I
O I
( I
3 I
) I
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
- O
mediated O
production O
of O
reactive O
oxygen B
species O
is O
an O
essential O
step O
in O
the O
mechanism O
of O
action O
to O
accelerate O
human O
keratinocyte O
differentiation O
. O

Chloracne O
is O
commonly O
observed O
in O
humans O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
; O
yet O
, O
the O
mechanism O
of O
toxicity O
is O
not O
well O
understood O
. O

The O
authors O
examined O
the O
toxicity O
of O
two O
fire O
retardant O
products O
, O
PHOS B
- I
CHEK I
259F I
and I
LC I
- I
95A I
, O
to O
salmon O
undergoing O
parr O
- O
smolt O
transformation O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine B
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
long O
- O
acting O
sustained O
- O
release O
microspheres O
with O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
dopamine B
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine B
( O
e O
. O
g O
. O
, O
hyperactivity O
and O
stereotype O
, O
decreased O
serum O
prolactin O
level O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
and O
carboxymethycellulos O
sodium B
( O
e O
. O
g O
. O
, O
increased O
mononuclear O
cells O
and O
neutrophils O
, O
thymus O
atrophy O
and O
vacuolar O
degeneration O
of O
adrenal O
cortex O
, O
foreign O
body O
granuloma O
with O
foam O
cells O
accumulation O
at O

1 O
. O
The O
absorption O
, O
metabolism O
and O
excretion O
of O
darexaban B
( O
YM150 B
) O
, O
a O
novel O
oral O
direct O
factor O
Xa O
inhibitor O
, O
were O
investigated O
after O
a O
single O
oral O
administration O
of O
[ B
( I
14 I
) I
C I
] I
darexaban I
maleate I
at O
a O
dose O
of O
60 O
mg O
in O
healthy O
male O
human O
subjects O
. O

Principal O
metabolic O
pathways O
included O
hydroxylation O
on O
alkyl B
side O
chain O
, O
particularly O
at O
3 B
- I
, I
omega I
- I
1 I
- I
, I
and I
omega I
- I
carbons I
, O
and O
further O
oxidation O
and O
conjugation O
. O

The O
disposition O
of O
ertugliflozin B
( O
PF B
- I
04971729 I
) O
, O
an O
orally O
active O
selective O
inhibitor O
of O
the O
sodium B
- O
dependent O
glucose B
cotransporter O
2 O
, O
was O
studied O
after O
a O
single O
25 O
- O
mg O
oral O
dose O
of O
[ B
( I
14 I
) I
C I
] I
- I
ertugliflozin I
to O
healthy O
human O
subjects O
. O

The O
structure O
of O
M4a O
and O
M4c O
were O
confirmed O
to O
be O
ertugliflozin B
- I
4 I
- I
O I
- I
beta I
- I
and I
- I
3 I
- I
O I
- I
beta I
- I
glucuronide I
, O
respectively O
, O
via O
comparison O
of O
the O
HPLC O
retention O
time O
and O
mass O
spectra O
with O
authentic O
standards O
. O

The O
involvement O
of O
a O
secondary O
solvent O
in O
the O
phase O
transfer O
process O
had O
only O
small O
effects O
on O
the O
particle O
size O
and O
distribution O
, O
zeta O
potential O
, O
and O
mobility O
of O
the O
nC B
( I
60 I
) I
products O
but O
significantly O
influenced O
the O
capability O
of O
nC B
( I
60 I
) I
to O
enhance O
the O
transport O
of O
2 B
, I
2 I
' I
, I
5 I
, I
5 I
' I
- I
polychlorinated I
biphenyl I
( O
PCB B
) O
in O
a O
saturated O
sandy O
soil O
column O
, O
regardless O
of O
whether O
the O
secondary O
solvent O
was O
water O
- O
miscible O
or O
non O
- O
water O
- O
miscible O
. O

Hydroalcoholic O
extracts O
, O
obtained O
from O
the O
red O
propolis O
, O
revealed O
polyphenol B
content O
, O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
scavenging O
potential O
and O
enzymatic O
activities O
for O
catalase O
- O
like O
and O
superoxide B
dismutase O
- O
like O
. O

The O
reaction O
mechanism O
of O
CO B
oxidation O
on O
the O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
and O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
surfaces O
is O
investigated O
by O
means O
of O
spin O
- O
polarized O
density O
functional O
theory O
( O
DFT O
) O
within O
the O
GGA O
+ O
U O
framework O
. O

The O
reaction O
mechanism O
of O
CO B
oxidation O
on O
the O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
and O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
surfaces O
is O
investigated O
by O
means O
of O
spin O
- O
polarized O
density O
functional O
theory O
( O
DFT O
) O
within O
the O
GGA O
+ O
U O
framework O
. O

( I
2 I
) I
( O
a O
) O
+ O
CO B
( O
g O
) O
- O
- O
> O
CO B
( I
2 I
) I
( O
g O
) O
+ O
O B
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO B
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO B
oxidation O
follows O
the O
order O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co B

( I
2 I
) I
( O
a O
) O
+ O
CO B
( O
g O
) O
- O
- O
> O
CO B
( I
2 I
) I
( O
g O
) O
+ O
O B
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO B
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO B
oxidation O
follows O
the O
order O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co B

( I
2 I
) I
( O
a O
) O
+ O
CO B
( O
g O
) O
- O
- O
> O
CO B
( I
2 I
) I
( O
g O
) O
+ O
O B
( O
a O
) O
] O
on O
( O
110 O
) O
- O
A O
/ O
( O
111 O
) O
- O
A O
; O
4 O
) O
CO B
oxidation O
is O
a O
structure O
- O
sensitive O
reaction O
, O
and O
the O
activation O
energy O
of O
CO B
oxidation O
follows O
the O
order O
of O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
A O
( O
0 O
. O
78 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
111 O
) O
- O
B O
( O
0 O
. O
68 O
eV O
) O
> O
Co B
( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
A O
( O
0 O
. O
51 O
eV O
) O
> O
Co B

( I
3 I
) I
O I
( I
4 I
) I
( O
110 O
) O
- O
B O
( O
0 O
. O
41 O
eV O
) O
, O
that O
is O
, O
the O
( O
110 O
) O
surface O
shows O
higher O
reactivity O
for O
CO B
oxidation O
than O
the O
( O
111 O
) O
surface O
; O
5 O
) O
in O
addition O
to O
the O
O B
( O
2f O
) O
, O
it O
was O
also O
found O
that O
Co B
( I
3 I
+ I
) I
is O
more O
active O
than O
Co B
( I
2 I
+ I
) I
, O
so O
both O
O B
( O
2f O
) O
and O
Co B
( I
3 I
+ I
) I
control O
the O
catalytic O
activity O
of O
CO B
oxidation O
on O
Co B
( I
3 I
) I
O I
( I
4 I
) I
, O
as O
opposed O
to O
a O
previous O
DFT O
study O
which O
concluded O
that O
either O
Co B
( I
3 I
+ I
) I
or O
O B
( O

The O
main O
physiological O
actions O
of O
the O
biologically O
most O
active O
metabolite O
of O
vitamin B
D I
, O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
) O
, O
are O
calcium B
and O
phosphorus B
uptake O
and O
transport O
and O
thereby O
controlling O
bone O
formation O
. O

The O
main O
physiological O
actions O
of O
the O
biologically O
most O
active O
metabolite O
of O
vitamin B
D I
, O
1 B
alpha I
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
) O
, O
are O
calcium B
and O
phosphorus B
uptake O
and O
transport O
and O
thereby O
controlling O
bone O
formation O
. O

Other O
emergent O
areas O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
action O
are O
in O
the O
control O
of O
immune O
functions O
, O
cellular O
growth O
and O
differentiation O
. O

All O
genomic O
actions O
of O
1 B
alpha I
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
( I
3 I
) I
are O
mediated O
by O
the O
transcription O
factor O
vitamin B
D I
receptor O
( O
VDR O
) O
that O
has O
been O
the O
subject O
of O
intense O
study O
since O
the O
1980 O
' O
s O
. O

Accordingly O
, O
rattus O
cardiomyocyte O
line O
, O
H9C2 O
, O
was O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
heart O
ischemia O
- O
reperfusion O
model O
followed O
by O
incubation O
with O
low O
molecular O
weight O
hyaluronan O
( O
LMW O
- O
HA O
, O
100 O
kDa O
) O
or O
high O
molecular O
weight O
hyaluronan O
( O
HMW O
- O
HA O
, O
1000 O
kDa O
) O
and O
proteomic O
analysis O
was O
performed O
to O
investigate O
the O
physiologic O
protection O
of O
HA O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
induced O
ischemia O
- O
reperfusion O
in O

Accordingly O
, O
rattus O
cardiomyocyte O
line O
, O
H9C2 O
, O
was O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
heart O
ischemia O
- O
reperfusion O
model O
followed O
by O
incubation O
with O
low O
molecular O
weight O
hyaluronan O
( O
LMW O
- O
HA O
, O
100 O
kDa O
) O
or O
high O
molecular O
weight O
hyaluronan O
( O
HMW O
- O
HA O
, O
1000 O
kDa O
) O
and O
proteomic O
analysis O
was O
performed O
to O
investigate O
the O
physiologic O
protection O
of O
HA O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
induced O
ischemia O
- O
reperfusion O
in O

The O
self O
- O
assembly O
of O
the O
aliphatic O
biodegradable O
copolyester O
PBS B
/ O
PBDL B
( O
poly B
( I
butylene I
succinate I
- I
co I
- I
butylene I
dilinoleate I
) I
) O
and O
HPMA B
- O
based O
copolymers O
( O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
- O
based O
copolymers O
) O
hydrophobically O
modified O
by O
the O
incorporation O
of O
cholesterol B
led O
to O
the O
formation O
of O
narrow O
- O
size O
- O
distributed O
( O
PDI O
< O
0 O
. O
10 O
) O
sub O
- O
200 O
- O
nm O
polymeric O
nanoparticles O
suitable O
for O
passive O
tumor O
- O

The O
self O
- O
assembly O
of O
the O
aliphatic O
biodegradable O
copolyester O
PBS B
/ O
PBDL B
( O
poly B
( I
butylene I
succinate I
- I
co I
- I
butylene I
dilinoleate I
) I
) O
and O
HPMA B
- O
based O
copolymers O
( O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
- O
based O
copolymers O
) O
hydrophobically O
modified O
by O
the O
incorporation O
of O
cholesterol B
led O
to O
the O
formation O
of O
narrow O
- O
size O
- O
distributed O
( O
PDI O
< O
0 O
. O
10 O
) O
sub O
- O
200 O
- O
nm O
polymeric O
nanoparticles O
suitable O
for O
passive O
tumor O
- O

Intergrowth O
of O
two O
partially O
miscible O
phases O
of O
BiFeO B
( I
3 I
) I
and O
BiMnO B
( I
3 I
) I
gives O
a O
new O
class O
of O
room O
- O
temperature O
multiferroic O
phase O
, O
Bi B
( I
3 I
) I
Fe I
( I
2 I
) I
Mn I
( I
2 I
) I
O I
( I
10 I
+ I
delta I
) I
, O
which O
has O
a O
unique O
supercell O
( O
SC O
) O
structure O
. O

17 O
beta O
- O
HSD3 O
- O
dependent O
reduction O
of O
Delta B
4 I
- I
androstene I
- I
3 I
, I
17 I
- I
dione I
was O
affected O
by O
neither O
coexpression O
with O
11 O
beta O
- O
HSD1 O
nor O
overexpression O
or O
knockdown O
of O
hexose B
- I
6 I
- I
phosphate I
dehydrogenase O
. O

One O
pot O
synthesis O
and O
biological O
activity O
evaluation O
of O
novel O
Schiff B
bases I
derived O
from O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
. O

Considering O
the O
structural O
features O
of O
a O
group O
of O
known O
potent O
inhibitors O
of O
human O
platelet O
aggregation O
containing O
hydrazone B
structural O
backbone O
, O
a O
series O
of O
novel O
hydrazone B
derivatives O
of O
2 B
- I
hydrazinyl I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazole I
were O
synthesized O
using O
a O
one O
- O
pot O
process O
and O
tested O
for O
their O
inhibitory O
activity O
against O
platelet O
aggregation O
induced O
by O
arachidonic B
acid I
and O
ADP B
. O

2 B
, I
5 I
- I
Dihydroxy I
- I
4 I
- I
methoxybenzophenone I
: O
a O
novel O
major O
in O
vitro O
metabolite O
of O
benzophenone B
- I
3 I
formed O
by O
rat O
and O
human O
liver O
microsomes O
. O

1 O
. O
When O
benzophenone B
- I
3 I
( O
2 B
- I
hydroxy I
- I
4 I
- I
methoxybenzophenone I
; O
BP B
- I
3 I
) O
was O
incubated O
with O
liver O
microsomes O
of O
untreated O
rats O
in O
the O
presence O
of O
NADPH B
, O
the O
5 O
- O
hydroxylated O
metabolite O
, O
2 B
, I
5 I
- I
dihydroxy I
- I
4 I
- I
methoxybenzophenone I
( O
5 B
- I
OH I
- I
BP I
- I
3 I
) O
, O
was O
formed O
as O
a O
major O
novel O
metabolite O
of O
BP B
- I
3 I
. O

The O
performance O
of O
these O
modified O
electrodes O
was O
evaluated O
and O
compared O
to O
bare O
GCE O
by O
cyclic O
voltammetry O
experiments O
and O
by O
flow O
injection O
analysis O
( O
FIA O
) O
with O
amperometric O
detection O
monitoring O
the O
response O
of O
gallic B
, I
caffeic I
, I
ferulic I
and I
p I
- I
coumaric I
acids I
in O
0 O
. O
050 O
M O
acetate B
buffer O
pH O
4 O
. O
5 O
containing O
100 O
mM O
NaCl B
. O

The O
anticancer O
effect O
of O
CPP O
in O
human O
gastric O
cancer O
HeLa O
cells O
was O
also O
evaluated O
by O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
. O

A O
variety O
of O
5 B
- I
, I
6 I
- I
and I
8 I
- I
( I
4 I
- I
aminobutyloxy I
) I
quinolines I
as O
novel O
oxygen B
analogues O
of O
known O
4 B
- I
and I
8 I
- I
( I
4 I
- I
aminobutylamino I
) I
quinoline I
antimalarial O
drugs O
was O
generated O
from O
hydroxyquinolines B
through O
a O
three O
- O
step O
approach O
with O
a O
rhodium B
- O
catalyzed O
hydroformylation O
as O
the O
key O
step O
. O

A O
variety O
of O
5 B
- I
, I
6 I
- I
and I
8 I
- I
( I
4 I
- I
aminobutyloxy I
) I
quinolines I
as O
novel O
oxygen B
analogues O
of O
known O
4 B
- I
and I
8 I
- I
( I
4 I
- I
aminobutylamino I
) I
quinoline I
antimalarial O
drugs O
was O
generated O
from O
hydroxyquinolines B
through O
a O
three O
- O
step O
approach O
with O
a O
rhodium B
- O
catalyzed O
hydroformylation O
as O
the O
key O
step O
. O

Although O
the O
tumor O
- O
promoting O
effects O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
coplanar O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
and O
related O
compounds O
in O
liver O
tissue O
are O
primarily O
attributed O
to O
the O
activation O
of O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
, O
the O
underlying O
molecular O
mechanisms O
are O
still O
unclear O
. O

Water O
- O
soluble O
star O
- O
like O
poly B
( I
vinyl I
alcohol I
) I
/ O
C B
( I
60 I
) I
and O
poly B
{ I
[ I
poly I
( I
ethylene I
glycol I
) I
acrylate I
] I
- I
co I
- I
( I
vinyl I
acetate I
) I
} I
/ O
C B
( I
60 I
) I
nanohybrids O
are O
prepared O
by O
grafting O
macroradicals O
onto O
C B
( I
60 I
) I
and O
are O
assessed O
as O
photosensitizers O
for O
photodynamic O
therapy O
. O

The O
advantages O
of O
both O
nanohybrids O
are O
encountered O
in O
a O
third O
one O
, O
poly B
[ I
( I
N I
- I
vinylpyrrolidone I
) I
- I
co I
- I
( I
vinyl I
acetate I
) I
] I
/ O
C B
( I
60 I
) I
, O
which O
has O
linear O
grafts O
without O
hydroxyl B
groups O
, O
and O
shows O
a O
better O
photodynamic O
activity O
. O

In O
the O
present O
studies O
, O
the O
effects O
of O
CB O
( O
1 O
) O
agonists O
[ O
( B
6aR I
, I
10aR I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
6 I
, I
6 I
, I
9 I
- I
trimethyl I
- I
6a I
, I
7 I
, I
10 I
, I
10a I
- I
tetrahydrobenzo I
[ I
c I
] I
chromen I
- I
1 I
- I
ol I
( O
AM411 B
) O
, O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
( O
AM4054 B
) O
, O
R B
- I
( I
+ I
) I
- I
[ I
2 I

In O
the O
present O
studies O
, O
the O
effects O
of O
CB O
( O
1 O
) O
agonists O
[ O
( B
6aR I
, I
10aR I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
6 I
, I
6 I
, I
9 I
- I
trimethyl I
- I
6a I
, I
7 I
, I
10 I
, I
10a I
- I
tetrahydrobenzo I
[ I
c I
] I
chromen I
- I
1 I
- I
ol I
( O
AM411 B
) O
, O
9 B
beta I
- I
( I
hydroxymethyl I
) I
- I
3 I
- I
( I
1 I
- I
adamantyl I
) I
- I
hexahydrocannabinol I
( O
AM4054 B
) O
, O
R B
- I
( I
+ I
) I
- I
[ I
2 I

, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
( O
WIN55 B
, I
212 I
. I
2 I
) O
, O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta B
( I
9 I
) I
- I
THC I
) O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
arachidonyl I
- I
1 I
' I
- I
hydroxy I
- I
2 I
' I
- I

propylamide I
( I
methanandamide I
) I
] O
, O
CB O
( O
1 O
) O
antagonists O
[ O
5 B
- I
( I
4 I
- I
chlorophenyl I
) I
- I
1 I
- I
( I
2 I
, I
4 I
- I
dichloro I
- I
phenyl I
) I
- I
4 I
- I
methyl I
- I
N I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
SR141716A B
) O
, O
5 B
- I
( I
4 I
- I
alkylphenyl I
) I
- I
1 I
- I
( I
2 I
, I
4 I
- I
dichlorophenyl I
) I
- I
4 I
- I
methyl I
- I
N I
- I
( I

piperidin I
- I
1 I
- I
yl I
) I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
AM4113 B
) O
] O
, O
and O
dopamine B
( O
DA O
) O
- O
related O
[ O
methamphetamine B
, O
( B
+ I
/ I
- I
) I
- I
6 I
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrobromide I
( O
SKF82958 B
) O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
7 I

piperidin I
- I
1 I
- I
yl I
) I
- I
1H I
- I
pyrazole I
- I
3 I
- I
carboxamide I
( O
AM4113 B
) O
] O
, O
and O
dopamine B
( O
DA O
) O
- O
related O
[ O
methamphetamine B
, O
( B
+ I
/ I
- I
) I
- I
6 I
- I
chloro I
- I
7 I
, I
8 I
- I
dihydroxy I
- I
3 I
- I
allyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrobromide I
( O
SKF82958 B
) O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
7 I

- I
chloro I
- I
8 I
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrochloride I
( O
SCH23390 B
) O
, O
( B
6aR I
) I
- I
5 I
, I
6 I
, I
6a I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
propyl I
- I
4H I
- I
dibenzo I
[ I
de I
, I
g I
] I
quinoline I
- I
10 I
, I
11 I
- I
diol I
( O
R B
- I
( I
- I
) I
- I
NPA I
) O
, O
haloperidol B
] O
and O

- I
chloro I
- I
8 I
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrochloride I
( O
SCH23390 B
) O
, O
( B
6aR I
) I
- I
5 I
, I
6 I
, I
6a I
, I
7 I
- I
tetrahydro I
- I
6 I
- I
propyl I
- I
4H I
- I
dibenzo I
[ I
de I
, I
g I
] I
quinoline I
- I
10 I
, I
11 I
- I
diol I
( O
R B
- I
( I
- I
) I
- I
NPA I
) O
, O
haloperidol B
] O
and O

Glycosides O
of O
( B
Z I
) I
- I
3 I
- I
hexen I
- I
1 I
- I
ol I
and O
hexanol B
( O
green O
- O
note O
volatiles O
) O
were O
present O
in O
considerable O
amounts O
. O

GC O
- O
olfactometry O
analysis O
of O
the O
hydrolysates O
of O
ripe O
' O
Hayward O
' O
and O
' O
Hort16A O
' O
revealed O
the O
presence O
of O
2 B
- I
phenylethanol I
, O
beta B
- I
damascenone I
, O
vanillin B
and O
2 B
, I
5 I
- I
dimethyl I
- I
4 I
- I
hydroxy I
- I
3 I
( I
2H I
) I
- I
furanone I
( O
DMHF B
) O
. O

( B
- I
) I
- I
6 I
- I
( I
7 I
- I
Methoxy I
- I
2 I
- I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyridin I
- I
4 I
- I
yl I
) I
- I
5 I
- I
methyl I
- I
4 I
, I
5 I
- I
dihydropyridazin I
- I
3 I
( I
2H I
) I
- I
one I
( O
KCA B
- I
1490 I
) O
exhibits O
moderate O
dual O
PDE3 O
/ O
4 O
- O
inhibitory O
activity O
and O
promises O
as O
a O
combined O
bronchodilatory O
/ O
anti O
- O
inflammatory O
agent O
. O

Addition O
of O
a O
6 B
- I
aryl I
- I
4 I
, I
5 I
- I
dihydropyridazin I
- I
3 I
( I
2H I
) I
- I
one I
extension O
to O
the O
N B
- O
alkyl O
group O
facilitates O
both O
enhancement O
of O
PDE4 O
- O
inhibitory O
activity O
and O
restoration O
of O
potent O
PDE3 O
inhibition O
. O

The O
self O
- O
assembling O
co O
- O
polymer O
stearoyl B
- I
PEG I
- I
poly I
- I
sulfadimethoxine I
methacrylate I
( O
stearoyl B
- I
PEG I
- I
polySDM I
) O
was O
prepared O
to O
obtain O
micelles O
with O
responsive O
behaviour O
in O
the O
physiopathologic O
pH O
range O
. O

Fenamiphos B
( O
ethyl B
4 I
- I
methylthio I
- I
m I
- I
tolyl I
isopropylphosphorami I
) O
is O
a O
racemic O
organophosphorus B
nematicide O
widely O
used O
in O
agriculture O
around O
the O
world O
. O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

The O
aim O
of O
this O
work O
is O
to O
evaluate O
vitamins B
B I
antimutagenic O
effect O
against O
alkylatings O
methyl B
- I
N I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
( O
MNNG B
) O
, O
ethyl B
- I
N I
- I
nitro I
- I
N I
' I
- I
nitrosoguanidine I
( O
ENNG B
) O
, O
frameshift O
mutagens O
2 B
- I
aminoanthracene I
( O
2AA B
) O
and O
2 B
- I
acetyl I
- I
amino I
- I
fluorene I
( O
2AF B
) O
and O
ROS O
- O
generating O
antibiotics O
norfloxacin B
( O
NOR B
) O
and O
nalidixic B
acid I
( O
NLX B
) O
, O
using O

Much O
work O
has O
been O
focused O
on O
aprotic O
Li B
- I
O I
( I
2 I
) I
cells O
( O
mostly O
with O
carbonate B
- O
based O
electrolytes O
and O
Li B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
potential O
discharge O
product O
) O
, O
where O
large O
overpotentials O
are O
observed O
and O
a O
complex O
cell O
chemistry O
is O
found O
. O

A O
series O
of O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
phenyl I
- I
3 I
- I
oxoprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
4 O
) O
and O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
phenylprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
5 O
) O
were O
synthesized O
and O
evaluated O
for O
their O
IL O
- O
5 O
inhibitory O
activity O
. O

A O
series O
of O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
phenyl I
- I
3 I
- I
oxoprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
4 O
) O
and O
( B
E I
) I
- I
5 I
- I
alkoxy I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
phenylprop I
- I
1 I
- I
enyl I
) I
- I
4H I
- I
chromen I
- I
4 I
- I
ones I
( O
5 O
) O
were O
synthesized O
and O
evaluated O
for O
their O
IL O
- O
5 O
inhibitory O
activity O
. O

Synthesis O
, O
antibacterial O
activity O
and O
docking O
of O
14 B
- I
membered I
9 I
- I
O I
- I
( I
3 I
- I
arylalkyl I
) I
oxime I
11 I
, I
12 I
- I
cyclic I
carbonate I
ketolides I
. O

A O
series O
of O
9 B
- I
O I
- I
( I
3 I
- I
aryl I
- I
2 I
- I
propargyl I
) I
oxime I
ketolides I
8 O
was O
synthesized O
and O
evaluated O
for O
in O
vitro O
antibacterial O
activity O
. O

Hybrid O
compound O
N B
' I
- I
( I
4 I
- I
phenyl I
- I
3 I
- I
furoxanylmethylidene I
) I
isoniazide I
9 O
showed O
the O
best O
antibacterial O
profile O
with O
MIC O
value O
4 O
. O
5 O
lesser O
than O
the O
value O
for O
the O
reference O
isoniazid B
against O
MDR O
strain O
. O

Furoxanyl B
N I
- I
acylhydrazone I
( B
E I
) I
- I
2 I
- I
methyl I
- I
N I
' I
- I
( I
4 I
- I
phenyl I
- I
3 I
- I
furoxanylmethylidene I
) I
- I
4H I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
pyridine I
- I
3 I
- I
carbohydrazide I
15 O
was O
ten O
- O
fold O
more O
potent O
against O
T O
. O
cruzi O
Amastigotes O
than O
the O
standard O
drug O
nifurtimox O
. O

On O
the O
other O
hand O
, O
derivatives O
( B
E I
) I
- I
N I
' I
- I
( I
5 I
- I
benzofuroxanylmethyl I
) I
benzo I
[ I
d I
] I
[ I
1 I
, I
3 I
] I
dioxole I
- I
5 I
- I
carbohydrazide I
25 O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenylmethyli I
) I
- I
3 I
- I
methylfuroxan I
- I
4 I
- I
carbohydrazide I
37 O
emerged O
as O
leads O
for O
the O
development O
of O
new O
leishmanicidal O
agents O
. O

On O
the O
other O
hand O
, O
derivatives O
( B
E I
) I
- I
N I
' I
- I
( I
5 I
- I
benzofuroxanylmethyl I
) I
benzo I
[ I
d I
] I
[ I
1 I
, I
3 I
] I
dioxole I
- I
5 I
- I
carbohydrazide I
25 O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
methoxyphenylmethyli I
) I
- I
3 I
- I
methylfuroxan I
- I
4 I
- I
carbohydrazide I
37 O
emerged O
as O
leads O
for O
the O
development O
of O
new O
leishmanicidal O
agents O
. O

We O
report O
that O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
significantly O
impairs O
this O
regeneration O
. O

On O
the O
basis O
of O
a O
vertically O
aligned O
ultralong O
Pb B
( I
Zr I
( I
0 I
. I
52 I
) I
Ti I
( I
0 I
. I
48 I
) I
) I
O I
( I
3 I
) I
( O
PZT B
) O
nanowire O
array O
fabricated O
using O
electrospinning O
nanofibers O
, O
we O
developed O
a O
new O
type O
of O
integrated O
nanogenerator O
( O
NG O
) O
with O
ultrahigh O
output O
voltage O
of O
209 O
V O
and O
current O
density O
of O
23 O
. O
5 O
mu O
A O
/ O
cm O
( O
2 O
) O
, O
which O
are O
3 O
. O
6 O
times O
and O
2 O
. O
9 O
times O
of O
the O
previous O
record O
values O
, O
respectively O
. O

Herein O
, O
the O
present O
article O
reports O
the O
novel O
multifunctional O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
/ O
SiO B
( I
2 I
) I
/ O
Au B
core O
- O
shell O
microspheres O
that O
display O
long O
- O
range O
plasmon O
transfer O
of O
Ag B
to O
Au B
leading O
to O
enhanced O
Raman O
scattering O
. O

As O
a O
result O
, O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
/ O
SiO B
( I
2 I
) I
/ O
Au B
microspheres O
have O
the O
best O
enhancement O
effect O
in O
the O
Raman O
active O
research O
by O
using O
Rhodamine B
- I
b I
( O
RdB B
) O
as O
a O
probe O
molecule O
. O

The O
enhancement O
factor O
is O
estimated O
to O
be O
2 O
. O
2 O
x O
10 O
( O
4 O
) O
for O
RdB B
from O
the O
long O
- O
range O
plasmon O
transfer O
of O
Ag B
to O
Au B
, O
corresponding O
to O
an O
attenuation O
of O
the O
enhancement O
by O
a O
factor O
of O
only O
0 O
. O
672 O
x O
10 O
( O
4 O
) O
compared O
to O
RdB B
adsorbed O
directly O
on O
the O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
@ O
Ag B
microspheres O
. O

Key O
reactions O
in O
the O
synthesis O
include O
desymmetrization O
of O
the O
bis B
( I
dimethylamide I
) I
unit O
of O
tartaric B
acid I
, O
Zn B
( I
BH I
( I
4 I
) I
) I
( I
2 I
) I
- O
mediated O
anti O
- O
selective O
reduction O
, O
and O
a O
Horner O
- O
Wadsworth O
- O
Emmons O
olefination O
. O

This O
smart O
fluid O
is O
an O
aqueous O
solution O
of O
cationic O
surfactant O
oleyl B
bis I
( I
2 I
- I
hydroxyethyl I
) I
methyl I
ammonium I
chloride I
( O
OHAC B
, O
3 O
. O
4 O
mM O
) O
and O
the O
sodium B
salt O
of O
4 B
- I
phenylazo I
benzoic I
acid I
( O
ACA B
, O
2 O
mM O
) O
. O

We O
found O
ADP B
- O
ribosylating O
activity O
for O
the O
SCO5461 O
protein O
product O
through O
its O
co O
- O
incubation O
with O
guanosine B
and O
NAD B
( I
+ I
) I
, O
which O
resulted O
in O
the O
formation O
of O
N B
( I
2 I
) I
- I
( I
ADP I
- I
ribos I
- I
1 I
- I
yl I
) I
- I
guanosine I
( O
( B
ar2 I
) I
Guo I
) O
, O
with O
a O
K O
( O
m O
) O
value O
of O
110 O
mu O
M O
. O

We O
have O
shown O
that O
E O
( O
2 O
) O
at O
physiological O
concentrations O
prevented O
apoptosis O
induced O
by O
H B
( I
2 I
) I
O I
( I
2 I
) I
in O
C2C12 O
skeletal O
myoblasts O
. O

Pretreatment O
with O
E O
( O
2 O
) O
prevented O
MPTP O
opening O
induced O
by O
H B
( I
2 I
) I
O I
( I
2 I
) I
, O
which O
preceded O
loss O
of O
mitochondrial O
membrane O
potential O
. O

In O
addition O
, O
it O
was O
observed O
that O
H B
( I
2 I
) I
O I
( I
2 I
) I
induced O
translocation O
of O
Bax O
to O
mitochondria O
; O
however O
, O
in O
the O
presence O
of O
the O
steroid B
this O
effect O
was O
abrogated O
suggesting O
that O
members O
of O
the O
Bcl O
- O
2 O
family O
may O
be O
regulated O
by O
E O
( O
2 O
) O
to O
exert O
an O
antiapoptotic O
effect O
. O

3 B
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
2 I
- I
[ I
3 I
- I
( I
4 I
- I
nitrophenyl I
) I
ureido I
] I
propanamide I
enantiomers O
with O
human O
formyl B
- O
peptide O
receptor O
agonist O
activity O
: O
molecular O
modeling O
of O
chiral O
recognition O
by O
FPR2 O
. O

Unlike O
previously O
reported O
6 B
- I
methyl I
- I
2 I
, I
4 I
- I
disubstituted I
pyridazin I
- I
3 I
( I
2H I
) I
- I
ones I
, O
whose O
R O
- O
forms O
preferentially O
activated O
FPR1 O
/ O
FPR2 O
, O
we O
found O
that O
four O
S O
- O
enantiomers O
in O
the O
seven O
ureidopropanamide B
pairs O
tested O
preferentially O
activated O
intracellular O
Ca B
( I
2 I
+ I
) I
flux O
in O
FPR2 O
- O
transfected O
cells O
, O
while O
the O
R O
- O
counterpart O
was O
more O
active O
in O
two O
enantiomer O
pairs O
. O

This O
study O
investigated O
cytotoxicity O
, O
endocrine O
disruption O
, O
effects O
mediated O
via O
AhR O
, O
lipid O
peroxidation O
and O
effects O
on O
expression O
of O
enzymes O
of O
xenobiotic O
metabolism O
caused O
by O
di B
- I
( I
2 I
- I
ethy I
hexyl I
) I
phthalate I
( O
DEHP B
) O
, O
diethyl B
phthalate I
( O
DEP B
) O
, O
dibutyl B
phthalate I
( O
DBP B
) O
and O
benzyl B
butyl I
phthalate I
( O
BBP B
) O
in O
developing O
fish O
embryos O
. O

Also O
, O
the O
DOX B
modulatory O
effect O
on O
choline B
uptake O
transport O
system O
was O
assessed O
by O
measuring O
the O
uptake O
of O
[ B
( I
3 I
) I
H I
] I
- I
choline I
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
NAD B
( I
+ I
) I
- O
dependent O
protein O
N B
( I
epsilon I
) I
- I
acetyl I
- I
lysine I
( O
AcK B
) O
deacetylases O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
novel O
11 B
, I
4 I
' I
' I
- I
disubstituted I
azithromycin I
analogs O
with O
greatly O
improved O
activity O
against O
erythromycin B
- O
resistant O
bacteria O
. O

A O
series O
of O
novel O
11 B
, I
4 I
' I
' I
- I
disubstituted I
azithromycin I
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
antibacterial O
activity O
. O

Neutral O
and O
charged O
phosphine B
/ I
scorpionate I
copper I
( I
I I
) I
complexes I
: O
effects O
of O
ligand O
assembly O
on O
their O
antiproliferative O
activity O
. O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

Ligand O
- O
exchange O
reactions O
of O
copper B
( I
I I
) I
precursors O
( O
[ B
Cu I
( I
CH I
( I
3 I
) I
CN I
) I
( I
4 I
) I
] I
BF I
( I
4 I
) I
, O
CuCl B
) O
with O
a O
panel O
of O
bis B
( I
azolyl I
) I
borates I
or O
poly B
( I
pyrazolyl I
) I
methanes I
and O
a O
tertiary B
monodentate I
phosphine I
( O
PTA B
= O
1 B
, I
3 I
, I
5 I
- I
triaza I
- I
7 I
- I
phosphaadamantane I
, O
PCN B
= O
tris B
( I
cyanoethyl I
) I
phosphine I
) O
produced O
two O
series O
of O
heteroleptic O
, O

Conversely O
, O
' O
2 O
+ O
1 O
+ O
1 O
' O
complexes O
exhibit O
increased O
propensity O
to O
dissociation O
as O
shown O
by O
ESI O
- O
MS O
measurements O
and O
X O
- O
ray O
structure O
determination O
at O
low O
temperature O
( O
150 O
K O
) O
of O
the O
polymeric O
complex O
{ B
[ I
H I
( I
2 I
) I
B I
( I
tz I
( I
NO2 I
) I
) I
( I
2 I
) I
] I
Cu I
[ I
PCN I
] I
} I
( I
n I
) I
6b O
. O

We O
identified O
one O
compound O
, O
E235 B
( B
N I
- I
( I
1 I
- I
benzyl I
- I
piperidin I
- I
4 I
- I
yl I
) I
- I
2 I
- I
( I
4 I
- I
fluoro I
- I
phenyl I
) I
- I
benzo I
[ I
d I
] I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
7 I
- I
carboxamide I
) I
, O
that O
activated O
the O
ISR O
and O
dose O
- O
dependently O
increased O
levels O
of O
ATF4 O
in O
transformed O
cells O
. O

By O
analyses O
of O
the O
MS O
, O
IR O
, O
UV O
, O
1D O
and O
2D O
NMR O
data O
, O
the O
two O
new O
compounds O
were O
identified O
as O
3 B
beta I
, I
4 I
alpha I
- I
dihydroxy I
- I
1 I
- I
( I
3 I
- I
phenylpropanoyl I
) I
- I
piperidine I
- I
2 I
- I
one I
( O
1 O
) O
and O
( B
2E I
, I
4E I
, I
14Z I
) I
- I
6 I
- I
hydroxyl I
- I
N I
- I
isobutyleicosa I
- I
2 I
, I
4 I
, I
14 I
- I
trienamide I
( O
2 O
) O
. O

By O
analyses O
of O
the O
MS O
, O
IR O
, O
UV O
, O
1D O
and O
2D O
NMR O
data O
, O
the O
two O
new O
compounds O
were O
identified O
as O
3 B
beta I
, I
4 I
alpha I
- I
dihydroxy I
- I
1 I
- I
( I
3 I
- I
phenylpropanoyl I
) I
- I
piperidine I
- I
2 I
- I
one I
( O
1 O
) O
and O
( B
2E I
, I
4E I
, I
14Z I
) I
- I
6 I
- I
hydroxyl I
- I
N I
- I
isobutyleicosa I
- I
2 I
, I
4 I
, I
14 I
- I
trienamide I
( O
2 O
) O
. O

A O
series O
of O
GPR119 O
agonists O
based O
on O
a O
2 B
, I
6 I
- I
diazatricyclo I
[ I
3 I
. I
3 I
. I
1 I
. I
1 I
~ I
3 I
, I
7 I
~ I
] I
decane I
ring O
system O
is O
described O
. O

The O
basis O
for O
the O
use O
of O
this O
complex O
framework O
lies O
in O
an O
attempt O
to O
constrain O
one O
end O
of O
the O
molecule O
in O
the O
" O
agonist O
conformation O
" O
as O
was O
previously O
described O
for O
3 B
- I
oxa I
- I
7 I
- I
aza I
- I
bicyclo I
[ I
3 I
. I
3 I
. I
1 I
] I
nonanes I
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine B
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine B
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

Here O
we O
report O
the O
functionalization O
of O
monodisperse O
iron B
oxide I
nanoparticles O
( O
NPs O
) O
with O
commercially O
available O
functional O
acids O
containing O
multiple O
double O
bonds O
such O
as O
linolenic B
( I
LLA I
) I
and I
linoleic I
( I
LEA I
) I
acids I
or O
pyridine B
moieties O
such O
as O
6 B
- I
methylpyridine I
- I
2 I
- I
carboxylic I
acid I
, O
isonicotinic B
acid I
, O
3 B
- I
hydroxypicolinic I
acid I
, O
and O
6 B
- I
( I
1 I
- I
piperidinyl I
) I
pyridine I
- I
3 I
- I
carboxlic I
acid I
( O
PPCA B
) O
. O

We O
determined O
that O
both O
LLA B
and O
LEA B
stabilize O
magnetic O
iron B
oxide I
NPs O
, O
allowing O
the O
formation O
of O
pi O
- O
complexes O
with O
bis B
( I
acetonitrile I
) I
dichloropalladium I
( I
II I
) I
in O
the O
NP O
shells O
. O

The O
most O
potent O
of O
these O
compounds O
is O
ethyl B
2 I
- I
( I
N I
- I
( I
( I
4 I
- I
iodo I
- I
6 I
- I
methoxypyrimidin I
- I
2 I
- I
yl I
) I
carbamoyl I
) I
sulfamoyl I
) I
benzoate I
( O
10c O
) O
, O
which O
has O
a O
K O
( O
i O
) O
value O
of O
3 O
. O
8 O
nM O
for O
C O
. O
albicans O
AHAS O
and O
an O
MIC O
9 O
0 O
of O
0 O
. O
7 O
mu O
g O
/ O
mL O
for O
this O
fungus O
in O
cell O
- O
based O
assays O
. O

This O
study O
demonstrates O
that O
chelidonine B
and O
an O
alkaloid O
extract O
from O
Chelidonium O
majus O
, O
which O
contains O
protoberberine B
and I
benzo I
[ I
c I
] I
phenanthridine I
alkaloids I
, O
has O
the O
ability O
to O
overcome O
MDR O
of O
different O
cancer O
cell O
lines O
through O
interaction O
with O
ABC O
- O
transporters O
, O
CYP3A4 O
and O
GST O
, O
by O
induction O
of O
apoptosis O
, O
and O
cytotoxic O
effects O
. O

Caught O
in O
the O
act O
: O
The O
FRET O
- O
Capture O
approach O
exploits O
a O
bound O
solvatochromic O
fluorophore O
, O
4 B
- I
N I
, I
N I
- I
dimethylamino I
- I
1 I
, I
8 I
- I
naphthalimide I
, O
as O
a O
FRET O
donor O
in O
both O
inter O
- O
and O
intramolecular O
energy O
transfer O
. O

3 B
, I
14 I
- I
Bis I
( I
p I
- I
nitrophenyl I
) I
- I
17 I
, I
17 I
- I
dipentyltetrabenzo I
[ I
a I
, I
c I
, I
g I
, I
i I
] I
- I
fluorene I
: O
a O
new O
fluorophore O
displaying O
both O
remarkable O
solvatochromism O
and O
crystalline O
- O
induced O
emission O
. O

A O
series O
of O
17 B
, I
17 I
- I
dialkyl I
- I
3 I
, I
14 I
- I
diaryltetrabenzofluo I
were O
efficiently O
prepared O
by O
using O
Suzuki O
- O
Miyaura O
cross O
- O
coupling O
reactions O
of O
the O
corresponding O
3 B
, I
14 I
- I
dibromo I
derivatives O
. O

Using O
a O
rapid O
, O
high O
- O
throughput O
polymerization O
and O
screening O
platform O
with O
a O
comprehensive O
library O
of O
66 O
monomer O
- O
grafted O
membrane O
surfaces O
, O
the O
optimal O
substrate O
, O
N B
- I
[ I
3 I
- I
( I
dimethylamino I
) I
propyl I
] I
methacrylamide I
( O
DMAPMA B
) O
has O
been O
identified O
to O
support O
strong O
attachment O
, O
high O
expansion O
capacity O
, O
and O
long O
- O
term O
self O
- O
renewal O
of O
ES O
cells O
( O
up O
to O
7 O
passages O
) O
. O

In O
addition O
, O
GaAs B
was O
found O
to O
grow O
perfectly O
as O
a O
shell O
layer O
on O
In B
( I
0 I
. I
2 I
) I
Ga I
( I
0 I
. I
8 I
) I
As I
with O
an O
extraordinary O
thickness O
, O
which O
is O
15 O
times O
greater O
than O
the O
theoretical O
thin O
- O
film O
critical O
thickness O
for O
a O
1 O
. O
5 O
% O
lattice O
mismatch O
. O

A O
comparative O
study O
of O
the O
rotational O
dynamics O
of O
PF6 B
( I
- I
) I
anions O
in O
the O
crystals O
and O
liquid O
states O
of O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
: O
results O
from O
31P B
NMR O
spectroscopy O
. O

The O
rotational O
dynamics O
of O
the O
hexafluorophosphate B
anion O
( O
PF B
( I
6 I
) I
( I
- I
) I
) O
in O
the O
crystalline O
and O
liquid O
states O
of O
the O
archetypal O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
4 I
) I
mim I
] I
PF I
( I
6 I
) I
) O
are O
investigated O
using O
( B
31 I
) I
P I
NMR O
spectroscopy O
line O
shape O
analyses O
and O
spin O
- O
lattice O
relaxation O
time O
measurements O
. O

The O
rotational O
dynamics O
of O
the O
hexafluorophosphate B
anion O
( O
PF B
( I
6 I
) I
( I
- I
) I
) O
in O
the O
crystalline O
and O
liquid O
states O
of O
the O
archetypal O
room O
temperature O
ionic O
liquid O
( O
RTIL O
) O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
4 I
) I
mim I
] I
PF I
( I
6 I
) I
) O
are O
investigated O
using O
( B
31 I
) I
P I
NMR O
spectroscopy O
line O
shape O
analyses O
and O
spin O
- O
lattice O
relaxation O
time O
measurements O
. O

A O
new O
gemini O
surfactant O
with O
a O
long O
and O
rigid O
spacer O
, O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
dibenzenediol I
( O
referred O
to O
as O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
) O
, O
has O
been O
synthesized O
. O

A O
new O
gemini O
surfactant O
with O
a O
long O
and O
rigid O
spacer O
, O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
dibenzenediol I
( O
referred O
to O
as O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
) O
, O
has O
been O
synthesized O
. O

The O
homologue O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
benzenediol I
( O
C B
( I
12 I
) I
phi I
C I
( I
12 I
) I
) O
whose O
spacer O
only O
contains O
a O
single O
phenyl B
group O
was O
also O
examined O
for O
comparison O
. O

The O
homologue O
O B
, I
O I
' I
- I
bis I
( I
sodium I
2 I
- I
dodecylcarboxylate I
) I
- I
p I
- I
benzenediol I
( O
C B
( I
12 I
) I
phi I
C I
( I
12 I
) I
) O
whose O
spacer O
only O
contains O
a O
single O
phenyl B
group O
was O
also O
examined O
for O
comparison O
. O

Dynamic O
light O
scattering O
( O
DLS O
) O
revealed O
the O
unexpected O
existence O
of O
large O
aggregates O
in O
the O
solution O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
. O

However O
, O
C B
( I
12 I
) I
phi I
C I
( I
12 I
) I
showed O
rather O
normal O
aggregation O
behavior O
. O

Both O
the O
results O
of O
intrinsic O
viscosity O
and O
light O
scattering O
demonstrated O
a O
loose O
structure O
for O
the O
large O
aggregates O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
. O

This O
behavior O
was O
attributed O
to O
an O
extending O
configuration O
of O
C B
( I
12 I
) I
phi I
( I
2 I
) I
C I
( I
12 I
) I
with O
the O
two O
alkyl B
tails O
stretching O
toward O
the O
solution O
due O
to O
the O
rigidity O
of O
the O
long O
spacer O
. O

A O
dimeric O
form O
of O
N B
- I
methoxycarbonyl I
- I
2 I
- I
amino I
- I
1 I
, I
8 I
- I
naphthyridine I
bound O
to O
the O
A O
- O
A O
mismatch O
in O
the O
CAG O
/ O
CAG O
base O
triad O
in O
dsRNA O
. O

A O
dimeric O
form O
of O
N B
- I
methoxycarbonyl I
- I
2 I
- I
amino I
- I
1 I
, I
8 I
- I
naphthyridine I
( O
MCND B
) O
connected O
at O
the O
C2 O
position O
with O
a O
three O
- O
atom O
linker O
was O
examined O
for O
the O
binding O
to O
mismatches O
in O
double O
stranded O
RNA O
. O

CAs O
were O
passively O
encapsulated O
with O
323 O
mOs O
kg O
( O
- O
1 O
) O
into O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphodiglycerol I
50 O
/ O
20 O
/ O
30 O
( O
mol O
/ O
mol O
) O
TSL O
( O
DPPG B
( I
2 I
) I
- O
TSL O
) O

CAs O
were O
passively O
encapsulated O
with O
323 O
mOs O
kg O
( O
- O
1 O
) O
into O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphodiglycerol I
50 O
/ O
20 O
/ O
30 O
( O
mol O
/ O
mol O
) O
TSL O
( O
DPPG B
( I
2 I
) I
- O
TSL O
) O

CAs O
were O
passively O
encapsulated O
with O
323 O
mOs O
kg O
( O
- O
1 O
) O
into O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
/ O
1 B
, I
2 I
- I
dipalmitoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphodiglycerol I
50 O
/ O
20 O
/ O
30 O
( O
mol O
/ O
mol O
) O
TSL O
( O
DPPG B
( I
2 I
) I
- O
TSL O
) O

Disruption O
of O
planarity O
at O
the O
aglycone O
moiety O
by O
3 O
- O
bromination O
or O
chlorination O
afforded O
3 B
- I
bromo I
- I
and I
3 I
- I
chlorodiosmin I
, O
displaying O
a O
dramatic O
solubility O
increase O
compared O
with O
the O
parent O
compound O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 B
- I
( I
2 I
- I
hydroxyethyl I
) I
piperazine I
- I
1 I
- I
ethanesulfonic I
acid I
( O
HEPES B
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran B
( O
THF B
) O
, O
1 B
, I
3 I
- I
dioxolane I
, I
1 I
, I
4 I
- I
dioxane I
, I
1 I
- I
propanol I
, O
2 B
- I
propanol I
, O
tert B
- I
butanol I
, O
acetonitrile B
, O
or O
acetone B
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

Here O
, O
for O
the O
first O
time O
, O
we O
show O
that O
with O
addition O
of O
a O
biological O
buffer O
, O
4 B
- I
( I
2 I
- I
hydroxyethyl I
) I
piperazine I
- I
1 I
- I
ethanesulfonic I
acid I
( O
HEPES B
) O
, O
into O
aqueous O
solutions O
of O
tetrahydrofuran B
( O
THF B
) O
, O
1 B
, I
3 I
- I
dioxolane I
, I
1 I
, I
4 I
- I
dioxane I
, I
1 I
- I
propanol I
, O
2 B
- I
propanol I
, O
tert B
- I
butanol I
, O
acetonitrile B
, O
or O
acetone B
, O
the O
organic O
solvent O
can O
be O
excluded O
from O
water O
to O
form O
a O
new O
liquid O
phase O
. O

Superconductivity O
in O
the O
cuprate O
YBa B
( I
2 I
) I
Cu I
( I
3 I
) I
O I
( I
7 I
) I
( O
YBCO B
) O
persists O
up O
to O
huge O
magnetic O
fields O
( O
B O
) O
up O
to O
several O
tens O
of O
Teslas O
, O
and O
sensitive O
direct O
current O
( O
dc O
) O
superconducting O
quantum O
interference O
devices O
( O
SQUIDs O
) O
can O
be O
realized O
in O
epitaxially O
grown O
YBCO B
films O
by O
using O
grain O
boundary O
Josephson O
junctions O
( O
GBJs O
) O
. O

The O
photophysics O
of O
7 B
- I
( I
N I
, I
N I
' I
- I
diethylamino I
) I
coumarin I
- I
3 I
- I
carboxylic I
acid I
in O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
: O
an O
excitation O
wavelength O
dependent O
study O
. O

In O
this O
manuscript O
we O
have O
studied O
the O
photophysics O
of O
7 B
- I
( I
N I
, I
N I
' I
- I
diethylamino I
) I
coumarin I
- I
3 I
- I
carboxylic I
acid I
( O
7 B
- I
DCCA I
) O
in O
water O
/ O
AOT B
/ O
isooctane B
reverse O
micelles O
. O

Despite O
that O
separately O
molecule O
and O
nanoparticle O
are O
achiral O
and O
consequently O
optically O
inactive O
, O
the O
Ag B
( I
55 I
) I
- I
SCH I
( I
3 I
) I
compound O
emerges O
with O
a O
new O
symmetry O
, O
which O
may O
be O
chiral O
or O
not O
depending O
on O
the O
adsorption O
site O
and O
orientation O
of O
the O
molecule O
. O

For O
instance O
, O
crystals O
grown O
at O
the O
interface O
of O
a O
0 O
. O
01 O
% O
diglycerol B
monolaurate I
( O
C B
( I
12 I
) I
G I
( I
2 I
) I
) O
nonionic O
surfactant O
in O
butanol B
with O
benzene B
lead O
to O
the O
formation O
of O
flower O
- O
shaped O
microcrystals O
of O
average O
sizes O
in O
the O
range O
of O
10 O
- O
35 O
mu O
m O
. O

Mixtures O
of O
flower O
- O
shaped O
C B
( I
60 I
) I
crystals O
and O
free O
- O
standing O
C B
( I
60 I
) I
nanotubes O
are O
found O
in O
the O
0 O
. O
1 O
% O
C B
( I
12 I
) I
G I
( I
2 I
) I
/ O
butanol B
system O
. O

However O
, O
clusters O
or O
giant O
aggregates O
of O
nanowhiskers O
lacking O
any O
specific O
shape O
are O
observed O
in O
the O
1 O
% O
C B
( I
12 I
) I
G I
( I
2 I
) I
/ O
butanol O
system O
although O
these O
crystals O
exhibit O
hexagonal O
close O
- O
packed O
structures O
. O

Here O
we O
characterized O
a O
potent O
and O
selective O
mGlu O
( O
7 O
) O
negative O
allosteric O
modulator O
( O
NAM O
) O
( B
+ I
) I
- I
6 I
- I
( I
2 I
, I
4 I
- I
dimethylphenyl I
) I
- I
2 I
- I
ethyl I
- I
6 I
, I
7 I
- I
dihydrobenzo I
[ I
d I
] I
oxazol I
- I
4 I
( I
5H I
) I
- I
one I
( O
ADX71743 B
) O
. O

In O
vitro O
, O
Schild O
plot O
analysis O
and O
reversibility O
tests O
at O
the O
target O
confirmed O
the O
NAM O
properties O
of O
the O
compound O
and O
attenuation O
of O
L B
- I
( I
+ I
) I
- I
2 I
- I
amino I
- I
4 I
- I
phosphonobutyric I
acid I
- O
induced O
synaptic O
depression O
confirmed O
activity O
at O
the O
native O
receptor O
. O

Whereas O
ADX71743 B
caused O
a O
small O
reduction O
in O
amphetamine B
- O
induced O
hyperactivity O
in O
mice O
, O
it O
was O
inactive O
in O
the O
mouse O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
- O
induced O
head O
twitch O
and O
the O
rat O
conditioned O
avoidance O
response O
tests O
. O

Synthesis O
of O
substituted O
6 B
- I
amino I
- I
4 I
- I
( I
2 I
, I
4 I
- I
dimethoxyphenyl I
) I
- I
[ I
1 I
, I
2 I
] I
dithiolo I
[ I
4 I
, I
3 I
- I
b I
] I
pyrrol I
- I
5 I
- I
ones I
and O
their O
raising O
leukocyte O
count O
activities O
. O

The O
design O
and O
synthesis O
of O
a O
series O
of O
substituted O
6 B
- I
amino I
- I
4 I
- I
( I
2 I
, I
4 I
- I
dimethoxyphenyl I
) I
- I
[ I
1 I
, I
2 I
] I
dithiolo I
[ I
4 I
, I
3 I
- I
b I
] I
pyrrol I
- I
5 I
- I
ones I
are O
described O
. O

( B
4 I
, I
4 I
' I
) I
- I
Bipyridine I
in O
vacuo O
and O
in O
solvents O
: O
a O
quantum O
chemical O
study O
of O
a O
prototypical O
floppy O
molecule O
from O
a O
molecular O
transport O
perspective O
. O

We O
report O
results O
of O
quantum O
chemical O
calculations O
for O
the O
neutral O
and O
anionic O
species O
of O
( B
4 I
, I
4 I
' I
) I
- I
bipyridine I
( O
44BPY B
) O
, O
a O
prototypical O
molecule O
with O
a O
floppy O
degree O
of O
freedom O
, O
placed O
in O
vacuo O
and O
in O
solvents O
. O

5 B
- I
cholesten I
- I
3 I
beta I
, I
25 I
- I
diol I
3 I
- I
sulfate I
decreases O
lipid O
accumulation O
in O
diet O
- O
induced O
nonalcoholic O
fatty O
liver O
disease O
mouse O
model O
. O

We O
previously O
reported O
that O
a O
cholesterol B
metabolite O
, O
5 B
- I
cholesten I
- I
3 I
beta I
, I
25 I
- I
diol I
3 I
- I
sulfate I
( O
25HC3S B
) O
, O
inhibits O
the O
LXR O
alpha O
signaling O
and O
reduces O
lipogenesis O
by O
decreasing O
SREBP O
- O
1c O
expression O
in O
primary O
hepatocytes O
. O

In O
recent O
studies O
an O
enhancement O
of O
the O
ionic O
conductivity O
was O
indeed O
observed O
in O
micro O
- O
/ O
nanoscaled O
Y B
( I
2 I
) I
O I
( I
3 I
) I
- O
stabilised O
ZrO B
( I
2 I
) I
( O
YSZ B
) O
composites O
and O
hetero O
multilayers O
of O
thin O
films O
. O

In O
order O
to O
obtain O
independent O
information O
on O
the O
role O
of O
heterophase O
boundaries O
for O
fast O
transport O
in O
strained O
solid O
electrolytes O
, O
systematic O
measurements O
of O
the O
( B
18 I
) I
O I
- O
tracer O
diffusion O
coefficient O
in O
nanoscaled O
YSZ B
/ O
Y B
( I
2 I
) I
O I
( I
3 I
) I
multilayers O
were O
performed O
. O

Multilayer O
samples O
were O
prepared O
by O
Pulsed O
Laser O
Deposition O
( O
PLD O
) O
on O
( O
0001 O
) O
Al B
( I
2 I
) I
O I
( I
3 I
) I
substrates O
and O
characterised O
by O
X O
- O
Ray O
Diffraction O
( O
XRD O
) O
, O
Scanning O
Electron O
Microscopy O
( O
HRSEM O
) O
and O
Time O
- O
of O
- O
Flight O
Secondary O
Ion O
Mass O
Spectrometry O
( O
ToF O
- O
SIMS O
) O
. O

Here O
, O
iron B
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
, O
interpreted O
using O
a O
valence O
bond O
configuration O
interaction O
multiplet O
model O
, O
is O
applied O
to O
directly O
probe O
the O
electronic O
structure O
of O
the O
iron B
in O
the O
biomimetic O
Fe B
- O
O B
( I
2 I
) I
heme B
complex O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
( O
pfp B
( O
" O
picket B
fence I
porphyrin I
" O
) O
= O
meso B
- I
tetra I
( I
alpha I
, I
alpha I
, I
alpha I
, I
alpha I
- I
o I
- I
pivalamidophenyl I
) I
porphyrin I
or O
TpivPP B
) O
. O

Here O
, O
iron B
L O
- O
edge O
X O
- O
ray O
absorption O
spectroscopy O
, O
interpreted O
using O
a O
valence O
bond O
configuration O
interaction O
multiplet O
model O
, O
is O
applied O
to O
directly O
probe O
the O
electronic O
structure O
of O
the O
iron B
in O
the O
biomimetic O
Fe B
- O
O B
( I
2 I
) I
heme B
complex O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
( O
pfp B
( O
" O
picket B
fence I
porphyrin I
" O
) O
= O
meso B
- I
tetra I
( I
alpha I
, I
alpha I
, I
alpha I
, I
alpha I
- I
o I
- I
pivalamidophenyl I
) I
porphyrin I
or O
TpivPP B
) O
. O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp B
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp B
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp B
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

The O
L O
- O
edge O
spectrum O
of O
[ B
Fe I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
O I
( I
2 I
) I
] I
is O
further O
compared O
to O
those O
of O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
( I
1 I
- I
MeIm I
) I
( I
2 I
) I
] I
, O
[ B
Fe I
( I
II I
) I
( I
pfp I
) I
] I
, O
and O
[ B
Fe I
( I
III I
) I
( I
tpp I
) I
( I
ImH I
) I
( I
2 I
) I
] I
Cl I
( O
tpp B
= O
meso B
- I
tetraphenylporphyrin I
) O
which O
have O
Fe B
( I
II I
) I
S O
= O
0 O
, O
Fe B
( I
II I
) I
S O
= O
1 O
, O
and O
Fe B
( I
III I
) I
S O

Salsolinol B
( O
SAL B
) O
, O
a O
catechol B
isoquinoline I
has O
invited O
considerable O
attention O
due O
to O
its O
structural O
similarity O
with O
dopaminergic O
neurotoxin O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
. O

Synthesis O
, O
crystal O
structure O
and O
antidiabetic O
activity O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
one I
. O

A O
novel O
series O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
onewere I
synthesized O
starting O
from O
2 B
- I
aminobenzothiazole I
and O
1 B
- I
aryl I
- I
3 I
, I
3 I
- I
bis I
- I
( I
methylsulfanyl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
onesin I
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B
hydride I
in O
THF B
. O

A O
novel O
series O
of O
substituted O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
onewere I
synthesized O
starting O
from O
2 B
- I
aminobenzothiazole I
and O
1 B
- I
aryl I
- I
3 I
, I
3 I
- I
bis I
- I
( I
methylsulfanyl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
onesin I
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B
hydride I
in O
THF B
. O

These O
compounds O
were O
evaluated O
for O
their O
antidiabetic O
activity O
, O
and O
most O
of O
the O
derivatives O
of O
( B
E I
) I
- I
3 I
- I
( I
Benzo I
[ I
d I
] I
thiazol I
- I
2 I
- I
ylamino I
) I
phenylprop I
- I
2 I
- I
en I
- I
1 I
- I
one I
displayed O
significant O
antidiabetic O
activity O
. O

First O
, O
a O
multiblock O
backbone O
biodegradable O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
PTX B
conjugate O
( O
mP O
- O
PTX B
) O
with O
molecular O
weight O
( O
Mw O
) O
of O
335 O
kDa O
was O
synthesized O
by O
RAFT O
( O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
) O
copolymerization O
, O
followed O
by O
chain O
extension O
. O

C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
from O
stems O
and O
leaves O
of O
Paris O
polyphylla O
var O
. O
yunnanensis O
. O

Further O
phytochemical O
investigation O
on O
the O
stems O
and O
leaves O
of O
Paris O
polyphylla O
var O
. O
yunnanensis O
has O
led O
to O
the O
isolation O
of O
three O
C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
. O

This O
is O
the O
first O
report O
of O
C B
( I
22 I
) I
- I
steroidal I
lactone I
glycosides I
isolated O
from O
the O
Paris O
genus O
. O

When O
preincubated O
oocytes O
with O
phorbol B
- I
12 I
- I
myristate I
- I
13 I
- I
acetate I
( O
PMA B
, O
a O
PKC O
activator O
) O
were O
exposed O
to O
caffeine B
, O
PMA B
- O
induced O
increase O
in O
EAAT3 O
activity O
was O
abolished O
. O

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag B
( I

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag B
( I

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag B
( I

The O
electrochemical O
reduction O
of O
benzoic B
acid I
in O
the O
presence O
and O
absence O
of O
hydrogen B
( O
H B
( I
2 I
) I
) O
has O
been O
investigated O
using O
a O
10 O
mu O
m O
diameter O
platinum B
microelectrode O
in O
four O
different O
room O
temperature O
ionic O
liquids O
( O
RTILs O
) O
, O
namely O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mpyrr I
] I
[ I
NTf I
( I
2 I
) I
] I
, O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
OTf I
] I
and O
[ B
C I
( I
4 I
) I
mim I
] I
[ I
BF I
( I
4 I
) I
] I
, O
versus O
Ag B
/ O
Ag B
( I

Furthermore O
, O
the O
adsorbed O
H B
atoms O
, O
formed O
from O
the O
reduction O
of O
benzoic B
acid I
, O
could O
be O
used O
to O
achieve O
the O
rapid O
hydrogenolysis O
of O
the O
organic O
compound O
( O
bis B
( I
benzyloxycarbonyl I
) I
- I
l I
- I
lysine I
) O
on O
the O
timescale O
of O
the O
voltammetric O
technique O
under O
moderate O
conditions O
( O
25 O
degrees O
C O
) O
. O

Furthermore O
, O
we O
show O
for O
the O
first O
time O
that O
in O
the O
presence O
of O
iron B
and O
L B
- I
cysteine I
, O
an O
[ O
Fe B
( I
4 I
) I
S I
( I
4 I
) I
] O
cluster O
is O
formed O
within O
the O
quaternary O
complex O
that O
can O
be O
transferred O
to O
mammalian O
aconitase O
( O
mACO2 O
) O
to O
generate O
an O
active O
enzyme O
. O

The O
method O
explores O
the O
ABTS B
radical O
( O
2 B
, I
2 I
' I
- I
azinobis I
( I
3 I
- I
ethylbenzothiazoline I
- I
6 I
- I
sulphonic I
acid I
) I
) O
assay O
as O
a O
redox O
probe O
and O
it O
relays O
on O
measuring O
catalytic O
voltammetric O
currents O
. O

The O
electrocatalysis O
comprises O
redox O
regeneration O
of O
the O
electrochemically O
created O
ABTS B
( I
+ I
) I
radical O
either O
by O
Trolox B
( O
6 B
- I
hydroxy I
- I
2 I
, I
5 I
, I
7 I
, I
8 I
- I
tetramethychroman I
- I
2 I
- I
carboxylic I
acid I
) O
or O
by O
antioxidants O
present O
in O
studied O
oils O
. O

We O
have O
isolated O
the O
bacterial O
strain O
SY8519 O
, O
which O
has O
been O
shown O
to O
metabolize O
daidzein B
to O
O B
- I
desmethylangolensin I
and O
to O
produce O
2 B
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
genistein B
. O

According O
to O
chiral O
HPLC O
analysis O
, O
the O
2 B
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
obtained O
from O
the O
bacterium O
was O
optically O
active O
. O

To O
determine O
the O
absolute O
stereochemistry O
of O
the O
microbial O
product O
, O
we O
prepared O
( B
S I
) I
- I
2 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
propionic I
acid I
from O
( B
S I
) I
- I
2 I
- I
phenylpropionic I
and O
concluded O
that O
the O
microbial O
product O
had O
an O
R O
- O
configuration O
by O
chiral O
HPLC O
analysis O
. O

The O
ionic O
liquids O
with O
different O
cations O
and O
anions O
were O
investigated O
in O
this O
work O
and O
0 O
. O
5 O
M O
1 B
- I
butyl I
- I
3 I
- I
methylimidazolium I
bromide I
solution O
was O
selected O
as O
solvent O
. O

Comparative O
formation O
of O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
creatinine B
/ O
phenylalanine B
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
reaction O
mixtures O
. O

The O
comparative O
formation O
of O
the O
heterocyclic O
aromatic O
amine O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
in O
both O
creatinine B
/ O
phenylalanine B
( O
CRN B
/ O
Phe B
) O
and O
creatinine B
/ O
phenylalanine B
/ O
4 B
- I
oxo I
- I
2 I
- I
nonenal I
( O
CRN B
/ O
Phe B
/ O
ON O
) O
systems O
was O
studied O
to O
analyse O
the O
ability O
of O
lipid O
- O
derived O
reactive O
carbonyls B
to O
promote O
PhIP B
formation O
. O

CMs O
rapidly O
accumulated O
9 B
, I
10 I
- I
epoxy I
- I
18 I
- I
hydroxyoctadecanoic I
acid I
at O
a O
very O
early O
stage O
of O
leaf O
development O
. O

Highly O
selective O
separation O
of O
arsenite B
species O
[ O
As B
( I
III I
) I
] O
was O
achieved O
by O
chelation O
with O
sodium B
diethyldithiocarbama I
( O
DDTC B
) O
followed O
by O
dispersion O
with O
40 O
mg O
of O
1 B
- I
octyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
8 I
) I
mim I
] I
[ I
PF I
( I
6 I
) I
] I
) O
IL O
. O

Highly O
selective O
separation O
of O
arsenite B
species O
[ O
As B
( I
III I
) I
] O
was O
achieved O
by O
chelation O
with O
sodium B
diethyldithiocarbama I
( O
DDTC B
) O
followed O
by O
dispersion O
with O
40 O
mg O
of O
1 B
- I
octyl I
- I
3 I
- I
methylimidazolium I
hexafluorophosphate I
( O
[ B
C I
( I
8 I
) I
mim I
] I
[ I
PF I
( I
6 I
) I
] I
) O
IL O
. O

MRP O
obtained O
by O
ultrasound O
exhibited O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
scavenging O
activity O
and O
possessed O
increased O
iron B
- O
chelating O
activity O
and O
reducing O
power O
. O

The O
ripeness O
of O
the O
raw O
strawberries O
influences O
the O
concentrations O
of O
some O
of O
the O
compounds O
in O
the O
spreads O
, O
such O
as O
isobutyl B
acetate I
, O
butyl B
butyrate I
, O
3 B
- I
hexen I
- I
1 I
- I
yl I
acetate I
or O
propan B
- I
2 I
- I
ol I
. O

Novel O
limonene B
and O
citral B
based O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazoles I
: O
a O
natural O
product O
coupled O
approach O
to O
semicarbazones B
for O
antiepileptic O
activity O
. O

Two O
novel O
series O
of O
N B
( I
4 I
) I
- I
( I
5 I
- I
( I
2 I
/ I
3 I
/ I
4 I
- I
substituted I
- I
phenyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I
yl I
) I
- I
N I
( I
1 I
) I
- I
( I
2 I
- I
methyl I
- I
5 I
- I
( I
prop I
- I
1 I
- I
en I
- I
2 I
- I
yl I
) I
cyclohex I
- I
2 I
- I
enylidene I
) I
semicarbazide I
and O
N B
( I
4 I
) I
- I
( I
5 I
- I
( I
2 I
/ I
3 I
/ I
4 I
- I
substituted I
- I
phenyl I
) I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazol I
- I
2 I
- I

The O
anticonvulsant O
activities O
of O
the O
compounds O
were O
investigated O
using O
maximal O
electroshock O
seizure O
( O
MES O
) O
, O
subcutaneous O
pentylenetrtrazole B
( O
scPTZ O
) O
and O
subcutaneous O
strychnine B
( O
scSTY O
) O
models O
. O

One O
analogue O
, O
1 B
, I
14 I
- I
spermine I
- I
di I
- I
( I
2 I
- I
hydroxyphenylacetami I
) I
( O
3 O
) O
, O
exhibited O
two O
orders O
of O
magnitude O
increased O
anti O
- O
P O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

Tri B
- I
and I
diorganotin I
( I
IV I
) I
orotates I
of O
general O
formula O
, O
R B
( I
n I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
m I
) I
[ O
n O
= O
3 O
/ O
2 O
, O
m O
= O
1 O
/ O
2 O
, O
R O
= O
Me B
, O
n B
- I
Bu I
, O
n B
- I
Oct I
and O
Ph B
; O
H B
( I
2 I
) I
Or I
( I
- I
) I
= O
monoanion O
of O
orotic B
acid I
( O
H B
( I
3 I
) I
Or I
) O
] O
( O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
as O
an O
exception O
) O
have O
been O
synthesized O
. O

On O
the O
basis O
of O
various O
spectroscopic O
studies O
it O
is O
revealed O
that O
R B
( I
3 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
and O
R B
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
exhibit O
distorted O
trigonal O
- O
bipyramidal O
and O
distorted O
octahedral O
geometry O
, O
respectively O
, O
and O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
shows O
both O
five O
and O
six O
coordination O
geometry O
around O
tin O
. O

On O
the O
basis O
of O
various O
spectroscopic O
studies O
it O
is O
revealed O
that O
R B
( I
3 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
and O
R B
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
exhibit O
distorted O
trigonal O
- O
bipyramidal O
and O
distorted O
octahedral O
geometry O
, O
respectively O
, O
and O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
shows O
both O
five O
and O
six O
coordination O
geometry O
around O
tin O
. O

On O
the O
basis O
of O
various O
spectroscopic O
studies O
it O
is O
revealed O
that O
R B
( I
3 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
and O
R B
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
exhibit O
distorted O
trigonal O
- O
bipyramidal O
and O
distorted O
octahedral O
geometry O
, O
respectively O
, O
and O
n B
- I
Bu I
( I
2 I
) I
Sn I
( I
HOr I
) I
shows O
both O
five O
and O
six O
coordination O
geometry O
around O
tin O
. O

In O
vitro O
anti O
- O
cancer O
screening O
against O
MCF O
- O
7 O
( O
mammary O
) O
, O
HEK O
- O
293 O
( O
kidney O
) O
, O
PC O
- O
3 O
( O
prostate O
) O
, O
HCT O
- O
15 O
( O
colon O
) O
and O
HepG O
- O
2 O
( O
liver O
) O
cancer O
cell O
lines O
suggest O
that O
the O
n B
- I
Oct I
( I
2 I
) I
Sn I
( I
H I
( I
2 I
) I
Or I
) I
( I
2 I
) I
is O
the O
most O
active O
complex O
among O
all O
of O
the O
studied O
complexes O
. O

Fourteen O
sterols B
( O
1 O
- O
14 O
) O
, O
including O
two O
new O
sterols B
, O
trihydroxysitosterol B
( O
2 O
) O
and O
5 B
alpha I
, I
6 I
beta I
, I
7 I
alpha I
- I
7 I
alpha I
- I
acetoxysitosterol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
branches O
and O
leaves O
of O
Phyllanthus O
emblica O
L O
. O

Radioreceptor O
binding O
assays O
showed O
a O
significant O
increase O
in O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazole I
propionate I
and O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
density O
which O
was O
confirmed O
by O
immunohistochemical O
studies O
. O

Neu2000 B
[ O
2 B
- I
hydroxy I
- I
5 I
- I
( I
2 I
, I
3 I
, I
5 I
, I
6 I
- I
tetrafluoro I
- I
4 I
trifluoromethylbenzy I
) I
benzoic I
acid I
] O
is O
a O
dual O
- O
acting O
neuroprotective O
agent O
that O
functions O
both O
as O
a O
noncompetitive O
N B
- I
methyl I
- I
d I
- I
aspartate I
( O
NMDA O
) O
receptor O
antagonist O
and O
a O
free O
radical O
scavenger O
. O

In O
comparison O
, O
when O
isolated O
from O
ethanol B
- O
treated O
( O
two O
doses O
of O
2 O
g O
/ O
kg O
, O
2 O
h O
apart O
) O
7 O
- O
day O
- O
old O
mouse O
pups O
, O
brain O
mitochondria O
displayed O
a O
transient O
decrease O
in O
oxygen B
consumption O
but O
no O
change O
in O
PTP O
regulation O
or O
H B
( I
2 I
) I
O I
( I
2 I
) I
production O
. O

Safrole B
- I
2 I
' I
, I
3 I
' I
- I
oxide I
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein O
E O
- O
knockout O
mice O
. O

Safrole B
- I
2 I
' I
, I
3 I
' I
- I
oxide I
( O
SFO B
) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole B
( O
4 B
- I
allyl I
- I
1 I
, I
2 I
- I
methylenedioxybenzen I
) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O

Safrole B
- I
2 I
' I
, I
3 I
' I
- I
oxide I
( O
SFO B
) O
is O
the O
major O
electrophilic O
metabolite O
of O
safrole B
( O
4 B
- I
allyl I
- I
1 I
, I
2 I
- I
methylenedioxybenzen I
) O
, O
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs O
, O
such O
as O
pesto O
sauce O
, O
cola O
beverages O
and O
bologna O
sausages O
. O

In O
vitro O
and O
in O
vivo O
anti O
- O
inflammatory O
effects O
of O
4 B
- I
methoxy I
- I
5 I
- I
hydroxycanthin I
- I
6 I
- I
one I
, O
a O
natural O
alkaloid O
from O
Picrasma O
quassioides O
. O

In O
the O
present O
study O
, O
we O
evaluated O
the O
anti O
- O
inflammatory O
effect O
of O
4 B
- I
methoxy I
- I
5 I
- I
hydroxycanthin I
- I
6 I
- I
one I
( O
CAN B
) O
, O
a O
natural O
alkaloid O
isolated O
from O
Picrasma O
quassioides O
. O

Infrared O
multiple O
photon O
dissociation O
( O
IRMPD O
) O
spectroscopy O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
ions O
( O
where O
A O
is O
adenine B
and O
G O
is O
guanine B
) O
has O
been O
performed O
in O
two O
spectral O
regions O
, O
950 O
- O
1900 O
and O
2900 O
- O
3700 O
cm O
( O
- O
1 O
) O
. O

Infrared O
multiple O
photon O
dissociation O
( O
IRMPD O
) O
spectroscopy O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
ions O
( O
where O
A O
is O
adenine B
and O
G O
is O
guanine B
) O
has O
been O
performed O
in O
two O
spectral O
regions O
, O
950 O
- O
1900 O
and O
2900 O
- O
3700 O
cm O
( O
- O
1 O
) O
. O

Quantum O
chemical O
calculations O
at O
the O
B3LYP O
/ O
LACV3P O
/ O
6 O
- O
311G O
* O
* O
level O
yield O
the O
optimized O
geometries O
and O
IR O
spectra O
for O
the O
conceivable O
isomers O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
, O
whereby O
the O
cisplatin B
residue O
is O
attached O
to O
the O
N7 O
, O
N3 O
, O
or O
carbonyl B
oxygen I
atom O
, O
( O
O6 B
) O
, O

Quantum O
chemical O
calculations O
at O
the O
B3LYP O
/ O
LACV3P O
/ O
6 O
- O
311G O
* O
* O
level O
yield O
the O
optimized O
geometries O
and O
IR O
spectra O
for O
the O
conceivable O
isomers O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
and O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
, O
whereby O
the O
cisplatin B
residue O
is O
attached O
to O
the O
N7 O
, O
N3 O
, O
or O
carbonyl B
oxygen I
atom O
, O
( O
O6 B
) O
, O

In O
agreement O
with O
computational O
results O
, O
the O
IR O
characterization O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
points O
to O
a O
covalent O
structure O
where O
Pt B
is O
bound O
to O
the O
N7 O
atom O
of O
guanine B
. O

The O
experimental O
C B
= I
O I
stretching O
feature O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
G I
) I
Cl I
] I
( I
+ I
) I
at O
1718 O
cm O
( O
- O
1 O
) O
, O
remarkably O
red O
- O
shifted O
with O
respect O
to O
an O
unperturbed O
C B
= I
O I
stretching O
mode O
, O
is O
indicative O
of O
a O
lengthened O
CO B
bond O
in O
guanine B
, O
a O
signature O
that O
this O
group O
is O
involved O
in O
hydrogen B
bonding O
. O

The O
IRMPD O
spectra O
of O
cis B
- I
[ I
Pt I
( I
NH I
( I
3 I
) I
) I
( I
2 I
) I
( I
A I
) I
Cl I
] I
( I
+ I
) I
are O
consistent O
with O
the O
presence O
of O
two O
major O
isomers O
, O
PtAN3 B
and O
PtAN1 B
, O
where O
Pt B
is O
bound O
to O
the O
N3 O
and O
N1 O
positions O
of O
native O
adenine B
, O
respectively O
. O

Mag1 O
excises O
N3 B
- I
and I
N7 I
- I
alkylguanines I
and O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenine I
from O
DNA O
, O
whereas O
Mag2 O
has O
been O
reported O
to O
have O
no O
detectible O
alkylpurine B
base O
excision O
activity O
despite O
high O
sequence O
and O
active O
site O
similarity O
to O
Mag1 O
. O

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 B
, I
4 I
- I
methylenedioxy I
- I
alpha I
- I
ethylphenethylamine I
( O
3 B
, I
4 I
- I
BDB I
) O
, O
the O
hallucinogen O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
, O
the O
abused O
alkaloid O
glaucine B
, O
the O
opioid O
- O
like O
drugs O
N B
- I
iso I
- I
propyl I
- I
1 I
, I
2 I
- I
diphenylethylamine I
( O
NPDPA B
) O
, O
and O
N B
- I
( I
1 I
- I
phenylcyclohexyl I
) I
- I

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 B
, I
4 I
- I
methylenedioxy I
- I
alpha I
- I
ethylphenethylamine I
( O
3 B
, I
4 I
- I
BDB I
) O
, O
the O
hallucinogen O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
, O
the O
abused O
alkaloid O
glaucine B
, O
the O
opioid O
- O
like O
drugs O
N B
- I
iso I
- I
propyl I
- I
1 I
, I
2 I
- I
diphenylethylamine I
( O
NPDPA B
) O
, O
and O
N B
- I
( I
1 I
- I
phenylcyclohexyl I
) I
- I

ATPase O
stimulation O
kinetics O
could O
be O
modeled O
for O
the O
entactogen O
3 B
, I
4 I
- I
methylenedioxy I
- I
alpha I
- I
ethylphenethylamine I
( O
3 B
, I
4 I
- I
BDB I
) O
, O
the O
hallucinogen O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
, O
the O
abused O
alkaloid O
glaucine B
, O
the O
opioid O
- O
like O
drugs O
N B
- I
iso I
- I
propyl I
- I
1 I
, I
2 I
- I
diphenylethylamine I
( O
NPDPA B
) O
, O
and O
N B
- I
( I
1 I
- I
phenylcyclohexyl I
) I
- I

3 I
- I
ethoxypropanamine I
( O
PCEPA B
) O
, O
with O
K O
( O
m O
) O
and O
V O
( O
max O
) O
values O
within O
the O
same O
range O
as O
for O
verapamil B
or O
sertraline B
. O

To O
examine O
this O
, O
pigeons O
were O
trained O
to O
discriminate O
the O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
( B
R I
, I
S I
) I
- I
5 I
, I
7 I
- I
di I
- I
tert I
- I
butyl I
- I
3 I
- I
hydroxy I
- I
3 I
- I
trifluoromethyl I
- I
3H I
- I
benzofuran I
- I
2 I
- I
one I
( O
rac B
- I
BHFF I
) O
from O
its O
vehicle O
. O

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
antagonized O
by O
the O
GABA B
( O
B O
) O
receptor O
antagonist O
3 B
- I
aminopropyl I
( I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP35348 B
) O
but O
were O
attenuated O
by O
the O
less O
efficacious O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
2 B
, I
6 I
- I
di I
- I
tert I
- I
butyl I
- I
4 I
- I
( I
3 I
- I
hydroxy I
- I
2 I
, I
2 I
- I
dimethylpropyl I
) I
phenol I
( O
CGP7930 B
) O
, O
suggesting O
the O
possibility O
that O
rac B
- I

The O
discriminative O
stimulus O
effects O
of O
rac B
- I
BHFF I
were O
not O
antagonized O
by O
the O
GABA B
( O
B O
) O
receptor O
antagonist O
3 B
- I
aminopropyl I
( I
diethoxymethyl I
) I
phosphinic I
acid I
( O
CGP35348 B
) O
but O
were O
attenuated O
by O
the O
less O
efficacious O
GABA B
( O
B O
) O
receptor O
- O
positive O
modulator O
2 B
, I
6 I
- I
di I
- I
tert I
- I
butyl I
- I
4 I
- I
( I
3 I
- I
hydroxy I
- I
2 I
, I
2 I
- I
dimethylpropyl I
) I
phenol I
( O
CGP7930 B
) O
, O
suggesting O
the O
possibility O
that O
rac B
- I

Toluene B
( O
TOL B
) O
is O
a O
neurotoxic O
, O
ototoxic O
and O
reprotoxic O
solvent O
which O
is O
metabolized O
via O
the O
glutathione B
pathway O
, O
producing O
benzylmercapturic B
, I
o I
- I
, I
m I
- I
and I
p I
- I
toluylmercapturic I
acids I
( O
MAs B
) O
. O

Structure O
- O
based O
design O
, O
synthesis O
and O
evaluation O
of O
novel O
anthra B
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
derivatives O
as O
telomerase O
inhibitors O
and O
potential O
for O
cancer O
polypharmacology O
. O

A O
series O
of O
anthra B
[ I
1 I
, I
2 I
- I
d I
] I
imidazole I
- I
6 I
, I
11 I
- I
dione I
derivatives O
were O
synthesized O
and O
evaluated O
for O
telomerase O
inhibition O
, O
hTERT O
expression O
and O
suppression O
of O
cancer O
cell O
growth O
in O
vitro O
. O

These O
products O
exhibited O
substantial O
activity O
against O
T O
. O
cruzi O
, O
especially O
2 B
- I
( I
( I
8E I
, I
11Z I
) I
- I
heptadeca I
- I
8 I
, I
11 I
- I
dienyl I
) I
- I
3 I
- I
hydroxynaphthalene I
- I
1 I
, I
4 I
- I
dione I
( O
9 O
) O
with O
IC O
( O
50 O
) O
of O
7 O
. O
8 O
mu O
M O
. O

Synthesis O
and O
Biological O
Evaluation O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
Triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
Tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
Derivatives O
Bearing O
Substituted O
Benzylpiperazine B
Moieties O
as O
Positive O
Inotropic O
Agents O
. O

Synthesis O
and O
Biological O
Evaluation O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
Triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
Tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
Derivatives O
Bearing O
Substituted O
Benzylpiperazine B
Moieties O
as O
Positive O
Inotropic O
Agents O
. O

Two O
series O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
derivatives O
bearing O
substituted O
benzylpiperazine B
moieties O
have O
been O
synthesized O
and O
evaluated O
for O
their O
positive O
inotropic O
activity O
by O
measuring O
left O
atrium O
stroke O
volume O
on O
isolated O
rabbit O
heart O
preparations O
. O

Two O
series O
of O
[ B
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
3 I
, I
4 I
- I
a I
] I
phthalazine I
and O
tetrazolo B
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
derivatives O
bearing O
substituted O
benzylpiperazine B
moieties O
have O
been O
synthesized O
and O
evaluated O
for O
their O
positive O
inotropic O
activity O
by O
measuring O
left O
atrium O
stroke O
volume O
on O
isolated O
rabbit O
heart O
preparations O
. O

The O
majority O
of O
the O
derivatives O
exhibited O
better O
in O
vitro O
activity O
than O
the O
existing O
drug O
, O
milrinone B
, O
and O
6 B
- I
( I
( I
4 I
- I
( I
4 I
- I
methoxyphenyl I
) I
piperazin I
- I
1 I
- I
yl I
) I
methyl I
) I
tetrazolo I
[ I
5 I
, I
1 I
- I
a I
] I
phthalazine I
. O

Practical O
synthesis O
of O
( B
20S I
) I
- I
10 I
- I
( I
3 I
- I
aminopropyloxy I
) I
- I
7 I
- I
ethylcamptothecin I
, O
a O
water O
- O
soluble O
analogue O
of O
camptothecin B
. O

A O
robust O
, O
practical O
synthesis O
of O
( B
20S I
) I
- I
10 I
- I
( I
3 I
- I
aminopropyloxy I
) I
- I
7 I
- I
ethylcamptothecin I
( O
T B
- I
2513 I
, O
5 O
) O
, O
which O
is O
a O
water O
- O
soluble O
analogue O
of O
camptothecin B
, O
has O
been O
developed O
. O

The O
key O
step O
in O
this O
synthesis O
is O
a O
highly O
diastereoselective O
ethylation O
at O
the O
C20 O
position O
by O
using O
N B
- I
arylsulfonyl I
- I
( I
R I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydroisoquinoli I
- I
3 I
- I
carboxylic I
acid I
ester I
as O
a O
chiral O
auxiliary O
, O
which O
affords O
the O
key O
intermediate O
ethyl B
- I
( I
S I
) I
- I
2 I
- I
acyloxy I
- I
2 I
- I
( I
6 I
- I
cyano I
- I
5 I
- I
oxo I
- I
1 I
, I
2 I
, I
3 I
, I
5 I
- I
tetrahydroindolizin I
- I
7 I
- I

Optically O
pure O
compound O
8k O
was O
obtained O
by O
a O
single O
recrystallization O
from O
acetone B
and O
its O
further O
elaboration O
through O
Friedlander O
condensation O
afforded O
compound O
5 O
. O

In O
this O
paper O
, O
the O
fabrication O
, O
characterization O
, O
and O
application O
in O
oxygen B
sensing O
are O
reported O
for O
a O
novel O
multifunctional O
nanomaterial O
of O
[ O
Ru B
( I
bpy I
) I
( I
2 I
) I
phen I
- O
MMS O
] O
( O
bpy B
, O
2 B
, I
2 I
' I
- I
bipyridyl I
; O
phen B
, O
phenathrolin B
) O
which O
was O
simply O
prepared O
by O
covalently O
grafting O
the O
ruthenium B
( I
II I
) I
polypyridyl I
compounds O
into O
the O
channels O
of O
magnetic O
mesoporous O
silica B
nanocomposites O
( O
MMS O
) O
. O

THP O
- O
1 O
cells O
were O
pre O
- O
loaded O
with O
a O
ROS O
sensitive O
fluorescent O
dye O
, O
5 B
- I
( I
and I
6 I
- I
) I
- I
chloromethyl I
- I
2 I
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
, O
acetyl B
ester I
( O
CM B
- I
H2DCFDA I
) O
, O
for O
15min O
, O
then O
incubated O
with O
test O
chemicals O
for O
30min O
. O

The O
consecutive O
arrangement O
of O
2 B
' I
- I
deoxy I
- I
6 I
- I
thioguanosines I
( O
s B
( I
6 I
) I
Gs I
) O
and O
4 B
- I
thiothymidines I
( O
s B
( I
4 I
) I
Ts I
) O
in O
antiparallel O
triplex O
- O
forming O
oligonucleotides O
( O
TFOs O
) O
considerably O
stabilized O
the O
resulting O
antiparallel O
triplexes O
with O
high O
base O
recognition O
ability O
by O
the O
strong O
stacking O
effects O
of O
thiocarbonyl B
groups O
. O

Compared O
to O
their O
wild O
- O
type O
littermates O
, O
Glu B
- O
CB1 O
- O
KO O
displayed O
a O
small O
decrease O
of O
CB1 O
mRNA O
amount O
, O
immunoreactivity O
and O
[ B
( I
3 I
) I
H I
] I
CP55 I
, I
940 I
binding O
. O

Surprisingly O
, O
however O
, O
saturation O
analysis O
of O
HU210 B
- O
stimulated O
[ B
( I
35 I
) I
S I
] I
GTP I
gamma I
S I
binding O
demonstrated O
that O
' O
glutamatergic O
' O
CB1 O
is O
more O
efficiently O
coupled O
to O
G O
protein O
signalling O
than O
' O
GABAergic O
' O
CB1 O
. O

A O
series O
of O
novel O
pyrazole B
integrated O
benzophenones B
( O
9a O
- O
j O
) O
have O
been O
designed O
, O
synthesized O
from O
1 B
- I
methyl I
- I
5 I
- I
( I
2 I
, I
4 I
, I
6 I
- I
trimethoxy I
- I
phenyl I
) I
- I
1H I
- I
pyrazole I
6 O
. O

Our O
previous O
studies O
indicate O
that O
the O
aryl B
hydrocarbon I
receptor O
( O
AhR O
) O
agonist O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
attenuates O
light O
- O
induced O
phase O
resetting O
in O
early O
night O
. O

Steroid B
parts O
of O
the O
molecular O
" O
ribbons O
" O
are O
linked O
by O
heterocyclic O
moiety O
, O
namely O
by O
2 B
, I
6 I
- I
bis I
( I
( I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
1 I
- I
yl I
) I
- I
methyl I
) I
pyridine I
. O

This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O
N B
- I
methyl I
- I
N I
' I
- I
nitro I
- I
N I
- I
nitrosoguanidine I
, O
acridin B
and O
aflatoxin B
. O

Three O
new O
ent B
- I
eudesmane I
sesquiterpenoids I
, O
arundinols B
A I
- I
C I
( O
1 O
- O
3 O
) O
, O
one O
isochroman B
- I
1 I
- I
one I
, O
arundinone B
A I
( O
4 O
) O
, O
and O
a O
polyoxygenated B
benzofuran I
- I
3 I
( I
2H I
) I
- I
one I
dimer O
, O
arundinone B
B I
( O
5 O
) O
, O
were O
isolated O
from O
the O
extract O
of O
a O
plant O
endophytic O
fungus O
, O
Microsphaeropsis O
arundinis O
. O

The O
absolute O
configuration O
of O
1 O
was O
assigned O
by O
X O
- O
ray O
crystallography O
using O
Cu B
K O
alpha O
radiation O
, O
whereas O
those O
of O
the O
C O
- O
11 O
tertiary B
alcohols I
in O
2 O
and O
3 O
were O
deduced O
via O
the O
circular O
dichroism O
data O
of O
the O
in O
situ O
formed O
[ B
Rh I
( I
2 I
) I
( I
OCOCF I
( I
3 I
) I
) I
( I
4 I
) I
] I
complexes O
. O

Arundinone B
B I
( O
5 O
) O
represents O
the O
first O
dimeric O
benzofuran B
- I
3 I
( I
2H I
) I
- I
one I
, O
showing O
cytotoxicity O
against O
T24 O
and O
A549 O
cells O
. O

SKF83959 B
( O
3 B
- I
methyl I
- I
6 I
- I
chloro I
- I
7 I
, I
8 I
- I
hydroxy I
- I
1 I
- I
[ I
3 I
- I
methylphenyl I
] I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
) O
, O
an O
atypical O
dopamine B
receptor O
- O
1 O
( O
D O
( O
1 O
) O
receptor O
) O
agonist O
, O
has O
shown O
many O
D O
( O
1 O
) O
receptor O
- O
independent O
effects O
, O
such O
as O
neuroprotection O
, O
blockade O
of O
Na B
( I
+ I
) I
channel O
, O
and O
promotion O
of O
spontaneous O
glutamate B
release O
, O
which O
resemble O
the O
effects O
of O

The O
results O
indicated O
that O
SKF83959 B
dramatically O
promoted O
the O
binding O
of O
( B
3 I
) I
H I
( I
+ I
) I
- I
pentazocine I
( O
a O
selective O
sigma O
- O
1 O
receptor O
agonist O
) O
to O
the O
sigma O
- O
1 O
receptor O
in O
brain O
and O
liver O
tissues O
but O
produced O
no O
effect O
on O
( B
3 I
) I
H I
- I
progesterone I
binding O
( O
a O
sigma O
- O
1 O
receptor O
antagonist O
) O
. O

We O
further O
demonstrated O
that O
the O
SKF83959 B
analogs O
, O
such O
as O
SCH22390 B
[ O
( B
R I
) I
- I
( I
1 I
) I
- I
7 I
- I
chloro I
- I
8 I
- I
hydroxy I
- I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
1H I
- I
3 I
- I
benzazepine I
hydrochloride I
] O
and O
SKF38393 B
[ O
( B
+ I
/ I
- I
) I
- I
1 I
- I
phenyl I
- I
2 I
, I
3 I
, I
4 I
, I
5 I
- I
tetrahydro I
- I
( I
1H I
) I
- I
3 I
- I
benzazepine I

Moreover O
, O
all O
three O
tested O
chemicals O
elicited O
no O
significant O
effect O
on O
( B
3 I
) I
H I
- I
1 I
, I
3 I
- I
di I
( I
2 I
- I
tolyl I
) I
- I
guanidine I
( O
( B
3 I
) I
H I
- I
DTG I
) O
binding O
to O
the O
sigma O
- O
2 O
receptor O
. O

Furthermore O
, O
a O
humanized O
CYP3A4 O
/ O
3A7 O
mouse O
model O
showed O
in O
vivo O
induction O
of O
CYP3A4 O
mRNA O
and O
protein O
by O
[ O
4 B
- I
chloro I
- I
6 I
- I
( I
2 I
, I
3 I
- I
xylidino I
) I
- I
2 I
- I
pyrimidinylthio I
] I
acetic I
acid I
( O
WY14 B
, I
643 I
) O
in O
liver O
but O
not O
in O
intestine O
, O
whereas O
hepatic O
occupancy O
of O
PBRs O
by O
PPAR O
alpha O
was O
ligand O
independent O
. O

Interestingly O
, O
the O
common O
phospholipid O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I
glycerol I
- I
3 I
- I
phosphocholine I
( O
16 O
: O
0 O
/ O
18 O
: O
1 O
- O
PC O
) O
, O
previously O
proposed O
to O
reflect O
nutritional O
status O
and O
shown O
to O
be O
a O
specific O
endogenous O
ligand O
of O
PPAR O
alpha O
, O
induced O
CYP3A4 O
( O
up O
to O
4 O
- O
fold O
) O
and O
other O
biotransformation O
genes O
in O
hepatocytes O
with O
similar O
selectivity O
and O
potency O
as O
WY14 B
, I
643 I
. O

Poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
nanoparticles O
were O
prepared O
using O
a O
modified O
emulsification O
/ O
solvent O
diffusion O
method O
. O

For O
a O
larger O
buckybowl O
, O
C B
( I
36 I
) I
H I
( I
12 I
) I
, O
the O
beta O
( O
0 O
) O
value O
per O
molecule O
of O
its O
pentamer O
reaches O
191 O
. O
4 O
x O
10 O
( O
- O
30 O
) O
esu O
which O
is O
much O
higher O
than O
conventional O
dipolar O
or O
octupolar O
NLO O
chromophores O
ones O
. O

A O
systematic O
set O
of O
borotellurite B
glasses O
doped O
with O
manganese B
( B
1 I
- I
x I
) I
[ I
( I
B I
( I
2 I
) I
O I
( I
3 I
) I
) I
( I
0 I
. I
3 I
) I
( I
TeO I
( I
2 I
) I
) I
( I
0 I
. I
7 I
) I
] I
- I
xMnO I
, O
with O
x O
= O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
0 O
. O
3 O
and O
0 O
. O
4 O
mol O
% O
, O
were O
successfully O
synthesized O
by O
using O
a O
conventional O
melt O
and O
quench O
- O
casting O
technique O
. O

Blocking O
spinal O
5 B
- I
hydroxytryptamine I
- O
7 O
receptors O
with O
( B
2R I
) I
- I
1 I
- I
[ I
( I
3 I
- I
hydroxyphenyl I
) I
sulfonyl I
] I
- I
2 I
- I
[ I
2 I
- I
( I
4 I
- I
methyl I
- I
1 I
- I
piperidinyl I
) I
ethyl I
] I
pyrrolidine I
hydrochloride I
suggested O
that O
the O
effects O
of O
milnacipran B
in O
the O
late O
phase O
were O
partly O
mediated O
by O
these O
receptors O
, O
and O
that O
descending O
serotonergic O
inhibition O
was O
increased O
in O
this O
phase O
. O

Methadone B
metabolism O
clinically O
occurs O
primarily O
by O
N B
- O
demethylation O
to O
2 B
- I
ethyl I
- I
1 I
, I
5 I
- I
dimethyl I
- I
3 I
, I
3 I
- I
diphenylpyrrolidine I
( O
EDDP B
) O
, O
catalyzed O
predominantly O
by O
CYP2B6 O
. O

In O
addition O
, O
the O
new O
compound O
perviridicin B
B I
( O
2 O
) O
, O
three O
known O
rocaglate B
derivatives O
( O
9 O
, O
11 O
, O
12 O
) O
, O
and O
a O
known O
sesquiterpene B
, O
2 B
- I
oxaisodauc I
- I
5 I
- I
en I
- I
12 I
- I
al I
( O
17 O
) O
, O
showed O
significant O
NF O
- O
kappa O
B O
( O
p65 O
) O
inhibitory O
activity O
in O
an O
ELISA O
assay O
. O

Among O
these O
derivatives O
were O
N B
- I
( I
3 I
- I
oxobutyl I
) I
- I
Tyr I
and O
two O
acetylated O
compounds O
, O
N B
- I
acetyl I
- I
Tyr I
and O
O B
- I
acetyl I
- I
Tyr I
, O
which O
were O
synthesized O
by O
reaction O
of O
Tyr B
with O
methyl B
vinyl I
ketone I
and O
acetic B
anhydride I
, O
respectively O
, O
at O
37 O
degrees O
C O
. O

Successful O
application O
of O
an O
ionic O
liquid O
carrying O
the O
fluoride B
counter O
- O
ion O
in O
biomacromolecular O
chemistry O
: O
microwave O
- O
assisted O
acylation O
of O
cellulose O
in O
the O
presence O
of O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
fluoride I
/ O
DMSO B
mixtures O
. O

Neat O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
fluoride I
( O
AlMeImF B
) O
is O
used O
as O
a O
solvent O
in O
microwave O
- O
assisted O
acylation O
of O
cellulose O
. O

The O
results O
are O
comparable O
to O
those O
obtained O
when O
pure O
1 B
- I
allyl I
- I
3 I
- I
methylimidazolium I
chloride I
is O
employed O
. O

Treating O
N B
- I
propylnorglaucine I
with O
90 O
% O
H2SO4 B
yielded O
one O
additional O
product O
, O
an O
11 B
- I
sulfonyl I
- I
1 I
, I
11 I
- I
anhydroaporphine I
. O

To O
overcome O
this O
issue O
, O
Bioglass O
is O
used O
to O
form O
a O
composite O
scaffold O
with O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA B
) O
, O
a O
biodegradable O
polymer O
. O

LY2090314 B
( O
3 B
- I
[ I
9 I
- I
fluoro I
- I
2 I
- I
( I
piperidin I
- I
1 I
- I
ylcarbonyl I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
[ I
1 I
, I
4 I
] I
diazepino I
[ I
6 I
, I
7 I
, I
1 I
- I
hi I
] I
indol I
- I
7 I
- I
yl I
] I
- I
4 I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
pyridin I
- I
3 I
- I
yl I
- I
1H I
- I
pyrrole I
- I
2 I
, I
5 I
- I
dione I
) O
is O
an O
intravenous O
glycogen O
synthase O
kinase O
- O
3 O
inhibitor O

On O
the O
basis O
of O
1D O
and O
2D O
NMR O
, O
HR O
- O
ESI O
- O
MS O
, O
and O
circular O
dichroism O
( O
CD O
) O
spectroscopic O
analysis O
, O
structures O
of O
the O
new O
compounds O
were O
elucidated O
as O
2 B
- I
( I
2 I
' I
- I
methoxy I
- I
4 I
' I
- I
hydroxy I
) I
- I
aryl I
- I
3 I
- I
methy I
- I
6 I
- I
hydroxy I
- I
benzofuran I
( O
1 O
) O
, O
( B
2S I
) I
- I
6 I
, I
7 I
- I
( I
2 I
, I
2 I
- I
dimethyldihydropyran I
) I
- I
8 I
- I
prenyl I
- I
4 I
' I
- I
hydroxyflavanone I
( O
2 O

On O
the O
basis O
of O
1D O
and O
2D O
NMR O
, O
HR O
- O
ESI O
- O
MS O
, O
and O
circular O
dichroism O
( O
CD O
) O
spectroscopic O
analysis O
, O
structures O
of O
the O
new O
compounds O
were O
elucidated O
as O
2 B
- I
( I
2 I
' I
- I
methoxy I
- I
4 I
' I
- I
hydroxy I
) I
- I
aryl I
- I
3 I
- I
methy I
- I
6 I
- I
hydroxy I
- I
benzofuran I
( O
1 O
) O
, O
( B
2S I
) I
- I
6 I
, I
7 I
- I
( I
2 I
, I
2 I
- I
dimethyldihydropyran I
) I
- I
8 I
- I
prenyl I
- I
4 I
' I
- I
hydroxyflavanone I
( O
2 O

) O
, O
and O
6 B
- I
prenyl I
- I
7 I
, I
3 I
' I
, I
4 I
' I
- I
trihydroxyflavone I
( O
3 O
) O
. O

Mitochondrial O
dysfunction O
contributes O
to O
the O
cytotoxicity O
of O
some O
3 B
, I
5 I
- I
bis I
( I
benzylidene I
) I
- I
4 I
- I
piperidone I
derivatives O
in O
colon O
HCT O
- O
116 O
cells O
. O

Effects O
of O
tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
and O
triphenyl B
phosphate I
on O
receptor O
- O
associated O
mRNA O
expression O
in O
zebrafish O
embryos O
/ O
larvae O
. O

Tris B
( I
1 I
, I
3 I
- I
dichloro I
- I
2 I
- I
propyl I
) I
phosphate I
( O
TDCPP B
) O
and O
triphenyl B
phosphate I
( O
TPP B
) O
are O
frequently O
detected O
in O
biota O
, O
including O
fish O
. O

This O
research O
aimed O
at O
evaluating O
the O
effects O
of O
cadmium B
( O
2 O
x O
10 O
( O
- O
8 O
) O
; O
10 O
( O
- O
7 O
) O
mol O
L O
( O
- O
1 O
) O
Cd B
) O
on O
lipid O
class O
and O
fatty B
acid I
composition O
of O
the O
microalga O
Chlorella O
vulgaris O
under O
varying O
phosphate B
( O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
concentrations O
( O
6 O
. O
0 O
x O
10 O
( O
- O
7 O
) O
to O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
) O
. O

Under O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd B
stress O
, O
the O
storage O
lipid O
class O
triacylglycerol B
( O
TAG B
) O
was O
the O
most O
accumulated O
among O
the O
lipid O
classes O
. O

Fatty B
acid I
composition O
revealed O
that O
the O
degree O
of O
saturation O
increased O
with O
increasing O
Cd B
stress O
and O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
. O

Decreasing O
PO B
( I
4 I
) I
( I
3 I
- I
) I
and O
increasing O
Cd B
concentrations O
resulted O
in O
higher O
saturated B
fatty I
acid I
( O
SAFA B
) O
and O
monounsaturated B
FA I
( O
MUFA B
) O
concentrations O
. O

Total O
polyunsaturated B
FA I
( O
PUFA B
) O
and O
omega B
3 I
PUFA I
, O
and O
PUFA B
: O
SAFA B
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
cells O
than O
in O
either O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
or O
Cd B
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

Total O
polyunsaturated B
FA I
( O
PUFA B
) O
and O
omega B
3 I
PUFA I
, O
and O
PUFA B
: O
SAFA B
ratios O
were O
higher O
in O
the O
control O
( O
2 O
. O
3 O
x O
10 O
( O
- O
4 O
) O
mol O
L O
( O
- O
1 O
) O
PO B
( I
4 I
) I
( I
3 I
- I
) I
) O
cells O
than O
in O
either O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
or O
Cd B
stress O
, O
or O
in O
the O
combination O
of O
both O
stresses O
. O

Contrasting O
with O
all O
the O
other O
PUFAs B
, O
18 O
: O
2n O
- O
6 O
increased O
as O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
increased O
. O

Total O
SAFA B
, O
14 O
: O
0 O
, O
18 O
: O
1n O
- O
9 O
and O
18 O
: O
2n O
- O
6 O
were O
positively O
correlated O
with O
Cd B
and O
negatively O
with O
PO B
( I
4 I
) I
( I
3 I
- I
) I
concentrations O
. O

The O
microalga O
responded O
to O
combined O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd B
exposure O
by O
increasing O
its O
total O
lipid O
production O
and O
significantly O
altering O
its O
lipid O
composition O
. O

The O
FA O
18 O
: O
2n O
- O
6 O
may O
be O
considered O
a O
stress O
biomarker O
for O
PO B
( I
4 I
) I
( I
3 I
- I
) I
limitation O
and O
Cd B
stress O
in O
C O
. O
vulgaris O
. O

Hypoxia O
- O
selective O
O6 B
- I
alkylguanine I
- O
DNA O
alkyltransferase O
inhibitors O
: O
design O
, O
synthesis O
, O
and O
evaluation O
of O
6 B
- I
( I
benzyloxy I
) I
- I
2 I
- I
( I
aryldiazenyl I
) I
- I
9H I
- I
purines I
as O
prodrugs O
of O
O6 B
- I
benzylguanine I
. O

In O
this O
study O
, O
we O
report O
thermosensitive O
hydrogels O
based O
on O
poly B
( I
ethylene I
glycol I
) I
- I
block I
- I
poly I
( I
gamma I
- I
propargyl I
- I
l I
- I
glutamate I
) I
( O
PEG B
- I
PPLG I
) O
. O

Of O
these O
, O
the O
newly O
synthesized O
6 B
, I
8 I
- I
diallyl I
- I
5 I
, I
7 I
- I
dihydroxycoumarin I
( O
8a O
) O
was O
produced O
in O
three O
steps O
in O
high O
chemical O
yield O
from O
floroglucinol B
and O
found O
to O
be O
the O
most O
potent O
of O
this O
series O
, O
exhibiting O
activity O
similar O
to O
the O
reference O
coumestan B
LQB B
- I
34 I
. O

Identification O
of O
N B
- I
acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
and O
their O
orally O
active O
prodrug O
esters B
as O
dual O
- O
acting O
alpha4 O
- O
beta1 O
and O
alpha4 O
- O
beta7 O
receptor O
antagonists O
. O

N B
- I
Acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
of O
type O
4 O
were O
designed O
to O
replace O
the O
2 B
, I
6 I
- I
dichlorobenzoylamine I
portion O
of O
compound O
1 O
in O
order O
to O
identify O
novel O
compounds O
with O
improved O
potency O
against O
alpha O
4 O
- O
integrins O
. O

Investigation O
of O
N B
- I
acyl I
4 I
- I
( I
5 I
- I
pyrimidine I
- I
2 I
, I
4 I
- I
dionyl I
) I
phenylalanine I
derivatives O
led O
to O
the O
discovery O
of O
several O
very O
potent O
dual O
- O
acting O
alpha O
4 O
- O
integrin O
antagonists O
. O

Here O
, O
using O
CCI O
in O
adult O
male O
mice O
, O
we O
set O
to O
determine O
whether O
3 B
, I
5 I
, I
3 I
' I
- I
triiodothyronine I
( O
T3 O
) O
attenuates O
posttraumatic O
neurodegeneration O
and O
neuroinflammation O
in O
an O
experimental O
model O
of O
TBI O
. O

These O
biological O
activities O
are O
likely O
due O
to O
the O
high O
content O
of O
malvidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
and O
petunidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
. O

These O
biological O
activities O
are O
likely O
due O
to O
the O
high O
content O
of O
malvidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
and O
petunidin B
3 I
- I
O I
- I
p I
- I
coumaroyl I
- I
rutinoside I
- I
5 I
- I
O I
- I
glucoside I
. O

Effects O
of O
2 B
- I
amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
on O
histopathology O
, O
oxidative O
stress O
, O
and O
expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
and O
p16 O
in O
rat O
stomachs O
. O

2 B
- I
Amino I
- I
1 I
- I
methyl I
- I
6 I
- I
phenylimidazo I
[ I
4 I
, I
5 I
- I
b I
] I
pyridine I
( O
PhIP B
) O
is O
one O
of O
the O
most O
abundant O
heterocyclic B
amines I
( O
HCAs B
) O
generated O
from O
overcooking O
meat O
at O
high O
temperatures O
. O

Although O
the O
levels O
of O
amino B
acid I
neurotransmitters O
, O
including O
glutamate B
, O
did O
not O
show O
marked O
alteration O
, O
the O
expression O
of O
the O
glutamatergic O
signaling O
pathway O
such O
as O
N B
- I
methyl I
- I
D I
- I
aspartate I
receptors O
, O
a B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
receptor O
, O
calmodulin O
, O
Ca B
( I
2 I
+ I
) I
/ O
calmodulin O
- O
dependent O
protein O
kinases O
- O
II O
and O
cyclic B
adenosine I
monophosphate I
responsive O
element O
binding O
protein O
, O
was O
significantly O
reduced O
by O
TBT B
exposure O

SiO B
( I
2 I
) I
NPs O
( O
concentration O
range O
25 O
- O
200 O
micro O
g O
/ O
ml O
) O
induced O
dose O
- O
dependent O
cytotoxicity O
in O
both O
types O
of O
cells O
, O
which O
was O
demonstrated O
by O
cell O
viability O
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazoliumb I
) O
and O
lactate B
dehydrogenase O
leakage O
assays O
. O

Exposure O
to O
low O
micromolar O
concentrations O
of O
Mn B
( I
2 I
+ I
) I
, O
but O
not O
divalent B
copper I
, I
cadmium I
, I
nickel I
, I
cobalt I
, I
zinc I
, I
and I
iron I
, O
induced O
a O
significant O
production O
of O
H2O2 B
from O
rat O
microglial O
but O
not O
astroglial O
cells O
. O

The O
polymer O
, O
poly B
( I
ethylene I
glycol I
) I
- I
poly I
( I
serinol I
hexamethylene I
urethane I
) I
( O
ESHU B
) O
, O
forms O
a O
physical O
gel O
when O
heated O
to O
37 O
degrees O
C O
and O
shows O
good O
cytocompatibility O
with O
ocular O
cells O
. O

The O
known O
rhamnosyl B
analogue O
of O
paraben B
( O
9 O
) O
was O
also O
isolated O
along O
with O
a O
new O
rhamnosylated O
derivative O
of O
N B
- I
methyl I
- I
p I
- I
aminobenzoic I
acid I
( O
10 O
) O
. O

Synthesis O
and O
evaluation O
of O
antibacterial O
activity O
of O
7 B
- I
alkyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
derivatives O
. O

In O
this O
study O
, O
a O
series O
of O
7 B
- I
alkyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
derivatives O
was O
synthesized O
and O
tested O
for O
their O
antibacterial O
activity O
against O
various O
bacterial O
strains O
. O

Compound O
7p O
( O
7 B
- I
heptyloxy I
- I
4 I
, I
5 I
- I
dihydro I
- I
imidazo I
[ I
1 I
, I
2 I
- I
a I
] I
quinoline I
) O
was O
found O
to O
be O
the O
most O
potent O
inhibitor O
. O

Cardioprotective O
potential O
of O
N B
, I
alpha I
- I
L I
- I
rhamnopyranosyl I
vincosamide I
, O
an O
indole B
alkaloid I
, O
isolated O
from O
the O
leaves O
of O
Moringa O
oleifera O
in O
isoproterenol B
induced O
cardiotoxic O
rats O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Hitherto O
unknown O
protective O
effect O
of O
N B
, I
alpha I
- I
L I
- I
rhamnopyranosyl I
vincosamide I
( O
VR O
) O
, O
isolated O
from O
Moringa O
oleifera O
leaves O
in O
isoproterenol B
( O
ISO B
) O
- O
induced O
cardiac O
toxicity O
was O
evaluated O
in O
rats O
. O

In O
this O
Minireview O
, O
we O
summarized O
the O
reported O
heterocycles O
as O
nonclassical O
bioisosteres O
of O
alpha B
- I
amino I
acids I
, O
which O
include O
quinoxaline B
- I
2 I
, I
4 I
( I
1H I
) I
- I
dione I
, O
quinoxaline B
- I
2 I
, I
3 I
( I
1H I
) I
- I
dione I
and O
quinolin B
- I
2 I
( I
1H I
) I
- I
one I
, O
azagrevellin B
and O
azepine B
- O
derived O
structures O
. O

In O
this O
Minireview O
, O
we O
summarized O
the O
reported O
heterocycles O
as O
nonclassical O
bioisosteres O
of O
alpha B
- I
amino I
acids I
, O
which O
include O
quinoxaline B
- I
2 I
, I
4 I
( I
1H I
) I
- I
dione I
, O
quinoxaline B
- I
2 I
, I
3 I
( I
1H I
) I
- I
dione I
and O
quinolin B
- I
2 I
( I
1H I
) I
- I
one I
, O
azagrevellin B
and O
azepine B
- O
derived O
structures O
. O

In O
this O
Minireview O
, O
we O
summarized O
the O
reported O
heterocycles O
as O
nonclassical O
bioisosteres O
of O
alpha B
- I
amino I
acids I
, O
which O
include O
quinoxaline B
- I
2 I
, I
4 I
( I
1H I
) I
- I
dione I
, O
quinoxaline B
- I
2 I
, I
3 I
( I
1H I
) I
- I
dione I
and O
quinolin B
- I
2 I
( I
1H I
) I
- I
one I
, O
azagrevellin B
and O
azepine B
- O
derived O
structures O
. O

Four O
new O
metabolites O
M O
- O
1 O
[ O
1 B
, I
2 I
, I
18 I
, I
19 I
- I
tetradehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
2 O
[ O
1 B
, I
2 I
, I
4 I
, I
21 I
, I
18 I
, I
19 I
- I
hexadehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
3 O
[ O
1 B
, I
2 I
, I
18 I
, I
19 I

Four O
new O
metabolites O
M O
- O
1 O
[ O
1 B
, I
2 I
, I
18 I
, I
19 I
- I
tetradehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
2 O
[ O
1 B
, I
2 I
, I
4 I
, I
21 I
, I
18 I
, I
19 I
- I
hexadehydro I
- I
4 I
- I
demethyl I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
M O
- O
3 O
[ O
1 B
, I
2 I
, I
18 I
, I
19 I

- I
tetradehydro I
- I
4 I
- I
demethyl I
- I
4 I
- I
formaldehyde I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
, O
and O
M O
- O
4 O
[ O
1 B
, I
2 I
, I
4 I
, I
21 I
, I
18 I
, I
19 I
- I
hexadehydro I
- I
4 I
- I
demethyl I
- I
4 I
- I
oxy I
- I
3 I
, I
17 I
- I
epoxy I
- I
7 I
, I
20 I
( I
2H I
, I
19H I
) I
- I
cyclovobasan I
] O
were O
isolated O
from O
the O
chloroform B
extract O
of O
koumine B

Remarkable O
superlattice O
structures O
were O
identified O
for O
the O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
, O
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
. O

Remarkable O
superlattice O
structures O
were O
identified O
for O
the O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
, O
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
. O

Remarkable O
superlattice O
structures O
were O
identified O
for O
the O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
, O
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
. O

Remarkable O
superlattice O
structures O
were O
identified O
for O
the O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
, O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
, O
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
. O

The O
coexisting O
cubic O
- O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
NWs O
exhibited O
an O
exclusively O
uniform O
superlattice O
structure O
consisting O
of O
2 O
. O
2 O
nm O
period O
slabs O
. O

The O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
adopted O
an O
innovative O
structure O
; O
3Sb B
( I
2 I
) I
layers O
intercalated O
the O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
1 I
) I
Te I
( I
4 I
) I
domains O
, O
respectively O
, O
producing O
3 O
. O
4 O
and O
2 O
. O
7 O
nm O
period O
slabs O
. O

The O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
adopted O
an O
innovative O
structure O
; O
3Sb B
( I
2 I
) I
layers O
intercalated O
the O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
1 I
) I
Te I
( I
4 I
) I
domains O
, O
respectively O
, O
producing O
3 O
. O
4 O
and O
2 O
. O
7 O
nm O
period O
slabs O
. O

The O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
adopted O
an O
innovative O
structure O
; O
3Sb B
( I
2 I
) I
layers O
intercalated O
the O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
1 I
) I
Te I
( I
4 I
) I
domains O
, O
respectively O
, O
producing O
3 O
. O
4 O
and O
2 O
. O
7 O
nm O
period O
slabs O
. O

The O
rhombohedral O
phase O
Ge B
( I
3 I
) I
Sb I
( I
8 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
7 I
) I
Te I
( I
4 I
) I
NWs O
adopted O
an O
innovative O
structure O
; O
3Sb B
( I
2 I
) I
layers O
intercalated O
the O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
and O
Ge B
( I
2 I
) I
Sb I
( I
1 I
) I
Te I
( I
4 I
) I
domains O
, O
respectively O
, O
producing O
3 O
. O
4 O
and O
2 O
. O
7 O
nm O
period O
slabs O
. O

The O
current O
- O
voltage O
measurement O
of O
the O
individual O
NW O
revealed O
that O
the O
vacancy O
layers O
of O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
and O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
decreased O
the O
electrical O
conductivity O
. O

The O
current O
- O
voltage O
measurement O
of O
the O
individual O
NW O
revealed O
that O
the O
vacancy O
layers O
of O
Ge B
( I
8 I
) I
Sb I
( I
2 I
) I
Te I
( I
11 I
) I
and O
Ge B
( I
3 I
) I
Sb I
( I
2 I
) I
Te I
( I
6 I
) I
decreased O
the O
electrical O
conductivity O
. O

A O
new O
flavonoid B
, O
6 B
- I
( I
5 I
- I
acetyl I
- I
2 I
- I
methoxyphenyl I
) I
- I
apigenin I
( O
1 O
) O
, O
together O
with O
nine O
known O
compounds O
( O
2 O
- O
10 O
) O
, O
was O
isolated O
from O
Selaginella O
uncinata O
( O
Desv O
. O
) O
Spring O
. O

We O
report O
a O
novel O
phase O
separation O
phenomenon O
observed O
in O
the O
growth O
of O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
by O
metalorganic O
chemical O
vapor O
deposition O
. O

It O
has O
been O
found O
that O
for O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
high O
precursor O
flow O
rates O
generate O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
cores O
with O
In O
- O
rich O
shells O
, O
while O
low O
precursor O
flow O
rates O
produce O
binary O
GaAs B
cores O
with O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
shells O
. O

It O
has O
been O
found O
that O
for O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
high O
precursor O
flow O
rates O
generate O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
cores O
with O
In O
- O
rich O
shells O
, O
while O
low O
precursor O
flow O
rates O
produce O
binary O
GaAs B
cores O
with O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
shells O
. O

It O
has O
been O
found O
that O
for O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
nanowires O
high O
precursor O
flow O
rates O
generate O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
cores O
with O
In O
- O
rich O
shells O
, O
while O
low O
precursor O
flow O
rates O
produce O
binary O
GaAs B
cores O
with O
ternary O
In B
( I
x I
) I
Ga I
( I
1 I
- I
x I
) I
As I
shells O
. O

Synthesis O
and O
antibacterial O
evaluation O
of O
typharin B
analog O
: O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styryl I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
. O

Synthesis O
of O
the O
6 B
- I
hydroxy I
- I
7 I
- I
methyl I
analog O
of O
typharin B
( O
8 B
- I
dihydroxy I
- I
3 I
- I
styryl I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
) O
isolated O
from O
the O
rhizomes O
of O
Typha O
capensis O
has O
been O
described O
. O

Direct O
condensation O
of O
3 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
methylhomophthalic I
acid I
( O
1 O
) O
with O
cinnamoyl B
chloride I
at O
elevated O
temperature O
under O
inert O
conditions O
afforded O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styrylisocoumarin I
( O
2 O
) O
. O

Direct O
condensation O
of O
3 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
methylhomophthalic I
acid I
( O
1 O
) O
with O
cinnamoyl B
chloride I
at O
elevated O
temperature O
under O
inert O
conditions O
afforded O
6 B
, I
8 I
- I
dihydroxy I
- I
7 I
- I
methyl I
- I
3 I
- I
styrylisocoumarin I
( O
2 O
) O
. O

Hydrolysis O
of O
isocoumarin B
to O
keto B
acid I
( O
3 O
) O
followed O
by O
reduction O
and O
cyclodehydration O
of O
hydroxy B
acid I
analog O
( O
4 O
) O
afforded O
( B
+ I
/ I
- I
) I
- I
6 I
, I
8 I
- I
dimethoxy I
- I
3 I
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
3 I
, I
4 I
- I
dihydroisocoumarin I
( O
5 O
) O
. O

The O
highest O
encapsulation O
was O
obtained O
with O
an O
organic O
phase O
consisting O
of O
acetone B
: O
dichloromethane B
( O
1 O
: O
1 O
) O
, O
polyD B
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
( O
PLGA B
) O
50 O
: O
50 O
as O
polymer O
and O
an O
initial O
mass O
of O
6 O
. O
6 O
mg O
of O
methylprednisolone B
. O

Aglinin B
A I
( O
1 O
) O
is O
a O
mixture O
of O
C O
( O
24 O
) O
- O
epimeric O
20S B
, I
24 I
- I
epoxy I
- I
24 I
, I
25 I
- I
dihydroxy I
- I
3 I
, I
4 I
- I
secodammar I
- I
4 I
( I
28 I
) I
- I
en I
- I
3 I
- I
oic I
acid I
and O
present O
in O
plants O
of O
the O
family O
Meliaceae O
. O

A O
CpIMPDH O
- O
selective O
N B
- I
aryl I
- I
3 I
, I
4 I
- I
dihydro I
- I
3 I
- I
methyl I
- I
4 I
- I
oxo I
- I
1 I
- I
phthalazineacetamide I
inhibitor O
was O
previously O
identified O
in O
a O
high O
throughput O
screening O
campaign O
. O

1 B
- I
[ I
( I
4 I
- I
Chlorophenyl I
) I
( I
phenyl I
) I
methylene I
] I
- I
4 I
- I
( I
6 I
- I
nitrobenzothiazol I
- I
2 I
- I
yl I
) I
semicarbazide I
emerged O
as O
the O
lead O
MAO O
- O
B O
inhibitor O
, O
with O
top O
ranking O
in O
both O
the O
experimental O
MAO O
- O
B O
assay O
( O
IC O
( O
50 O
) O
: O
0 O
. O
004 O
+ O
/ O
- O
0 O
. O
001 O
mu O
M O
) O
and O
in O
computational O
docking O
studies O
( O
K O
( O
i O
) O
: O
1 O
. O
08 O
mu O
M O
) O
. O

Metabolism O
of O
ABT B
- I
107 I
was O
investigated O
in O
in O
vitro O
hepatic O
systems O
, O
in O
rat O
and O
monkey O
receiving O
[ B
( I
14 I
) I
C I
] I
ABT I
- I
107 I
, O
and O
in O
vivo O
plasma O
in O
rat O
, O
dog O
, O
monkey O
and O
human O
. O

The O
macrocyclic B
tetrapeptide I
natural O
product O
CJ B
- I
15 I
, I
208 I
( O
cyclo B
[ I
Phe I
- I
d I
- I
Pro I
- I
Phe I
- I
Trp I
] I
) O
exhibited O
both O
dose O
- O
dependent O
antinociception O
and O
kappa O
opioid O
receptor O
( O
KOR O
) O
antagonist O
activity O
after O
oral O
administration O
. O

The O
cis B
- I
[ I
Ru I
( I
bpy I
) I
( I
2 I
) I
( I
py I
) I
NO I
( I
2 I
) I
] I
( I
PF I
( I
6 I
) I
) I
specie O
( O
RuBPY B
) O
has O
been O
used O
as O
nitric B
oxide I
( O
NO B
) O
delivery O
agent O
. O

A O
new O
aliphatic O
enone O
, O
( B
17Z I
, I
20Z I
) I
- I
hexacosa I
- I
17 I
, I
20 I
- I
dien I
- I
9 I
- I
one I
( O
3 O
) O
, O
and O
one O
new O
bisindole B
alkaloid I
, O
gangenoid B
( O
6 O
) O
, O
together O
with O
seven O
known O
compounds O
were O
isolated O
from O
the O
roots O
and O
aerial O
parts O
of O
Desmodium O
gangeticum O
( O
family O
: O
Leguminosae O
) O
. O

High O
- O
resolution O
real O
- O
space O
mapping O
of O
Li B
- O
ion O
diffusion O
in O
the O
LiNi B
( I
1 I
/ I
3 I
) I
Co I
( I
1 I
/ I
3 I
) I
Mn I
( I
1 I
/ I
3 I
) I
O I
2 I
cathode O
within O
an O
all O
- O
solid O
- O
state O
thin O
film O
Li B
- O
ion O
battery O
has O
been O
conducted O
using O
advanced O
scanning O
probe O
microscopy O
techniques O
, O
namely O
, O
band O
excitation O
electrochemical O
strain O
microscopy O
( O
BE O
- O
ESM O
) O
and O
conductive O
atomic O
force O
microscopy O
. O

In O
addition O
, O
local O
variations O
of O
the O
electrochemical O
response O
in O
the O
LiNi B
( I
1 I
/ I
3 I
) I
Co I
( I
1 I
/ I
3 I
) I
Mn I
( I
1 I
/ I
3 I
) I
O I
2 I
thin O
film O
cathode O
at O
different O
cycling O
stages O
have O
been O
investigated O
. O

3H B
- I
1 I
, I
2 I
, I
4 I
- I
Dithiazol I
- I
3 I
- I
one I
compounds O
as O
novel O
potential O
affordable O
antitubercular O
agents O
. O

Herein O
we O
synthesized O
a O
series O
of O
novel O
compounds O
by O
bioisosteric O
replacement O
of O
the O
oxathiazol B
- I
2 I
- I
one I
ring O
with O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
, O
and O
also O
fifteen O
1 B
, I
3 I
, I
4 I
- I
oxathiazol I
- I
2 I
- I
one I
molecules O
in O
order O
for O
potency O
comparison O
and O
structure O
- O
activity O
relationship O
elucidation O
since O
their O
antibacterial O
effects O
on O
the O
virulent O
strains O
were O
not O
evaluated O
before O
. O

Herein O
we O
synthesized O
a O
series O
of O
novel O
compounds O
by O
bioisosteric O
replacement O
of O
the O
oxathiazol B
- I
2 I
- I
one I
ring O
with O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
, O
and O
also O
fifteen O
1 B
, I
3 I
, I
4 I
- I
oxathiazol I
- I
2 I
- I
one I
molecules O
in O
order O
for O
potency O
comparison O
and O
structure O
- O
activity O
relationship O
elucidation O
since O
their O
antibacterial O
effects O
on O
the O
virulent O
strains O
were O
not O
evaluated O
before O
. O

Among O
the O
tested O
compounds O
, O
3H B
- I
1 I
, I
2 I
, I
4 I
- I
dithiazol I
- I
3 I
- I
one I
compound O
4n O
was O
found O
to O
be O
the O
most O
active O
with O
a O
lowest O
MIC O
( O
90 O
) O
value O
of O
1 O
mu O
g O
/ O
mL O
. O

The O
decatungstate O
anion O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
4 I
- I
) I
is O
widely O
used O
as O
a O
photocatalyst O
in O
different O
transformations O
, O
during O
which O
it O
undergoes O
one O
- O
electron O
reduction O
to O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
5 I
- I
) I
, O
possibly O
protonated O
; O
the O
bi O
- O
reduced O
species O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
6 I
- I
) I
is O
obtained O
by O
ensuing O
disproportionation O
. O

The O
decatungstate O
anion O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
4 I
- I
) I
is O
widely O
used O
as O
a O
photocatalyst O
in O
different O
transformations O
, O
during O
which O
it O
undergoes O
one O
- O
electron O
reduction O
to O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
5 I
- I
) I
, O
possibly O
protonated O
; O
the O
bi O
- O
reduced O
species O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
6 I
- I
) I
is O
obtained O
by O
ensuing O
disproportionation O
. O

The O
decatungstate O
anion O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
4 I
- I
) I
is O
widely O
used O
as O
a O
photocatalyst O
in O
different O
transformations O
, O
during O
which O
it O
undergoes O
one O
- O
electron O
reduction O
to O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
5 I
- I
) I
, O
possibly O
protonated O
; O
the O
bi O
- O
reduced O
species O
[ B
W I
( I
10 I
) I
O I
( I
32 I
) I
] I
( I
6 I
- I
) I
is O
obtained O
by O
ensuing O
disproportionation O
. O

Backbone O
degradable O
, O
linear O
, O
multiblock O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
doxorubicin B
( O
DOX B
) O
conjugates O
are O
synthesized O
by O
reversible O
addition O
- O
fragmentation O
chain O
transfer O
( O
RAFT O
) O
polymerization O
followed O
by O
chain O
extension O
via O
thiol B
- O
ene O
click O
reaction O
. O

Mass O
spectrometry O
analysis O
of O
aging O
in O
either O
H B
( I
2 I
) I
( I
16 I
) I
O I
or O
H B
( I
2 I
) I
( I
18 I
) I
O I
furthermore O
allowed O
us O
to O
identify O
the O
inhibition O
steps O
, O
in O
which O
water O
molecules O
are O
involved O
, O
thus O
providing O
insights O
into O
the O
mechanistic O
details O
of O
inhibition O
. O

Mass O
spectrometry O
analysis O
of O
aging O
in O
either O
H B
( I
2 I
) I
( I
16 I
) I
O I
or O
H B
( I
2 I
) I
( I
18 I
) I
O I
furthermore O
allowed O
us O
to O
identify O
the O
inhibition O
steps O
, O
in O
which O
water O
molecules O
are O
involved O
, O
thus O
providing O
insights O
into O
the O
mechanistic O
details O
of O
inhibition O
. O

5 B
- I
( I
( I
1 I
- I
Aroyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
methylene I
) I
- I
2 I
- I
thioxodihydropyrimid I
- I
4 I
, I
6 I
( I
1H I
, I
5H I
) I
- I
diones I
as O
potential O
anticancer O
agents O
with O
anti O
- O
inflammatory O
properties O
. O

A O
series O
of O
novel O
5 B
- I
( I
( I
1 I
- I
aroyl I
- I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
methylene I
) I
- I
2 I
- I
thioxodihydropyrimid I
- I
4 I
, I
6 I
( I
1H I
, I
5H I
) I
- I
diones I
( O
3a O
- O
z O
) O
have O
been O
evaluated O
for O
in O
vitro O
cytotoxicity O
against O
a O
panel O
of O
60 O
human O
tumor O
cell O
lines O
. O

Cell O
death O
was O
induced O
at O
relatively O
low O
concentrations O
by O
perfluorooctyl B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctane B
sulfonylamide I
( O
PFOSA B
) O
and O
the O
fluorotelomer B
alcohol I
1H B
, I
1H I
, I
2H I
, I
2H I
- I
perfluorodecanol I
( O
FTOH B
8 I
: I
2 I
) O
with O
EC O
( O
50 O
) O
- O
values O
of O
62 O
+ O
/ O
- O
7 O
. O
6 O
, O
13 O
+ O
/ O
- O
1 O
. O
8 O
and O
15 O
+ O
/ O
- O
4 O
. O
2 O
mu O
M O
( O
mean O
+ O
/ O
- O
SD O
) O
respectively O
. O

NMR O
crystallography O
of O
alpha B
- I
poly I
( I
L I
- I
lactide I
) I
. O

All O
the O
samples O
contained O
3 B
, I
3 I
, I
5 I
, I
5 I
, I
8 I
, I
8 I
- I
hexamethyl I
- I
7 I
- I
oxabicyclo I
[ I
4 I
. I
3 I
. I
0 I
] I
non I
- I
1 I
( I
6 I
) I
- I
ene I
- I
2 I
, I
4 I
- I
dione I
( O
up O
to O
4 O
. O
9 O
% O
) O
. O

To O
unravel O
the O
role O
of O
doping O
in O
iron B
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe B
( I
2 I
) I
As I
( I
2 I
) I
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba B
( I
Fe I
( I
1 I
- I
x I
) I
Co I
( I
x I
) I
) I
( I
2 I
) I
As I
( I
2 I
) I
, O
BaFe B
( I
2 I
) I
( I
As I
( I
1 I
- I
x I
) I
P I
( I
x I
) I
) I
( I
2 I
) I
, O
and O
Ba B
( I
1 I
- I
x I
) I
K I
( I
x I
) I
Fe I
( I
2 I
) I
As I
( I
2 I
) I
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

To O
unravel O
the O
role O
of O
doping O
in O
iron B
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe B
( I
2 I
) I
As I
( I
2 I
) I
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba B
( I
Fe I
( I
1 I
- I
x I
) I
Co I
( I
x I
) I
) I
( I
2 I
) I
As I
( I
2 I
) I
, O
BaFe B
( I
2 I
) I
( I
As I
( I
1 I
- I
x I
) I
P I
( I
x I
) I
) I
( I
2 I
) I
, O
and O
Ba B
( I
1 I
- I
x I
) I
K I
( I
x I
) I
Fe I
( I
2 I
) I
As I
( I
2 I
) I
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

To O
unravel O
the O
role O
of O
doping O
in O
iron B
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe B
( I
2 I
) I
As I
( I
2 I
) I
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba B
( I
Fe I
( I
1 I
- I
x I
) I
Co I
( I
x I
) I
) I
( I
2 I
) I
As I
( I
2 I
) I
, O
BaFe B
( I
2 I
) I
( I
As I
( I
1 I
- I
x I
) I
P I
( I
x I
) I
) I
( I
2 I
) I
, O
and O
Ba B
( I
1 I
- I
x I
) I
K I
( I
x I
) I
Fe I
( I
2 I
) I
As I
( I
2 I
) I
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

To O
unravel O
the O
role O
of O
doping O
in O
iron B
- O
based O
superconductors O
, O
we O
investigated O
the O
in O
- O
plane O
resistivity O
of O
BaFe B
( I
2 I
) I
As I
( I
2 I
) I
doped O
at O
one O
of O
the O
three O
different O
lattice O
sites O
, O
Ba B
( I
Fe I
( I
1 I
- I
x I
) I
Co I
( I
x I
) I
) I
( I
2 I
) I
As I
( I
2 I
) I
, O
BaFe B
( I
2 I
) I
( I
As I
( I
1 I
- I
x I
) I
P I
( I
x I
) I
) I
( I
2 I
) I
, O
and O
Ba B
( I
1 I
- I
x I
) I
K I
( I
x I
) I
Fe I
( I
2 I
) I
As I
( I
2 I
) I
, O
focusing O
on O
the O
doping O
effect O
in O
the O
low O
- O
temperature O
antiferromagnetic O
/ O

A O
cobalt B
chlorin I
complex O
( O
Co B
( I
II I
) I
( I
Ch I
) I
) O
efficiently O
and O
selectively O
catalyzed O
two O
- O
electron O
reduction O
of O
dioxygen B
( O
O B
( I
2 I
) I
) O
by O
one O
- O
electron O
reductants O
( O
ferrocene B
derivatives O
) O
to O
produce O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
in O
the O
presence O
of O
perchloric B
acid I
( O
HClO B
( I
4 I
) I
) O
in O
benzonitrile B
( O
PhCN B
) O
at O
298 O
K O
. O

The O
detailed O
kinetic O
studies O
have O
revealed O
that O
the O
rate O
- O
determining O
step O
in O
the O
catalytic O
cycle O
is O
the O
proton O
- O
coupled O
electron O
transfer O
reduction O
of O
O B
( I
2 I
) I
with O
the O
protonated O
Co B
( I
II I
) I
( I
Ch I
) I
( O
[ B
Co I
( I
II I
) I
( I
ChH I
) I
] I
( I
+ I
) I
) O
that O
is O
produced O
by O
facile O
electron O
- O
transfer O
reduction O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
by O
ferrocene B
derivative O
in O
the O
presence O
of O
HClO B
( I
4 I
) I
. O

The O
detailed O
kinetic O
studies O
have O
revealed O
that O
the O
rate O
- O
determining O
step O
in O
the O
catalytic O
cycle O
is O
the O
proton O
- O
coupled O
electron O
transfer O
reduction O
of O
O B
( I
2 I
) I
with O
the O
protonated O
Co B
( I
II I
) I
( I
Ch I
) I
( O
[ B
Co I
( I
II I
) I
( I
ChH I
) I
] I
( I
+ I
) I
) O
that O
is O
produced O
by O
facile O
electron O
- O
transfer O
reduction O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
by O
ferrocene B
derivative O
in O
the O
presence O
of O
HClO B
( I
4 I
) I
. O

The O
one O
- O
electron O
- O
reduction O
potential O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
was O
positively O
shifted O
from O
0 O
. O
37 O
V O
( O
vs O
SCE O
) O
to O
0 O
. O
48 O
V O
by O
the O
addition O
of O
HClO B
( I
4 I
) I
due O
to O
the O
protonation O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
. O

The O
one O
- O
electron O
- O
reduction O
potential O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
was O
positively O
shifted O
from O
0 O
. O
37 O
V O
( O
vs O
SCE O
) O
to O
0 O
. O
48 O
V O
by O
the O
addition O
of O
HClO B
( I
4 I
) I
due O
to O
the O
protonation O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
. O

Such O
a O
positive O
shift O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
by O
protonation O
resulted O
in O
enhancement O
of O
the O
catalytic O
reactivity O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
for O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
with O
a O
lower O
overpotential O
as O
compared O
with O
that O
of O
[ B
Co I
( I
III I
) I
( I
OEP I
) I
] I
( I
+ I
) I
. O

Such O
a O
positive O
shift O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
by O
protonation O
resulted O
in O
enhancement O
of O
the O
catalytic O
reactivity O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
for O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
with O
a O
lower O
overpotential O
as O
compared O
with O
that O
of O
[ B
Co I
( I
III I
) I
( I
OEP I
) I
] I
( I
+ I
) I
. O

Such O
a O
positive O
shift O
of O
[ B
Co I
( I
III I
) I
( I
Ch I
) I
] I
( I
+ I
) I
by O
protonation O
resulted O
in O
enhancement O
of O
the O
catalytic O
reactivity O
of O
[ B
Co I
( I
III I
) I
( I
ChH I
) I
] I
( I
2 I
+ I
) I
for O
the O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
with O
a O
lower O
overpotential O
as O
compared O
with O
that O
of O
[ B
Co I
( I
III I
) I
( I
OEP I
) I
] I
( I
+ I
) I
. O

Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
with O
acetone B
and O
ethanol B
by O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
hexyl I
- I
3 I
- I
methylimidazolium I
bis I
( I

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
hexyl I
- I
3 I
- I
methylimidazolium I
bis I
( I

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
hexyl I
- I
3 I
- I
methylimidazolium I
bis I
( I

trifluoromethylsulfo I
) I
imide I
) O
with O
acetone B
and O
ethanol B
were O
studied O
in O
dependence O
on O
composition O
in O
the O
temperature O
range O
from O
283 O
. O
15 O
to O
323 O
. O
15 O
K O
, O
applying O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Ile I
- I
HEMA I
, O
1c O
) O
, O
and O
Boc B
- I
L I
- I
isoleucine I
acryloyloxyethyl I
ester I
( O
Boc B
- I
L I
- I
Ile I
- I
HEA I
, O
1d O
) O
, O
are O
reported O
. O

No O
significant O
difference O
was O
found O
between O
the O
groups O
with O
regard O
to O
perfluorooctane B
sulfonate I
( O
PFOS B
) O
, O
perfluorooctanoic B
acid I
( O
PFOA B
) O
, O
mono B
- I
ethylhexyl I
phthalate I
( O
MEHP B
) O
and O
di B
- I
( I
2 I
- I
ethylhexyl I
) I
phthalate I
( O
DEHP B
) O
concentrations O
. O

Among O
the O
isolated O
compounds O
, O
ent B
- I
18 I
- I
acetoxykaur I
- I
16 I
- I
en I
- I
15 I
- I
one I
( O
20 O
) O
displayed O
the O
most O
significant O
inhibition O
of O
superoxide B
anion O
generation O
and O
elastase O
release O
. O

Prednisolone B
tablets O
were O
coated O
with O
a O
double O
- O
coating O
formulation O
by O
applying O
an O
inner O
layer O
composed O
of O
EUDRAGIT B
( O
R O
) O
S O
neutralised O
to O
pH O
8 O
. O
0 O
and O
a O
buffer O
salt O
( O
10 O
% O
KH B
( I
2 I
) I
PO I
( I
4 I
) I
) O
, O
which O
was O
overcoated O
with O
layer O
of O
standard O
EUDRAGIT B
( O
R O
) O
S O
organic O
solution O
. O

Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5 O
, O
termed O
the O
MPEP B
( O
2 B
- I
Methyl I
- I
6 I
- I
( I
phenylethynyl I
) I
pyridine I
) O
binding O
site O
. O

However O
, O
one O
mGlu5 O
PAM O
, O
CPPHA B
( O
N B
- I
( I
4 I
- I
chloro I
- I
2 I
- I
[ I
( I
1 I
, I
3 I
- I
dioxo I
- I
1 I
, I
3 I
- I
dihydro I
- I
2H I
- I
isoindol I
- I
2 I
- I
yl I
) I
methyl I
] I
phenyl I
) I
- I
2 I
- I
hydroxybenzamide I
) O
, O
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5 O
. O

Using O
cell O
- O
based O
assays O
and O
brain O
slice O
preparations O
, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 O
PAM O
from O
the O
CPPHA B
series O
termed O
NCFP B
( O
N B
- I
( I
4 I
- I
chloro I
- I
2 I
- I
( I
( I
4 I
- I
fluoro I
- I
1 I
, I
3 I
- I
dioxoisoindolin I
- I
2 I
- I
yl I
) I
methyl I
) I
phenyl I
) I
picolinamide I
) O
. O

Previously O
we O
reported O
that O
infusion O
of O
the O
mu O
- O
opioid O
receptor O
agonist O
[ B
D I
- I
Ala2 I
, I
N I
- I
Me I
- I
Phe4 I
, I
Glycinol5 I
] I
- I
Enkephalin I
( O
DAMGO B
) O
into O
the O
mu O
- O
opioid O
receptor O
expressing O
lateral O
parabrachial O
nucleus O
increases O
feeding O
. O

Our O
results O
showed O
that O
an O
ultra O
- O
low O
concentration O
of O
( B
- I
) I
- I
naloxone I
( O
0 O
. O
001 O
nM O
) O
and O
several O
concentrations O
of O
( B
+ I
) I
- I
naloxone I
( O
0 O
. O
01 O
- O
10 O
nM O
) O
enhanced O
DAMGO B
- O
stimulated O
guanosine B
- I
5 I
' I
- I
0 I
- I
( I
gamma I
- I
thio I
) I
- I
triphosphate I
incorporation O
in O
parabrachial O
sections O
in O
vitro O
. O

Eight O
constituents O
possessing O
the O
high O
absolute O
mean O
impact O
value O
were O
identified O
to O
have O
significant O
cytotoxicity O
, O
and O
the O
cytotoxic O
effect O
of O
these O
constituents O
was O
partly O
confirmed O
by O
subsequent O
MTT B
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
) O
assays O
and O
previous O
reports O
. O

Cleavage O
of O
DNA O
by O
proton O
- O
coupled O
electron O
transfer O
to O
a O
photoexcited O
, O
hydrated B
Ru I
( I
II I
) I
1 I
, I
10 I
- I
phenanthroline I
- I
5 I
, I
6 I
- I
dione I
complex O
. O

Visible O
light O
irradiation O
of O
a O
ruthenium B
( I
II I
) I
quinone B
- O
containing O
complex O
, O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phendione I
) I
] I
( I
2 I
+ I
) I
( O
1 O
( O
2 O
+ O
) O
) O
, O
where O
phendione B
= O
1 B
, I
10 I
- I
phenanthroline I
- I
5 I
, I
6 I
- I
dione I
, O
leads O
to O
DNA O
cleavage O
in O
an O
oxygen B
independent O
manner O
. O

Visible O
light O
irradiation O
of O
a O
ruthenium B
( I
II I
) I
quinone B
- O
containing O
complex O
, O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phendione I
) I
] I
( I
2 I
+ I
) I
( O
1 O
( O
2 O
+ O
) O
) O
, O
where O
phendione B
= O
1 B
, I
10 I
- I
phenanthroline I
- I
5 I
, I
6 I
- I
dione I
, O
leads O
to O
DNA O
cleavage O
in O
an O
oxygen B
independent O
manner O
. O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile B
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone B
functionality O
, O
giving O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phenH I
( I
2 I
) I
O I
) I
] I
( I
2 I
+ I
) I
( O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
, O
where O
phenH B
( I
2 I
) I
O I
= O
1 B
, I
10 I
- I
phenanthroline I
- I
6 I
- I
one I
- I
5 I
- I
diol I
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile B
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone B
functionality O
, O
giving O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phenH I
( I
2 I
) I
O I
) I
] I
( I
2 I
+ I
) I
( O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
, O
where O
phenH B
( I
2 I
) I
O I
= O
1 B
, I
10 I
- I
phenanthroline I
- I
6 I
- I
one I
- I
5 I
- I
diol I
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

A O
combination O
of O
NMR O
analyses O
, O
transient O
absorption O
spectroscopy O
, O
and O
fluorescence O
measurements O
in O
water O
and O
acetonitrile B
reveal O
that O
complex O
1 O
( O
2 O
+ O
) O
must O
be O
hydrated O
at O
the O
quinone B
functionality O
, O
giving O
[ B
( I
phen I
) I
( I
2 I
) I
Ru I
( I
phenH I
( I
2 I
) I
O I
) I
] I
( I
2 I
+ I
) I
( O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
, O
where O
phenH B
( I
2 I
) I
O I
= O
1 B
, I
10 I
- I
phenanthroline I
- I
6 I
- I
one I
- I
5 I
- I
diol I
) O
, O
in O
order O
to O
access O
a O
long O
- O
lived O
( O
3 O
) O

The O
resulting O
excited O
state O
in O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
has O
photophysical O
properties O
similar O
to O
the O
( O
3 O
) O
MLCT O
state O
in O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
with O
the O
added O
functionality O
of O
basic O
sites O
at O
the O
ligand O
periphery O
. O

The O
resulting O
excited O
state O
in O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
has O
photophysical O
properties O
similar O
to O
the O
( O
3 O
) O
MLCT O
state O
in O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
with O
the O
added O
functionality O
of O
basic O
sites O
at O
the O
ligand O
periphery O
. O

Whereas O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
does O
not O
show O
direct O
DNA O
cleavage O
, O
the O
deprotonated O
form O
of O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
does O
via O
a O
proton O
- O
coupled O
electron O
transfer O
( O
PCET O
) O
mechanism O
where O
the O
peripheral O
basic O
oxygen B
sites O
act O
as O
the O
proton O
acceptor O
. O

Whereas O
[ B
Ru I
( I
phen I
) I
( I
3 I
) I
] I
( I
2 I
+ I
) I
* O
does O
not O
show O
direct O
DNA O
cleavage O
, O
the O
deprotonated O
form O
of O
1H B
( I
2 I
) I
O I
( I
2 I
+ I
) I
* O
does O
via O
a O
proton O
- O
coupled O
electron O
transfer O
( O
PCET O
) O
mechanism O
where O
the O
peripheral O
basic O
oxygen B
sites O
act O
as O
the O
proton O
acceptor O
. O

In O
the O
absence O
of O
added O
salt O
, O
alternating O
adsorption O
of O
5 O
bilayers O
of O
protonated O
poly B
( I
allylamine I
) I
( O
PAH B
) O
and O
comb O
- O
like O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
- I
graft I
- I
poly I
( I
acrylic I
acid I
) I
( O
PHEMA B
- I
g I
- I
PAA I
) O
leads O
to O
~ O
2 O
- O
fold O
thicker O
coatings O
than O
adsorption O
of O
PAH B
and O
linear O
PAA B
, O
and O
the O
difference O
in O
the O
thicknesses O
of O
the O
two O
coatings O
increases O
with O
the O
number O
of O
bilayers O
. O

Biosynthesis O
and O
characterization O
of O
diblock O
copolymer O
of O
p B
( I
3 I
- I
Hydroxypropionate I
) I
- I
block I
- I
p I
( I
4 I
- I
hydroxybutyrate I
) I
from O
recombinant O
Escherichia O
coli O
. O

Two O
block O
copolymers O
were O
formed O
from O
this O
study O
, O
including O
the O
P3HP B
- O
b O
- O
29 O
% O
P4HB B
and O
P3HP B
- O
b O
- O
37 O
% O
P4HB B
, O
they O
showed O
superior O
properties O
over O
random O
copolymers O
P B
( I
3HP I
- I
co I
- I
4HB I
) I
. O

New O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
active O
pharmacophores O
: O
synthesis O
and O
anticonvulsant O
studies O
. O

Five O
new O
series O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridines I
carrying O
biologically O
active O
pyrazoline B
( O
4a O
- O
e O
) O
, O
cyanopyridone B
( O
5a O
, O
b O
) O
, O
cyanopyridine B
( O
6a O
- O
f O
) O
, O
2 B
- I
aminopyrimidine I
( O
7a O
- O
f O
) O
and O
pyrimidine B
- I
2 I
- I
thione I
( O
8a O
- O
d O
) O
systems O
were O
designed O
and O
synthesized O
as O
prominent O
anticonvulsant O
agents O
. O

Compounds O
4b O
, O
5a O
, O
5b O
, O
6a O
, O
7e O
and O
8d O
possessing O
4 B
- I
fluorophenyl I
substituent O
at O
2nd O
position O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyridine I
ring O
displayed O
potent O
anticonvulsant O
activity O
without O
displaying O
any O
toxicity O
. O

Poly B
( I
styrene I
oxide I
) I
- I
poly I
( I
ethylene I
oxide I
) I
block O
copolymers O
: O
From O
" O
classical O
" O
chemotherapeutic O
nanocarriers O
to O
active O
cell O
- O
response O
inducers O
. O

Two O
poly B
( I
styrene I
oxide I
) I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PSO B
- I
PEO I
) O
triblock O
copolymers O
with O
different O
chain O
lengths O
were O
analyzed O
as O
potential O
chemotherapeutic O
nanocarriers O
, O
and O
their O
ability O
to O
inhibit O
the O
P O
- O
glycoprotein O
( O
P O
- O
gp O
) O
efflux O
pump O
in O
a O
multidrug O
resistant O
( O
MDR O
) O
cell O
line O
were O
measured O
in O
order O
to O
establish O
possible O
cell O
- O
responses O
induced O
by O
the O
presence O
of O
the O
copolymer O
molecules O
. O

1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
Penta I
- I
O I
- I
galloyl I
- I
beta I
- I
d I
- I
glucose I
, O
a O
bioactivity O
guided O
isolated O
compound O
from O
Mangifera O
indica O
inhibits O
11 O
beta O
- O
HSD O
- O
1 O
and O
ameliorates O
high O
fat O
diet O
- O
induced O
diabetes O
in O
C57BL O
/ O
6 O
mice O
. O

The O
EA O
- O
7 O
/ O
8 O
- O
9 O
/ O
10 O
- O
4 O
fraction O
was O
evolved O
as O
a O
most O
potent O
fraction O
among O
all O
the O
fractions O
and O
it O
was O
identified O
as O
well O
known O
gallotannin B
compound O
1 B
, I
2 I
, I
3 I
, I
4 I
, I
6 I
penta I
- I
O I
- I
galloyl I
- I
beta I
- I
d I
- I
glucose I
( O
PGG B
) O
by O
spectral O
analysis O
. O

Synthesis O
of O
an O
MIF B
- I
1 I
analogue O
containing O
enantiopure O
( B
S I
) I
- I
alpha I
- I
trifluoromethyl I
- I
proline I
and O
biological O
evaluation O
on O
nociception O
. O

Leu B
- I
Gly I
- I
NH2 I
and O
the O
( B
S I
) I
- I
alpha I
- I
Tfm I
- I
proline I
. O

The O
results O
are O
in O
favor O
of O
a O
participation O
of O
both O
system O
since O
pretreatment O
, O
20 O
min O
before O
injection O
of O
the O
CF3 B
- I
( I
MIF I
- I
1 I
) I
2 O
, O
with O
the O
non O
- O
competitive O
antagonist O
of O
opiate O
receptors O
naloxone B
, O
the O
nitric B
oxide I
synthase O
( O
NOS O
) O
inhibitor O
l B
- I
N I
( I
G I
) I
- I
nitroarginine I
ester I
( O
l B
- I
NAME I
) O
or O
the O
nitric B
oxide I
( O
NO B
) O
donor O
l B
- I
arginine I
( O
l B
- I
Arg I
) O
significantly O
decreased O
the O
pain O
perception O
in O
PP O
and O
HP O
tests O
. O

Synthesis O
, O
characterization O
, O
cytotoxicity O
and O
antimicrobial O
studies O
on O
bis B
( I
N I
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamato I
- I
S I
, I
S I
' I
) I
zinc I
( I
II I
) I
and O
its O
nitrogen B
donor O
adducts O
. O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

[ O
Zn B
( I
fpedtc I
) I
2 I
] O
( O
1 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
py I
) I
] O
( O
2 O
) O
, O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
1 I
, I
10 I
- I
phen I
) I
] O
( O
3 O
) O
and O
[ O
Zn B
( I
fpedtc I
) I
2 I
( I
2 I
, I
2 I
' I
- I
bipy I
) I
] O
( O
4 O
) O
( O
where O
fpedtc B
= O
N B
- I
furfuryl I
- I
N I
- I
( I
2 I
- I
phenylethyl I
) I
dithiocarbamate I
, O
py O
= O
pyridine B
, O
1 B
, I
10 I
- I
phen I
= O

A O
series O
of O
mono B
- I
substituted I
4 I
- I
phenylpiperidines I
and I
- I
piperazines I
have O
been O
synthesized O
and O
their O
effects O
on O
the O
dopaminergic O
system O
tested O
in O
vivo O
. O

Here O
we O
describe O
polymersomes O
able O
to O
encapsulate O
up O
to O
6 O
% O
( O
w O
/ O
w O
) O
of O
doxorubicin B
( O
DOX B
) O
together O
with O
30 O
% O
( O
w O
/ O
w O
) O
of O
superparamagnetic O
iron B
oxide I
nanoparticles O
( O
USPIO O
; O
gamma B
- I
Fe I
( I
2 I
) I
O I
( I
3 I
) I
) O
. O

Importantly O
, O
pharmacological O
inhibition O
of O
CTH O
in O
human O
melanoma O
cells O
also O
reconstituted O
senescence O
in O
the O
majority O
of O
cell O
lines O
, O
and O
CTH O
knockdown O
reduced O
tumorigenic O
effects O
such O
as O
proliferation O
, O
H B
( I
2 I
) I
O I
( I
2 I
) I
resistance O
and O
soft O
agar O
growth O
. O

Support O
for O
5 O
- O
HT2C O
receptor O
functional O
selectivity O
in O
vivo O
utilizing O
structurally O
diverse O
, O
selective O
5 O
- O
HT2C O
receptor O
ligands O
and O
the O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
elicited O
head O
- O
twitch O
response O
model O
. O

There O
are O
seemingly O
conflicting O
data O
in O
the O
literature O
regarding O
the O
role O
of O
serotonin B
( O
5 B
- I
HT I
) O
5 O
- O
HT2C O
receptors O
in O
the O
mouse O
head O
- O
twitch O
response O
( O
HTR O
) O
elicited O
by O
the O
hallucinogenic O
5 O
- O
HT2A O
/ O
2B O
/ O
2C O
receptor O
agonist O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
) O
. O

Commercially O
- O
available O
5 O
- O
HT2C O
agonists O
( O
CP B
809101 I
, O
Ro B
60 I
- I
0175 I
, O
WAY B
161503 I
, O
mCPP B
, O
and O
1 B
- I
methylpsilocin I
) O
, O
novel O
4 B
- I
phenyl I
- I
2 I
- I
N I
, I
N I
- I
dimethyl I
- I
aminotetralin I
( O
PAT B
) O
- O
type O
5 O
- O
HT2C O
agonists O
( O
with O
5 O
- O
HT2A O
/ O
2B O
antagonist O
activity O
) O
, O
and O
antagonists O
selective O
for O
5 O
- O
HT2A O
( O
M100907 B
) O
, O
5 O
- O
HT2C O
( O
SB B
- I

For O
this O
purpose O
phosphatidylcholine B
liposome O
formulations O
as O
well O
as O
d B
- I
alpha I
- I
tocopheryl I
polyethylene I
glycol I
1000 I
succinate I
( O
TPGS B
) O
micelle O
dispersions O
and O
polyvinylpyrrolidone B
( O
PVP B
) O
supersaturated O
solutions O
were O
prepared O
in O
order O
to O
increase O
the O
apparent O
solubility O
of O
HC O
. O

beta B
- I
Asarone I
( O
1 B
- I
propenyl I
- I
2 I
, I
4 I
, I
5 I
- I
methoxybenzol I
) O
is O
a O
compound O
from O
the O
traditional O
medical O
herb O
Acorus O
calamus O
Linn O
. O

Didehydrostemofoline B
and O
eleven O
of O
its O
derivatives O
were O
synthesized O
and O
the O
cytotoxicity O
and O
their O
effect O
on O
doxorubicin B
, O
vinblastine B
and O
paclitaxel B
sensitivity O
in O
drug O
resistant O
( O
KB O
- O
V1 O
and O
K562 O
/ O
Adr O
) O
and O
drug O
sensitive O
( O
KB O
- O
3 O
- O
1 O
and O
K562 O
) O
cell O
lines O
by O
a O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
( O
MTT B
) O
assay O
were O
determined O
. O

As O
the O
results O
of O
structure O
- O
activity O
relationship O
( O
SAR O
) O
study O
of O
the O
series O
, O
the O
compounds O
with O
4 B
- I
methyl I
- I
quinazoline I
- I
2 I
- I
yl I
- I
methyl I
group O
at O
N O
- O
1 O
position O
and O
2 B
- I
aminoethylaminomethy I
group O
gave O
better O
activities O
. O

A O
series O
of O
N O
- O
14 O
sidechain O
substituted O
analogues O
of O
styelsamine B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridine I
) O
and O
cystodytin B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridin I
- I
4 I
- I
one I
) O
alkaloids O
have O
been O
prepared O
and O
evaluated O
for O
their O
DNA O
binding O
affinity O
and O
antiproliferative O
activity O
towards O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

A O
series O
of O
N O
- O
14 O
sidechain O
substituted O
analogues O
of O
styelsamine B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridine I
) O
and O
cystodytin B
( O
pyrido B
[ I
4 I
, I
3 I
, I
2 I
- I
mn I
] I
acridin I
- I
4 I
- I
one I
) O
alkaloids O
have O
been O
prepared O
and O
evaluated O
for O
their O
DNA O
binding O
affinity O
and O
antiproliferative O
activity O
towards O
a O
panel O
of O
human O
tumor O
cell O
lines O
. O

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly B
( I
glycidyl I
methacrylate I
) I
and O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
microspheres O
containing O
amino B
and O
/ O
or O
carboxyl B
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha B
, I
omega I
- I
bis I
- I
carboxy I
poly I
( I
ethylene I
glycol I
) I
and O
amino B
- O
terminated O
poly B
( I
ethylene I
glycol I
- I
co I
- I
propylene I
glycol I
) I
or O
alpha B
- I
methoxy I
- I
omega I
- I
amino I

To O
minimize O
non O
- O
specific O
protein O
adsorption O
on O
macroporous O
poly B
( I
glycidyl I
methacrylate I
) I
and O
poly B
( I
2 I
- I
hydroxyethyl I
methacrylate I
) I
microspheres O
containing O
amino B
and O
/ O
or O
carboxyl B
groups O
, O
the O
microspheres O
are O
coated O
with O
alpha B
, I
omega I
- I
bis I
- I
carboxy I
poly I
( I
ethylene I
glycol I
) I
and O
amino B
- O
terminated O
poly B
( I
ethylene I
glycol I
- I
co I
- I
propylene I
glycol I
) I
or O
alpha B
- I
methoxy I
- I
omega I
- I
amino I

Adsorption O
of O
bovine O
serum O
albumin O
( O
BSA O
) O
, O
gamma O
- O
globulin O
, O
( B
125 I
) I
I I
- O
BSA O
, O
pepsin O
, O
and O
chymotrypsin O
on O
neat O
and O
PEGylated O
microspheres O
is O
determined O
by O
UV O
- O
VIS O
spectroscopy O
of O
supernatants O
and O
eluates O
or O
by O
measurement O
of O
radioactivity O
in O
an O
ionization O
chamber O
. O

In O
vitro O
and O
mechanistic O
studies O
of O
an O
antiamyloidogenic O
self O
- O
assembled O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
architecture O
. O

Given O
the O
significant O
similarities O
between O
amyloids O
and O
the O
architecture O
of O
self O
- O
assembled O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
, O
we O
hypothesized O
that O
the O
latter O
may O
bind O
and O
stabilize O
a O
nontoxic O
form O
of O
A O
beta O
, O
thereby O
preventing O
its O
aggregation O
into O
toxic O
forms O
. O

By O
screening O
a O
focused O
library O
of O
six O
- O
residue O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
and O
optimizing O
the O
activity O
of O
a O
lead O
peptide O
, O
we O
found O
one O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
( O
CP B
- I
2 I
) O
that O
interacts O
strongly O
with O
A O
beta O
and O
inhibits O
its O
aggregation O
. O

By O
screening O
a O
focused O
library O
of O
six O
- O
residue O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
and O
optimizing O
the O
activity O
of O
a O
lead O
peptide O
, O
we O
found O
one O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptide I
( O
CP B
- I
2 I
) O
that O
interacts O
strongly O
with O
A O
beta O
and O
inhibits O
its O
aggregation O
. O

Further O
studies O
will O
show O
whether O
these O
kinds O
of O
abiotic O
cyclic B
D I
, I
L I
- I
alpha I
- I
peptides I
are O
also O
beneficial O
as O
an O
intervention O
in O
related O
in O
vivo O
models O
. O

X O
- O
ray O
absorption O
spectroscopy O
and O
energy O
storage O
of O
Ni B
- O
doped O
cobalt B
nitride I
, O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
, O
prepared O
by O
a O
simple O
synthesis O
route O
. O

Metal B
nitride I
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
are O
prepared O
by O
nitridation O
using O
NiCo B
( I
2 I
) I
O I
( I
4 I
) I
as O
a O
precursor O
material O
by O
heating O
at O
335 O
degrees O
C O
for O
2 O
h O
in O
flowing O
NH B
( I
3 I
) I
+ O
N B
( I
2 I
) I
gas O
and O
characterized O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
field O
emission O
- O
scanning O
electron O
microscopy O
( O
FE O
- O
SEM O
) O
, O
high O
resolution O
- O
transmission O
electron O
microscopy O
( O
HR O
- O
TEM O
) O
, O
along O
with O
selective O
area O
electron O
diffraction O
( O
SAED O
) O
and O
X O

Metal B
nitride I
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
are O
prepared O
by O
nitridation O
using O
NiCo B
( I
2 I
) I
O I
( I
4 I
) I
as O
a O
precursor O
material O
by O
heating O
at O
335 O
degrees O
C O
for O
2 O
h O
in O
flowing O
NH B
( I
3 I
) I
+ O
N B
( I
2 I
) I
gas O
and O
characterized O
by O
X O
- O
ray O
diffraction O
( O
XRD O
) O
, O
field O
emission O
- O
scanning O
electron O
microscopy O
( O
FE O
- O
SEM O
) O
, O
high O
resolution O
- O
transmission O
electron O
microscopy O
( O
HR O
- O
TEM O
) O
, O
along O
with O
selective O
area O
electron O
diffraction O
( O
SAED O
) O
and O
X O

The O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
showed O
a O
shift O
in O
edge O
energy O
towards O
lower O
values O
due O
to O
Ni B
- O
doping O
to O
cobalt O
site O
. O

The O
Li B
- O
storage O
behaviour O
of O
( B
Ni I
( I
0 I
. I
33 I
) I
Co I
( I
0 I
. I
67 I
) I
) I
N I
nanoparticles O
was O
evaluated O
by O
galvanostatic O
cycling O
and O
cyclic O
voltammetry O
in O
the O
cells O
with O
Li B
- O
metal O
as O
counter O
electrode O
in O
the O
voltage O
range O
of O
0 O
. O
005 O
- O
3 O
. O
0 O
V O
at O
ambient O
temperature O
. O

Data O
is O
presented O
for O
ethylammonium B
nitrate I
( O
EAN B
) O
and O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoro I
- I
methylsulfonyl I
) I
imide I
( O
EMIm B
TFSI I
) O
. O

As O
a O
preliminary O
electrochemical O
application O
, O
the O
obtained O
Ag B
@ O
Pt B
nanostructures O
were O
applied O
in O
the O
methanol B
oxidation O
reaction O
( O
MOR O
) O
in O
0 O
. O
5 O
M O
H B
( I
2 I
) I
SO I
( I
4 I
) I
solution O
containing O
0 O
. O
5 O
M O
methanol B
. O

Serum O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
( I
3 I
) I
( O
1 B
, I
25D I
) O
rose O
and O
exceeded O
the O
normal O
range O
. O

By O
applying O
the O
cation O
exchange O
to O
FeO B
/ O
CoFe B
( I
2 I
) I
O I
( I
4 I
) I
core O
/ O
shell O
nanocrystals O
the O
Ne O
e O
l O
temperature O
of O
the O
core O
material O
is O
increased O
and O
exchange O
- O
bias O
effects O
are O
enhanced O
so O
that O
vertical O
shifts O
of O
the O
hysteresis O
loops O
are O
obtained O
which O
are O
superior O
to O
those O
in O
any O
other O
system O
. O

The O
precursors O
were O
chosen O
to O
be O
elemental O
Se B
and O
iron B
acetylacetonate I
[ O
Fe B
( I
III I
) I
( I
C I
5 I
H I
8 I
O I
2 I
) I
3 I
] O
. O

The O
carbohydrate B
- O
based O
diol B
2 B
, I
4 I
: I
3 I
, I
5 I
- I
di I
- I
O I
- I
methylene I
- I
d I
- I
mannitol I
( O
Manx O
) O
has O
been O
used O
to O
obtain O
aliphatic O
polyesters B
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachloro I
dibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
an O
endocrine O
- O
disrupting O
environmental O
pollutant O
, O
has O
been O
found O
to O
cause O
male O
reproductive O
toxicity O
. O

The O
contrasting O
activity O
of O
iodido B
versus O
chlorido B
ruthenium I
and O
osmium B
arene I
azo I
- I
and I
imino I
- I
pyridine I
anticancer O
complexes O
: O
control O
of O
cell O
selectivity O
, O
cross O
- O
resistance O
, O
p53 O
dependence O
, O
and O
apoptosis O
pathway O
. O

Organometallic O
half O
- O
sandwich O
complexes O
[ B
M I
( I
p I
- I
cymene I
) I
( I
azo I
/ I
imino I
- I
pyridine I
) I
X I
] I
( I
+ I
) I
where O
M B
= I
Ru I
( I
II I
) I
or I
Os I
( I
II I
) I
and O
X B
= I
Cl I
or I
I I
, O
exhibit O
potent O
antiproliferative O
activity O
toward O
a O
range O
of O
cancer O
cells O
. O

Organometallic O
half O
- O
sandwich O
complexes O
[ B
M I
( I
p I
- I
cymene I
) I
( I
azo I
/ I
imino I
- I
pyridine I
) I
X I
] I
( I
+ I
) I
where O
M B
= I
Ru I
( I
II I
) I
or I
Os I
( I
II I
) I
and O
X B
= I
Cl I
or I
I I
, O
exhibit O
potent O
antiproliferative O
activity O
toward O
a O
range O
of O
cancer O
cells O
. O

Four O
new O
compounds O
, O
( B
- I
) I
- I
petrosynoic I
acids I
A I
- I
D I
( O
1 O
- O
4 O
) O
, O
and O
five O
known O
congeners O
, O
pellynols B
A I
( I
5 I
) I
, I
C I
( I
6 I
) I
, I
D I
( I
7 I
) I
, I
F I
( I
8 I
) I
, I
and I
I I
( O
9 O
) O
, O
were O
isolated O
from O
a O
Petrosia O
sp O
. O
marine O
sponge O
collected O
in O
American O
Samoa O
. O

Four O
new O
compounds O
, O
( B
- I
) I
- I
petrosynoic I
acids I
A I
- I
D I
( O
1 O
- O
4 O
) O
, O
and O
five O
known O
congeners O
, O
pellynols B
A I
( I
5 I
) I
, I
C I
( I
6 I
) I
, I
D I
( I
7 I
) I
, I
F I
( I
8 I
) I
, I
and I
I I
( O
9 O
) O
, O
were O
isolated O
from O
a O
Petrosia O
sp O
. O
marine O
sponge O
collected O
in O
American O
Samoa O
. O

Biobased O
polyesters B
with O
composition O
- O
dependent O
thermomechanical O
properties O
: O
synthesis O
and O
characterization O
of O
poly B
( I
butylene I
succinate I
- I
co I
- I
butylene I
azelate I
) I
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA B
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

Environmentally O
friendly O
poly B
( I
butylenesuccinate I
- I
co I
- I
butyleneazelate I
) I
( O
P B
( I
BS I
- I
co I
- I
BAz I
) I
s I
) O
aliphatic B
copolyesters I
with O
composition O
- O
dependent O
thermomechanical O
properties O
were O
synthesized O
from O
succinic B
acid I
( O
SuA B
) O
, O
1 B
, I
4 I
- I
butanediol I
( O
BDO B
) O
, O
and O
dimethylazelate B
( O
DMAz B
) O
through O
a O
two O
- O
step O
polycondensation O
reaction O
. O

NMR O
, O
DSC O
, O
DMTA O
, O
and O
XRD O
results O
show O
that O
depending O
on O
their O
composition O
the O
P B
( I
BS I
- I
co I
- I
BAz I
) I
copolyesters I
might O
find O
applications O
from O
elastomers O
to O
high O
- O
impact O
thermoplastics O
. O

Synthesis O
of O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
2a O
- O
c O
) O
, O
3 B
- I
substituted I
aminomethyl I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
- I
2 I
( I
3H I
) I
- I
thione I
( O
4a O
- O
m O
) O
and O
2 B
- I
substituted I
thio I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
5a O
, O
b O
) O
had O
been O
described O
. O

Synthesis O
of O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
2a O
- O
c O
) O
, O
3 B
- I
substituted I
aminomethyl I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
- I
2 I
( I
3H I
) I
- I
thione I
( O
4a O
- O
m O
) O
and O
2 B
- I
substituted I
thio I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
5a O
, O
b O
) O
had O
been O
described O
. O

Synthesis O
of O
2 B
, I
5 I
- I
disubstituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
2a O
- O
c O
) O
, O
3 B
- I
substituted I
aminomethyl I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
- I
2 I
( I
3H I
) I
- I
thione I
( O
4a O
- O
m O
) O
and O
2 B
- I
substituted I
thio I
- I
5 I
- I
substituted I
- I
1 I
, I
3 I
, I
4 I
- I
oxadiazole I
( O
5a O
, O
b O
) O
had O
been O
described O
. O

A O
simple O
and O
sensitive O
method O
for O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
: O
application O
for O
an O
in O
vivo O
pharmacokinetic O
study O
. O

Abstract O
Purpose O
: O
To O
develop O
and O
to O
validate O
a O
simple O
but O
sensitive O
method O
for O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
. O

Rats O
were O
administered O
intravenously O
by O
0 O
. O
1 O
mg O
/ O
kg O
of O
vitamin B
D I
( I
3 I
) I
or I
K I
( I
1 I
) I
and O
the O
blood O
samples O
were O
withdrawn O
pre O
- O
administration O
and O
at O
pre O
- O
determined O
time O
points O
post O
- O
administration O
. O

Conclusion O
: O
The O
developed O
HPLC O
- O
UV O
assay O
is O
a O
simple O
and O
sensitive O
method O
for O
the O
determination O
of O
vitamins B
D I
( I
3 I
) I
and I
K I
( I
1 I
) I
in O
rat O
plasma O
. O

The O
specificity O
of O
polymer O
conjugates O
based O
on O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
bearing O
cytostatic O
drugs O
for O
cancer O
cells O
could O
be O
significantly O
increased O
by O
the O
incorporation O
of O
a O
suitable O
targeting O
ligand O
, O
such O
as O
a O
monoclonal O
antibody O
( O
mAb O
) O
. O

5 B
- I
Nitropyrimidine I
analogs O
with O
( B
2 I
- I
fluoro I
- I
4 I
- I
methylsulfonyl I
) I
phenylamino I
group O
( O
8 O
, O
10 O
, O
12 O
, O
14 O
) O
showed O
more O
potent O
GPR119 O
activation O
activities O
than O
the O
analogs O
without O
fluorine B
in O
all O
cases O
( O
7 O
, O
9 O
, O
11 O
, O
13 O
) O
. O

2 O
' O
, O
4 O
' O
- O
BNA O
/ O
LNA O
aptamers O
: O
CE O
- O
SELEX O
using O
a O
DNA O
- O
based O
library O
of O
full O
- O
length O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
bridged I
/ I
linked I
bicyclic I
ribonucleotides I
. O

DNA O
- O
based O
aptamers O
that O
contain O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
bridged I
/ I
linked I
bicyclic I
ribonucleotides I
( O
B O
/ O
L O
nucleotides B
) O
over O
the O
entire O
length O
were O
successfully O
obtained O
using O
a O
capillary O
electrophoresis O
systematic O
evolution O
of O
ligands O
by O
exponential O
enrichment O
( O
CE O
- O
SELEX O
) O
method O
. O

3 B
' I
- I
R I
/ I
S I
- I
Hydroxyvoacamine I
, O
a O
potent O
acetylcholinesterase O
inhibitor O
from O
Tabernaemontana O
divaricata O
. O

Guided O
by O
the O
acetylcholinesterase O
inhibiting O
activity O
, O
the O
bisindole B
alkaloid I
3 B
' I
- I
R I
/ I
S I
- I
hydroxyvoacamine I
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata O
, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory O
. O

It O
suggested O
that O
there O
was O
12 O
. O
4 O
% O
( O
w O
/ O
w O
) O
of O
3 B
' I
- I
R I
/ I
S I
- I
hydroxyvoacamine I
in O
the O
alkaloid O
enriched O
fraction O
of O
T O
. O
divaricata O
stem O
. O

Synthesis O
and O
biological O
evaluation O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
as O
anti O
- O
inflammatory O
and O
analgesic O
agents O
. O

Synthesis O
and O
biological O
evaluation O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
as O
anti O
- O
inflammatory O
and O
analgesic O
agents O
. O

A O
new O
series O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
was O
synthesized O
. O

A O
new O
series O
of O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
and O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidines I
was O
synthesized O
. O

In O
general O
, O
the O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
derivatives O
exhibited O
better O
biological O
activities O
than O
the O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
. O

In O
general O
, O
the O
thieno B
[ I
2 I
, I
3 I
- I
d I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
derivatives O
exhibited O
better O
biological O
activities O
than O
the O
thieno B
[ I
2 I
' I
, I
3 I
' I
: I
4 I
, I
5 I
] I
pyrimido I
[ I
1 I
, I
2 I
- I
b I
] I
[ I
1 I
, I
2 I
, I
4 I
] I
triazines I
. O

Among O
the O
various O
oxidized O
bases O
, O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydroguanine I
seems O
to O
be O
the O
most O
critical O
during O
the O
transfer O
of O
genetic O
information O
because O
it O
can O
pair O
with O
both O
cytosine B
and O
adenine B
. O

When O
( B
14 I
) I
C I
- I
labeled I
8 I
- I
oxo I
- I
GTP I
was O
applied O
to O
CaCl2 B
- O
permeabilized O
cells O
of O
a O
mutT O
( O
- O
) O
mutant O
strain O
, O
it O
could O
be O
incorporated O
into O
RNA O
at O
4 O
% O
of O
the O
rate O
for O
GTP B
. O

Escherichia O
coli O
cells O
appear O
to O
possess O
mechanisms O
to O
prevent O
misincorporation O
of O
8 B
- I
oxo I
- I
7 I
, I
8 I
- I
dihydroguanine I
into O
RNA O
. O

We O
describe O
herein O
the O
discovery O
of O
a O
series O
of O
M O
( O
5 O
) O
- O
preferring O
orthosteric O
antagonists O
based O
on O
the O
scaffold O
of O
1 B
, I
2 I
, I
5 I
, I
6 I
- I
tetrahydropyridine I
- I
3 I
- I
carboxylic I
acid I
. O

This O
compound O
, O
although O
exhibiting O
modest O
affinity O
( O
K O
( O
i O
) O
= O
2 O
. O
24 O
mu O
M O
) O
for O
the O
[ B
( I
3 I
) I
H I
] I
N I
- I
methylscopolamine I
binding O
site O
on O
the O
M O
( O
5 O
) O
receptor O
, O
is O
potent O
( O
IC O
( O
50 O
) O
= O
0 O
. O
45 O
nM O
) O
in O
inhibiting O
oxotremorine B
- O
evoked O
[ B
( I
3 I
) I
H I
] I
DA I
release O
from O
rat O
striatal O
slices O
. O

Herein O
we O
report O
the O
near O
complete O
HN B
, O
N B
, O
CO B
, O
C O
alpha O
, O
and O
C O
beta O
chemical O
shift O
assignment O
of O
the O
P O
. O
aeruginosa O
HemO O
in O
the O
absence O
and O
presence O
of O
inhibitors O
( B
E I
) I
- I
3 I
- I
( I
4 I
- I
( I
phenylamino I
) I
phenylcarbamoyl I
) I
acrylic I
acid I
( O
3 O
) O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
( I
dimethylamino I
) I
benzylidene I
) I
diazenecarboximidhyd I
( O
5 O
) O
. O

Herein O
we O
report O
the O
near O
complete O
HN B
, O
N B
, O
CO B
, O
C O
alpha O
, O
and O
C O
beta O
chemical O
shift O
assignment O
of O
the O
P O
. O
aeruginosa O
HemO O
in O
the O
absence O
and O
presence O
of O
inhibitors O
( B
E I
) I
- I
3 I
- I
( I
4 I
- I
( I
phenylamino I
) I
phenylcarbamoyl I
) I
acrylic I
acid I
( O
3 O
) O
and O
( B
E I
) I
- I
N I
' I
- I
( I
4 I
- I
( I
dimethylamino I
) I
benzylidene I
) I
diazenecarboximidhyd I
( O
5 O
) O
. O

Next O
, O
we O
examined O
the O
impact O
produced O
on O
the O
same O
abilities O
by O
intra O
- O
VS O
infusion O
of O
ineffective O
doses O
of O
amphetamine B
( O
0 O
. O
3 O
mu O
g O
/ O
side O
) O
in O
association O
with O
N B
- I
methyl I
- I
D I
- I
aspartate I
( O
NMDA B
) O
( O
3 O
. O
125 O
ng O
/ O
side O
) O
or O
alpha B
- I
amino I
- I
3 I
- I
hydroxy I
- I
5 I
- I
methylisoxazole I
- I
4 I
- I
propionic I
acid I
( O
AMPA B
) O
( O
0 O
. O
25 O
ng O
/ O
side O
) O
receptor O
antagonist O
. O

The O
studies O
reported O
here O
were O
conducted O
to O
investigate O
the O
transport O
characteristics O
of O
apixaban B
( O
1 B
- I
( I
4 I
- I
methoxyphenyl I
) I
- I
7 I
- I
oxo I
- I
6 I
- I
( I
4 I
- I
( I
2 I
- I
oxopiperidin I
- I
1 I
- I
yl I
) I
phenyl I
) I
- I
4 I
, I
5 I
, I
6 I
, I
7 I
- I
tetrahydro I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
c I
] I
pyridine I
- I
3 I
- I
carboxamide I
) O
and O
to O
understand O
the O
impact O
of O
transporters O
on O
apixaban O
distribution O
and O
disposition O
. O

These O
conjugates O
were O
able O
to O
quickly O
release O
an O
active O
form O
of O
the O
drug O
( O
Gemcitabine B
5 I
' I
- I
mono I
- I
, I
di I
- I
and I
triphosphates I
) O
by O
specific O
enzymatic O
activities O
, O
or O
slowly O
during O
hydrolysis O
. O

Synthesis O
and O
antibacterial O
activities O
of O
new O
piperidine B
substituted O
( B
5R I
) I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolylmethyl I
and I
( I
5R I
) I
- I
[ I
( I
4 I
- I
F I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolyl I
) I
methyl I
] I
oxazolidinones I
. O

A O
novel O
series O
of O
5 B
( I
R I
) I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolylmethyl I
and I
( I
5R I
) I
- I
[ I
( I
4 I
- I
F I
- I
[ I
1 I
, I
2 I
, I
3 I
] I
triazolyl I
) I
methyl I
] I
oxazolidinones I
having O
various O
piperidine B
group O
were O
synthesized O
and O
evaluated O
antibacterial O
activity O
against O
clinically O
isolated O
resistant O
strains O
of O
Gram O
- O
positive O
and O
Gram O
- O
negative O
bacteria O
. O

Nocapyrones B
H I
- I
J I
, O
3 B
, I
6 I
- I
Disubstituted I
alpha I
- I
Pyrones I
from O
the O
Marine O
Actinomycete O
Nocardiopsis O
sp O
. O

Three O
new O
3 B
, I
6 I
- I
disubstituted I
alpha I
- I
pyrones I
, O
nocapyrones B
H I
- I
J I
( O
1 O
- O
3 O
) O
, O
were O
isolated O
from O
the O
marine O
actinomycete O
Nocardiopsis O
sp O
. O

Their O
structures O
were O
assigned O
to O
be O
3 B
- I
alkylated I
6 I
- I
( I
1 I
- I
methyl I
- I
1 I
- I
propenyl I
) I
- I
2H I
- I
pyran I
- I
2 I
- I
ones I
on O
the O
basis O
of O
UV O
, O
MS O
, O
NMR O
, O
and O
high O
resolution O
( O
HR O
) O
- O
FAB O
- O
MS O
analyses O
. O

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Results O
: O
The O
chemical O
stability O
half O
- O
life O
values O
for O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
, O
diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
( I
racemic I
) I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
valproate B
- I
beta I
- I
d I
- I

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Diclofenac B
- I
beta I
- I
d I
- I
glucuronide I
, O
clopidogrel B
- I
beta I
- I
d I
- I
glucuronide I
, O
ibuprofen B
- I
beta I
- I
d I
- I
glucuronide I
, O
( B
R I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
, O
and O
( B
S I
) I
- I
naproxen I
- I
beta I
- I
d I
- I
glucuronide I
selectively O
inhibited O
hCES1 O
, O
with O
Ki O
values O
of O
4 O
. O
32 O
+ O
/ O
- O
0 O
. O
47 O
, O
24 O
. O
8 O
+ O
/ O
- O
4 O
. O
2 O
, O
355 O
+ O
/ O
- O
38 O
, O

Valproate B
- I
beta I
- I
d I
- I
glucuronide I
and O
CGP B
47292 I
- I
beta I
- I
d I
- I
glucuronide I
did O
not O
inhibit O
either O
hCES O
. O

Among O
the O
isolated O
compounds O
, O
heyneanone B
A I
( O
1 O
) O
, O
heyneanone B
C I
( O
3 O
) O
, O
4 B
, I
10 I
- I
epizedoarondiol I
( O
5 O
) O
, O
procurcumenol B
( O
16 O
) O
, O
aerugidiol B
( O
17 O
) O
, O
zerumin B
A I
( O
23 O
) O
, O
and O
( B
E I
) I
- I
15 I
, I
16 I
- I
bisnorlabda I
- I
8 I
( I
17 I
) I
, I
11 I
- I
dien I
- I
13 I
- I
one I
( O
24 O
) O
inhibited O
protein O
tyrosine B
phosphatase O
1B O
( O
PTP1B O
) O
with O
IC O
( O
50 O
) O
values O
of O
42 O

The O
amphiphilic O
diblock O
copolymer O
poly B
( I
epsilon I
- I
caprolactone I
) I
- I
b I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PCL B
- I
b I
- I
PEO I
) O
was O
first O
conjugated O
with O
the O
cyclic B
( I
Arginine I
- I
Glycine I
- I
Aspartic I
acid I
- I
d I
- I
Phenylalanine I
- I
Lysine I
) I
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein B
isothiocyannate I
( O
FITC B
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

The O
amphiphilic O
diblock O
copolymer O
poly B
( I
epsilon I
- I
caprolactone I
) I
- I
b I
- I
poly I
( I
ethylene I
oxide I
) I
( O
PCL B
- I
b I
- I
PEO I
) O
was O
first O
conjugated O
with O
the O
cyclic B
( I
Arginine I
- I
Glycine I
- I
Aspartic I
acid I
- I
d I
- I
Phenylalanine I
- I
Lysine I
) I
( O
c O
( O
RGDfK O
) O
) O
and O
fluorescein B
isothiocyannate I
( O
FITC B
) O
via O
the O
functional O
terminal O
groups O
of O
hydrophilic O
block O
, O
and O
then O
assembled O
into O
micelles O
. O

In O
this O
study O
, O
we O
compared O
their O
toxicity O
in O
vivo O
and O
in O
vitro O
based O
on O
the O
physicochemical O
properties O
of O
three O
different O
types O
of O
TiO B
( I
2 I
) I
nanowires O
, O
H B
( I
2 I
) I
Ti I
( I
3 I
) I
O I
( I
7 I
) I
nanowires O
( O
1HTO O
) O
, O
hydrothermal O
treatment O
( O
2HTO O
) O
, O
and O
calcination O
( O
3HTO O
) O
of O
1HTO O
. O

The O
supramolecular O
host O
assembly O
[ B
Ga4L6 I
] I
( I
12 I
- I
) I
[ O
1 O
; O
L O
= O
1 B
, I
5 I
- I
bis I
( I
2 I
, I
3 I
- I
dihydroxybenzamido I
) I
naphthalene I
] O
contains O
a O
flexible O
, O
hydrophobic O
interior O
cavity O
that O
can O
encapsulate O
cationic O
guest O
molecules O
and O
catalyze O
a O
variety O
of O
chemical O
transformations O
. O

A O
large O
number O
of O
aromatic B
/ I
heterocyclic I
sulfonamides I
and O
some O
5 B
- I
mercapto I
- I
1 I
, I
3 I
, I
4 I
- I
thiadiazoles I
were O
investigated O
as O
TcCA O
inhibitors O
. O

Pharmacokinetic O
Interactions O
between O
Monoamine B
Oxidase O
A O
Inhibitor O
Harmaline B
and O
5 B
- I
Methoxy I
- I
N I
, I
N I
- I
Dimethyltryptamine I
, O
and O
the O
Impact O
of O
CYP2D6 O
Status O
. O

5 B
- I
Methoxy I
- I
N I
, I
N I
- I
dimethyltryptamine I
( O
5 B
- I
MeO I
- I
DMT I
or O
street O
name O
" O
5 B
- I
MEO I
" O
) O
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines B
. O

Importantly O
, O
we O
identified O
tauro B
- I
conjugated I
beta I
- I
and I
alpha I
- I
muricholic I
acids I
as O
FXR O
antagonists O
. O

Further O
, O
the O
partitioning O
in O
lipid O
bilayer O
systems O
containing O
different O
hydrophobic O
tail O
groups O
( O
DOPC B
( O
1 B
, I
2 I
- I
dioleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
SOPC B
( O
stearoyl B
- I
oleoylphosphatidylch I
) O
, O
DMPC B
( O
1 B
, I
2 I
- I
dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
and O
POPC B
( O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I

Further O
, O
the O
partitioning O
in O
lipid O
bilayer O
systems O
containing O
different O
hydrophobic O
tail O
groups O
( O
DOPC B
( O
1 B
, I
2 I
- I
dioleoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
SOPC B
( O
stearoyl B
- I
oleoylphosphatidylch I
) O
, O
DMPC B
( O
1 B
, I
2 I
- I
dimyristoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
) O
, O
and O
POPC B
( O
1 B
- I
palmitoyl I
- I
2 I
- I
oleoyl I
- I
sn I
- I

To O
determine O
the O
influence O
of O
cholesterol B
as O
an O
important O
component O
of O
cellular O
membranes O
, O
free O
energy O
profiles O
in O
the O
presence O
of O
cholesterol B
were O
calculated O
and O
shown O
to O
be O
in O
good O
agreement O
with O
experimental O
data O
. O

Gas O
phase O
dissociative O
electron O
attachment O
( O
DEA O
) O
measurements O
with O
methyl B
- I
dialanine I
, O
C B
( I
7 I
) I
H I
( I
14 I
) I
N I
( I
2 I
) I
O I
( I
3 I
) I
, O
are O
performed O
in O
a O
crossed O
electron O
- O
molecular O
beam O
experiment O
at O
high O
energy O
resolution O
( O
~ O
120 O
meV O
) O
. O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N B
omega I
- I
nitro I
- I
L I
- I
arginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
( O
a O
non O
- O
specific O
nitric B
oxide I
synthase O
inhibitor O
) O
, O
indomethacin B
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
( O
a O
guanylyl O
cyclase O

Dose O
- O
response O
curves O
were O
also O
constructed O
for O
pre O
- O
incubation O
of O
vascular O
rings O
with O
N B
omega I
- I
nitro I
- I
L I
- I
arginine I
methyl I
ester I
( O
L B
- I
NAME I
) O
( O
a O
non O
- O
specific O
nitric B
oxide I
synthase O
inhibitor O
) O
, O
indomethacin B
( O
an O
unspecific O
cyclooxygenase O
inhibitor O
) O
, O
and O
1H B
- I
[ I
1 I
, I
2 I
, I
4 I
] I
oxadiazolo I
[ I
4 I
, I
3 I
- I
a I
] I
quinoxalin I
- I
1 I
- I
one I
( O
ODQ B
) O
( O
a O
guanylyl O
cyclase O

Here O
, O
we O
show O
that O
the O
anti O
- O
apoptotic O
activity O
of O
[ B
6 I
] I
- I
shogaol I
in O
astrocytes O
following O
exposure O
to O
hydrogen B
peroxide I
( O
H B
( I
2 I
) I
O I
( I
2 I
) I
) O
involves O
a O
marked O
up O
- O
regulation O
of O
neurotrophic O
factors O
such O
as O
nerve O
growth O
factor O
, O
glial O
cell O
line O
- O
derived O
neurotrophic O
factor O
, O
and O
brain O
- O
derived O
neurotrophic O
factor O
. O

Astrocytes O
co O
- O
treated O
with O
[ B
6 I
] I
- I
shogaol I
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
for O
1 O
h O
showed O
decrease O
in O
reactive O
oxygen B
species O
production O
compared O
with O
those O
only O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

Astrocytes O
co O
- O
treated O
with O
[ B
6 I
] I
- I
shogaol I
and O
H B
( I
2 I
) I
O I
( I
2 I
) I
for O
1 O
h O
showed O
decrease O
in O
reactive O
oxygen B
species O
production O
compared O
with O
those O
only O
treated O
with O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

Moreover O
, O
[ B
6 I
] I
- I
shogaol I
counteracted O
the O
reduced O
expression O
of O
ERK1 O
/ O
2 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
and O
protected O
these O
cells O
from O
oxidative O
stress O
and O
apoptosis O
by O
attenuating O
the O
impairment O
of O
mitochondrial O
function O
proteins O
such O
as O
Bcl O
- O
2 O
and O
Bcl O
- O
xL O
. O

Additionally O
, O
[ B
6 I
] I
- I
shogaol I
inhibits O
the O
expression O
of O
the O
apoptotic O
proteins O
Bax O
and O
caspase O
- O
3 O
in O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
treated O
astrocytes O
. O

Herein O
a O
library O
of O
hybrid O
Mn B
- O
Anderson O
polyoxometalates B
anions O
are O
presented O
: O
1 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
- I
C I
- I
( I
CH I
( I
2 I
) I
) I
( I
7 I
) I
CHCH I
( I
2 I
) I
) I
( I
2 I
) I
] I
( I
3 I
- I
) I
; O
compound O
2 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHCH I
( I
2 I
) I
C I
( I
16 I
) I
H I
( I
9 I
) I
) I
( I
2 I
) I
] I
( I
3 I
- I

) I
; O
compound O
3 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
( I
CH I
( I
2 I
) I
) I
( I
7 I
) I
CHCH I
( I
2 I
) I
) I
( I
1 I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHCH I
( I
2 I
) I
C I
( I
16 I
) I
H I
( I
9 I
) I
) I
( I
1 I
) I
] I
( I
3 I
- I
) I
; O
compound O
4 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHC I
( I
O I
) I
CH I
( I
2 I
) I

CHCH I
( I
2 I
) I
) I
( I
2 I
) I
] I
( I
3 I
- I
) I
and O
compounds O
5 O
- O
9 O
, O
[ B
( I
MnMo I
( I
6 I
) I
O I
( I
18 I
) I
) I
( I
( I
OCH I
( I
2 I
) I
) I
( I
3 I
) I
C I
- I
NHC I
( I
O I
) I
( I
CH I
( I
2 I
) I
) I
( I
x I
) I
CH I
( I
3 I
) I
) I
( I
2 I
) I
] I
) I
, O
where O
x O
= O
4 O
, O
10 O
, O
12 O
, O
14 O
, O
and O
18 O
respectively O
. O

Tacticity O
- O
induced O
changes O
in O
the O
micellization O
and O
degradation O
properties O
of O
poly B
( I
lactic I
acid I
) I
- I
block I
- I
poly I
( I
ethylene I
glycol I
) I
copolymers O
. O

Poly B
( I
lactic I
acid I
) I
- I
block I
- I
poly I
( I
ethylene I
glycol I
) I
copolymers O
( O
PLA B
- I
b I
- I
PEG I
) O
featuring O
varying O
tacticities O
( O
atactic O
, O
heterotactic O
, O
isotactic O
) O
in O
the O
PLA B
block O
were O
synthesized O
and O
investigated O
for O
their O
micellar O
stability O
, O
degradation O
, O
and O
thermal O
properties O
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

The O
copolymers O
were O
degraded O
in O
a O
methanolic O
solution O
of O
1 B
, I
5 I
, I
7 I
- I
triaza I
- I
bicyclo I
[ I
4 I
. I
4 I
. I
0 I
] I
dec I
- I
5 I
- I
ene I
and O
the O
degradation O
was O
measured O
by O
( B
1 I
) I
H I
NMR O
spectroscopic O
and O
gel O
permeation O
chromatographic O
analyses O
. O

Interestingly O
, O
while O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
and O
aluminum B
salan I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
copolymers O
exhibited O
similar O
micellization O
behavior O
, O
the O
aluminum B
salen I
- O
catalyzed O
PLA B
- I
b I
- I
PEG I
exhibited O
unique O
behavior O
at O
high O
micelle O
concentration O
in O
the O
presence O
of O
the O
pyrene B
probe O
. O

9 B
- I
( I
5 I
- I
O I
- I
alpha I
- I
D I
- I
galactopyranosyl I
) I
- I
D I
- I
arabinityl I
- I
1 I
, I
3 I
, I
7 I
- I
trihydropurine I
- I
2 I
, I
6 I
, I
8 I
- I
trione I
( O
1 O
) O
was O
designed O
and O
synthesized O
as O
a O
nonionic O
inhibitor O
for O
the O
donor O
binding O
site O
of O
human O
blood O
group O
B O
galactosyltransferas O
( O
GTB O
) O
. O

Effect O
of O
tocopherol B
on O
biochemical O
blood O
parameters O
in O
pleuritis O
- O
induced O
rats O
treated O
with O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
tocopherol B
on O
pleuritis O
- O
induced O
rats O
exposed O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

The O
magnetometer O
coil O
detected O
the O
HTR O
induced O
by O
the O
serotonergic O
hallucinogens O
2 B
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodoamphetamine I
( O
DOI B
; O
0 O
. O
25 O
, O
0 O
. O
5 O
, O
and O
1 O
. O
0 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
and O
lysergic B
acid I
diethylamide I
( O
LSD B
; O
0 O
. O
05 O
, O
0 O
. O
1 O
, O
0 O
. O
2 O
, O
and O
0 O
. O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
with O
extremely O
high O
sensitivity O
and O
specificity O
. O

To O
assess O
the O
PBDE B
concentration O
trend O
, O
and O
determine O
the O
concentrations O
of O
the O
emerging O
flame O
retardants O
Dechlorane B
Plus I
( O
DP O
) O
and O
bis B
( I
2 I
- I
ethylhexyl I
) I
- I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
tetrabromophthalate I
( O
TBPH B
) O
, O
the O
authors O
measured O
the O
concentrations O
of O
8 O
PBDE B
congeners O
, O
2 O
DP O
isomers O
, O
and O
TBPH B
in O
10 O
composite O
samples O
, O
which O
were O
pooled O
from O
the O
serum O
collected O
from O
305 O
Laizhou O
Bay O
residents O
in O
October O
2011 O
. O

N1 O
meta O
- O
substituted O
benzyl B
groups O
possessing O
an O
alpha O
- O
amino O
- O
3 B
- I
[ I
( I
methylamino I
) I
acyl I
] I
- O
group O
were O
the O
most O
potent O
N1 O
- O
substituents O
. O

The O
best O
compound O
of O
this O
series O
was O
the O
meta B
- I
fluoro I
- I
N I
- I
1 I
- I
phenyl I
pyrazolobenzothiazin I
derivative O
4a O
, O
which O
exhibited O
an O
EC50 O
= O
3 O
. O
6 O
mu O
M O
, O
EC90 O
= O
25 O
. O
6 O
mu O
M O
, O
and O
CC50 O
> O
180 O
mu O
M O
in O
the O
Huh O
9 O
- O
13 O
replicon O
system O
, O
thus O
providing O
a O
good O
starting O
point O
for O
further O
hit O
evolution O
. O

Synthesis O
and O
cancer O
stem O
cell O
- O
based O
activity O
of O
substituted O
5 B
- I
morpholino I
- I
7H I
- I
thieno I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
7 I
- I
ones I
designed O
as O
next O
generation O
PI3K O
inhibitors O
. O

This O
work O
resulted O
in O
the O
discovery O
of O
the O
5 B
- I
morpholino I
- I
7H I
- I
thieno I
[ I
3 I
, I
2 I
- I
b I
] I
pyran I
- I
7 I
- I
one I
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K O
inhibitors O
having O
improved O
potency O
toward O
PI3K O
. O

Synthesis O
and O
physicochemical O
properties O
of O
new O
tripodal O
amphiphiles O
bearing O
fatty B
acids I
as O
a O
hydrophobic O
group O
. O

Seven O
new O
cyclotriphosphazene B
amphiphiles O
were O
prepared O
from O
combinations O
of O
hydrophilic O
MPEGs B
with O
different O
molecular O
weights O
of O
350 O
, O
550 O
, O
750 O
and O
1000 O
and O
four O
different O
fatty B
acids I
of O
different O
hydrophobicity O
including O
lauric B
, I
myristic I
, I
palmitic I
and I
stearic I
acids I
. O

The O
flavone B
, O
tricin B
( O
5 B
, I
7 I
, I
4 I
' I
- I
trihydroxy I
- I
3 I
' I
, I
5 I
' I
- I
dimethoxyflavone I
) O
has O
great O
potential O
as O
an O
anticancer O
agent O
, O
due O
to O
its O
specific O
chemopreventive O
activity O
. O

Simultaneous O
determination O
of O
Mn2 B
+ I
and O
Fe3 B
+ I
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
complexes O
in O
some O
foods O
, O
vegetable O
and O
water O
samples O
by O
artificial O
neural O
networks O
. O

It O
relies O
on O
the O
complexation O
of O
analytes O
with O
recently O
synthesised O
bis O
pyrazol B
base O
ligand O
as O
4 B
, I
4 I
' I
[ I
( I
4 I
- I
cholorophenyl I
) I
methylene I
] I
bis I
( I
3 I
- I
methyl I
- I
1 I
- I
phenyl I
- I
1H I
- I
pyrazol I
- I
5 I
- I
ol I
) I
( O
CMBPP B
) O
. O

This O
is O
the O
first O
time O
that O
compounds O
belonging O
to O
the O
epi O
series O
of O
2 B
, I
6 I
- I
diaryl I
- I
3 I
, I
7 I
- I
dioxabicyclo I
[ I
3 I
. I
3 I
. I
0 I
] I
octane I
type O
furofuran B
lignans I
have O
been O
found O
in O
Lactuca O
species O
. O

Determination O
of O
total O
iron B
in O
food O
samples O
after O
flow O
injection O
preconcentration O
on O
polyurethane B
foam O
functionalized O
with O
N B
, I
N I
- I
bis I
( I
salicylidene I
) I
- I
1 I
, I
3 I
- I
propanediamine I
. O

Iron B
( I
III I
) I
was O
reduced O
to O
iron B
( I
II I
) I
by O
ascorbic B
acid I
and O
preconcentrated O
on O
a O
mini O
- O
column O
packed O
with O
polyurethane B
foam O
( O
PUF O
) O
functionalized O
with O
N B
, I
N I
- I
bis I
( I
salicylidene I
) I
- I
1 I
, I
3 I
- I
propanediamine I
( O
SPDA B
) O
. O

The O
retained O
Fe B
( I
II I
) I
was O
eluted O
with O
hydrochloric B
acid I
and O
subsequently O
reacted O
to O
2 B
, I
4 I
, I
6 I
- I
tri I
( I
2 I
' I
- I
pyridyl I
) I
- I
1 I
, I
3 I
, I
5 I
- I
triazine I
( O
TPTZ B
) O
then O
measured O
at O
593 O
nm O
. O

Water O
and O
ethanolic O
extracts O
of O
16 O
species O
of O
seaweeds O
collected O
along O
the O
Danish O
coasts O
were O
screened O
for O
antioxidant O
activities O
using O
four O
in O
vitro O
antioxidant O
assays O
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
radical O
scavenging O
activity O
, O
reducing O
power O
, O
ferrous B
ion O
- O
chelating O
and O
liposome O
model O
system O
) O
. O

Secoisolariciresinol B
, O
lariciresinol B
, O
pinoresinol B
, O
7 B
- I
hydroxymatairesinol I
, O
syringaresinol B
, O
isolariciresinol B
, O
secoisolariciresinol B
diglycoside I
, O
lariciresinol B
monoglycoside I
, O
pinoresinol B
mono I
- I
, I
di I
- I
and I
triglycoside I
, O
sesaminol B
, O
sesaminol B
triglycoside I
, O
sesamolinol B
and O
sesamolinol B
diglycoside I
were O
identified O
. O

We O
analyzed O
the O
association O
of O
serum O
vitamin B
D I
level O
assessed O
by O
25 B
- I
hydroxyvitamin I
D I
( I
3 I
) I
{ O
25 B
( I
OH I
) I
D I
( I
3 I
) I
} O
with O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
in O
apparently O
healthy O
men O
. O

We O
performed O
a O
cross O
- O
sectional O
study O
of O
6 O
, O
567 O
Korean O
men O
who O
participated O
in O
a O
health O
screening O
program O
, O
evaluating O
the O
association O
of O
serum O
25 B
( I
OH I
) I
D I
( I
3 I
) I
levels O
with O
the O
risk O
of O
NAFLD O
assessed O
by O
abdominal O
ultrasonogram O
. O

Age O
, O
serum O
calcium B
, O
and O
aspartate B
aminotransferase O
levels O
showed O
weak O
but O
significant O
positive O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
; O
total O
cholesterol B
, O
triglycerides B
, O
low O
- O
density O
lipoprotein O
cholesterol B
and O
fasting O
insulin O
level O
showed O
weak O
but O
significant O
negative O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
. O

Age O
, O
serum O
calcium B
, O
and O
aspartate B
aminotransferase O
levels O
showed O
weak O
but O
significant O
positive O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
; O
total O
cholesterol B
, O
triglycerides B
, O
low O
- O
density O
lipoprotein O
cholesterol B
and O
fasting O
insulin O
level O
showed O
weak O
but O
significant O
negative O
correlations O
with O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
. O

The O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
was O
significantly O
lower O
in O
participants O
with O
NAFLD O
than O
in O
those O
without O
( O
38 O
. O
7 O
+ O
/ O
- O
9 O
. O
0 O
vs O
. O
39 O
. O
7 O
+ O
/ O
- O
9 O
. O
7 O
nmol O
/ O
L O
, O
p O
< O
0 O
. O
001 O
) O
. O

When O
participants O
were O
divided O
into O
tertiles O
based O
on O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
, O
the O
proportion O
with O
NAFLD O
significantly O
increased O
as O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
decreased O
( O
40 O
. O
0 O
, O
45 O
. O
0 O
and O
45 O
. O
9 O
% O
, O
p O
for O
linear O
trend O
< O
0 O
. O
001 O
) O
. O

When O
participants O
were O
divided O
into O
tertiles O
based O
on O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
, O
the O
proportion O
with O
NAFLD O
significantly O
increased O
as O
mean O
25 B
( I
OH I
) I
D I
( I
3 I
) I
level O
decreased O
( O
40 O
. O
0 O
, O
45 O
. O
0 O
and O
45 O
. O
9 O
% O
, O
p O
for O
linear O
trend O
< O
0 O
. O
001 O
) O
. O

Multiple O
logistic O
regression O
analyses O
with O
NAFLD O
as O
the O
dependent O
variable O
showed O
that O
the O
tertiles O
with O
lower O
25 B
( I
OH I
) I
D I
( I
3 I
) I
levels O
had O
a O
significantly O
increased O
risk O
for O
NAFLD O
compared O
with O
the O
highest O
tertile O
, O
even O
after O
adjusting O
for O
body O
mass O
index O
and O
metabolic O
syndrome O
( O
OR O
1 O
. O
247 O
and O
1 O
. O
408 O
vs O
. O
the O
highest O
tertile O
, O
p O
< O
0 O
. O
001 O
) O
. O

Thus O
, O
participants O
with O
higher O
serum O
25 B
( I
OH I
) I
D I
( I
3 I
) I
showed O
a O
significantly O
reduced O
risk O
for O
NAFLD O
compared O
with O
the O
low O
25 B
( I
OH I
) I
D I
( I
3 I
) I
groups O
, O
independent O
of O
obesity O
and O
metabolic O
syndrome O
. O

Thus O
, O
participants O
with O
higher O
serum O
25 B
( I
OH I
) I
D I
( I
3 I
) I
showed O
a O
significantly O
reduced O
risk O
for O
NAFLD O
compared O
with O
the O
low O
25 B
( I
OH I
) I
D I
( I
3 I
) I
groups O
, O
independent O
of O
obesity O
and O
metabolic O
syndrome O
. O

Aiming O
at O
the O
design O
of O
specific O
melanocortin O
- O
1 O
receptor O
( O
MC1R O
) O
targeted O
imaging O
probes O
, O
we O
report O
on O
the O
effect O
of O
different O
azolyl B
- O
ring O
substitution O
patterns O
( O
carboxylate B
at O
the O
4 O
- O
position O
and O
/ O
or O
methyl B
groups O
at O
the O
3 O
, O
5 O
positions O
) O
of O
pyrazolyl B
- I
diamine I
bifunctional O
chelators O
( O
Pz O
( O
2 O
) O
- O
Pz O
( O
4 O
) O
) O
on O
the O
pharmacokinetic O
profile O
of O
the O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- O
labeled O
lactam B
bridge O
- O
cyclized B
alpha I
- I

melanocyte I
stimulating I
hormone I
derivative O
, O
beta B
AlaNleCycMSH I
( I
hex I
) I
. O

The O
introduction O
of O
a O
carboxylate B
group O
in O
the O
azolyl B
- O
ring O
leads O
to O
a O
remarkable O
reduction O
of O
the O
kidney O
( O
> O
89 O
% O
) O
and O
liver O
( O
> O
91 O
% O
) O
accumulation O
for O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
when O
compared O
to O
the O
radiopeptide O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
1 I
) I

The O
introduction O
of O
a O
carboxylate B
group O
in O
the O
azolyl B
- O
ring O
leads O
to O
a O
remarkable O
reduction O
of O
the O
kidney O
( O
> O
89 O
% O
) O
and O
liver O
( O
> O
91 O
% O
) O
accumulation O
for O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
when O
compared O
to O
the O
radiopeptide O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
1 I
) I

The O
good O
tumor O
uptake O
and O
favorable O
tumor O
- O
to O
- O
nontarget O
- O
organs O
ratios O
of O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
highlights O
the O
potential O
of O
both O
compounds O
as O
melanoma O
imaging O
agents O
. O

The O
good O
tumor O
uptake O
and O
favorable O
tumor O
- O
to O
- O
nontarget O
- O
organs O
ratios O
of O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
3 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
and O
( B
99m I
) I
Tc I
( I
CO I
) I
3 I
- I
Pz I
( I
4 I
) I
- I
beta I
AlaNleCycMSH I
( I
hex I
) I
highlights O
the O
potential O
of O
both O
compounds O
as O
melanoma O
imaging O
agents O
. O

A O
series O
of O
novel O
5 B
- I
trans I
- I
hydroxyadamantan I
- I
2 I
- I
yl I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
azepin I
- I
4 I
( I
1H I
) I
- I
ones I
that O
inhibit O
11beta B
- I
hydroxysteroid I
dehydrogenase O
type O
1 O
are O
described O
. O

In O
order O
to O
develop O
potent O
and O
selective O
focal O
adhesion O
kinase O
( O
FAK O
) O
inhibitors O
, O
synthetic O
studies O
on O
pyrazolo B
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazines I
targeted O
for O
the O
FAK O
allosteric O
site O
were O
carried O
out O
. O

Based O
on O
the O
X O
- O
ray O
structural O
analysis O
of O
the O
co O
- O
crystal O
of O
the O
lead O
compound O
, O
8 B
- I
( I
4 I
- I
ethylphenyl I
) I
- I
5 I
- I
methyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazine I
4 I
, I
4 I
- I
dioxide I
1 O
with O
FAK O
, O
we O
designed O
and O
prepared O
1 B
, I
5 I
- I
dimethyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazin I
derivatives O
which O
selectively O
inhibited O
kinase O
activity O
of O
FAK O
without O
affecting O
seven O

Based O
on O
the O
X O
- O
ray O
structural O
analysis O
of O
the O
co O
- O
crystal O
of O
the O
lead O
compound O
, O
8 B
- I
( I
4 I
- I
ethylphenyl I
) I
- I
5 I
- I
methyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazine I
4 I
, I
4 I
- I
dioxide I
1 O
with O
FAK O
, O
we O
designed O
and O
prepared O
1 B
, I
5 I
- I
dimethyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazin I
derivatives O
which O
selectively O
inhibited O
kinase O
activity O
of O
FAK O
without O
affecting O
seven O

The O
optimized O
compound O
, O
N B
- I
( I
4 I
- I
tert I
- I
butylbenzyl I
) I
- I
1 I
, I
5 I
- I
dimethyl I
- I
1 I
, I
5 I
- I
dihydropyrazolo I
[ I
4 I
, I
3 I
- I
c I
] I
[ I
2 I
, I
1 I
] I
benzothiazin I
- I
8 I
- I
amine I
4 I
, I
4 I
- I
dioxide I
30 O
possessed O
significant O
FAK O
kinase O
inhibitory O
activities O
both O
in O
cell O
- O
free O
( O
IC50 O
= O
0 O
. O
64 O
mu O
M O
) O
and O
in O
cellular O
assays O
( O
IC50 O
= O
7 O
. O
1 O
mu O
M O
) O
. O

Substituted O
piperidinyl B
glycinyl I
2 I
- I
cyano I
- I
4 I
, I
5 I
- I
methano I
pyrrolidines I
as O
potent O
and O
stable O
dipeptidyl O
peptidase O
IV O
inhibitors O
. O

Synthesis O
and O
structure O
- O
activity O
relationship O
of O
a O
series O
of O
substituted O
piperidinyl B
glycine I
2 I
- I
cyano I
- I
4 I
, I
5 I
- I
methano I
pyrroline I
DPP O
- O
IV O
inhibitors O
are O
described O
. O

The O
nephrotoxicity O
and O
nephrocarcinogenicit O
of O
trichloroethylene B
( O
TCE B
) O
and O
tetrachloroethylene B
( O
PCE B
) O
are O
believed O
to O
be O
mediated O
primarily O
through O
the O
cysteine B
S B
- O
conjugate O
beta O
- O
lyase O
- O
dependent O
bioactivation O
of O
the O
corresponding O
cysteine B
S B
- O
conjugate O
metabolites O
S B
- I
( I
1 I
, I
2 I
- I
dichlorovinyl I
) I
- I
l I
- I
cysteine I
( O
DCVC B
) O
and O
S B
- I
( I
1 I
, I
2 I
, I
2 I
- I
trichlorovinyl I
) I
- I
l I
- I

cysteine I
( O
TCVC B
) O
, O
respectively O
. O

Because O
DCVC B
and O
TCVC B
can O
also O
be O
bioactivated O
through O
sulfoxidation O
to O
yield O
the O
potent O
nephrotoxicants O
S B
- I
( I
1 I
, I
2 I
- I
dichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
DCVCS B
) O
and O
S B
- I
( I
1 I
, I
2 I
, I
2 I
- I
trichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
TCVCS B
) O
, O
respectively O
, O
the O
mutagenic O
potential O
of O
these O
two O
sulfoxides B
was O
investigated O
using O
the O
Ames O
Salmonella O
typhimurium O
TA100 O
mutagenicity O
assay O

Because O
DCVC B
and O
TCVC B
can O
also O
be O
bioactivated O
through O
sulfoxidation O
to O
yield O
the O
potent O
nephrotoxicants O
S B
- I
( I
1 I
, I
2 I
- I
dichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
DCVCS B
) O
and O
S B
- I
( I
1 I
, I
2 I
, I
2 I
- I
trichlorovinyl I
) I
- I
l I
- I
cysteine I
sulfoxide I
( O
TCVCS B
) O
, O
respectively O
, O
the O
mutagenic O
potential O
of O
these O
two O
sulfoxides B
was O
investigated O
using O
the O
Ames O
Salmonella O
typhimurium O
TA100 O
mutagenicity O
assay O

First O
synthesis O
and O
biological O
evaluation O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
and O
related O
derivatives O
. O

The O
synthesis O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
was O
achieved O
by O
intramolecular O
Friedel O
- O
Crafts O
reaction O
of O
the O
acid B
chloride I
3 B
- I
methyl I
- I
1 I
, I
6 I
- I
diphenyl I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazine I
- I
5 I
- I
carboxylic I
acid I
chloride I
( O
4 O
) O
using O
AlCl3 B
in O
boiling O
CS2 B
. O

The O
synthesis O
of O
indeno B
[ I
2 I
, I
1 I
- I
e I
] I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazin I
- I
5 I
- I
one I
was O
achieved O
by O
intramolecular O
Friedel O
- O
Crafts O
reaction O
of O
the O
acid B
chloride I
3 B
- I
methyl I
- I
1 I
, I
6 I
- I
diphenyl I
- I
1H I
- I
pyrazolo I
[ I
3 I
, I
4 I
- I
b I
] I
pyrazine I
- I
5 I
- I
carboxylic I
acid I
chloride I
( O
4 O
) O
using O
AlCl3 B
in O
boiling O
CS2 B
. O

Following O
administration O
of O
the O
5 B
- I
HT I
( O
1A O
/ O
7 O
) O
agonist O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
stereotypical O
head O
weaving O
and O
forepaw O
treading O
were O
increased O
more O
in O
DAT O
- O
KO O
mice O
than O
in O
DAT O
- O
WT O
or O
- O
HET O
mice O
. O

By O
contrast O
, O
head O
twitches O
induced O
by O
treatment O
with O
the O
5 B
- I
HT I
( O
2A O
/ O
2C O
) O
agonist O
( B
+ I
/ I
- I
) I
- I
2 I
, I
5 I
- I
dimethoxy I
- I
4 I
- I
iodophenyl I
- I
2 I
- I
aminopropane I
( O
DOI B
) O
were O
similar O
in O
mice O
of O
all O
three O
DAT O
genotypes O
. O

All O
of O
these O
active O
compounds O
possess O
C O
( O
19 O
) O
- O
O B
- I
acyl I
group O
, O
and O
among O
which O
, O
ent B
- I
kaur I
- I
16 I
- I
ene I
- I
13 I
, I
19 I
- I
diol I
19 I
- I
O I
- I
4 I
' I
, I
4 I
' I
, I
4 I
' I
- I
trifluorocrotonate I
( O
14 O
) O
exhibited O
potent O
cytotoxicities O
against O
four O
cell O
lines O
with O
IC O
( O
50 O
) O
values O
in O
the O
range O
of O
1 O
. O
2 O
- O
4 O
. O
1 O
mu O
M O
. O

Two O
new O
compounds O
, O
5 B
beta I
- I
pregnane I
- I
2 I
alpha I
, I
6 I
alpha I
, I
20 I
( I
S I
) I
- I
triol I
( O
1 O
) O
and O
8 B
- I
hydroxyl I
- I
3 I
- I
methoxyl I
- I
2 I
( I
1H I
) I
- I
quinolone I
( O
2 O
) O
, O
were O
isolated O
from O
Scolopendra O
multidens O
Newport O
. O

Two O
new O
compounds O
, O
5 B
beta I
- I
pregnane I
- I
2 I
alpha I
, I
6 I
alpha I
, I
20 I
( I
S I
) I
- I
triol I
( O
1 O
) O
and O
8 B
- I
hydroxyl I
- I
3 I
- I
methoxyl I
- I
2 I
( I
1H I
) I
- I
quinolone I
( O
2 O
) O
, O
were O
isolated O
from O
Scolopendra O
multidens O
Newport O
. O

Three O
new O
lanostanoid B
triterpenes I
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
methyl I
ester I
( O
2 O
) O
, O
and O
3 B
beta I
, I
15 I
beta I
- I
dihydroxy I
- I
7 I
, I
11 I
, I
23 I
- I
trioxo I

Three O
new O
lanostanoid B
triterpenes I
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
( O
1 O
) O
, O
3 B
beta I
, I
7 I
beta I
, I
15 I
beta I
- I
trihydroxy I
- I
11 I
, I
23 I
- I
dioxo I
- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
methyl I
ester I
( O
2 O
) O
, O
and O
3 B
beta I
, I
15 I
beta I
- I
dihydroxy I
- I
7 I
, I
11 I
, I
23 I
- I
trioxo I

- I
lanost I
- I
8 I
, I
16 I
- I
dien I
- I
26 I
- I
oic I
acid I
methyl I
ester I
( O
3 O
) O
were O
isolated O
from O
the O
EtOAc B
extract O
of O
the O
fruiting O
bodies O
of O
Ganoderma O
tropicum O
. O

3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
) I
- I
2 I
, I
5 I
- I
diphenyl I
tetrazolium I
bromide I
( O
MTT B
) O
assay O
was O
used O
to O
investigate O
the O
reversal O
index O
of O
RA O
in O
SGC7901 O
/ O
Adr B
cell O
line O
. O

Two O
new O
drimane B
sesquiterpenoids B
, O
11 B
, I
12 I
- I
dihydroxy I
- I
15 I
- I
drimeneoic I
acid I
( O
1 O
) O
and O
3 B
alpha I
, I
11 I
, I
15 I
- I
trihydroxydrimene I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
, O
together O
with O
one O
known O
compound O
3 B
beta I
, I
11 I
, I
12 I
- I
trihydroxydrimene I
( O
3 O
) O
. O

Two O
new O
drimane B
sesquiterpenoids B
, O
11 B
, I
12 I
- I
dihydroxy I
- I
15 I
- I
drimeneoic I
acid I
( O
1 O
) O
and O
3 B
alpha I
, I
11 I
, I
15 I
- I
trihydroxydrimene I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
, O
together O
with O
one O
known O
compound O
3 B
beta I
, I
11 I
, I
12 I
- I
trihydroxydrimene I
( O
3 O
) O
. O

Two O
new O
drimane B
sesquiterpenoids B
, O
11 B
, I
12 I
- I
dihydroxy I
- I
15 I
- I
drimeneoic I
acid I
( O
1 O
) O
and O
3 B
alpha I
, I
11 I
, I
15 I
- I
trihydroxydrimene I
( O
2 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
basidiomycete O
Agaricus O
arvensis O
, O
together O
with O
one O
known O
compound O
3 B
beta I
, I
11 I
, I
12 I
- I
trihydroxydrimene I
( O
3 O
) O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Two O
new O
sesquiterpenoids B
, O
tremulenolide B
D I
( O
1 O
) O
and O
muurolane B
- I
10 I
beta I
, I
15 I
- I
diol I
( O
2 O
) O
, O
together O
with O
four O
known O
sesquiterpenoids B
, O
tremulenediol B
A I
( O
3 O
) O
, O
2 B
beta I
- I
hydroxy I
- I
alpha I
- I
candinol I
( O
4 O
) O
, O
epicubenol B
( O
5 O
) O
, O
and O
3 B
beta I
- I
hydroxy I
- I
delta I
- I
candinol I
( O
6 O
) O
, O
were O
isolated O
from O
cultures O
of O
the O
fungus O
Ceriporia O
alachuana O
. O

Three O
new O
phenyl B
- I
ethanediols I
, O
( B
1R I
) I
- I
( I
3 I
- I
ethenylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
1 O
) O
, O
( B
1R I
) I
- I
( I
3 I
- I
formylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
2 O
) O
, O
and O
( B
1R I
) I
- I
( I
3 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
, O
together O
with O
two O
related O
known O
compounds O
, O
( B
3 I
- I
ethylphenyl I

Three O
new O
phenyl B
- I
ethanediols I
, O
( B
1R I
) I
- I
( I
3 I
- I
ethenylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
1 O
) O
, O
( B
1R I
) I
- I
( I
3 I
- I
formylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
2 O
) O
, O
and O
( B
1R I
) I
- I
( I
3 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
, O
together O
with O
two O
related O
known O
compounds O
, O
( B
3 I
- I
ethylphenyl I

Three O
new O
phenyl B
- I
ethanediols I
, O
( B
1R I
) I
- I
( I
3 I
- I
ethenylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
1 O
) O
, O
( B
1R I
) I
- I
( I
3 I
- I
formylphenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
2 O
) O
, O
and O
( B
1R I
) I
- I
( I
3 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
3 O
) O
, O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
the O
mushroom O
Fomes O
fomentarius O
, O
together O
with O
two O
related O
known O
compounds O
, O
( B
3 I
- I
ethylphenyl I

) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
4 O
) O
and O
( B
4 I
- I
acetophenyl I
) I
- I
1 I
, I
2 I
- I
ethanediol I
( O
5 O
) O
. O

A O
solid O
solution O
series O
of O
lithium B
nickel I
metal I
oxides I
, O
Li B
[ I
Ni I
( I
1 I
- I
x I
) I
M I
( I
x I
) I
] I
O2 I
( O
with O
M O
= O
Co B
, O
Mn B
, O
and O
Al B
) O
have O
been O
investigated O
intensively O
to O
enhance O
the O
inherent O
structural O
instability O
of O
LiNiO2 B
. O

In O
an O
attempt O
to O
overcome O
these O
problems O
, O
LiNi0 B
. I
62Co0 I
. I
14Mn0 I
. I
24O2 I
cathode O
material O
with O
pillar O
layers O
in O
which O
Ni B
( I
2 I
+ I
) I
ions O
were O
resided O
in O
Li B
slabs O
near O
the O
surface O
having O
a O
thickness O
of O
~ O
10 O
nm O
was O
prepared O
using O
a O
polyvinylpyrrolidone B
( O
PVP B
) O
functionalized O
Mn B
precursor O
coating O
on O
Ni0 B
. I
7Co0 I
. I
15Mn0 I
. I
15 I
( I
OH I
) I
2 I
. O

Chromatographic O
separation O
of O
the O
ethyl B
acetate I
soluble O
part O
of O
the O
methanolic O
extract O
from O
Seriphidium O
stenocephalum O
yielded O
three O
new O
compounds O
: O
stenocepflavone B
( O
1 O
) O
, O
stenocepflavan B
( O
2 O
) O
, O
and O
stenocephol B
( O
3 O
) O
, O
together O
with O
cirsimaritin B
( O
4 O
) O
, O
5 B
, I
7 I
, I
5 I
' I
- I
trihydroxy I
- I
3 I
' I
, I
4 I
' I
, I
6 I
- I
trimethoxyflavone I
( O
5 O
) O
, O
5 B
, I
6 I
, I
7 I
, I
5 I
' I
- I
tetrahydroxy I

- I
4 I
' I
- I
methoxyflavone I
( O
6 O
) O
, O
and O
axillaroside B
( O
7 O
) O
. O

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

) I
gallate I
( O
8 O
) O
, O
quercetin B
3 I
- I
O I
- I
beta I
- I
d I
- I
glucopyranoside I
( O
9 O
) O
, O
rutin B
( O
10 O
) O
, O
and O
peltatoside B
( O
11 O
) O
, O
were O
isolated O
from O
the O
leafy O
twigs O
of O
Nigerian O
mistletoe O
Loranthus O
micranthus O
( O
Linn O
. O
) O
parasitic O
on O
Hevea O
brasiliensis O
. O

The O
antioxidant O
activities O
of O
the O
isolated O
compounds O
( O
1 O
- O
11 O
) O
were O
evaluated O
using O
the O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
) O
assay O
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly B
{ I
N I
' I
- I
[ I
N I
- I
( I
2 I
- I
aminoethyl I
) I
- I
2 I
- I
aminoethyl I
] I
aspartamide I
} I
P B
[ I
Asp I
( I
DET I
) I
] I
and O
block O
copolymer O
: O
polyethylene B
glycol I
( B
PEG I
) I
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

A O
block O
/ O
homo O
- O
mixed O
polyplex O
micelle O
, O
comprising O
of O
cationic O
homo O
polymer O
: O
poly B
{ I
N I
' I
- I
[ I
N I
- I
( I
2 I
- I
aminoethyl I
) I
- I
2 I
- I
aminoethyl I
] I
aspartamide I
} I
P B
[ I
Asp I
( I
DET I
) I
] I
and O
block O
copolymer O
: O
polyethylene B
glycol I
( B
PEG I
) I
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
, O
has O
been O
reported O
to O
exhibit O
the O
efficient O
transgene O
expression O
in O
vivo O
by O
intratracheal O
and O
systemic O
administration O
. O

For O
evaluation O
of O
transgene O
expression O
in O
vivo O
, O
block O
/ O
homo O
polyplex O
micelles O
showed O
12 O
- O
fold O
higher O
level O
in O
luciferase O
expression O
evaluated O
by O
bioluminescence O
imaging O
system O
at O
24h O
after O
the O
i O
. O
p O
. O
administration O
compared O
with O
block O
polyplex O
micelles O
composed O
with O
only O
PEG B
- I
b I
- I
P I
[ I
Asp I
( I
DET I
) I
] I
in O
nude O
mice O
bearing O
peritoneal O
dissemination O
. O

In O
fact O
, O
the O
baseline O
proportion O
of O
hypodiploid O
cells O
and O
the O
mitochondrial O
potential O
and O
mass O
were O
higher O
in O
adults O
, O
whereas O
8 B
- I
hydroxy I
- I
2 I
' I
- I
deoxyguanosine I
( O
8 B
- I
oxo I
- I
dGuo I
) O
levels O
, O
the O
proportion O
of O
necrotic O
cells O
, O
and O
the O
extent O
of O
autophagy O
were O
higher O
early O
in O
life O
. O

Synthesis O
, O
in O
vitro O
antiplatelet O
activity O
and O
molecular O
modelling O
studies O
of O
10 B
- I
substituted I
2 I
- I
( I
1 I
- I
piperazinyl I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
ones I
. O

The O
multistep O
preparation O
of O
the O
new O
10 B
- I
substituted I
2 I
- I
( I
1 I
- I
piperazinyl I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
ones I
6a O
- O
o O
, O
and O
of O
the O
two O
isomers O
10 B
- I
ethyl I
- I
2 I
- I
( I
diethylamino I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
one I
6p O
and O
10 B
- I
ethyl I
- I
4 I
- I
( I
diethylamino I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I

The O
multistep O
preparation O
of O
the O
new O
10 B
- I
substituted I
2 I
- I
( I
1 I
- I
piperazinyl I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
ones I
6a O
- O
o O
, O
and O
of O
the O
two O
isomers O
10 B
- I
ethyl I
- I
2 I
- I
( I
diethylamino I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I
benzimidazol I
- I
4 I
( I
10H I
) I
- I
one I
6p O
and O
10 B
- I
ethyl I
- I
4 I
- I
( I
diethylamino I
) I
pyrimido I
[ I
1 I
, I
2 I
- I
a I
] I

benzimidazol I
- I
2 I
( I
10H I
) I
- I
one I
13 O
, O
as O
well O
as O
the O
in O
vitro O
evaluation O
of O
their O
inhibitory O
activity O
on O
human O
platelet O
aggregation O
induced O
in O
platelet O
- O
rich O
plasma O
by O
ADP B
, O
collagen O
or O
the O
Ca B
( I
2 I
+ I
) I
ionophore O
A23187 B
were O
here O
described O
. O

2 B
- I
Arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amino I
derivatives O
as O
new O
potent O
and O
selective O
human O
A3 O
Adenosine B
receptor O
antagonists O
. O

On O
the O
basis O
of O
our O
previously O
reported O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
ones I
, O
a O
set O
of O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amines I
were O
designed O
as O
new O
human O
( O
h O
) O
A3 O
adenosine B
receptor O
( O
AR O
) O
antagonists O
. O

On O
the O
basis O
of O
our O
previously O
reported O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
ones I
, O
a O
set O
of O
2 B
- I
arylpyrazolo I
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amines I
were O
designed O
as O
new O
human O
( O
h O
) O
A3 O
adenosine B
receptor O
( O
AR O
) O
antagonists O
. O

A O
few O
selected O
pyrazolo B
[ I
4 I
, I
3 I
- I
d I
] I
pyrimidin I
- I
7 I
- I
amides I
were O
effective O
in O
counteracting O
oxaliplatin B
- O
induced O
apoptosis O
in O
rat O
astrocyte O
cell O
cultures O
, O
an O
in O
vitro O
model O
of O
neurotoxicity O
. O

The O
major O
compounds O
present O
in O
the O
extracts O
were O
: O
the O
flavonoid B
, O
phloretin B
- I
3 I
' I
, I
5 I
' I
- I
di I
- I
C I
- I
glucoside I
in O
C O
. O
subternata O
, O
the O
xanthone B
, O
mangiferin B
in O
unfermented O
C O
. O
maculata O
and O
the O
flavanone B
, O
hesperidin O
in O
fermented O
C O
. O
maculata O
. O

( B
- I
) I
- I
Delta I
( I
9 I
) I
- I
Tetrahydrocannabinol I
has O
been O
demonstrated O
to O
have O
beneficial O
effects O
in O
the O
airways O
, O
but O
its O
psychoactive O
effects O
preclude O
its O
therapeutic O
use O
for O
the O
treatment O
of O
airways O
diseases O
. O

In O
mice O
, O
in O
utero O
exposure O
to O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis O
. O

The O
four O
reported O
Mn B
( I
III I
) I
- I
OOR I
compounds O
extend O
the O
number O
of O
known O
end O
- O
on O
Mn B
( I
III I
) I
- I
( I
eta I
( I
1 I
) I
- I
peroxos I
) I
to O
six O
. O

Control O
over O
the O
oxidation O
state O
and O
crystalline O
phase O
of O
thin O
- O
film O
iron B
oxides I
was O
achieved O
by O
low O
- O
temperature O
atomic O
layer O
deposition O
( O
ALD O
) O
, O
utilizing O
a O
novel O
iron B
precursor O
, O
bis B
( I
2 I
, I
4 I
- I
methylpentadienyl I
) I
iron I
. O

Studies O
on O
an O
( B
S I
) I
- I
2 I
- I
amino I
- I
3 I
- I
( I
3 I
- I
hydroxy I
- I
5 I
- I
methyl I
- I
4 I
- I
isoxazolyl I
) I
propionic I
acid I
( O
AMPA B
) O
receptor O
antagonist O
IKM B
- I
159 I
: O
asymmetric O
synthesis O
, O
neuroactivity O
, O
and O
structural O
characterization O
. O

By O
employment O
of O
( B
R I
) I
- I
2 I
- I
amino I
- I
2 I
- I
( I
4 I
- I
methoxyphenyl I
) I
ethanol I
as O
a O
chiral O
auxiliary O
, O
( B
2R I
) I
- I
IKM I
- I
159 I
and O
the O
( O
2S O
) O
- O
counterpart O
were O
successfully O
synthesized O
in O
0 O
. O
70 O
% O
and O
1 O
. O
5 O
% O
yields O
, O
respectively O
, O
over O
a O
total O
of O
18 O
steps O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic B
acid I
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic B
acid I
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

A O
new O
member O
of O
5 B
alpha I
H I
, I
6 I
beta I
H I
, I
7 I
alpha I
H I
, I
11 I
alpha I
H I
- I
guaian I
- I
12 I
, I
6 I
alpha I
- I
olides I
, O
11 B
- I
epi I
- I
8 I
alpha I
- I
hydroxyarborescin I
, O
together O
with O
a O
mixture O
of O
( B
24R I
) I
- I
and I
( I
24S I
) I
- I
cycloart I
- I
25 I
- I
en I
- I
3b I
, I
24 I
- I
diols I
, O
palmitic B
acid I
and O
1 B
- I
octacosanol I
were O
isolated O
from O
the O
leaves O
of O
Artemisia O
roxburghiana O
Bess O
. O

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz B
[ I
a I
] I
pyrene I
- I
4 I
, I
5 I
- I

P450 O
1B1 O
is O
well O
- O
known O
to O
oxidize O
many O
carcinogenic O
PAHs B
, O
and O
we O
found O
that O
several O
PAHs B
( O
i O
. O
e O
. O
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
, O
7 B
, I
12 I
- I
dimethylbenz I
[ I
a I
] I
anthracene I
- I
5 I
, I
6 I
- I
diol I
, O
benzo B
[ I
c I
] I
phenanthrene I
, O
fluoranthene B
, O
fluoranthene B
- I
2 I
, I
3 I
- I
diol I
, O
5 B
- I
methylchrysene I
, O
benz B
[ I
a I
] I
pyrene I
- I
4 I
, I
5 I
- I

diol I
, O
benzo B
[ I
a I
] I
pyrene I
- I
7 I
, I
8 I
- I
diol I
, O
1 B
- I
nitropyrene I
, O
2 B
- I
aminoanthracene I
, O
2 B
- I
aminofluorene I
, O
and O
2 B
- I
acetylaminofluorene I
) O
interacted O
with O
P450 O
1B1 O
, O
producing O
Reverse O
Type O
I O
binding O
spectra O
. O

A O
library O
of O
novel O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
diaryl I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitriles I
have O
been O
synthesized O
regioselectively O
in O
good O
yields O
through O
the O
one O
- O
pot O
domino O
reactions O
of O
5 B
- I
aryldihydro I
- I
3 I
( I
2H I
) I
- I
thiophenones I
, O
malononitrile B
and O
aromatic B
aldehydes I
in O
the O
presence O
of O
morpholine B
. O

A O
library O
of O
novel O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
diaryl I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitriles I
have O
been O
synthesized O
regioselectively O
in O
good O
yields O
through O
the O
one O
- O
pot O
domino O
reactions O
of O
5 B
- I
aryldihydro I
- I
3 I
( I
2H I
) I
- I
thiophenones I
, O
malononitrile B
and O
aromatic B
aldehydes I
in O
the O
presence O
of O
morpholine B
. O

These O
compounds O
were O
evaluated O
for O
their O
acetylcholinesterase O
( O
AChE O
) O
inhibitory O
activity O
and O
5 B
- I
amino I
- I
2 I
, I
7 I
- I
bis I
( I
4 I
- I
methoxyphenyl I
) I
- I
2 I
, I
3 I
- I
dihydrobenzo I
[ I
b I
] I
thiophene I
- I
4 I
, I
6 I
- I
dicarbonitrile I
was O
found O
to O
be O
the O
most O
potent O
against O
AChE O
with O
IC50 O
4 O
. O
16 O
mu O
mol O
/ O
L O
. O

2 B
- I
( I
Benzothiazol I
- I
2 I
- I
yl I
) I
- I
phenyl I
- I
beta I
- I
d I
- I
galactopyranoside I
derivatives O
as O
fluorescent O
pigment O
dyeing O
substrates O
and O
their O
application O
for O
the O
assay O
of O
beta O
- O
d O
- O
galactosidase O
activities O
. O

2 B
- I
( I
Benzothiazol I
- I
2 I
- I
yl I
) I
- I
phenyl I
- I
beta I
- I
d I
- I
galactopyranoside I
derivatives O
were O
synthesized O
as O
novel O
artificial O
fluorescent O
pigment O
dyeing O
substrates O
for O
beta O
- O
d O
- O
galactosidase O
. O

Noninvasive O
molecular O
imaging O
of O
H B
( I
2 I
) I
O I
( I
2 I
) I
using O
fluorogenic O
systems O
represents O
an O
effective O
way O
to O
detect O
and O
measure O
the O
accumulation O
of O
this O
metabolite O
. O

Herein O
, O
we O
detail O
the O
development O
of O
robust O
H B
( I
2 I
) I
O I
( I
2 I
) I
- O
sensitive O
fluorescent O
probes O
using O
a O
boronic B
ester I
trigger O
appended O
to O
the O
fluorophore O
through O
a O
benzyl B
ether I
linkage O
. O

The O
sensitivity O
of O
the O
probes O
was O
evaluated O
in O
simulated O
physiological O
conditions O
, O
showing O
micromolar O
sensitivity O
to O
H B
( I
2 I
) I
O I
( I
2 I
) I
. O

The O
probes O
were O
tested O
in O
biological O
model O
systems O
, O
demonstrating O
effective O
imaging O
of O
unstimulated O
, O
endogenous O
H B
( I
2 I
) I
O I
( I
2 I
) I
levels O
in O
RAW O
264 O
. O
7 O
cells O
and O
murine O
brain O
tissue O
. O

We O
found O
that O
when O
isolated O
rat O
epitrochlearis O
muscle O
was O
incubated O
with O
a O
Pu O
- O
erh O
tea O
hot O
- O
water O
extract O
( O
PTE O
) O
for O
30 O
min O
, O
the O
rate O
of O
3 B
- I
O I
- I
methyl I
- I
D I
- I
glucose I
( O
3MG B
) O
transport O
increased O
in O
the O
absence O
of O
insulin O
. O

Discovery O
, O
biological O
evaluation O
, O
and O
structure O
- O
activity O
and O
- O
selectivity O
relationships O
of O
6 B
' I
- I
substituted I
( I
E I
) I
- I
2 I
- I
( I
benzofuran I
- I
3 I
( I
2H I
) I
- I
ylidene I
) I
- I
N I
- I
methylacetamides I
, O
a O
novel O
class O
of O
potent O
and O
selective O
monoamine B
oxidase O
inhibitors O
. O

Here O
, O
the O
discovery O
of O
a O
new O
class O
of O
compounds O
acting O
as O
monoamine B
oxidase O
inhibitors O
( O
MAO O
- O
Is O
) O
and O
bearing O
a O
6 B
' I
- I
substituted I
( I
E I
) I
- I
2 I
- I
( I
benzofuran I
- I
3 I
( I
2H I
) I
- I
ylidene I
) I
- I
N I
- I
alkylacetamide I
skeleton O
is O
reported O
. O

The O
rigid O
E O
- O
geometry O
of O
the O
exocyclic O
double O
bond O
allowed O
a O
more O
efficient O
binding O
conformation O
compared O
to O
more O
flexible O
and O
less O
active O
2 B
- I
( I
1 I
- I
benzofuran I
- I
3 I
- I
yl I
) I
- I
N I
- I
methylacetamide I
isomers O
and O
4 B
- I
N I
- I
methylcarboxamidomet I
analogues O
. O

Pyranose B
ring O
flexing O
( O
puckering O
) O
in O
2 B
- I
O I
- I
sulfo I
- I
alpha I
- I
l I
- I
iduronic I
acid I
, O
which O
underlies O
heparin O
- O
mediated O
anticoagulation O
, O
was O
modulated O
by O
polymerization O
( O
chain O
position O
and O
adjacent O
residues O
) O
, O
which O
is O
supported O
by O
previous O
experiments O
. O

Synthesis O
and O
antiproliferative O
activity O
evaluation O
of O
imidazole B
- O
based O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
derivatives O
. O

A O
series O
of O
new O
imidazole B
substituted O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
derivatives O
were O
synthesized O
and O
evaluated O
for O
their O
antiproliferative O
effects O
on O
HeLa O
, O
LS180 O
, O
MCF O
- O
7 O
and O
Jurkat O
human O
cancer O
cell O
lines O
. O

The O
results O
of O
this O
study O
proposed O
that O
some O
of O
the O
imidazole B
substituted O
indeno B
[ I
1 I
, I
2 I
- I
b I
] I
quinoline I
- I
9 I
, I
11 I
- I
dione I
compounds O
may O
act O
as O
efficient O
anticancer O
agents O
in O
vitro O
, O
emphasizing O
their O
potential O
role O
as O
a O
source O
for O
rational O
design O
of O
potent O
antiproliferative O
agents O
. O

Spur O
reactions O
observed O
by O
picosecond O
pulse O
radiolysis O
in O
highly O
concentrated O
bromide B
aqueous O
solutions O
. O

Three O
thiol B
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1 O
: O
glutathione B
disulfide I
, O
5 B
, I
5 I
' I
- I
dithiobis I
( I
2 I
- I
nitrobenzoic I
acid I
) I
, O
and O
1 B
, I
1 I
' I
- I
azobis I
( I
N I
, I
N I
- I
dimethylformamide I
) O
( O
diamide B
) O
. O

Three O
thiol B
oxidants O
were O
used O
as O
model O
compounds O
to O
investigate O
their O
effects O
on O
homogeneous O
preparations O
of O
hSULT2A1 O
: O
glutathione B
disulfide I
, O
5 B
, I
5 I
' I
- I
dithiobis I
( I
2 I
- I
nitrobenzoic I
acid I
) I
, O
and O
1 B
, I
1 I
' I
- I
azobis I
( I
N I
, I
N I
- I
dimethylformamide I
) O
( O
diamide B
) O
. O

The O
photochemistry O
of O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
P B
( I
OMe I
) I
3 I
/ O
CH2Cl2 B
solution O
has O
been O
studied O
using O
picosecond O
time O
- O
resolved O
infrared O
( O
TRIR O
) O
spectroscopy O
. O

Photolysis O
at O
400 O
nm O
leads O
to O
the O
formation O
of O
17 O
- O
electron O
CpRu B
( I
CO I
) I
2 I
( I
* I
) I
radicals O
, O
which O
react O
on O
the O
picosecond O
time O
scale O
to O
form O
19 O
- O
electron O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
adducts O
. O

Photolysis O
at O
400 O
nm O
leads O
to O
the O
formation O
of O
17 O
- O
electron O
CpRu B
( I
CO I
) I
2 I
( I
* I
) I
radicals O
, O
which O
react O
on O
the O
picosecond O
time O
scale O
to O
form O
19 O
- O
electron O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
adducts O
. O

This O
spectral O
assignment O
is O
supported O
by O
analogous O
experiments O
on O
[ B
CpFe I
( I
CO I
) I
2 I
] I
2 I
in O
the O
same O
solvent O
, O
combined O
with O
DFT O
studies O
on O
the O
structures O
of O
the O
19 O
- O
electron O
adducts O
. O

The O
DFT O
results O
predict O
a O
bent O
CO B
ligand O
in O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
, O
whereas O
approximately O
linear O
Fe B
- I
C I
- I
O I
bond O
angles O
are O
predicted O
for O
CpFe B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
. O

The O
DFT O
results O
predict O
a O
bent O
CO B
ligand O
in O
CpRu B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
, O
whereas O
approximately O
linear O
Fe B
- I
C I
- I
O I
bond O
angles O
are O
predicted O
for O
CpFe B
( I
CO I
) I
2P I
( I
OMe I
) I
3 I
( I
* I
) I
. O

TRIR O
spectra O
were O
also O
collected O
for O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
neat O
CH2Cl2 B
, O
and O
it O
is O
interesting O
to O
note O
that O
no O
singly O
bridged O
[ B
CpRu I
( I
CO I
) I
] I
2 I
( I
mu I
- I
CO I
) I
photoproduct O
was O
observed O
to O
form O
following O
400 O
- O
or O
267 O
- O
nm O
excitation O
, O
despite O
previous O
observations O
of O
this O
species O
on O
longer O
time O
scales O
. O

TRIR O
spectra O
were O
also O
collected O
for O
[ B
CpRu I
( I
CO I
) I
2 I
] I
2 I
in O
neat O
CH2Cl2 B
, O
and O
it O
is O
interesting O
to O
note O
that O
no O
singly O
bridged O
[ B
CpRu I
( I
CO I
) I
] I
2 I
( I
mu I
- I
CO I
) I
photoproduct O
was O
observed O
to O
form O
following O
400 O
- O
or O
267 O
- O
nm O
excitation O
, O
despite O
previous O
observations O
of O
this O
species O
on O
longer O
time O
scales O
. O

Discovery O
of O
7 B
- I
methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
4 I
- I
methyl I
- I
1 I
, I
3 I
- I
thiazol I
- I
2 I
- I
yl I
) I
- I
1H I
- I
imidazol I
- I
5 I
- I
yl I
] I
- I
1 I
, I
3 I
- I
benzothiazole I
( O
TASP0382088 B
) O
: O
a O
potent O
and O
selective O
transforming O
growth O
factor O
- O
beta O
type O
I O
receptor O
inhibitor O
as O
a O
topical O
drug O
for O
alopecia O
. O

7 B
- I
Methoxy I
- I
6 I
- I
[ I
4 I
- I
( I
4 I
- I
methyl I
- I
1 I
, I
3 I
- I
thiazol I
- I
2 I
- I
yl I
) I
- I
1H I
- I
imidazol I
- I
5 I
- I
yl I
] I
- I
1 I
, I
3 I
- I
benzothiazole I
11 O
( O
TASP0382088 B
) O
was O
synthesized O
and O
evaluated O
as O
transforming O
growth O
factor O
- O
beta O
( O
TGF O
- O
beta O
) O
type O
I O
receptor O
( O
also O
known O
as O
activin O
receptor O
- O
like O
kinase O
5 O
or O
ALK5 O
) O
inhibitor O
. O

The O
asymmetric O
synthesis O
of O
( B
R I
) I
- I
dihydro I
- I
beta I
- I
ionol I
, O
one O
of O
the O
most O
valuable O
raw O
materials O
for O
fragrance O
and O
flavor O
, O
was O
performed O
from O
inexpensive O
beta B
- I
ionone I
via O
lipase O
- O
catalyzed O
dynamic O
kinetic O
resolution O
followed O
by O
reduction O
. O

To O
evaluate O
their O
anti O
- O
oxidative O
activities O
, O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
/ O
free O
radical O
scavenging O
activity O
and O
nitroblue B
tetrazolium I
( O
NBT B
) O
/ O
superoxide B
anion O
scavenging O
activity O
were O
determined O
. O

We O
found O
that O
2 B
- I
{ I
1 I
- I
[ I
1 I
- I
( I
6 I
- I
chloro I
- I
5 I
- I
fluoropyrimidin I
- I
4 I
- I
yl I
) I
ethyl I
] I
piperidin I
- I
4 I
- I
ylamino I
} I
- I
N I
- I
( I
3 I
- I
chlorophenyl I
) I
pyridine I
- I
3 I
- I
carboxamide I
( O
BRN B
- I
250 I
) O
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
( O
HUVECs O
) O
proliferation O
, O
migration O
, O
tube O
formation O
, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10 O
- O
100 O
nM O
. O

These O
fatty B
acids I
included O
jacaric B
and I
punicic I
acid I
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha B
- I
and I
beta I
- I
calendic I
and I
catalpic I
acid I
) O
and O
two O
mono B
- I
unsaturated I
C I
- I
18 I
fatty I
acids I
( O
trans B
- I
and I
cis I
- I
vaccenic I
acid I
) O
. O

These O
fatty B
acids I
included O
jacaric B
and I
punicic I
acid I
found O
in O
jacaranda O
and O
pomegranate O
seed O
oil O
, O
respectively O
, O
three O
octadecatrienoic O
geometric O
isomers O
( O
alpha B
- I
and I
beta I
- I
calendic I
and I
catalpic I
acid I
) O
and O
two O
mono B
- I
unsaturated I
C I
- I
18 I
fatty I
acids I
( O
trans B
- I
and I
cis I
- I
vaccenic I
acid I
) O
. O

Synthesis O
and O
anti O
- O
acetylcholinesterase O
properties O
of O
novel O
beta B
- I
and I
gamma I
- I
substituted I
alkoxy I
organophosphonates I
. O

In O
this O
report O
, O
we O
prepared O
a O
panel O
of O
beta B
- I
substituted I
ethoxy I
and I
gamma I
- I
substituted I
propoxy I
phosphonoesters I
of O
the O
type O
p B
- I
NO I
( I
2 I
) I
PhO I
- I
P I
( I
X I
) I
( I
R I
) I
[ I
( I
O I
( I
CH I
( I
2 I
) I
) I
( I
n I
) I
Z I
] I
( O
R B
= I
Me I
, I
Et I
; I
X I
= I
O I
, I
S I
; I
n I
= I
2 I
, I
3 I
; I
Z I
= I
halogen I
, I
OTs I
) O
and O
examined O
the O
inhibition O
of O
three O
AChEs O
by O
select O
structures O
in O
the O
panel O
. O

In O
this O
report O
, O
we O
prepared O
a O
panel O
of O
beta B
- I
substituted I
ethoxy I
and I
gamma I
- I
substituted I
propoxy I
phosphonoesters I
of O
the O
type O
p B
- I
NO I
( I
2 I
) I
PhO I
- I
P I
( I
X I
) I
( I
R I
) I
[ I
( I
O I
( I
CH I
( I
2 I
) I
) I
( I
n I
) I
Z I
] I
( O
R B
= I
Me I
, I
Et I
; I
X I
= I
O I
, I
S I
; I
n I
= I
2 I
, I
3 I
; I
Z I
= I
halogen I
, I
OTs I
) O
and O
examined O
the O
inhibition O
of O
three O
AChEs O
by O
select O
structures O
in O
the O
panel O
. O

In O
this O
report O
, O
we O
prepared O
a O
panel O
of O
beta B
- I
substituted I
ethoxy I
and I
gamma I
- I
substituted I
propoxy I
phosphonoesters I
of O
the O
type O
p B
- I
NO I
( I
2 I
) I
PhO I
- I
P I
( I
X I
) I
( I
R I
) I
[ I
( I
O I
( I
CH I
( I
2 I
) I
) I
( I
n I
) I
Z I
] I
( O
R B
= I
Me I
, I
Et I
; I
X I
= I
O I
, I
S I
; I
n I
= I
2 I
, I
3 I
; I
Z I
= I
halogen I
, I
OTs I
) O
and O
examined O
the O
inhibition O
of O
three O
AChEs O
by O
select O
structures O
in O
the O
panel O
. O

The O
beta B
- I
fluoroethoxy I
methylphosphonate I
analog O
( O
R B
= I
Me I
, I
Z I
= I
F I
, I
n I
= I
2 I
) O
was O
the O
most O
potent O
anti O
- O
AChE O
compound O
comparable O
( O
ki O
~ O
6 O
x O
10 O
( O
6 O
) O
M O
( O
- O
1 O
) O
min O
( O
- O
1 O
) O
) O
to O
paraoxon B
against O
EEAChE O
. O

Analogs O
with O
Z B
= I
Br I
, I
I I
, I
or I
OTs I
were O
weak O
inhibitors O
of O
the O
AChEs O
, O
and O
methyl B
phosphonates I
( O
R B
= I
Me I
) O
were O
more O
potent O
than O
the O
corresponding O
ethyl B
phosphonates I
( O
R B
= I
Et I
) O
. O

2 B
- I
Substituted I
- I
2 I
- I
amino I
- I
6 I
- I
boronohexanoic I
acids I
as O
arginase O
inhibitors O
. O

Substitution O
at O
the O
alpha O
center O
of O
the O
known O
human O
arginase O
inhibitor O
2 B
- I
amino I
- I
6 I
- I
boronohexanoic I
acid I
( O
ABH B
) O
is O
acceptable O
in O
the O
active O
site O
pockets O
of O
both O
human O
arginase O
I O
and O
arginase O
II O
. O

In O
the O
present O
work O
, O
GSH B
( O
1 O
) O
or O
( B
R I
) I
- I
alpha I
- I
lipoic I
acid I
( O
LA O
) O
( O
2 O
) O
have O
been O
covalently O
linked O
with O
the O
NMDA B
receptor O
antagonists O
memantine B
( O
MEM B
) O
. O

To O
enhance O
localization O
of O
Photofrin B
to O
tumors O
, O
we O
have O
formulated O
Photofrin B
with O
the O
tumor O
- O
localizing O
graft O
copolymer O
poly B
( I
ethylene I
glycol I
) I
- I
grafted I
poly I
( I
l I
- I
lysine I
) I
, O
PLL B
- I
g I
- I
PEG I
. O

Two O
new O
cyclic B
polyamine I
disulfides I
, O
based O
on O
hexa B
- I
and I
octa I
- I
amine I
inserts O
, O
were O
prepared O
and O
their O
transfection O
efficacies O
and O
cytotoxicities O
compared O
with O
our O
previously O
reported O
cyclic B
tri I
- I
and I
tetra I
- I
amine I
disulfides I
. O

The O
new O
cyclic B
hexa I
- I
and I
octa I
- I
amine I
disulfides I
prove O
more O
effective O
at O
transfection O
in O
vitro O
, O
especially O
of O
lung O
epithelial O
A549 O
cell O
line O
. O

As O
a O
new O
treatment O
option O
for O
CDS O
, O
rotigotine B
- O
loaded O
microspheres O
( O
RoMS O
) O
, O
a O
long O
- O
acting O
sustained O
- O
release O
microspheres O
for O
injection O
with O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
as O
drug O
carrier O
, O
are O
now O
being O
evaluated O
in O
clinical O
trial O
. O

The O
major O
toxicological O
effects O
were O
associated O
with O
the O
dopamine B
agonist O
- O
related O
pharmacodynamic O
properties O
of O
rotigotine B
( O
e O
. O
g O
. O
hyperactivity O
and O
stereotype O
, O
enlarged O
ovary O
, O
sporadic O
gastric O
mucous O
membrane O
lesions O
, O
decreased O
body O
weight O
, O
food O
consumption O
and O
prolactin O
, O
and O
increased O
mononuclear O
cell O
, O
neutrophil O
granulocyte O
, O
aspartate B
aminotransferase O
and O
alanine B
aminotransferase O
) O
and O
foreign O
body O
removal O
reaction O
induced O
by O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
and O

The O
extracted O
DNA O
was O
hydrolyzed O
and O
2 B
' I
- I
deoxycytidine I
and O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
were O
determined O
by O
HPLC O
- O
UV O
. O

The O
% O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
content O
of O
DNA O
was O
significantly O
higher O
in O
the O
brain O
compared O
to O
the O
liver O
. O

Moreover O
, O
there O
was O
no O
difference O
in O
the O
% O
5 B
- I
methyl I
- I
2 I
' I
- I
deoxycytidine I
content O
of O
DNA O
between O
the O
cocaine B
and O
the O
heroin B
treated O
animals O
. O

A O
variety O
of O
2 B
- I
alkoxy I
- I
4 I
- I
aryl I
- I
6 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
3 I
- I
pyridinecarbonitrile I
4a O
- O
r O
were O
prepared O
via O
either O
regioselective O
reaction O
of O
3 B
- I
aryl I
- I
1 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
ones I
3 O
with O
malononitrile B
or O
ylidenemalononitrile B
6 O
with O
2 B
- I
acetyl I
- I
1H I
- I
benzimidazoles I
1 O
in O

A O
variety O
of O
2 B
- I
alkoxy I
- I
4 I
- I
aryl I
- I
6 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
3 I
- I
pyridinecarbonitrile I
4a O
- O
r O
were O
prepared O
via O
either O
regioselective O
reaction O
of O
3 B
- I
aryl I
- I
1 I
- I
( I
1H I
- I
benzimidazol I
- I
2 I
- I
yl I
) I
- I
2 I
- I
propen I
- I
1 I
- I
ones I
3 O
with O
malononitrile B
or O
ylidenemalononitrile B
6 O
with O
2 B
- I
acetyl I
- I
1H I
- I
benzimidazoles I
1 O
in O

Nonclassical O
antifolates O
, O
part O
3 O
: O
Synthesis O
, O
biological O
evaluation O
and O
molecular O
modeling O
study O
of O
some O
new O
2 B
- I
heteroarylthio I
- I
quinazolin I
- I
4 I
- I
ones I
. O

A O
new O
series O
of O
2 B
- I
heteroarylthio I
- I
6 I
- I
substituted I
- I
quinazolin I
- I
4 I
- I
one I
analogs O
was O
designed O
, O
synthesized O
, O
and O
evaluated O
for O
their O
in O
vitro O
DHFR O
inhibition O
, O
antimicrobial O
, O
and O
antitumor O
activities O
. O

zearalenol I
- I
4 I
- I
glucoside I
, O
beta B
- I
zearalenol I
- I
4 I
- I
glucoside I
and O
zearalenone B
- I
4 I
- I
sulfate I
. O

According O
to O
a O
probabilistic O
exposure O
analysis O
, O
the O
mean O
( O
and O
P95 O
) O
mycotoxin O
intake O
for O
the O
sum O
of O
the O
deoxynivalenol B
- O
equivalents O
, O
zearalenone B
- O
equivalents O
, O
and O
the O
sum O
of O
HT B
- I
2 I
- I
and I
T I
- I
2 I
- I
toxin I
for O
all O
cereal O
- O
based O
foods O
was O
0 O
. O
1162 O
( O
0 O
. O
4047 O
, O
P95 O
) O
, O
0 O
. O
0447 O
( O
0 O
. O
1568 O
, O
P95 O
) O
and O
0 O
. O
0258 O
( O
0 O
. O
0924 O
, O
P95 O
) O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O

These O
values O
were O
below O
the O
tolerable O
daily O
intake O
( O
TDI O
) O
levels O
for O
deoxynivalenol B
, O
zearalenone B
and O
the O
sum O
of O
T B
- I
2 I
and I
HT I
- I
2 I
toxin I
( O
1 O
. O
0 O
, O
0 O
. O
25 O
and O
0 O
. O
1 O
mu O
g O
kg O
( O
- O
1 O
) O
body O
weight O
day O
( O
- O
1 O
) O
, O
respectively O
) O
. O

Two O
new O
triterpenoids B
, O
( B
24R I
/ I
S I
) I
- I
24 I
- I
hydroxy I
- I
3 I
alpha I
10 I
alpha I
- I
epoxy I
- I
9 I
- I
eip I
- I
cucurbita I
- I
25 I
- I
ene I
( O
1a O
, O
b O
) O
, O
as O
well O
as O
six O
known O
compounds O
( O
3 O
- O
8 O
) O
, O
were O
isolated O
from O
the O
extraction O
of O
Fructus O
Viticis O
Negundo O
. O

In O
particular O
, O
biodegradable O
nanoparticles O
formulated O
from O
poly B
( I
D I
, I
L I
- I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
have O
been O
extensively O
investigated O
for O
sustained O
and O
targeted O
delivery O
of O
different O
agents O
, O
including O
recombinant O
proteins O
, O
plasmid O
DNA O
, O
and O
low O
molecular O
weight O
compounds O
. O

In O
antioxidant O
assays O
all O
of O
the O
tested O
meroterpenes B
, O
and O
in O
particular O
cystodiones B
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
6 B
- I
cis I
- I
amentadione I
- I
1 I
' I
- I
methyl I
ether I
( O
7 O
) O
, O
and O
amentadione B
- I
1 I
' I
- I
methyl I
ether I
( O
8 O
) O
, O
exhibited O
strong O
radical O
- O
scavenging O
activity O
. O

When O
its O
ability O
to O
release O
[ B
( I
3 I
) I
H I
] I
- I
dopamine I
from O
striatal O
slices O
was O
tested O
in O
a O
functional O
assay O
, O
compound O
1 O
behaved O
as O
a O
partial O
agonist O
with O
an O
EC50 O
of O
5 O
. O
8 O
mu O
M O
and O
an O
Emax O
that O
was O
43 O
% O
that O
of O
nicotine B
. O

We O
demonstrate O
that O
the O
formation O
of O
a O
supported O
lipid O
membrane O
can O
be O
quantitatively O
monitored O
from O
the O
characteristic O
fluorescence O
of O
( B
157 I
) I
Gd I
( I
3 I
+ I
) I
ions O
bound O
to O
the O
headgroup O
of O
chelator O
lipids O
. O

Moreover O
, O
we O
were O
able O
to O
localize O
the O
( B
157 I
) I
Gd I
( I
3 I
+ I
) I
ions O
along O
the O
surface O
normal O
with O
nanometer O
precision O
. O

This O
study O
proposes O
a O
multimaterial O
system O
to O
sustain O
the O
release O
by O
covering O
the O
hydrogel O
with O
a O
poly B
( I
alkyl I
- I
2 I
- I
cyanoacrylate I
) I
[ O
PACA B
] O
- O
based O
film O
, O
which O
should O
be O
formed O
by O
an O
in O
situ O
polymerization O
on O
the O
hydrogel O
surface O
initiated O
upon O
contact O
with O
water O
. O

Successful O
synthesis O
of O
PACA B
at O
the O
hydrogel O
surface O
was O
confirmed O
and O
the O
PACA B
layer O
was O
identified O
to O
be O
most O
homogeneous O
for O
poly B
( I
n I
- I
butyl I
- I
2 I
- I
cyanoacrylate I
) I
on O
both O
the O
micro O
- O
and O
nanolevel O
. O

The O
structure O
of O
the O
new O
compound O
was O
determined O
as O
methyl B
3 I
- I
( I
5 I
, I
7 I
- I
dihydroxy I
- I
2 I
- I
( I
4 I
- I
hydroxyphenyl I
) I
- I
4 I
- I
oxo I
- I
4H I
- I
chromen I
- I
6 I
- I
yl I
) I
- I
4 I
- I
methoxybenzoate I
by O
means O
of O
spectroscopic O
evidence O
, O
including O
UV O
, O
IR O
, O
1D O
and O
2D O
NMR O
analyses O
as O
well O
as O
HR O
- O
ESI O
- O
MS O
. O

These O
compounds O
( O
1 O
- O
5 O
) O
were O
evaluated O
for O
the O
antioxidant O
activity O
in O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
assay O
system O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmane I
- O
type O
sesquiterpenoids B
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa O
, O
and O
their O
structures O
were O
elucidated O
as O
8 B
- I
oxo I
- I
tri I
- I
nor I
- I
eudesm I
- I
6 I
- I
en I
- I
5 I
alpha I
- I
ol I
( O
1 O
) O
and O
tri B
- I
nor I
- I
eudesm I
- I
5 I
- I
en I
- I
7 I
beta I
, I
8 I
beta I
- I
diol I
( O
2 O
) O
. O

Two O
new O
tri B
- I
nor I
- I
eudesmane I
- O
type O
sesquiterpenoids B
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa O
, O
and O
their O
structures O
were O
elucidated O
as O
8 B
- I
oxo I
- I
tri I
- I
nor I
- I
eudesm I
- I
6 I
- I
en I
- I
5 I
alpha I
- I
ol I
( O
1 O
) O
and O
tri B
- I
nor I
- I
eudesm I
- I
5 I
- I
en I
- I
7 I
beta I
, I
8 I
beta I
- I
diol I
( O
2 O
) O
. O

In O
this O
work O
, O
we O
treated O
rat O
hepatocytes O
with O
[ B
( I
14 I
) I
C I
] I
- I
TASO I
and O
submitted O
the O
mitochondrial O
, O
microsomal O
, O
and O
cytosolic O
fractions O
to O
2DGE O
, O
which O
revealed O
a O
total O
of O
321 O
radioactive O
protein O
spots O
. O

To O
facilitate O
the O
identification O
of O
target O
proteins O
and O
adducted O
peptides O
, O
we O
also O
treated O
cells O
with O
a O
mixture O
of O
TASO B
/ O
[ B
( I
13 I
) I
C2D3 I
] I
- I
TASO I
. O

A O
novel O
series O
of O
prodrugs O
containing O
dabigatran B
and O
methyl B
( I
E I
) I
- I
3 I
- I
( I
4 I
- I
hydroxy I
- I
2 I
- I
methoxyphenyl I
) I
propenoate I
( O
methyl B
ferulate I
) O
were O
synthesized O
. O

A O
new O
series O
of O
N2 B
- I
substituted I
- I
5 I
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
analogues O
as O
alpha O
- O
glucosidase O
inhibitors O
. O

Several O
members O
of O
a O
new O
family O
of O
non O
- O
sugar B
- O
type O
alpha O
- O
glycosidase O
inhibitors O
, O
bearing O
a O
5 B
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
moiety O
and O
various O
substituent O
at O
the O
N2 O
position O
, O
were O
synthesized O
and O
their O
activities O
were O
investigated O
. O

Structure O
- O
activity O
relationship O
studies O
indicated O
that O
5 B
- I
( I
p I
- I
toluenesulfonylamino I
) I
phthalimide I
moiety O
is O
a O
favorable O
scaffold O
to O
exert O
the O
alpha O
- O
glucosidase O
inhibitory O
activity O
and O
substituents O
at O
the O
N2 O
position O
have O
considerable O
influence O
on O
the O
efficacy O
of O
the O
inhibition O
activities O
. O

Efficient O
synthesis O
and O
antimicrobial O
activity O
of O
some O
novel O
S B
- I
beta I
- I
d I
- I
glucosides I
of O
5 B
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
thiones I
derivatives O
. O

A O
series O
of O
3 B
- I
S I
- I
beta I
- I
d I
- I
glucosides I
- I
4 I
- I
arylideneamino I
- I
5 I
- I
aryl I
- I
1 I
, I
2 I
, I
4 I
- I
triazoles I
were O
rationally O
designed O
and O
synthesized O
according O
to O
the O
principle O
of O
superposition O
of O
bioactive O
substructures O
by O
the O
combination O
of O
1 B
, I
2 I
, I
4 I
- I
triazole I
, O
Schiff B
base I
and O
glucosides B
. O

In O
order O
to O
enhance O
the O
bioactivity O
of O
this O
compound O
, O
chemical O
modification O
of O
1 O
to O
the O
dihydro O
analog O
, O
ent B
- I
16 I
beta I
- I
hydroxybeyeran I
- I
19 I
- I
oic I
acid I
( O
2 O
) O
, O
was O
undertaken O
. O

Compound O
2 O
was O
then O
converted O
to O
the O
corresponding O
acetate B
derivative O
, O
ent B
- I
16 I
beta I
- I
acetoxybeyeran I
- I
19 I
- I
oic I
acid I
( O
3 O
) O
. O

The O
metabolite O
4 O
, O
ent B
- I
7 I
alpha I
- I
hydroxy I
- I
16 I
- I
ketobeyeran I
- I
19 I
- I
oic I
acid I
, O
exhibited O
the O
most O
highly O
potent O
activity O
, O
with O
EC50 O
of O
3 O
. O
46 O
nM O
, O
whereas O
the O
parent O
compound O
1 O
showed O
relatively O
low O
activity O
( O
EC50 O
57 O
. O
41 O
nM O
) O
. O

The O
formation O
from O
D B
- I
glucose I
of O
both O
enantiomers O
of O
2 B
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
iminoribonic I
acid I
is O
the O
first O
chemical O
synthesis O
of O
unprotected O
3 B
- I
hydroxyazetidine I
carboxylic I
acids I
. O

The O
structure O
of O
N B
, I
3 I
- I
O I
- I
dibenzyl I
- I
2 I
, I
4 I
- I
dideoxy I
- I
2 I
, I
4 I
- I
imino I
- I
D I
- I
ribonic I
acid I
was O
established O
by O
X O
- O
ray O
crystallographic O
analysis O
. O

Complementary O
density O
functional O
theory O
calculations O
suggest O
that O
the O
reaction O
is O
most O
likely O
mediated O
by O
a O
monothiolate O
RS B
- I
Au I
complex O
bonded O
to O
the O
gold O
surface O
, O
which O
forms O
a O
trithiolate B
RS B
- I
Au I
- I
( I
SR I
) I
- I
Au I
- I
SR I
complex O
as O
a O
key O
intermediate O
. O

Toxoplasma O
gondii O
is O
sensitive O
to O
bulky O
pyrazolo B
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidine I
( O
PP O
) O
inhibitors O
due O
to O
the O
presence O
of O
a O
Gly B
gatekeeper O
in O
the O
essential O
calcium B
dependent O
protein O
kinase O
1 O
( O
CDPK1 O
) O
. O

Preliminary O
screening O
of O
the O
compounds O
involved O
scavenging O
hydroxyl B
radicals O
and O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
( O
DPPH B
( I
. I
) I
) O
, O
croton O
oil O
- O
induced O
ear O
edema O
in O
mice O
, O
and O
analysis O
of O
the O
mRNA O
expression O
of O
adhesion O
molecules O
in O
ECs O
. O

1 B
- I
Acetyl I
- I
sinapic I
acyl I
- I
4 I
- I
( I
3 I
' I
- I
chlorine I
- I
) I
benzylpiperazine I
( O
SA9 B
) O
had O
the O
strongest O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
both O
in O
vitro O
and O
in O
vivo O
. O

Measurement O
of O
Transport O
Activities O
of O
3 B
beta I
- I
Hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
Acids I
in O
Bile B
Salt I
Export O
Pump O
and O
Multidrug O
Resistance O
- O
Associated O
Proteins O
Using O
LC O
- O
MS O
/ O
MS O
. O

A O
method O
has O
been O
developed O
for O
the O
measurement O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
Sf9 O
cells O
for O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
by O
high O
- O
performance O
liquid O
chromatography O
- O
electrospray O
ionization O
- O
tandem O
mass O
spectrometry O
. O

Calibration O
curves O
for O
the O
bile B
acids I
were O
linear O
over O
the O
range O
of O
10 O
to O
2000 O
pmol O
/ O
mL O
, O
and O
the O
detection O
limit O
was O
less O
than O
1 O
pmol O
/ O
mL O
for O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
using O
selected O
reaction O
monitoring O
analysis O
. O

The O
analytical O
method O
was O
applied O
to O
measurements O
of O
transport O
activities O
in O
membrane O
vesicles O
obtained O
from O
human O
multidrug O
resistance O
- O
associated O
protein O
2 O
- O
, O
3 O
- O
, O
and O
human O
bile B
salt I
export O
pump O
- O
expressing O
Sf9 O
cells O
for O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
. O

The O
present O
study O
demonstrated O
that O
human O
multidrug O
resistance O
- O
associated O
protein O
3 O
vesicles O
accepted O
conjugated O
3 B
beta I
- I
hydroxy I
- I
Delta I
( I
5 I
) I
- I
bile I
acids I
along O
with O
common O
bile B
acids I
such O
as O
glycocholic B
acid I
and O
taurolithocholic B
acid I
3 I
- I
sulfate I
. O

Chemical O
investigation O
of O
n B
- I
butanol I
fraction O
afforded O
alpha B
- I
amyrin I
3 I
- I
O I
- I
glucopyranoside I
( O
1 O
) O
, O
patuletin B
7 I
- I
O I
- I
glucopyranoside I
( O
2 O
) O
, O
myricitrin B
( O
3 O
) O
and O
a O
new O
oleanane B
triterpene I
saponin I
derivative O
( O
4 O
) O
, O
sophradiol B
3 I
- I
O I
- I
alpha I
- I
L I
- I
( I
1 I
) I
C4 I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
4 I
' I
' I
) I
- I
O I
- I
beta I
- I
D I
- I
( I
4 I
) I
C1 I
- I
galactopyranosyl I

Acute O
Myocardial O
Infarction O
During O
Regadenoson B
Myocardial O
Perfusion O
Imaging O
. O

Enthalpies O
of O
dilution O
of O
aqueous O
solutions O
of O
aliphatic B
6 I
, I
12 I
- I
and I
12 I
, I
12 I
- I
ionene I
bromides I
and I
fluorides I
and O
enthalpies O
of O
mixing O
with O
low O
molecular O
- O
weight O
salts O
, O
such O
as O
sodium B
fluoride I
and I
bromide I
, O
are O
determined O
. O

The O
polyelectrolytes O
examined O
in O
this O
part O
of O
the O
work O
are O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
6 I
, I
12 I
- I
, I
and I
12 I
, I
12 I
- I
ionenes I
. O

We O
show O
that O
the O
salts O
when O
ordered O
by O
heat O
effects O
produced O
by O
mixing O
of O
NaF B
and O
NaBr B
with O
3 B
, I
3 I
- I
, I
6 I
, I
9 I
- I
, I
or I
6 I
, I
12 I
- I
ionene I
fluorides I
and I
bromides I
follow O
the O
opposite O
ordering O
than O
in O
the O
case O
when O
the O
same O
alkali B
halide I
salts O
are O
mixed O
with O
more O
hydrophobic O
12 B
, I
12 I
- I
ionene I
salts O
. O

Discovery O
of O
( B
R I
) I
- I
2 I
- I
amino I
- I
6 I
- I
borono I
- I
2 I
- I
( I
2 I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
hexanoic I
acid I
and O
congeners O
as O
highly O
potent O
inhibitors O
of O
human O
arginases O
I O
and O
II O
for O
treatment O
of O
myocardial O
reperfusion O
injury O
. O

The O
lead O
candidate O
, O
( B
R I
) I
- I
2 I
- I
amino I
- I
6 I
- I
borono I
- I
2 I
- I
( I
2 I
- I
( I
piperidin I
- I
1 I
- I
yl I
) I
ethyl I
) I
hexanoic I
acid I
, O
compound O
9 O
, O
inhibits O
human O
arginases O
I O
and O
II O
with O
IC50s O
of O
223 O
and O
509 O
nM O
, O
respectively O
, O
and O
is O
active O
in O
a O
recombinant O
cellular O
assay O
overexpressing O
human O
arginase O
I O
( O
CHO O
cells O
) O
. O

Design O
, O
Synthesis O
, O
and O
Biological O
Evaluation O
of O
a O
Series O
of O
Benzo B
[ I
de I
] I
[ I
1 I
, I
7 I
] I
naphthyridin I
- I
7 I
( I
8H I
) I
- I
ones I
Bearing O
a O
Functionalized O
Longer O
Chain O
Appendage O
as O
Novel O
PARP1 O
Inhibitors O
. O

A O
series O
of O
benzo B
[ I
de I
] I
[ I
1 I
, I
7 I
] I
naphthyridin I
- I
7 I
( I
8H I
) I
- I
ones I
possessing O
a O
functionalized O
long O
- O
chain O
appendage O
have O
been O
designed O
and O
evaluated O
as O
novel O
PARP1 O
inhibitors O
. O

The O
initial O
effort O
led O
to O
the O
first O
- O
generation O
PARP1 O
inhibitor O
26 O
bearing O
a O
terminal O
phthalazin B
- I
1 I
( I
2H I
) I
- I
one I
framework O
and O
showing O
remarkably O
high O
PARP1 O
inhibitory O
activity O
( O
0 O
. O
31 O
nM O
) O
but O
only O
moderate O
potency O
in O
the O
cell O
. O

Nanoparticles O
of O
a O
three O
- O
dimensional O
coordination O
polymer O
, O
[ B
Pb I
( I
L I
) I
( I
mu I
2 I
- I
Br I
) I
( I
H2O I
) I
] I
n I
( O
1 O
) O
, O
( O
L O
( O
- O
) O
= O
1H B
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
carboxylate I
) O
, O
have O
been O
synthesized O
by O
an O
ultrasonic O
method O
and O
characterized O
by O
scanning O
electron O
microscopy O
, O
X O
- O
ray O
powder O
diffraction O
, O
IR O
spectroscopy O
and O
elemental O
analyses O
. O

Nanoparticles O
of O
a O
three O
- O
dimensional O
coordination O
polymer O
, O
[ B
Pb I
( I
L I
) I
( I
mu I
2 I
- I
Br I
) I
( I
H2O I
) I
] I
n I
( O
1 O
) O
, O
( O
L O
( O
- O
) O
= O
1H B
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
carboxylate I
) O
, O
have O
been O
synthesized O
by O
an O
ultrasonic O
method O
and O
characterized O
by O
scanning O
electron O
microscopy O
, O
X O
- O
ray O
powder O
diffraction O
, O
IR O
spectroscopy O
and O
elemental O
analyses O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
the O
melanoma O
targeting O
property O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
in O
B16 O
/ O
F1 O
melanoma O
- O
bearing O
C57 O
mice O
. O

( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
exhibited O
high O
receptor O
- O
mediated O
melanoma O
uptake O
and O
fast O
urinary O
clearance O
. O

The O
tumor O
uptake O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
was O
20 O
. O
25 O
+ O
/ O
- O
4 O
. O
59 O
and O
21 O
. O
63 O
+ O
/ O
- O
6 O
. O
27 O
% O
ID O
/ O
g O
at O
0 O
. O
5 O
and O
2h O
post O
- O
injection O
, O
respectively O
. O

( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
showed O
high O
tumor O
to O
normal O
organ O
uptake O
ratios O
except O
for O
the O
kidneys O
. O

The O
tumor O
/ O
kidney O
uptake O
ratios O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
were O
2 O
. O
76 O
and O
1 O
. O
74 O
at O
2 O
and O
24h O
post O
- O
injection O
. O

The O
melanoma O
lesions O
were O
clearly O
visualized O
by O
SPECT O
/ O
CT O
using O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
as O
an O
imaging O
probe O
at O
2h O
post O
- O
injection O
. O

Overall O
, O
high O
melanoma O
uptake O
coupled O
with O
fast O
urinary O
clearance O
of O
( B
177 I
) I
Lu I
- I
DOTA I
- I
GGNle I
- I
CycMSHhex I
underscored O
its O
potential O
for O
melanoma O
treatment O
in O
the O
future O
. O

Synthesis O
and O
evaluation O
of O
3 B
- I
( I
benzylthio I
) I
- I
5 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
amines I
as O
Bcl O
- O
2 O
inhibitory O
anticancer O
agents O
. O

A O
series O
of O
substituted O
3 B
- I
( I
benzylthio I
) I
- I
5 I
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I
- I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
amines I
has O
been O
synthesised O
and O
tested O
in O
vitro O
as O
potential O
pro O
- O
apoptotic O
Bcl O
- O
2 O
- O
inhibitory O
anticancer O
agents O
. O

Recently O
, O
the O
discovery O
of O
the O
aminoisoindoles B
as O
potent O
and O
selective O
inhibitors O
of O
beta O
- O
secretase O
was O
reported O
, O
including O
the O
close O
structural O
analogs O
compound O
( B
S I
) I
- I
1 I
- I
pyridin I
- I
4 I
- I
yl I
- I
4 I
- I
fluoro I
- I
1 I
- I
( I
3 I
- I
( I
pyrimidin I
- I
5 I
- I
yl I
) I
phenyl I
) I
- I
1H I
- I
isoindol I
- I
3 I
- I
amine I
[ O
( O
S O
) O
- O
25 O
] O
and O
( B
S I
) I
- I
1 I
- I
( I
2 I
- I
( I
difluoromethyl I
) I
pyridin I
- I
4 I
- I
yl I
) I
- I
4 I
- I

fluoro I
- I
1 I
- I
( I
3 I
- I
( I
pyrimidin I
- I
5 I
- I
yl I
) I
phenyl I
) I
- I
1H I
- I
isoindol I
- I
3 I
- I
amine I
hemifumarate I
( O
AZD3839 B
) O
, O
the O
latter O
being O
recently O
progressed O
to O
the O
clinic O
. O

Moreover O
, O
the O
concomitant O
administration O
of O
subeffective O
doses O
of O
LSP1 B
- I
2111 I
( O
0 O
. O
3 O
- O
0 O
. O
5 O
mg O
/ O
kg O
) O
with O
a O
subeffective O
dose O
of O
5 O
- O
HT1A O
agonist O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
8 I
- I
Hydroxy I
- I
DPAT I
( O
0 O
. O
01 O
mg O
/ O
kg O
) O
, O
induced O
a O
clear O
antipsychotic O
- O
like O
effect O
in O
all O
of O
the O
procedures O
used O
. O

Herein O
we O
report O
a O
modified O
synthesis O
of O
a O
known O
RAR O
alpha O
antagonist O
, O
2 B
- I
fluoro I
- I
4 I
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
and O
a O
synthesis O
of O
its O
unknown O
, O
desfluoro O
analog O
, O
4 B
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
. O

Herein O
we O
report O
a O
modified O
synthesis O
of O
a O
known O
RAR O
alpha O
antagonist O
, O
2 B
- I
fluoro I
- I
4 I
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
and O
a O
synthesis O
of O
its O
unknown O
, O
desfluoro O
analog O
, O
4 B
- I
[ I
[ I
[ I
8 I
- I
bromo I
- I
2 I
, I
2 I
- I
dimethyl I
- I
4 I
- I
( I
4 I
- I
methylphenyl I
) I
chroman I
- I
6 I
- I
yl I
] I
carbonyl I
] I
amino I
] I
benzoic I
acid I
. O

We O
report O
a O
novel O
class O
of O
highly O
water O
- O
soluble O
decacationic B
methano I
[ I
60 I
] I
fullerene I
decaiodides I
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
- I
( I
I I
( I
- I
) I
) I
10 I
[ O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
] O
capable O
of O
co O
- O
producing O
singlet O
oxygen B
( O
Type O
- O
II O
) O
and O
highly O
reactive O
hydroxyl B
radicals O
, O
formed O
from O
superoxide B
radicals O
in O
Type O
- O
I O
photosensitizing O
reactions O
, O
upon O
illumination O
at O
both O
UVA O
and O
white O
light O
wavelengths O
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

The O
O2 B
( I
- I
) I
. I
- O
production O
efficiency O
of O
1 O
- O
( B
I I
( I
- I
) I
) I
10 I
was O
confirmed O
by O
using O
an O
O2 B
( I
- I
) I
. I
- O
reactive O
bis B
( I
2 I
, I
4 I
- I
dinitrobenzenesulfon I
) I
tetrafluorofluoresce I
probe O
and O
correlated O
to O
the O
photoinduced O
electron O
- O
transfer O
event O
going O
from O
iodide B
anions O
to O
( B
3 I
) I
C60 I
* I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
leading O
to O
C60 B
( I
- I
) I
. I
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
. O

We O
used O
the O
well O
- O
characterized O
malonato B
[ I
60 I
] I
fullerene I
diester I
monoadduct O
C60 B
[ I
> I
M I
( I
t I
- I
Bu I
) I
2 I
] I
as O
the O
starting O
fullerene B
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
via O
transesterification O
reaction O
under O
trifluoroacetic B
acid I
catalyzed O
conditions O
. O

We O
used O
the O
well O
- O
characterized O
malonato B
[ I
60 I
] I
fullerene I
diester I
monoadduct O
C60 B
[ I
> I
M I
( I
t I
- I
Bu I
) I
2 I
] I
as O
the O
starting O
fullerene B
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
via O
transesterification O
reaction O
under O
trifluoroacetic B
acid I
catalyzed O
conditions O
. O

Synthesis O
, O
antimicrobial O
, O
antiquorum O
- O
sensing O
, O
antitumor O
and O
cytotoxic O
activities O
of O
new O
series O
of O
fused O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
. O

New O
series O
of O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
3 I
, I
2 I
- I
a I
] I
pyrimidines I
, O
benzo B
[ I
h I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
2 I
, I
3 I
- I
b I
] I
quinazolines I
, O
benzothiadiazolotria B
, O
and O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
have O
been O
synthesized O
and O
characterized O
by O
analytical O
and O
spectrometrical O
methods O
( O
IR O
, O
MS O
, O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
) O
. O

New O
series O
of O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
3 I
, I
2 I
- I
a I
] I
pyrimidines I
, O
benzo B
[ I
h I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
2 I
, I
3 I
- I
b I
] I
quinazolines I
, O
benzothiadiazolotria B
, O
and O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
have O
been O
synthesized O
and O
characterized O
by O
analytical O
and O
spectrometrical O
methods O
( O
IR O
, O
MS O
, O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
) O
. O

New O
series O
of O
[ B
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
3 I
, I
2 I
- I
a I
] I
pyrimidines I
, O
benzo B
[ I
h I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazolo I
[ I
2 I
, I
3 I
- I
b I
] I
quinazolines I
, O
benzothiadiazolotria B
, O
and O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
[ I
1 I
, I
3 I
, I
4 I
] I
thiadiazoles I
have O
been O
synthesized O
and O
characterized O
by O
analytical O
and O
spectrometrical O
methods O
( O
IR O
, O
MS O
, O
( B
1 I
) I
H I
and O
( B
13 I
) I
C I
NMR O
) O
. O

Synthesis O
using O
microwave O
irradiation O
and O
antibacterial O
evaluation O
of O
new O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
. O

This O
paper O
describes O
a O
novel O
series O
of O
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
( O
7a O
- O
o O
) O
derived O
from O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinones I
that O
were O
synthesized O
and O
evaluated O
as O
potential O
antimicrobial O
agents O
. O

Three O
of O
our O
biologically O
active O
2 B
- I
amino I
- I
1 I
, I
4 I
- I
naphthoquinone I
N B
, I
O I
- I
acetals I
and O
N B
, I
S I
- I
acetals I
tested O
against O
hospital O
bacterial O
strains O
were O
identified O
as O
potential O
lead O
compounds O
. O

1 B
- I
Hexadecyl I
- I
3 I
- I
trifluoroethylglycer I
- I
sn I
- I
2 I
- I
phosphomethanol I
( O
MJ33 B
) O
is O
a O
fluorinated O
phospholipid O
analog O
that O
inhibits O
the O
phospholipase O
A2 O
( O
PLA2 O
) O
activity O
of O
peroxiredoxin O
6 O
( O
Prdx6 O
) O
. O

DNA O
Adducts O
in O
Aldehyde B
Dehydrogenase O
- O
Positive O
Lung O
Stem O
Cells O
of O
A O
/ O
J O
Mice O
Treated O
with O
the O
Tobacco O
Specific O
Lung O
Carcinogen O
4 B
- I
( I
Methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
( O
NNK B
) O
. O

To O
investigate O
the O
presence O
of O
DNA O
modifications O
in O
these O
cells O
, O
we O
isolated O
ALDH O
- O
positive O
lung O
cells O
from O
A O
/ O
J O
mice O
exposed O
to O
the O
lung O
carcinogen O
4 B
- I
( I
methylnitrosamino I
) I
- I
1 I
- I
( I
3 I
- I
pyridyl I
) I
- I
1 I
- I
butanone I
. O

Using O
LC O
- O
NSI O
- O
HRMS O
/ O
MS O
- O
PRM O
, O
O B
( I
6 I
) I
- I
methyl I
- I
G I
, O
7 B
- I
POB I
- I
G I
, O
and O
O B
( I
2 I
) I
- I
POB I
- I
dT I
were O
positively O
identified O
in O
ALDH O
- O
positive O
cell O
DNA O
. O

Using O
LC O
- O
NSI O
- O
HRMS O
/ O
MS O
- O
PRM O
, O
O B
( I
6 I
) I
- I
methyl I
- I
G I
, O
7 B
- I
POB I
- I
G I
, O
and O
O B
( I
2 I
) I
- I
POB I
- I
dT I
were O
positively O
identified O
in O
ALDH O
- O
positive O
cell O
DNA O
. O

Phytochemical O
investigation O
of O
the O
aerial O
parts O
of O
Prinsepia O
utilis O
Royle O
resulted O
in O
the O
isolation O
and O
identification O
of O
ten O
pentacyclic B
triterpenoids I
, O
including O
two O
new O
triterpenoids B
, O
2 B
alpha I
- I
O I
- I
trans I
- I
p I
- I
coumaroyl I
- I
3 I
beta I
, I
19 I
alpha I
- I
dihydroxy I
- I
urs I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
1 O
) O
and O
2 B
alpha I
- I
O I
- I
cis I
- I
p I
- I
coumaroyl I
- I
3 I
beta I
, I
19 I
alpha I
- I
dihydroxy I
- I
urs I
- I
12 I
- I
en I
- I
28 I
- I

oic I
acid I
( O
2 O
) O
, O
along O
with O
eight O
known O
pentacyclic B
triterpenoids I
( O
3 O
- O
10 O
) O
. O

N B
- I
[ I
9 I
- I
( I
ortho I
- I
Fluorobenzyl I
) I
- I
2 I
- I
Phenyl I
- I
8 I
- I
Azapurin I
- I
6 I
- I
yl I
] I
- I
Amides I
as O
Potent O
and O
Selective O
Ligands O
for O
A1 O
Adenosine B
Receptors O
. O

A O
series O
of O
N B
- I
[ I
9 I
- I
( I
ortho I
- I
fluorobenzyl I
) I
- I
2 I
- I
phenyl I
- I
8 I
- I
azapurin I
- I
6 I
- I
yl I
] I
- I
amides I
were O
synthesised O
and O
tested O
for O
their O
affinity O
toward O
A1 O
, O
A2A O
and O
A3 O
adenosine B
receptor O
subtypes O
. O

Furthermore O
, O
a O
molecular O
docking O
study O
was O
carried O
out O
in O
order O
to O
assess O
hypothetical O
binding O
mode O
of O
N B
- I
[ I
9 I
- I
( I
ortho I
- I
fluorobenzyl I
) I
- I
2 I
- I
phenyl I
- I
8 I
- I
azapurin I
- I
6 I
- I
yl I
] I
- I
amides I
to O
A1 O
adenosine B
receptors O
. O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl B
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

Aggregation O
and O
kinetic O
studies O
have O
been O
performed O
to O
understand O
the O
hydrolytic O
potencies O
of O
the O
series O
of O
oxime B
- O
functionalized O
surfactants O
, O
viz O
. O
, O
3 B
- I
hydroxyiminomethyl I
- I
1 I
- I
alkylpyridinium I
bromide I
( O
alkyl B
= O
CnH2n B
+ I
1 I
, O
n O
= O
10 O
, O
12 O
, O
14 O
, O
16 O
, O
18 O
) O
in O
the O
cleavage O
of O
phosphate B
esters I
, O
p B
- I
nitrophenyl I
diphenyl I
phosphate I
( O
PNPDPP B
) O
and O
bis B
( I
2 I
, I
4 I
- I
dinitrophenyl I
) I
phosphate I
( O

We O
studied O
the O
equilibrium O
conformations O
of O
a O
zinc B
porphyrin I
tweezer O
composed O
of O
two O
carboxylphenyl B
- O
functionalized O
zinc B
tetraphenyl I
porphyrin I
subunits O
connected O
by O
a O
1 B
, I
4 I
- I
butyndiol I
spacer O
, O
which O
was O
suspended O
inside O
the O
amphiphilic O
regions O
of O
1 B
, I
2 I
- I
distearoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DSPC B
) O
liposomes O
. O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

and O
23 B
- I
( I
10 I
- I
methyl I
) I
undecanoic I
acid I
demalony I
lazalomycin I
F4a I
ester I
( O
7 O
) O
. O

1 B
- I
Methylimidazolium I
hydrogen I
sulfate I
catalyzed O
convenient O
synthesis O
of O
2 B
, I
5 I
- I
dimethyl I
- I
N I
- I
substituted I
pyrroles I
under O
ultrasonic O
irradiation O
. O

Ethyl B
lauroyl I
arginate I
( O
LAE B
, O
ethyl B
- I
N I
- I
dodecanoyl I
- I
L I
- I
arginate I
hydrochloride I
) O
is O
a O
strong O
antimicrobial O
agent O
that O
was O
included O
as O
an O
active O
compound O
in O
an O
antimicrobial O
food O
packaging O
material O
. O

The O
evidence O
includes O
structures O
with O
Bis B
- I
Tris I
( I
2 I
, I
2 I
- I
bis I
( I
hydroxymethyl I
) I
- I
2 I
, I
2 I
' I
, I
2 I
' I
' I
- I
nitrilotriethanol I
) I
and O
l B
- I
ribose I
in O
the O
site O
and O
kinetic O
binding O
studies O
with O
substituted O
beta O
- O
galactosidases O
. O

Here O
, O
a O
main O
group O
seven O
- O
coordinated O
bismuth B
( I
III I
) I
complex O
[ O
Bi B
( I
L I
) I
( I
NO3 I
) I
2 I
( I
CH3CH2OH I
) I
] O
( O
1 O
) O
( O
HL O
= O
2 B
- I
acetylpyridine I
N I
( I
4 I
) I
- I
phenylthiosemicarbaz I
) O
has O
been O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
IR O
, O
( B
1 I
) I
H I
NMR O
and O
single O
- O
crystal O
X O
- O
ray O
diffraction O
studies O
. O

Here O
, O
a O
main O
group O
seven O
- O
coordinated O
bismuth B
( I
III I
) I
complex O
[ O
Bi B
( I
L I
) I
( I
NO3 I
) I
2 I
( I
CH3CH2OH I
) I
] O
( O
1 O
) O
( O
HL O
= O
2 B
- I
acetylpyridine I
N I
( I
4 I
) I
- I
phenylthiosemicarbaz I
) O
has O
been O
synthesized O
and O
characterized O
by O
elemental O
analysis O
, O
IR O
, O
( B
1 I
) I
H I
NMR O
and O
single O
- O
crystal O
X O
- O
ray O
diffraction O
studies O
. O

Identification O
and O
synthesis O
of O
N B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
benzamide I
derivatives O
as O
BRAF O
( O
V600E O
) O
inhibitors O
. O

In O
this O
study O
, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N B
- I
( I
thiophen I
- I
2 I
- I
yl I
) I
benzamide I
derivatives O
as O
potent O
BRAF O
( O
V600E O
) O
inhibitors O
. O

Synthesis O
and O
Structure O
- O
Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase O
- O
Sulfatase O
Inhibitor O
4 B
- I
{ I
[ I
( I
4 I
- I
Cyanophenyl I
) I
( I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
yl I
) I
amino I
] I
methyl I
} I
phenyl I
sulfamate I
. O

4 B
- I
{ I
[ I
( I
4 I
- I
Cyanophenyl I
) I
( I
4H I
- I
1 I
, I
2 I
, I
4 I
- I
triazol I
- I
4 I
- I
yl I
) I
amino I
] I
methyl I
} I
phenyl I
sulfamate I
and O
its O
ortho O
- O
halogenated O
( O
F B
, O
Cl B
, O
Br B
) O
derivatives O
are O
first O
- O
generation O
dual O
aromatase O
and O
sulfatase O
inhibitors O
( O
DASIs O
) O
. O

Structural O
Rearrangement O
in O
the O
Formation O
of O
Jet O
- O
Cooled O
Complexes O
of O
Chiral O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
Tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
with O
Methyl B
Lactate I
: O
Chirality O
Effect O
in O
Conformer O
Selection O
. O

The O
jet O
- O
cooled O
complexes O
between O
the O
two O
enantiomers O
of O
methyl B
lactate I
( O
ML O
) O
and O
( B
S I
) I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
- I
tetrahydro I
- I
3 I
- I
isoquinolinemethanol I
( O
THIQM B
) O
are O
studied O
by O
double O
resonance O
spectroscopy O
combined O
with O
ab O
initio O
calculations O
. O

Chrysoeriol B
, O
laricitrin B
, O
myricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
, O
pinocembrin B
, O
quercitrin B
, O
tamarixetin B
, O
tricetin B
and O
tricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
were O
also O
identified O
as O
novel O
flavonoid B
ABCG2 O
inhibitors O
. O

Chrysoeriol B
, O
laricitrin B
, O
myricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
, O
pinocembrin B
, O
quercitrin B
, O
tamarixetin B
, O
tricetin B
and O
tricetin B
3 I
' I
, I
4 I
' I
, I
5 I
' I
- I
trimethylether I
were O
also O
identified O
as O
novel O
flavonoid B
ABCG2 O
inhibitors O
. O

Aiming O
to O
know O
more O
about O
these O
modifications O
, O
the O
structurally O
related O
alpha B
- I
( I
1 I
- I
- I
> I
5 I
) I
- I
l I
- I
arabinotriose I
was O
roasted O
at O
200 O
degrees O
C O
and O
the O
products O
obtained O
were O
identified O
by O
ESI O
- O
MS O
and O
MALDI O
- O
MS O
and O
characterised O
by O
ESI O
- O
MS O
( O
n O
) O
. O

Identification O
of O
the O
odour O
- O
active O
cyclic O
diketone O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
in O
roasted O
Arabica O
coffee O
brew O
. O

Gas O
chromatography O
- O
olfactometry O
( O
GC O
- O
O O
) O
and O
multidimensional O
gas O
chromatography O
- O
mass O
spectrometry O
( O
MDGC O
- O
MS O
) O
of O
the O
fraction O
which O
contained O
a O
significant O
amount O
of O
the O
target O
unknown O
compound O
revealed O
the O
cyclic O
1 O
, O
4 O
- O
diketone O
, O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
, O
which O
had O
a O
pungent O
odour O
, O
and O
was O
thus O
first O
identified O
in O
roasted O
coffee O
. O

Model O
experiments O
revealed O
that O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
was O
formed O
via O
thermal O
degradation O
of O
sugars B
, O
especially O
monosaccharides B
, O
under O
alkaline O
conditions O
. O

Further O
, O
we O
demonstrated O
that O
2 B
- I
hydroxy I
- I
3 I
- I
pentanone I
and O
1 B
- I
hydroxy I
- I
2 I
- I
propanone I
, O
thermal O
degradation O
products O
of O
monosaccharides B
, O
were O
closely O
related O
to O
the O
formation O
of O
cis B
- I
2 I
, I
6 I
- I
dimethyl I
- I
1 I
, I
4 I
- I
cyclohexanedione I
. O

Synthesis O
, O
preliminary O
structure O
- O
activity O
relationships O
, O
and O
in O
vitro O
biological O
evaluation O
of O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
as O
potential O
anti O
- O
inflammatory O
agents O
. O

In O
our O
previous O
study O
, O
a O
series O
of O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
exhibited O
potent O
antiproliferative O
activities O
and O
an O
unique O
hepatocellular O
carcinoma O
( O
HCC O
) O
- O
specific O
anticancer O
activity O
was O
also O
observed O
. O

These O
results O
suggest O
that O
these O
6 B
- I
aryl I
- I
3 I
- I
amino I
- I
thieno I
[ I
2 I
, I
3 I
- I
b I
] I
pyridine I
derivatives O
might O
potentially O
constitute O
a O
novel O
class O
of O
anti O
- O
inflammatory O
agents O
, O
which O
require O
further O
studies O
. O

To O
assess O
the O
relation O
of O
the O
in O
- O
vitro O
release O
kinetics O
to O
the O
in O
- O
vivo O
fate O
of O
nanosuspensions O
, O
various O
[ B
( I
131 I
) I
I I
] I
iodinated I
fenofibrate I
formulations O
were O
subcutaneously O
applied O
to O
mice O
. O

The O
organ O
levels O
of O
[ B
( I
131 I
) I
I I
] I
labeled I
fenofibrate I
were O
found O
to O
be O
more O
constant O
in O
case O
of O
the O
pump O
with O
the O
higher O
viscous O
nanosuspension O
in O
contrast O
to O
the O
lower O
viscous O
counterpart O
. O

The O
key O
step O
was O
the O
elimination O
of O
HBr B
in O
a O
vicinal B
dibromo I
D I
- I
homosteroid I
by O
treatment O
with O
1 B
, I
4 I
- I
diazabicyclo I
[ I
2 I
. I
2 I
. I
2 I
] I
octane I
( O
DABCO B
) O
. O

The O
mechanisms O
by O
which O
oxysterols B
may O
influence O
proliferation O
are O
manifold O
: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol B
synthesis O
, O
3 B
- I
hydroxy I
- I
3 I
- I
methylglutaryl I
CoA I
reductase O
, O
by O
binding O
to O
Insig O
- O
1 O
, O
Insig O
- O
2 O
and O
liver O
X O
receptors O
. O

Novel O
chiral O
ferrocenylpyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
[ I
1 I
, I
4 I
] I
diazepin I
- I
4 I
- I
one I
derivatives O
- O
Synthesis O
, O
characterization O
and O
inhibition O
against O
lung O
cancer O
cells O
. O

A O
series O
of O
novel O
2 B
- I
ferrocenyl I
- I
7 I
- I
hydroxy I
- I
5 I
- I
phenethyl I
- I
5 I
, I
6 I
, I
7 I
, I
8 I
- I
tetrahydro I
- I
4H I
- I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
[ I
1 I
, I
4 I
] I
diazepin I
- I
4 I
- I
one I
derivatives O
with O
optical O
activity O
( O
2 O
) O
was O
synthesized O
in O
the O
microwave O
- O
assisted O
condition O
and O
characterized O
by O
means O
of O
IR O
, O
( B
1 I
) I
H I
NMR O
and O
mass O
spectroscopy O
, O
and O
furthermore O
confirmed O
by O
X O
- O
ray O
analysis O
of O
a O
representative O
compound O
( O
R O
) O
- O
2a O
. O

Effects O
of O
two O
fungicides O
, O
copper B
and O
dimethomorph B
( O
( B
E I
, I
Z I
) I
4 I
- I
[ I
3 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
3 I
- I
( I
3 I
- I
4dimethoxyphenyl I
) I
acryloyl I
] I
morpholine I
) O
on O
Lemna O
minor O
growth O
and O
phytoremediation O
were O
evaluated O
. O

Here O
we O
describe O
the O
LC O
- O
MS O
/ O
MS O
procedure O
enabling O
simultaneous O
determination O
of O
four O
regioisomers O
( O
8 B
- I
iso I
prostaglandin I
F2 I
alpha I
, O
8 B
- I
iso I
- I
15 I
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
, O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
) O
in O
plasma O
samples O
collected O
from O
mice O
. O

Here O
we O
describe O
the O
LC O
- O
MS O
/ O
MS O
procedure O
enabling O
simultaneous O
determination O
of O
four O
regioisomers O
( O
8 B
- I
iso I
prostaglandin I
F2 I
alpha I
, O
8 B
- I
iso I
- I
15 I
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
, O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
) O
in O
plasma O
samples O
collected O
from O
mice O
. O

The O
four O
plasma O
isoprostanes B
are O
determined O
by O
LC O
- O
ESI O
- O
MS O
/ O
MS O
with O
deuterated O
8 B
- I
iso I
- I
PGF2 I
alpha I
- I
d4 I
as O
an O
internal O
standard O
( O
I O
. O
S O
. O
) O
. O

The O
greatest O
rise O
was O
observed O
in O
the O
case O
of O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
by O
about O
50 O
% O
and O
70 O
% O
in O
plasma O
samples O
derived O
from O
mice O
exposed O
to O
DOX B
and O
TBHP B
, O
respectively O
. O

An O
amphiphilic O
diblock O
copolymer O
poly B
( I
acrylamidoethylamine I
) I
90 I
- I
block I
- I
poly I
( I
dl I
- I
lactide I
) I
40 I
( O
PAEA90 B
- I
b I
- I
PDLLA40 I
) O
was O
synthesized O
, O
self O
- O
assembled O
in O
aqueous O
solution O
, O
and O
shell O
cross O
- O
linked O
using O
a O
hydrolyzable O
cross O
- O
linker O
to O
afford O
deg O
- O
cSCKs O
with O
an O
average O
core O
diameter O
of O
45 O
+ O
/ O
- O
7 O
nm O
. O

Simple O
sulfonamides B
showed O
weak O
or O
moderate O
CgNce103 O
inhibitory O
properties O
, O
whereas O
acetazolamide B
, O
and O
a O
series O
of O
4 B
- I
substituted I
ureido I
- I
benzene I
- I
sulfonamides I
, O
sulfamates B
and O
sulfamides B
showed O
effective O
CgNce103 O
inhibitory O
properties O
, O
with O
KIs O
in O
the O
range O
of O
4 O
. O
1 O
- O
115nM O
, O
being O
also O
ineffective O
as O
human O
CA O
II O
inhibitors O
. O

The O
Aryl B
Hydrocarbon I
Receptor O
( O
AhR O
) O
is O
a O
ligand O
mediated O
basic O
helix O
- O
loop O
- O
helix O
transcription O
factor O
of O
Per O
/ O
Arnt O
/ O
Sim O
family O
that O
regulates O
adaptive O
and O
toxic O
responses O
to O
variety O
of O
chemical O
pollutants O
including O
polycyclic B
aromatic I
hydrocarbons I
( O
PAH B
) O
and O
halogenated B
aromatic I
hydrocarbons I
, O
most O
notably O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
. O

The O
major O
catechin B
from O
green O
tea O
is O
( B
- I
) I
- I
epigallocatechin I
- I
3 I
- I
gallate I
( O
EGCG B
) O
, O
which O
has O
garnered O
attention O
for O
its O
potential O
to O
prevent O
oxidative O
stress O
- O
related O
diseases O
. O

Neuroprotective O
Effects O
of O
Puerarin B
on O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
induced O
Parkinson O
' O
s O
Disease O
Model O
in O
Mice O
. O

In O
this O
study O
, O
we O
addressed O
that O
puerarin B
attenuated O
1 B
- I
methyl I
- I
4 I
- I
phenyl I
- I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridine I
( O
MPTP B
) O
- O
induced O
behavioral O
deficits O
, O
dopaminergic O
neuronal O
degeneration O
and O
dopamine B
depletion O
. O

The O
meso B
- I
tetra I
( I
2 I
, I
6 I
- I
dichloro I
- I
3 I
- I
sulfonatophenyl I
) I
porphyrinate I
of O
manganese B
( I
III I
) I
chloride I
[ B
Mn I
- I
( I
TDCPPS I
) I
Cl I
] I
biomimetic O
catalyst O
immobilized O
on O
spacer O
- O
functionalized O
kaolinite B
clay O
mineral O
was O
employed O
in O
the O
oxidative O
coupling O
reaction O
of O
a O
dissolved O
humic O
acid O
( O
HA O
) O
suprastructure O
with O
either O
chemical O
( O
H2O2 B
) O
or O
UV O
- O
light O
oxidation O
. O

The O
meso B
- I
tetra I
( I
2 I
, I
6 I
- I
dichloro I
- I
3 I
- I
sulfonatophenyl I
) I
porphyrinate I
of O
manganese B
( I
III I
) I
chloride I
[ B
Mn I
- I
( I
TDCPPS I
) I
Cl I
] I
biomimetic O
catalyst O
immobilized O
on O
spacer O
- O
functionalized O
kaolinite B
clay O
mineral O
was O
employed O
in O
the O
oxidative O
coupling O
reaction O
of O
a O
dissolved O
humic O
acid O
( O
HA O
) O
suprastructure O
with O
either O
chemical O
( O
H2O2 B
) O
or O
UV O
- O
light O
oxidation O
. O

We O
previously O
reported O
the O
comparison O
of O
the O
relative O
potencies O
of O
( B
+ I
) I
- I
and I
( I
- I
) I
- I
coniine I
enantiomers O
. O

The O
relative O
potencies O
of O
these O
piperidine B
alkaloids I
on O
cells O
expressing O
human O
fetal O
muscle O
- O
type O
nicotinic O
acetylcholine B
receptors O
had O
the O
rank O
order O
of O
gamma B
- I
coniceine I
> O
( B
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
/ I
- I
) I
- I
N I
- I
methylconiine I
> O
( B
+ I
) I
- I
N I
- I
methylconiine I
. O

The O
relative O
lethalities O
of O
gamma B
- I
coniceine I
and O
( B
- I
) I
- I
, I
( I
+ I
/ I
- I
) I
- I
, I
and I
( I
+ I
) I
- I
N I
- I
methylconiine I
in O
vivo O
using O
a O
mouse O
bioassay O
were O
4 O
. O
4 O
, O
16 O
. O
1 O
, O
17 O
. O
8 O
, O
and O
19 O
. O
2 O
mg O
/ O
kg O
, O
respectively O
. O

Structure O
and O
Absolute O
Configuration O
of O
Methyl B
( I
3R I
) I
- I
Malonyl I
- I
( I
13S I
) I
- I
hydroxycheilanth I
- I
17 I
- I
en I
- I
19 I
- I
oate I
, O
a O
Sesterterpene B
Derivative O
from O
the O
Roots O
of O
Aletris O
farinosa O
. O

The O
Androgen B
Metabolite O
, O
5 B
alpha I
- I
Androstane I
- I
3 I
beta I
, I
17 I
beta I
- I
Diol I
( O
3 B
beta I
- I
Diol I
) O
, O
Activates O
the O
Oxytocin B
Promoter O
Through O
an O
Estrogen B
Receptor O
- O
beta O
Pathway O
. O

The O
dihydrotestosterone B
metabolite O
, O
5 B
alpha I
- I
androstane I
- I
3 I
beta I
, I
17 I
beta I
- I
diol I
( O
3 B
beta I
- I
diol I
) O
, O
binds O
and O
activates O
estrogen B
receptor O
- O
beta O
( O
ER O
- O
beta O
) O
, O
the O
predominant O
ER O
in O
the O
PVN O
. O

Specifically O
, O
at O
least O
two O
alkaloids O
isolated O
from O
the O
plant O
Mitragyna O
speciosa O
, O
mitragynine B
( O
( B
E I
) I
- I
2 I
- I
[ I
( I
2S I
, I
3S I
) I
- I
3 I
- I
ethyl I
- I
8 I
- I
methoxy I
- I
1 I
, I
2 I
, I
3 I
, I
4 I
, I
6 I
, I
7 I
, I
12 I
, I
12b I
- I
octahydroindolo I
[ I
3 I
, I
2 I
- I
h I
] I
quinolizin I
- I
2 I
- I
yl I
] I
- I
3 I
- I
methoxyprop I
- I
2 I
- I
enoic I
acid I
methyl I
ester I
; O
9 B
- I
methoxy I
coryantheidine I
; O
MG O
) O
and O

Mass O
balance O
data O
and O
in O
vivo O
metabolite O
characterization O
obtained O
after O
administration O
of O
[ B
( I
14 I
) I
C I
] I
AMG I
221 I
to O
rat O
showed O
that O
AMG B
221 I
was O
completely O
absorbed O
from O
the O
gut O
lumen O
following O
an O
oral O
dose O
, O
primarily O
excreted O
in O
urine O
and O
was O
almost O
completely O
metabolized O
prior O
to O
excretion O
. O

Synthesis O
and O
biological O
activities O
of O
some O
novel O
aminomethyl B
derivatives O
of O
4 B
- I
substituted I
- I
5 I
- I
( I
2 I
- I
thienyl I
) I
- I
2 I
, I
4 I
- I
dihydro I
- I
3H I
- I
1 I
, I
2 I
, I
4 I
- I
triazole I
- I
3 I
- I
thiones I
. O

Specifically O
, O
positively O
charged O
, O
1 B
, I
2 I
- I
Dioleoyl I
- I
3 I
- I
Trimethylammonium I
- I
Propane I
( O
DOTAP B
) O
- O
cholesterol B
( O
DOTAP B
: O
Chol B
) O
liposome O
- O
formulated O
protocells O
revealed O
stable O
in O
vitro O
cargo O
release O
kinetics O
and O
cellular O
interleukin O
- O
10 O
( O
IL O
- O
10 O
) O
transgene O
transfection O
. O

Design O
, O
synthesis O
and O
structure O
- O
activity O
relationships O
of O
3 B
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazoles I
as O
inhibitors O
of O
arylamine B
N B
- O
acetyltransferase O
. O

The O
synthesis O
and O
inhibitory O
potencies O
of O
a O
novel O
series O
of O
3 B
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazoles I
as O
specific O
inhibitors O
of O
prokaryotic O
arylamine B
N B
- O
acetyltransferase O
enzymes O
is O
described O
. O

The O
series O
is O
based O
on O
hit O
compound O
1 B
3 I
, I
5 I
- I
diaryl I
- I
1H I
- I
pyrazole I
identified O
from O
a O
high O
- O
throughout O
screen O
that O
has O
been O
carried O
out O
previously O
and O
found O
to O
inhibit O
the O
growth O
of O
Mycobacterium O
tuberculosis O
. O

Coupling O
this O
computational O
technique O
with O
a O
high O
- O
quality O
low O
- O
throughput O
screen O
identified O
5 B
- I
( I
4 I
- I
piperidyl I
) I
- I
3 I
- I
isoxazolol I
( O
4 B
- I
PIOL I
) O
as O
a O
potent O
plasminogen O
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders O
. O

The O
integration O
of O
a O
tripeptide B
derivative O
, O
which O
is O
a O
versatile O
self O
- O
assembly O
motif O
, O
with O
a O
ruthenium B
( I
II I
) I
tris I
( I
bipyridine I
) I
complex O
affords O
the O
first O
supramolecular O
metallo O
- O
hydrogelator O
that O
not O
only O
self O
assembles O
in O
water O
to O
form O
a O
hydrogel O
but O
also O
exhibits O
gel O
- O
sol O
transition O
upon O
oxidation O
of O
the O
metal O
center O
. O

Efficient O
synthesis O
of O
new O
( B
R I
) I
- I
2 I
- I
amino I
- I
1 I
- I
butanol I
derived O
ureas B
, O
thioureas B
and O
acylthioureas B
and O
in O
vitro O
evaluation O
of O
their O
antimycobacterial O
activity O
. O

The O
synthesis O
of O
22 O
structurally O
diverse O
urea B
, O
thiourea B
and O
acylthiourea B
derivatives O
containing O
the O
( B
R I
) I
- I
2 I
- I
amino I
- I
1 I
- I
butanol I
motif O
has O
been O
performed O
. O

It O
has O
been O
found O
that O
use O
of O
2 B
, I
2 I
, I
3 I
, I
3 I
- I
tetrafluoro I
- I
1 I
, I
4 I
- I
butanediol I
as O
a O
fluorinated O
extender O
of O
prepolymer O
chains O
is O
essential O
to O
obtain O
coatings O
with O
increased O
hydrophobicity O
, O
applied O
among O
others O
as O
biomaterials O
- O
next O
to O
diphenylmethane B
diisocyanate I
and O
polyoxyethylene B
glycol I
. O

The O
in O
vivo O
degradation O
and O
elimination O
after O
subcutaneous O
implantation O
of O
injectable O
p B
( I
SA I
- I
RA I
) I
3 I
: I
7 I
copolymer O
in O
rats O
, O
followed O
by O
characterization O
of O
the O
polymer O
matrix O
composition O
during O
hydrolysis O
and O
erosion O
, O
is O
reported O
. O

We O
report O
results O
of O
noncellular O
tests O
, O
revealing O
the O
occurrence O
of O
photocatalytic O
interactions O
between O
titanium B
dioxide I
( O
TiO2 B
, O
titania B
) O
nanoparticles O
and O
the O
MTT B
[ O
3 B
- I
( I
4 I
, I
5 I
- I
Dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
- I
bromide I
] O
cytotoxicity O
indicator O
. O

In O
this O
work O
, O
we O
did O
not O
find O
a O
methyl B
- O
accepting O
substrate O
in O
A O
. O
nidulans O
with O
various O
assays O
including O
in O
vivo O
S B
- I
adenosyl I
- I
[ I
methyl I
- I
( I
3 I
) I
H I
] I
methionine I
labeling O
, O
targeted O
in O
vitro O
methylation O
experiments O
using O
putative O
protein O
substrates O
, O
or O
in O
vitro O
methylation O
assays O
using O
whole O
cell O
extracts O
grown O
under O
different O
conditions O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
7 B
- I
O I
- I
p I
- I
cyanobenzoyl I
pyripyropene I
A I
derivatives O
with O
modification O
at O
C1 O
and O
11 O
are O
described O
. O

Intra O
- O
dorsal O
hippocampus O
( O
DH O
) O
injections O
of O
8 B
- I
hydroxy I
- I
2 I
- I
( I
di I
- I
n I
- I
propylamino I
) I
tetralin I
( O
8 B
- I
OH I
- I
DPAT I
) O
, O
a O
serotonin B
- O
1A O
( O
5 B
- I
hydroxytryptamine I
( O
5 B
- I
HT I
) O
- O
1A O
) O
receptor O
agonist O
, O
were O
previously O
shown O
to O
inhibit O
the O
expression O
of O
contextual O
fear O
when O
administered O
six O
hours O
after O
conditioning O
. O

DNA O
Adduct O
Formation O
of O
2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
and O
2 B
- I
Amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
in O
Mouse O
Liver O
and O
Extrahepatic O
Tissues O
During O
a O
Subchronic O
Feeding O
Study O
. O

DNA O
Adduct O
Formation O
of O
2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
and O
2 B
- I
Amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
in O
Mouse O
Liver O
and O
Extrahepatic O
Tissues O
During O
a O
Subchronic O
Feeding O
Study O
. O

2 B
- I
Amino I
- I
9H I
- I
pyrido I
[ I
2 I
, I
3 I
- I
b I
] I
indole I
( O
A O
alpha O
C O
) O
is O
an O
abundant O
heterocyclic B
aromatic I
amine I
present O
in O
tobacco O
smoke O
. O

A O
alpha O
C O
( O
400 O
or O
800 O
ppm O
) O
and O
2 B
- I
amino I
- I
3 I
, I
4 I
- I
dimethylimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
quinoline I
( O
MeIQ B
) O
( O
300 O
ppm O
) O
, O
a O
liver O
and O
colon O
carcinogen O
in O
C57BL O
/ O
6 O
mice O
, O
were O
given O
in O
the O
diet O
for O
up O
to O
12 O
weeks O
. O

This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3 B
- I
methyl I
- I
1 I
- I
phenyl I
- I
2 I
- I
( I
phenylseleno I
) I
oct I
- I
2 I
- I
en I
- I
1 I
- I
one I
( O
C21H2HOSe B
; O
organoselenium B
) O
and O
sodium B
selenate I
( O
inorganic O
Se B
) O
on O
adenosine B
deaminase O
( O
ADA O
) O
activity O
, O
cell O
viability O
, O
lipid O
peroxidation O
, O
scavenger O
of O
nitric B
oxide I
( O
NO B
) O
and O
nonprotein O
thiols B
( O
NP O
- O
SH B
) O
content O
in O
the O
cerebral O
cortex O

Biotransformation O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
Tetrabromodiphenyl I
Ether I
( O
BDE B
- I
47 I
) O
by O
Human O
Liver O
Microsomes O
: O
Identification O
of O
Cytochrome O
P450 O
2B6 O
as O
the O
Major O
Enzyme O
Involved O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
in O
vitro O
oxidative O
metabolism O
of O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
a O
major O
PBDE B
detected O
in O
human O
tissue O
and O
environmental O
samples O
. O

Kinetic O
analysis O
of O
the O
rates O
of O
metabolite O
formation O
revealed O
that O
the O
major O
metabolites O
were O
5 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
5 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
6 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
6 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
and O
possibly O
the O
unidentified O
monohydroxy B
- O
tetrabrominated O
metabolite O
. O

Kinetic O
analysis O
of O
the O
rates O
of O
metabolite O
formation O
revealed O
that O
the O
major O
metabolites O
were O
5 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
5 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
6 B
- I
hydroxy I
- I
2 I
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabromodiphenyl I
ether I
( O
6 B
- I
OH I
- I
BDE I
- I
47 I
) O
, O
and O
possibly O
the O
unidentified O
monohydroxy B
- O
tetrabrominated O
metabolite O
. O

A O
new O
triterpene B
saponin I
( O
1 O
) O
was O
isolated O
from O
a O
methanol B
extract O
of O
Swartzia O
apetala O
Raddi O
var O
. O
glabra O
, O
together O
with O
the O
flavonoids B
mauritianin B
( O
2 O
) O
, O
kaempferol B
( O
3 O
) O
and O
the O
triterpene B
saponin I
beta B
- I
D I
- I
glucopyranosyl I
3 I
beta I
- I
hydroxy I
- I
olean I
- I
12 I
- I
en I
- I
28 I
- I
oate I
( O
4 O
) O
. O

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Two O
new O
tryptophan B
derivatives O
, O
N B
- I
sulfonyl I
- I
L I
- I
tryptophan I
( O
tryptorheedei B
A I
) O
( O
1 O
) O
and O
3 B
- I
( I
N I
- I
sulfonylindolyl I
) I
- I
D I
- I
lactic I
acid I
( O
tryptorheedei B
B I
) O
( O
2 O
) O
together O
with O
the O
known O
5 B
- I
O I
- I
beta I
- I
D I
- I
glucopyranosyl I
- I
2 I
- I
hydroxyphenylacetic I
acid I
( O
3 O
) O
, O
1 B
- I
O I
- I
methylglucopyranosid I
, O
entadamide B
A I
, O
homogentisic B
acid I
and O
3 B
- I
O I

Synthesis O
of O
some O
novel O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
as O
potential O
cytotoxic O
small O
molecules O
against O
breast O
cancer O
. O

A O
variety O
of O
novel O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
with O
different O
decorating O
functional O
groups O
were O
synthesized O
as O
a O
part O
of O
a O
study O
aiming O
to O
enrich O
the O
arsenal O
of O
chemotherapeutic O
agents O
for O
the O
treatment O
of O
cancer O
. O

The O
reported O
compounds O
herein O
are O
: O
4 B
- I
aminothienopyrimidin I
derivatives O
4a O
, O
b O
and O
their O
4 B
- I
substituted I
phenylamino I
analogues O
8a O
, O
b O
; O
4 B
- I
thienopyrimidin I
- I
4 I
- I
ones I
5a O
, O
b O
; O
N B
- I
alkyl I
thienopyrimidin I
- I
4 I
- I
ones I
6a O
- O
g O
; O
4 B
- I
chlorothienopyrimidi I
7a O
, O
b O
; O
and O
thienopyrimidoquinaz B
9a O
, O
b O
which O
are O
the O
structural O
mimics O
of O
8a O
, O
b O
. O

Novel O
6 B
- I
substituted I
- I
4 I
- I
cycloalkyloxy I
- I
pyridin I
- I
2 I
( I
1H I
) I
- I
ones I
were O
synthesized O
as O
non O
- O
nucleoside B
reverse O
transcriptase O
inhibitors O
( O
NNRTIs O
) O
, O
and O
their O
biological O
activity O
was O
evaluated O
. O

Synthesis O
of O
the O
conjugates O
was O
achieved O
via O
selective O
nucleophilic O
monofunctionalizatio O
of O
5 B
, I
10 I
, I
15 I
, I
20 I
- I
tetrahydroxyphenylpo I
with O
propargyl B
bromide I
followed O
by O
Cu B
( I
I I
) I
mediated O
cycloaddition O
with O
bile B
acid I
azides I
in O
good O
yields O
. O

A O
diazen B
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
analog O
of O
7 B
- I
azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
: O
Synthesis O
, O
nitric B
oxide I
and O
nitroxyl B
release O
, O
in O
vitro O
hemodynamic O
, O
and O
anti O
- O
hypertensive O
studies O
. O

A O
diazen B
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
analog O
of O
7 B
- I
azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
: O
Synthesis O
, O
nitric B
oxide I
and O
nitroxyl B
release O
, O
in O
vitro O
hemodynamic O
, O
and O
anti O
- O
hypertensive O
studies O
. O

1 B
- I
( I
7 I
- I
Azabenzobicyclo I
[ I
2 I
. I
2 I
. I
1 I
] I
heptane I
) I
diazen I
- I
1 I
- I
ium I
- I
1 I
, I
2 I
- I
diolate I
( O
16 O
) O
was O
designed O
with O
the O
expectation O
that O
it O
would O
act O
as O
a O
dual O
nitric B
oxide I
( O
NO B
) O
and O
nitroxyl B
( O
HNO B
) O
donor O
that O
is O
not O
carcinogenic O
or O
genotoxic O
. O

Structure O
- O
activity O
relationship O
of O
5 B
- I
chloro I
- I
2 I
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indole I
analogues O
as O
5 O
- O
HT6 O
receptor O
agonists O
. O

To O
further O
investigate O
the O
structure O
- O
activity O
relationship O
( O
SAR O
) O
of O
the O
5 B
- I
hydroxytryptamine I
type O
6 O
( O
5 O
- O
HT6 O
) O
receptor O
agonist O
5 B
- I
chloro I
- I
2 I
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indole I
( O
EMD386088 B
, O
6 O
) O
, O
a O
series O
of O
2 B
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indoles I

We O
focused O
on O
substituents O
made O
at O
the O
indole B
N O
( O
1 O
) O
- O
, O
2 O
- O
and O
5 O
- O
positions O
and O
these O
were O
found O
to O
not O
only O
influence O
the O
affinity O
at O
5 O
- O
HT6 O
receptors O
but O
also O
the O
intrinsic O
activity O
leading O
to O
antagonists O
, O
partial O
agonists O
and O
full O
agonists O
. O

A O
few O
compounds O
within O
the O
2 B
- I
methyl I
- I
3 I
- I
( I
1 I
, I
2 I
, I
3 I
, I
6 I
- I
tetrahydropyridin I
- I
4 I
- I
yl I
) I
- I
1H I
- I
indoles I
were O
also O
screened O
for O
off O
- O
targets O
and O
generally O
they O
displayed O
low O
affinity O
for O
other O
5 B
- I
HT I
subtypes O
and O
serotonin B
transporter O
protein O
( O
SERT O
) O
. O

We O
characterized O
the O
iron B
- I
sulfur I
cluster O
using O
inductively O
coupled O
plasma O
- O
atomic O
emission O
spectroscopy O
, O
absorbance O
spectroscopy O
, O
and O
electron O
paramagnetic O
resonance O
spectroscopy O
and O
found O
that O
it O
is O
an O
oxygen B
- O
sensitive O
[ B
4Fe I
- I
4S I
] I
( I
2 I
+ I
) I
cluster O
. O

Nanoparticles O
of O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
poly B
( I
d I
, I
l I
- I
lactide I
) I
and O
polyethylene B
glycol I
- I
block I
- I
poly I
( I
d I
, I
l I
- I
lactide I
) I
were O
developed O
to O
encapsulate O
chloroaluminium B
phthalocyanine I
( O
AlClPc B
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

Nanoparticles O
of O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
poly B
( I
d I
, I
l I
- I
lactide I
) I
and O
polyethylene B
glycol I
- I
block I
- I
poly I
( I
d I
, I
l I
- I
lactide I
) I
were O
developed O
to O
encapsulate O
chloroaluminium B
phthalocyanine I
( O
AlClPc B
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

Nanoparticles O
of O
poly B
( I
d I
, I
l I
- I
lactide I
- I
co I
- I
glycolide I
) I
, O
poly B
( I
d I
, I
l I
- I
lactide I
) I
and O
polyethylene B
glycol I
- I
block I
- I
poly I
( I
d I
, I
l I
- I
lactide I
) I
were O
developed O
to O
encapsulate O
chloroaluminium B
phthalocyanine I
( O
AlClPc B
) O
, O
a O
new O
hydrophobic O
photosensitiser O
used O
in O
photodynamic O
therapy O
( O
PDT O
) O
. O

The O
ameliorating O
effects O
of O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
, O
an O
oroxylin B
A I
derivative O
, O
against O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
in O
mice O
. O

The O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
effect O
of O
a O
novel O
oroxylin B
A I
derivative O
, O
5 B
, I
7 I
- I
dihydroxy I
- I
6 I
- I
methoxy I
- I
2 I
( I
4 I
- I
phenoxyphenyl I
) I
- I
4H I
- I
chromene I
- I
4 I
- I
one I
( O
DMPC B
) O
, O
on O
pharmacological O
models O
of O
schizophrenia O
, O
which O
exhibit O
memory O
impairment O
and O
sensorimotor O
gating O
deficit O
. O

A O
series O
of O
six O
/ O
five O
member O
( B
E I
/ I
Z I
) I
- I
Goniothalamin I
analogs O
were O
synthesized O
from O
commercially O
available O
( B
3 I
, I
4 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
yl I
) I
methanol I
/ O
5 B
- I
( I
hydroxymethyl I
) I
dihydrofuran I
- I
2 I
( I
3H I
) I
- I
one I
in O
three O
steps O
with O
good O
to O
moderate O
overall O
yields O
and O
their O
cytotoxicity O
against O
lymphoblastic O
leukemic O
T O
cell O
line O
( O
Jurkat O
E6 O
. O
1 O
) O
have O
been O
evaluated O
. O

A O
series O
of O
six O
/ O
five O
member O
( B
E I
/ I
Z I
) I
- I
Goniothalamin I
analogs O
were O
synthesized O
from O
commercially O
available O
( B
3 I
, I
4 I
- I
dihydro I
- I
2H I
- I
pyran I
- I
2 I
- I
yl I
) I
methanol I
/ O
5 B
- I
( I
hydroxymethyl I
) I
dihydrofuran I
- I
2 I
( I
3H I
) I
- I
one I
in O
three O
steps O
with O
good O
to O
moderate O
overall O
yields O
and O
their O
cytotoxicity O
against O
lymphoblastic O
leukemic O
T O
cell O
line O
( O
Jurkat O
E6 O
. O
1 O
) O
have O
been O
evaluated O
. O

After O
the O
exposure O
, O
cell O
viability O
using O
( O
3 B
- I
( I
4 I
, I
5 I
- I
dimethylthiazol I
- I
2 I
- I
yl I
) I
- I
2 I
, I
5 I
- I
diphenyltetrazolium I
bromide I
) O
and O
neutral B
red I
uptake O
assays O
and O
morphological O
changes O
in O
HepG2 O
cells O
were O
studied O
. O

The O
aqueous O
phase O
contains O
alkali B
- I
metal I
chlorides I
, O
including O
LiCl B
, O
NaCl B
, O
RbCl B
, O
or O
CsCl B
, O
and O
the O
organic O
phase O
is O
a O
1 B
, I
2 I
- I
dichloroethane I
solution O
of O
bis B
( I
triphenylphosphor I
anylidene I
) I
ammonium I
tetrakis I
( I
pentafluorophenyl I
) I
borate I
( O
BTPPATPFB B
) O
. O

A O
novel O
series O
of O
histamine B
H4 O
receptor O
antagonists O
based O
on O
the O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
scaffold O
: O
Comparison O
of O
hERG O
binding O
and O
target O
residence O
time O
with O
PF B
- I
3893787 I
. O

In O
this O
work O
we O
describe O
the O
optimization O
of O
a O
lead O
compound O
based O
on O
the O
quinazoline B
template O
to O
give O
a O
new O
series O
of O
potent O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
as O
histamine B
H4 O
receptor O
antagonists O
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidine I
ligands O
have O
significantly O
reduced O
hERG O
binding O
compared O
to O
clinical O
stage O
compound O
PF B
- I
3893787 I
while O
showing O
good O
affinities O
at O
the O
human O
and O
rodent O
histamine B
receptors O
. O

The O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
showed O
residence O
times O
lower O
than O
JNJ7777120 B
but O
comparable O
to O
the O
residence O
time O
of O
PF B
- I
3893787 I
. O

Overall O
, O
the O
pyrido B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidines I
show O
an O
excellent O
in O
vitro O
profile O
that O
warrants O
their O
further O
investigation O
in O
relevant O
models O
of O
human O
disease O
. O

Phorbol B
- I
12 I
- I
myristate I
- I
13 I
- I
acetate I
( O
TPA B
) O
was O
used O
as O
positive O
control O
and O
0 O
. O
5 O
% O
dimethyl B
sulfoxide I
( O
DMSO B
) O
as O
solvent O
control O
. O

Storable O
sunshine O
, O
reusable O
rays O
: O
A O
solar O
rechargeable O
redox O
flow O
battery O
is O
proposed O
based O
on O
the O
photoregeneration O
of O
I3 B
( I
- I
) I
/ O
I B
( I
- I
) I
and O
[ B
Fe I
( I
C10 I
H15 I
) I
2 I
] I
( I
+ I
) I
/ O
Fe B
( I
C10 I
H15 I
) I
2 I
soluble O
redox O
couples O
, O
which O
can O
be O
regenerated O
by O
flowing O
from O
a O
discharged O
redox O
flow O
battery O
( O
RFB O
) O
into O
a O
dye O
- O
sensitized O
solar O
cell O
( O
DSSC O
) O
and O
then O
stored O
in O
tanks O
for O
subsequent O
RFB O
applications O
This O
technology O
enables O
effective O
solar O
- O
to O
- O
chemical O
energy O
conversion O
. O

Temperature O
- O
Induced O
Emission O
Enhancement O
of O
Star O
Conjugated O
Copolymers O
with O
Poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
Coronas O
for O
Detection O
of O
Bacteria O
. O

The O
star O
copolymers O
( O
HCP O
- O
star O
- O
PDMAEMAs B
) O
with O
different O
poly B
( I
2 I
- I
( I
dimethylamino I
) I
ethyl I
methacrylate I
) I
( O
PDMAEMA B
) O
chain O
lengths O
were O
synthesized O
from O
the O
hyperbranched O
conjugated O
polymer O
( O
HCP O
) O
macroinitiator O
by O
atom O
transfer O
radical O
polymerization O
( O
ATRP O
) O
. O

It O
was O
found O
that O
the O
use O
of O
the O
tripeptide O
glutathione B
( O
GSH B
) O
results O
in O
smaller O
NP O
size O
when O
compared O
to O
N B
- I
( I
2 I
- I
mercapto I
- I
propionyl I
) I
glycine I
( O
MPG B
) O
, O
a O
pseudodipeptide O
, O
over O
a O
wide O
range O
of O
Au B
/ O
peptide O
molar O
ratios O
( O
20 O
: O
1 O
, O
10 O
: O
1 O
, O
5 O
: O
1 O
, O
and O
2 O
: O
1 O
) O
. O

Optimum O
conditions O
were O
determined O
to O
be O
40 O
degrees O
C O
and O
pH O
6 O
using O
4 B
- I
nitrophenyl I
beta I
- I
d I
- I
glucuronide I
as O
an O
indicator O
. O

The O
ethyl B
acetate I
and O
methanol B
bark O
extracts O
of O
Melicope O
glabra O
were O
evaluated O
for O
their O
antioxidant O
capacities O
by O
1 B
, I
1 I
- I
diphenyl I
- I
2 I
- I
picrylhydrazyl I
( O
DPPH B
) O
free O
radical O
scavenging O
activity O
and O
beta B
- I
carotene I
bleaching O
/ O
linoleic B
acid I
system O
. O

A O
sensitive O
and O
selective O
imprinted O
solid O
phase O
extraction O
coupled O
to O
HPLC O
for O
simultaneous O
detection O
of O
trace O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
and O
methyl B
- I
3 I
- I
quinoxaline I
- I
2 I
- I
carboxylic I
acid I
in O
animal O
muscles O
. O

MIP O
exhibited O
high O
affinity O
, O
fast O
kinetics O
for O
QCA B
and O
good O
selectivity O
for O
QCA B
and O
methyl B
- I
3 I
- I
quinoxaline I
- I
2 I
- I
carboxylic I
acid I
( O
MQCA B
) O
. O

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
malonylglucoside I
, O
myricetin B
3 I
- I
O I
- I
galactoside I
, O
and O
naringenin B
tri I
glycoside I
. O

However O
, O
2 B
, I
4 I
- I
di I
- I
tert I
- I
butylphenol I
, O
a O
degradation O
compound O
of O
phenolic B
antioxidants O
, O
was O
detected O
. O

This O
innovation O
has O
allowed O
the O
discovery O
that O
, O
in O
addition O
to O
13 B
( I
2 I
) I
OH I
chl I
a I
and O
15 B
( I
1 I
) I
OH I
lactone I
chl I
a I
, O
which O
are O
the O
first O
products O
of O
POD O
on O
chl B
a I
, O
the O
reaction O
process O
sequentially O
creates O
another O
series O
of O
oxidised O
chlorophyll B
derivatives O
which O
have O
not O
been O
previously O
described O
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Forty O
- O
nine O
animals O
were O
divided O
into O
7 O
groups O
( O
n O
= O
7 O
) O
and O
received O
by O
oral O
gavage O
30 O
% O
glucose B
plus O
0 O
. O
55g O
/ O
kg O
body O
mass O
of O
the O
following O
WPH O
components O
: O
( O
a O
) O
control O
; O
( O
b O
) O
WPH O
; O
( O
c O
) O
l B
- I
isoleucine I
; O
( O
d O
) O
l B
- I
leucine I
; O
( O
e O
) O
l B
- I
leucine I
plus O
l B
- I
isoleucine I
; O
( O
f O
) O
l B
- I
isoleucyl I
- I
l I
- I
leucine I
dipeptide I
; O
( O
g O
) O
l B
- I
leucyl I
- I
l I
- I
isoleucine I
dipeptide I
. O

Myricetin B
( O
3 B
, I
3 I
' I
, I
4 I
' I
, I
5 I
, I
5 I
' I
, I
7 I
- I
hexahydroxyflavone I
) O
was O
the O
most O
potent O
inhibitor O
of O
pols O
amongst O
the O
compounds O
tested O
, O
with O
IC50 O
values O
of O
21 O
. O
3 O
- O
40 O
. O
9 O
mu O
M O
. O

This O
candidate O
, O
( B
S I
) I
- I
3 I
- I
[ I
4 I
- I
( I
1 I
- I
{ I
3 I
, I
5 I
- I
dimethyl I
- I
4 I
- I
[ I
4 I
- I
( I
trifluoromethyl I
) I
- I
1H I
- I
pyrazol I
- I
1 I
- I
yl I
] I
phenoxy I
} I
butyl I
) I
benzamido I
] I
propanoic I
acid I
, O
has O
lower O
molecular O
weight O
and O
lipophilicity O
than O
historical O
glucagon O
receptor O
antagonists O
, O
resulting O
in O
excellent O
selectivity O
in O
broad O
- O
panel O
screening O
, O
lower O
cytotoxicity O
, O
and O
excellent O
overall O
in O
vivo O
safety O
in O
early O
pre O
- O
clinical O
testing O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
2 B
- I
amino I
- I
3 I
- I
carboxy I
- I
4 I
- I
phenylthiophenes I
as O
novel O
atypical O
protein O
kinase O
C O
inhibitors O
. O

Our O
study O
demonstrates O
the O
key O
structural O
elements O
that O
confer O
inhibitory O
activity O
and O
highlights O
the O
requirement O
for O
electron O
- O
donating O
moieties O
off O
the O
C O
- O
4 O
aryl O
moiety O
of O
the O
2 B
- I
amino I
- I
3 I
- I
carboxy I
- I
4 I
- I
phenylthiophene I
backbone O
. O

The O
main O
components O
found O
by O
LC O
- O
MS O
analysis O
were O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
kaempferol B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
quercetin B
- I
3 I
- I
O I
- I
rutinoside I
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
. O

The O
main O
components O
found O
by O
LC O
- O
MS O
analysis O
were O
quercetin B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
kaempferol B
- I
3 I
- I
O I
- I
( I
2 I
- I
rhamnosyl I
) I
rutinoside I
, O
quercetin B
- I
3 I
- I
O I
- I
rutinoside I
and O
kaempferol B
- I
3 I
- I
O I
- I
rutinoside I
. O

Results O
were O
verified O
using O
LC O
- O
MS O
( O
2 O
) O
, O
LC O
- O
MS O
/ O
MS O
with O
precursor O
- O
ion O
scanning O
, O
and O
LC O
- O
HRMS O
, O
leading O
to O
identification O
of O
8 O
major O
and O
17 O
minor O
microcystins B
in O
the O
sample O
, O
including O
analogues O
of O
microcystin B
- I
RY I
, I
- I
RL I
and I
- I
RA I
. O

Microcystin B
- I
YR I
( I
2 I
) I
, I
- I
RR I
( I
3 I
) I
, I
and I
- I
RY I
( I
9 I
) I
were O
isolated O
from O
bloom O
material O
from O
Lake O
Victoria O
, O
and O
the O
structure O
of O
9 O
was O
confirmed O
by O
NMR O
spectroscopic O
analysis O
and O
NMR O
spectral O
comparison O
with O
2 O
and O
3 O
. O

The O
salts O
of O
TEF B
and O
LOX B
with O
organic B
amines I
diethylamine B
( O
DEtA B
) O
, O
triethylamine B
( O
TEtA B
) O
, O
diethanolamine B
( O
DEA B
) O
, O
triethanolamine B
( O
TEA B
) O
and O
N B
- I
( I
2 I
' I
- I
hydroxy I
- I
ethanol I
) I
- I
piperdine I
( O
NP O
) O
were O
prepared O
to O
improve O
the O
skin O
permeation O
of O
the O
parent O
drug O
. O

The O
goal O
of O
the O
current O
study O
was O
to O
characterize O
the O
degradation O
of O
1 B
, I
2 I
- I
dilinolenoyl I
- I
sn I
- I
glycero I
- I
3 I
- I
phosphocholine I
( O
DLPC B
) O
during O
lyophilization O
and O
to O
also O
probe O
the O
influence O
of O
metal O
contaminants O
in O
promoting O
the O
observed O
degradation O
. O

Two O
novel O
ruthenium B
( I
II I
) I
complexes O
[ B
Ru I
( I
dmb I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
1 O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
2 O
) O
were O
synthesized O
. O

Two O
novel O
ruthenium B
( I
II I
) I
complexes O
[ B
Ru I
( I
dmb I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
1 O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
addppn I
) I
] I
( I
ClO4 I
) I
2 I
( O
2 O
) O
were O
synthesized O
. O

Synthesis O
of O
novel O
1 B
, I
3 I
, I
4 I
- I
trisubstituted I
pyrazoles I
as O
anti O
- O
inflammatory O
and O
analgesic O
agents O
. O

Some O
novel O
1 B
, I
3 I
, I
4 I
- I
trisubstituted I
pyrazoles I
were O
synthesized O
and O
screened O
for O
their O
anti O
- O
inflammatory O
and O
analgesic O
activities O
as O
well O
as O
their O
ulcerogenic O
liability O
. O

Herein O
, O
we O
report O
the O
antioxidant O
properties O
of O
some O
selected O
substituted O
2 B
- I
indolyl I
carbohydrazides I
( O
JL34 B
, O
JL40 B
, O
JL71 B
, O
JL87 B
, O
JL317 B
, O
JL432 B
, O
JL436 B
) O
, O
the O
substituted O
3 B
- I
indolyl I
carbohydrazide I
JL344 B
, O
3 B
- I
( I
3 I
- I
hydrazinylpropyl I
) I
- I
1H I
- I
indole I
( O
JL72 B
) O
and O
3 B
- I
( I
1H I
- I
indol I
- I
3 I
- I
yl I
) I

propanehydrazide I
( O
JL418 B
) O
, O
throughout O
the O
assessment O
of O
their O
antioxidative O
potential O
using O
different O
antioxidant O
assays O
such O
as O
DPPH B
, O
lipid O
peroxidation O
in O
the O
APPH O
, O
or O
the O
DMSO B
method O
. O

Among O
the O
33 O
substances O
that O
were O
tested O
, O
compound O
12 O
, O
i O
. O
e O
. O
4 B
, I
4 I
' I
- I
[ I
1 I
, I
12 I
- I
dodecanediyl I
( I
oxy I
) I
] I
bisbenzaldehyde I
, O
emerged O
as O
the O
most O
promising O
hit O
. O

Direct O
- O
type O
catalytic O
Mannich O
reaction O
for O
the O
synthesis O
of O
beta B
- I
aminoketones I
from O
cyclohexanone B
, O
substituted O
aromatic B
amines I
and I
aromatic I
or I
hetero I
- I
aromatic I
aldehydes I
has O
been O
applied O
in O
water O
with O
bismuth B
triflate I
under O
ultrasound O
. O

Ameliorative O
effect O
of O
lycopene B
against O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
pdioxin I
- O
induced O
rat O
liver O
microsomal O
toxicity O
: O
An O
in O
vitro O
study O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
potential O
oxidative O
damage O
of O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
in O
hepatic O
microsomal O
fractions O
in O
vitro O
and O
to O
further O
elucidate O
the O
potential O
modulatory O
effect O
of O
lycopene B
. O

The O
chi O
aa O
( O
N B
) O
values O
for O
the O
two O
isomers O
of O
protonated B
nitrous I
oxide I
are O
qualitatively O
consistent O
with O
the O
valence O
bond O
description O
of O
H B
- I
N I
= I
N I
( I
+ I
) I
= I
O I
for O
the O
electronic O
structure O
of O
the O
nitrogen B
- O
protonated O
form O
and O
N B
= I
N I
( I
+ I
) I
- I
O I
- I
H I
for O
the O
oxygen B
- O
protonated O
form O
. O

The O
chi O
aa O
( O
N B
) O
values O
for O
the O
two O
isomers O
of O
protonated B
nitrous I
oxide I
are O
qualitatively O
consistent O
with O
the O
valence O
bond O
description O
of O
H B
- I
N I
= I
N I
( I
+ I
) I
= I
O I
for O
the O
electronic O
structure O
of O
the O
nitrogen B
- O
protonated O
form O
and O
N B
= I
N I
( I
+ I
) I
- I
O I
- I
H I
for O
the O
oxygen B
- O
protonated O
form O
. O

TCE B
treatment O
also O
induced O
altered O
phospholipid O
homeostasis O
in O
serum O
, O
as O
revealed O
by O
increased O
serum O
lysophosphatidylchol B
18 I
: I
0 I
and I
18 I
: I
1 I
, O
and O
phosphatidylcholine B
metabolites O
. O

The O
single O
laser O
flash O
photolysis O
( O
FP O
) O
of O
2 B
- I
( I
4 I
- I
benzoylphenyl I
) I
- I
2 I
- I
phenyl I
- I
1 I
- I
methylenecyclopropan I
gave O
rise O
to O
a O
ground O
state O
trimethylenemethane B
( O
TMM B
) O
biradical O
with O
absorption O
bands O
at O
362 O
and O
545 O
nm O
and O
an O
excited O
state O
of O
this O
biradical O
that O
displays O
triplet O
- O
triplet O
fluorescence O
at O
580 O
nm O
. O

Treatment O
of O
these O
mice O
with O
3mg O
/ O
kg O
body O
weight O
of O
the O
model O
CAR O
activator O
1 B
, I
4 I
- I
bis I
- I
[ I
2 I
- I
( I
3 I
, I
5 I
- I
dichloropyridyloxy I
) I
] I
benzene I
( O
TCPOBOP B
) O
confirmed O
previous O
findings O
related O
to O
the O
coordinate O
regulation O
of O
drug O
metabolism O
by O
beta O
- O
catenin O
and O
CAR O
. O

Polyphenols B
in O
noni O
juice O
( O
NJ O
) O
are O
mainly O
composed O
of O
phenolic B
acids I
, O
mainly O
gentisic B
, I
p I
- I
hydroxybenoic I
, I
and I
chlorogenic I
acids I
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

An O
analytical O
method O
which O
offers O
accurate O
determination O
and O
identification O
of O
eight O
alpha B
- I
keto I
acids I
( O
alpha B
- I
ketoglutaric I
acid I
, O
pyruvic B
acid I
, O
4 B
- I
hydroxyphenylpyruvic I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxobutyric I
acid I
, O
alpha B
- I
keto I
- I
gamma I
- I
methylthiobutyric I
acid I
, O
4 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
3 B
- I
methyl I
- I
2 I
- I
oxovaleric I
acid I
, O
and O
phenylpyruvic B
acid I
) O
in O
pork O
meat O
and O
Iberian O
ham O
samples O
is O
reported O
. O

Twenty O
- O
six O
compounds O
were O
isolated O
and O
classified O
as O
10 O
skeletons O
, O
including O
two O
unusual O
new O
dihydrobenzofuroisoc B
, O
( B
+ I
) I
- I
platyphyllarin I
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
one O
new O
butanoate B
, O
ethyltributanoate B
( O
3 O
) O
, O
and O
two O
new O
homoisoflavanones B
, O
( B
- I
) I
- I
liriopein I
A I
( I
4 I
) I
and I
B I
( O
5 O
) O
, O
along O
with O
21 O
known O
compounds O
, O
including O
six O
homoisoflavonoids B
, O
one O
chalcone B
, O
six O
amides B
, O
one O
lignan B
, O
one O
fatty B
acid I

Twenty O
- O
six O
compounds O
were O
isolated O
and O
classified O
as O
10 O
skeletons O
, O
including O
two O
unusual O
new O
dihydrobenzofuroisoc B
, O
( B
+ I
) I
- I
platyphyllarin I
A I
( I
1 I
) I
and I
B I
( O
2 O
) O
, O
one O
new O
butanoate B
, O
ethyltributanoate B
( O
3 O
) O
, O
and O
two O
new O
homoisoflavanones B
, O
( B
- I
) I
- I
liriopein I
A I
( I
4 I
) I
and I
B I
( O
5 O
) O
, O
along O
with O
21 O
known O
compounds O
, O
including O
six O
homoisoflavonoids B
, O
one O
chalcone B
, O
six O
amides B
, O
one O
lignan B
, O
one O
fatty B
acid I

Among O
the O
11 O
phenolics B
characterised O
in O
leaves O
by O
high O
- O
performance O
liquid O
chromatography O
coupled O
to O
mass O
spectrometric O
detection O
, O
several O
caffeic B
acid I
derivatives O
, O
5 B
- I
feruloylquinic I
and I
5 I
- I
p I
- I
coumaroylquinic I
acids I
were O
tentatively O
identified O
for O
the O
first O
time O
. O

Racemic B
5 I
- I
( I
trans I
- I
2 I
- I
aminomethylcycloprop I
) I
indoles I
, O
5 B
- I
( I
trans I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
, O
and O
5 B
- I
( I
cis I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

Racemic B
5 I
- I
( I
trans I
- I
2 I
- I
aminomethylcycloprop I
) I
indoles I
, O
5 B
- I
( I
trans I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
, O
and O
5 B
- I
( I
cis I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

Racemic B
5 I
- I
( I
trans I
- I
2 I
- I
aminomethylcycloprop I
) I
indoles I
, O
5 B
- I
( I
trans I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
, O
and O
5 B
- I
( I
cis I
- I
2 I
- I
aminomethylcyclopent I
) I
indoles I
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

In O
this O
study O
we O
have O
demonstrated O
the O
use O
of O
poly B
( I
lactic I
acid I
- I
co I
- I
glycolic I
acid I
) I
( O
PLGA B
) O
/ O
collagen O
biodegradable O
microparticles O
formed O
using O
water O
- O
in O
- O
oil O
- O
in O
- O
water O
( O
W O
/ O
O O
/ O
W O
) O
double O
emulsion O
method O
, O
as O
a O
neurotrophic O
factor O
delivery O
vehicle O
. O

A O
butterfly O
- O
shaped O
pyrene O
derivative O
of O
cholesterol B
, O
namely O
, O
N B
, I
N I
' I
- I
( I
ethane I
- I
1 I
, I
2 I
- I
diyl I
) I
- I
bis I
( I
N I
- I
( I
2 I
- I
( I
chol I
- I
amino I
) I
ethyl I
) I
pyrene I
- I
1 I
- I
sulfonamide I
) I
( O
ECPS B
) O
, O
has O
been O
designed O
and O
synthesized O
. O

Here O
we O
provide O
a O
systematic O
review O
of O
the O
existing O
literature O
and O
present O
a O
detailed O
pathway O
diagram O
that O
describes O
the O
cholesterol B
biosynthesis O
pathway O
( O
the O
mevalonate B
, O
the O
Kandutch O
- O
Russell O
and O
the O
Bloch O
pathway O
) O
and O
shunt O
pathway O
that O
leads O
to O
24 B
( I
S I
) I
, I
25 I
- I
epoxycholesterol I
synthesis O
. O

Release O
of O
BSA O
( O
model O
protein O
) O
from O
hot O
- O
melt O
extruded O
poly B
( I
lactide I
- I
co I
- I
glycolide I
) I
( O
PLGA B
) O
- O
based O
implants O
was O
incomplete O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
new O
classes O
of O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidinone I
and O
thieno B
[ I
1 I
, I
2 I
, I
3 I
] I
triazine I
as O
inhibitor O
of O
vascular O
endothelial O
growth O
factor O
receptor O
- O
2 O
( O
VEGFR O
- O
2 O
) O
. O

Design O
, O
synthesis O
and O
biological O
evaluation O
of O
new O
classes O
of O
thieno B
[ I
3 I
, I
2 I
- I
d I
] I
pyrimidinone I
and O
thieno B
[ I
1 I
, I
2 I
, I
3 I
] I
triazine I
as O
inhibitor O
of O
vascular O
endothelial O
growth O
factor O
receptor O
- O
2 O
( O
VEGFR O
- O
2 O
) O
. O

Photocytotoxicity O
of O
copper B
( I
II I
) I
complexes O
of O
curcumin B
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
. O

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

Copper B
( I
II I
) I
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
cur I
) I
] I
( O
1 O
- O
3 O
) O
of O
curcumin B
( O
Hcur B
) O
and O
N B
- I
ferrocenylmethyl I
- I
l I
- I
amino I
acids I
( O
Fc B
- I
aa I
) O
, O
viz O
. O
, O
ferrocenylmethyl B
- I
l I
- I
tyrosine I
( O
Fc B
- I
TyrH I
) O
, O
ferrocenylmethyl B
- I
l I
- I
tryptophan I
( O
Fc B
- I
TrpH I
) O
and O
ferrocenylmethyl B
- I
l I
- I
methionine I

( O
Fc B
- I
MetH I
) O
, O
were O
prepared O
and O
characterized O
. O

Acetylacetonate B
( O
acac B
) O
complexes O
[ B
Cu I
( I
Fc I
- I
aa I
) I
( I
acac I
) I
] I
( O
4 O
- O
6 O
) O
were O
prepared O
and O
used O
as O
controls O
. O

Immobilized O
nickel B
catalysts O
SBA O
* O
- O
L O
- O
x O
/ O
Ni B
( O
L O
= O
bis B
( I
2 I
- I
pyridylmethyl I
) I
( I
1H I
- I
1 I
, I
2 I
, I
3 I
- I
triazol I
- I
4 I
- I
ylmethyl I
) I
amine I
) O
with O
various O
ligand O
densities O
( O
L O
content O
( O
x O
) O
= O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
mol O
% O
Si B
) O
have O
been O
prepared O
from O
azidopropyl B
- O
functionalized O
mesoporous O
silicas B
SBA O
- O
N3 O
- O
x O
. O

Related O
homogeneous O
ligand O
L B
( I
t I
) I
( I
Bu I
) I
and O
its O
Ni B
( I
II I
) I
complexes O
, O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
( I
OAc I
) I
2 I
( I
H2 I
O I
) I
] I
( I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
and O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
2 I
] I
BF4 I
( I
2 I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
, O
have O
been O
synthesized O
. O

Related O
homogeneous O
ligand O
L B
( I
t I
) I
( I
Bu I
) I
and O
its O
Ni B
( I
II I
) I
complexes O
, O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
( I
OAc I
) I
2 I
( I
H2 I
O I
) I
] I
( I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
and O
[ B
Ni I
( I
L I
( I
t I
) I
( I
Bu I
) I
) I
2 I
] I
BF4 I
( I
2 I
L I
( I
t I
) I
( I
Bu I
) I
/ I
Ni I
) I
, O
have O
been O
synthesized O
. O

Ligand O
Based O
Approach O
to O
L O
- O
Type O
Calcium B
Channel O
by O
Imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
Dihydropyridines I
: O
from O
Heart O
Activity O
to O
Brain O
Affinity O
. O

The O
synthesis O
, O
characterization O
, O
and O
functional O
in O
vitro O
assay O
in O
cardiac O
and O
smooth O
muscle O
( O
vascular O
and O
nonvascular O
) O
of O
a O
series O
of O
4 B
- I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
dihydropyridines I
are O
reported O
. O

To O
define O
the O
calcium B
blocker O
nature O
of O
the O
imidazo B
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
DHPs I
and O
their O
selectivity O
on O
Cav1 O
. O
2 O
and O
Cav1 O
. O
3 O
isoforms O
we O
performed O
binding O
studies O
on O
guinea O
pig O
atrial O
and O
ventricular O
membranes O
, O
on O
intact O
cells O
expressing O
the O
cloned O
Cav1 O
. O
2a O
subunit O
and O
on O
rat O
brain O
cortex O
. O

All O
the O
biological O
data O
collected O
and O
reported O
herein O
allowed O
us O
to O
rationalize O
the O
structure O
- O
activity O
relationship O
of O
the O
4 B
- I
imidazo I
[ I
2 I
, I
1 I
- I
b I
] I
thiazole I
- I
1 I
, I
4 I
- I
DHPs I
and O
to O
identify O
which O
of O
these O
enhanced O
the O
activity O
at O
the O
central O
level O
. O

Potency O
switch O
between O
CHK1 O
and O
MK2 O
: O
Discovery O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- O
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidine I
- O
based O
kinase O
inhibitors O
. O

Potency O
switch O
between O
CHK1 O
and O
MK2 O
: O
Discovery O
of O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazine I
- O
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidine I
- O
based O
kinase O
inhibitors O
. O

Chemistry O
has O
been O
developed O
to O
access O
both O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazines I
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidines I
. O

Chemistry O
has O
been O
developed O
to O
access O
both O
imidazo B
[ I
1 I
, I
2 I
- I
a I
] I
pyrazines I
and O
imidazo B
[ I
1 I
, I
2 I
- I
c I
] I
pyrimidines I
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
Tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
is O
the O
unintentional O
byproduct O
of O
various O
industrial O
processes O
, O
is O
classified O
as O
human O
carcinogen O
and O
could O
disrupt O
reproductive O
, O
developmental O
and O
endocrine O
systems O
. O

Reduction O
of O
the O
enniatins B
A I
, I
A1 I
, I
B I
, I
B1 I
by O
an O
in O
vitro O
degradation O
employing O
different O
strains O
of O
probiotic O
bacteria O
: O
Identification O
of O
degradation O
products O
by O
LC O
- O
MS O
- O
LIT O
. O

5 B
- I
Nitro I
- I
2 I
- I
( I
4 I
- I
methoxyphenyl I
) I
benzofuran I
( O
8 O
) O
is O
the O
most O
active O
compound O
of O
the O
benzofuran B
series O
, O
presenting O
MAO O
- O
B O
selectivity O
and O
reversible O
inhibition O
( O
IC50 O
= O
140 O
nM O
) O
. O

3 B
- I
( I
4 I
' I
- I
Methoxyphenyl I
) I
- I
6 I
- I
nitrocoumarin I
( O
15 O
) O
, O
with O
the O
same O
substitution O
pattern O
as O
that O
of O
compound O
8 O
, O
was O
found O
to O
be O
the O
most O
active O
MAO O
- O
B O
inhibitor O
of O
the O
coumarin B
series O
( O
IC50 O
= O
3 O
nM O
) O
. O

Polyelectrolyte O
- O
Surfactant O
Complexes O
of O
Poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
and O
Sodium B
Dodecyl I
Sulfate I
: O
Anomalous O
Self O
- O
Assembly O
Behavior O
. O

Polyelectrolyte O
- O
surfactant O
complexes O
( O
PE O
- O
S O
) O
formed O
by O
double O
hydrophilic O
cationic O
polyelectrolyte O
poly B
[ I
3 I
, I
5 I
- I
bis I
( I
dimethylaminomethyl I
) I
- I
4 I
- I
hydroxystyrene I
] I
- I
block I
- I
poly I
( I
ethylene I
oxide I
) I
( O
NPHOS B
- I
PEO I
) O
and O
anionic O
surfactant O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
in O
acidic O
aqueous O
solutions O
were O
studied O
by O
light O
scattering O
, O
SAXS O
, O
and O
scanning O
transmission O
electron O
microcopy O
in O
the O
environmental O
mode O
( O

Genistein O
- O
Modified O
Poly B
( I
ethylene I
oxide I
) I
/ O
Poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
Electrospun O
Mats O
with O
Improved O
Antioxidant O
and O
Anti O
- O
inflammatory O
Properties O
. O

Based O
on O
the O
guidance O
afforded O
by O
the O
ternary O
phase O
diagram O
of O
poly B
( I
d I
, I
l I
- I
lactic I
acid I
) I
( O
PDLLA B
) O
, O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
) O
, O
and O
genistein B
blends O
, O
certain O
selective O
compositions O
were O
electrospun O
. O

Biobased O
membranes O
that O
can O
selectively O
permeate O
hydrogen B
gas O
have O
been O
developed O
from O
aqueous O
dispersions O
of O
2 B
, I
2 I
, I
6 I
, I
6 I
- I
tetramethylpiperidin I
- I
1 I
- I
oxyl I
( O
TEMPO B
) O
- O
oxidized O
cellulose O
nanofibrils O
( O
TOCN O
) O
prepared O
from O
wood O
cellulose O
: O
TOCN O
- O
coated O
plastic O
films O
and O
self O
- O
standing O
TOCN O
films O
. O

A O
mixture O
containing O
new O
glycosphingolipids B
, O
named O
axidjiferoside B
- I
A I
, I
- I
B I
and I
- I
C I
, O
accounted O
for O
0 O
. O
07 O
% O
of O
sponge O
biomass O
( O
dry O
weight O
) O
and O
for O
2 O
. O
16 O
% O
of O
total O
lipids O
. O

They O
were O
identified O
as O
homologous O
beta B
- I
galactopyranosylcera I
composed O
of O
2 B
- I
amino I
- I
( I
6E I
) I
- I
octadec I
- I
6 I
- I
en I
- I
1 I
, I
3 I
, I
4 I
- I
triol I
, O
and O
the O
major O
one O
, O
axidjiferoside B
- I
A I
( O
around O
60 O
% O
) O
, O
contained O
2 B
- I
hydroxytetracosanoic I
acid I
. O

Following O
the O
natural O
product O
inspired O
design O
approach O
, O
a O
library O
of O
( B
E I
) I
- I
styryl I
- I
1H I
- I
benzo I
[ I
d I
] I
imidazoles I
was O
synthesized O
and O
evaluated O
with O
recombinant O
enzyme O
and O
on O
several O
cancer O
cell O
lines O
. O

The O
results O
indicate O
partial O
first O
order O
reaction O
kinetics O
with O
respect O
to O
IL O
with O
values O
ranging O
from O
19 O
500 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
Pro I
] I
) O
to O
3200 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
) O
at O
22 O
degrees O
C O
. O

ILs O
with O
aprotic O
heterocylic O
anions O
( O
AHA O
) O
, O
on O
the O
other O
hand O
, O
show O
small O
activation O
energies O
of O
18 O
and O
11 O
kJ O
mol O
( O
- O
1 O
) O
for O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
and O
[ B
P66614 I
] I
[ I
2 I
- I
CNpyr I
] I
, O
respectively O
. O

ILs O
with O
aprotic O
heterocylic O
anions O
( O
AHA O
) O
, O
on O
the O
other O
hand O
, O
show O
small O
activation O
energies O
of O
18 O
and O
11 O
kJ O
mol O
( O
- O
1 O
) O
for O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
and O
[ B
P66614 I
] I
[ I
2 I
- I
CNpyr I
] I
, O
respectively O
. O

The O
structures O
of O
the O
new O
compounds O
were O
established O
as O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
orientin I
( O
1 O
) O
and O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
vitexin I
( O
2 O
) O
on O
the O
basis O
of O
various O
spectroscopic O
analysis O
( O
including O
different O
1D O
and O
2D O
NMR O
spectroscopies O
, O
high O
- O
resolution O

The O
structures O
of O
the O
new O
compounds O
were O
established O
as O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
orientin I
( O
1 O
) O
and O
6 B
' I
' I
' I
- I
( I
3 I
- I
hydroxy I
- I
3 I
- I
methylglutaroyl I
) I
- I
2 I
' I
' I
- I
O I
- I
beta I
- I
d I
- I
galactopyranosyl I
vitexin I
( O
2 O
) O
on O
the O
basis O
of O
various O
spectroscopic O
analysis O
( O
including O
different O
1D O
and O
2D O
NMR O
spectroscopies O
, O
high O
- O
resolution O

A O
highly O
selective O
P450 O
1B1 O
inhibitor O
5 B
- I
hydroxy I
- I
4 I
' I
- I
propargyloxyflavone I
( O
5H4 B
' I
FPE I
) O
was O
discovered O
. O

In O
this O
study O
, O
tumor O
hyperthermia O
was O
utilized O
as O
a O
means O
to O
increase O
the O
active O
delivery O
of O
heat O
shock O
protein O
( O
HSP O
) O
targeted O
N B
- I
( I
2 I
- I
hydroxypropyl I
) I
methacrylamide I
( O
HPMA B
) O
copolymer O
- O
drug O
conjugates O
. O

Murine O
N2A O
and O
human O
SK O
- O
N O
- O
AS O
neuroblastoma O
cells O
and O
murine O
preadipocyte O
fibroblasts O
( O
3T3 O
- O
L1 O
) O
were O
exposed O
to O
tributyltin B
( O
TBT B
) O
, O
diethylstilbestrol B
( O
DES B
) O
, O
bisphenol B
A I
( O
BPA B
) O
, O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
[ I
p I
] I
- I
dioxin I
( O
TCDD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
- I

hexachlorobiphenyl I
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca B
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA B
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS B
) O
. O

hexachlorobiphenyl I
( O
PCB B
- I
153 I
) O
, O
hexachlorobenzene B
( O
HCB B
) O
, O
hexabromocyclododeca B
( O
HBCD B
) O
, O
2 B
, I
2 I
' I
, I
4 I
, I
4 I
' I
- I
tetrabrominated I
diphenyl I
ether I
( O
BDE B
- I
47 I
) O
, O
perfluorinated B
octyl I
acid I
( O
PFOA B
) O
and O
perfluorinated B
octyl I
sulfonate I
( O
PFOS B
) O
. O

From O
the O
10 O
isolated O
compounds O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
showed O
the O
most O
potent O
inhibition O
, O
with O
IC50 O
values O
of O
0 O
. O
30 O
and O
0 O
. O
67 O
mu O
M O
for O
rAR O
and O
rhAR O
, O
respectively O
. O

In O
the O
kinetic O
analyses O
using O
Lineweaver O
- O
Burk O
plots O
of O
1 O
/ O
velocity O
and O
1 O
/ O
substrate O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
showed O
competitive O
inhibition O
of O
rhAR O
. O

Furthermore O
, O
methyl B
- I
3 I
, I
5 I
- I
di I
- I
O I
- I
caffeoylquinate I
inhibited O
galactitol B
formation O
in O
the O
rat O
lens O
and O
in O
erythrocytes O
incubated O
with O
a O
high O
concentration O
of O
glucose B
, O
indicating O
that O
this O
compound O
may O
be O
effective O
in O
preventing O
diabetic O
complications O
. O

New O
human O
beta O
- O
glucocerebrosidase O
( O
GCase O
) O
ligands O
with O
rigid O
1 B
, I
6 I
- I
anhydro I
- I
beta I
- I
L I
- I
idonojirimycin I
cores O
have O
been O
designed O
with O
the O
aid O
of O
molecular O
modeling O
. O

Proteomic O
identification O
of O
the O
candidate O
target O
proteins O
of O
15 B
- I
deoxy I
- I
delta I
( I
12 I
, I
14 I
) I
- I
prostaglandin I
J2 I
. O

15 B
- I
deoxy I
- I
delta12 I
, I
14 I
- I
prostaglandin I
J2 I
( O
15d B
- I
PGJ2 I
) O
is O
an O
endogenous O
anti O
- O
inflammatory O
lipid O
derived O
from O
PGD2 B
. O

Here O
, O
a O
new O
and O
simple O
method O
based O
on O
controlled O
polymerization O
of O
2 B
- I
methacryloyloxyethyl I
phosphorylcholine I
( O
MPC B
) O
on O
the O
surface O
of O
styrene B
- I
block I
- I
( I
ethylene I
- I
co I
- I
butylene I
) I
- I
block I
- I
styrene I
( O
SEBS B
) O
is O
shown O
. O

A O
poly B
[ I
2 I
- I
( I
diethylamino I
) I
ethyl I
methacrylate I
] I
brush O
was O
grown O
on O
a O
large O
silicon B
crystal O
which O
acted O
as O
both O
a O
substrate O
for O
a O
neutron O
reflectivity O
solid O
/ O
liquid O
experiment O
but O
also O
as O
an O
FTIR O
- O
ATR O
spectroscopy O
crystal O
. O

3 B
- I
Hydroxy I
- I
3 I
- I
methylglutaryl I
coenzyme I
A I
reductase O
inhibitors O
( O
statins O
) O
exert O
pleiotropic O
effects O
on O
the O
cardiovascular O
system O
, O
in O
part O
through O
a O
decrease O
in O
reactive O
oxygen B
species O
( O
ROS O
) O
formation O
and O
reduction O
of O
vascular O
inflammation O
. O

The O
phytochemical O
investigations O
showed O
the O
presence O
of O
cyclopeptid B
alkaloids I
, O
flavonoids B
( O
e O
. O
g O
. O
, O
( B
- I
) I
- I
epicatechin I
, O
quercetin B
, O
kaempferol B
, O
kaempferol B
- I
3 I
- I
O I
- I
beta I
- I
d I
- I
( I
6 I
' I
' I
- I
E I
- I
p I
- I
coumaryl I
) I
- I
glucopyranoside I
) I
, O
tannins B
, O
sterols B
, O
terpenes B
, O
saponins B
, O
anthraquinones B
. O

A O
well O
- O
defined O
amphiphilic O
polypeptide O
, O
poly B
( I
glutamic I
acid I
) I
22 I
- I
block I
- I
poly I
( I
alanine I
) I
8 I
( O
PGlu22 B
- I
b I
- I
PAla8 I
) O
, O
which O
plays O
the O
roles O
of O
both O
soluble O
( O
functional O
) O
additive O
and O
insoluble O
( O
structural O
) O
matrix O
, O
is O
employed O
to O
mediate O
the O
mineralization O
of O
CaCO3 B
at O
the O
air O
/ O
water O
interface O
. O

Synthesis O
of O
Atactic O
and O
Isotactic O
Poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
: O
Degradable O
Polymers O
for O
Biomedical O
and O
Pharmaceutical O
Applications O
. O

The O
synthesis O
and O
characterization O
of O
atactic O
and O
isotactic O
linear O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
are O
reported O
. O

The O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
were O
obtained O
via O
the O
ring O
- O
opening O
copolymerization O
of O
rac B
- I
/ I
( I
R I
) I
- I
benzyl I
glycidyl I
ether I
with O
CO2 B
using O
[ B
SalcyCo I
( I
III I
) I
X I
] I
complexes O
with O
high O
carbonate B
linkage O
selectivity O
and O
polymer O
/ O
cyclic O
carbonate B
selectivity O
( O
> O
99 O
% O
) O
. O

The O
poly B
( I
benzyl I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
were O
obtained O
via O
the O
ring O
- O
opening O
copolymerization O
of O
rac B
- I
/ I
( I
R I
) I
- I
benzyl I
glycidyl I
ether I
with O
CO2 B
using O
[ B
SalcyCo I
( I
III I
) I
X I
] I
complexes O
with O
high O
carbonate B
linkage O
selectivity O
and O
polymer O
/ O
cyclic O
carbonate B
selectivity O
( O
> O
99 O
% O
) O
. O

Deprotection O
of O
the O
resultant O
polymers O
afforded O
poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
s I
with O
a O
functionalizable O
pendant O
primary B
hydroxyl I
group O
. O

Poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
showed O
a O
remarkable O
increase O
in O
degradation O
rate O
compared O
to O
poly B
( I
1 I
, I
3 I
- I
glycerol I
carbonate I
) I
with O
a O
t1 O
/ O
2 O
= O
~ O
2 O
- O
3 O
days O
. O

Poly B
( I
1 I
, I
2 I
- I
glycerol I
carbonate I
) I
showed O
a O
remarkable O
increase O
in O
degradation O
rate O
compared O
to O
poly B
( I
1 I
, I
3 I
- I
glycerol I
carbonate I
) I
with O
a O
t1 O
/ O
2 O
= O
~ O
2 O
- O
3 O
days O
. O

Diaion O
HP O
- O
2MG O
modified O
with O
2 B
- I
( I
2 I
, I
6 I
- I
dichlorobenzylidenea I
) I
benzenethiol I
as O
new O
adsorbent O
for O
solid O
phase O
extraction O
and O
flame O
atomic O
absorption O
spectrometric O
determination O
of O
metal O
ions O
. O

The O
antioxidant O
activity O
was O
measured O
by O
employing O
the O
scavenging O
activity O
on O
DPPH B
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
) O
and O
ABTS B
( O
2 B
, I
2 I
' I
- I
azinobis I
- I
3 I
- I
ethylbenzothiazoline I
- I
6 I
- I
sulfonate I
) O
radicals O
. O

The O
antioxidant O
activity O
was O
measured O
by O
employing O
the O
scavenging O
activity O
on O
DPPH B
( O
2 B
, I
2 I
- I
diphenyl I
- I
1 I
- I
picrylhydrazyl I
) O
and O
ABTS B
( O
2 B
, I
2 I
' I
- I
azinobis I
- I
3 I
- I
ethylbenzothiazoline I
- I
6 I
- I
sulfonate I
) O
radicals O
. O

Using O
[ B
1 I
- I
13C I
] I
- I
, I
[ I
2 I
- I
13C I
] I
- I
, I
[ I
6 I
- I
13C I
] I
- I
and I
[ I
U I
- I
13C6 I
] I
- I
glucose I
as O
carbon B
sources O
, O
we O
were O
able O
to O
determine O
the O
main O
central O
metabolic O
pathways O
involved O
in O
ectoines B
biosynthesis O
from O
glucose B
. O

Two O
types O
of O
modifications O
, O
namely O
, O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
beta I
- I
d I
- I
ribofuranose I
( O
beta O
- O
d O
- O
LNA O
) O
and O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
alpha I
- I
l I
- I
ribofuranose I
( O
alpha O
- O
l O
- O
LNA O
) O
, O
have O
been O
shown O
to O
yield O
RNA O
and O
DNA O
duplex O
- O
like O
structures O
, O
respectively O
. O

Two O
types O
of O
modifications O
, O
namely O
, O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
beta I
- I
d I
- I
ribofuranose I
( O
beta O
- O
d O
- O
LNA O
) O
and O
2 B
' I
- I
O I
, I
4 I
' I
- I
C I
- I
methylene I
- I
alpha I
- I
l I
- I
ribofuranose I
( O
alpha O
- O
l O
- O
LNA O
) O
, O
have O
been O
shown O
to O
yield O
RNA O
and O
DNA O
duplex O
- O
like O
structures O
, O
respectively O
. O

2 B
, I
3 I
, I
7 I
, I
8 I
- I
TCDD I
induces O
neurotoxicity O
and O
neuronal O
apoptosis O
in O
the O
rat O
brain O
cortex O
and O
PC12 O
cell O
line O
through O
the O
down O
- O
regulation O
of O
the O
Wnt O
/ O
beta O
- O
catenin O
signaling O
pathway O
. O

Self O
- O
assembled O
monolayers O
of O
meso B
- I
5 I
, I
10 I
, I
15 I
, I
20 I
- I
tetrakis I
( I
undecyl I
) I
porphyrin I
copper I
( I
ii I
) I
on O
a O
graphite B
/ O
1 B
- I
octanoic I
acid I
interface O
have O
been O
studied O
by O
Scanning O
Tunnelling O
Microscopy O
. O

Insertion O
of O
CO2 B
and O
COS B
into O
Bi B
- I
C I
Bonds O
: O
Reactivity O
of O
a O
Bismuth B
NCN I
Pincer O
Complex O
of O
an O
Oxyaryl B
Dianionic O
Ligand O
, O
[ B
2 I
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] I
Bi I
( I
C6H2tBu2O I
) I
. O

The O
reactivity O
of O
the O
unusual O
oxyaryl B
dianionic O
ligand O
, O
( B
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
2 I
- O
, O
in O
the O
Bi3 B
+ I
NCN I
pincer O
complex O
Ar B
' I
Bi I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
, O
1 O
, O
[ O
Ar O
' O
= O
2 B
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] O
has O
been O
explored O
with O
small O
molecule O
substrates O
and O
electrophiles O
. O

The O
reactivity O
of O
the O
unusual O
oxyaryl B
dianionic O
ligand O
, O
( B
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
2 I
- O
, O
in O
the O
Bi3 B
+ I
NCN I
pincer O
complex O
Ar B
' I
Bi I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
, O
1 O
, O
[ O
Ar O
' O
= O
2 B
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] O
has O
been O
explored O
with O
small O
molecule O
substrates O
and O
electrophiles O
. O

The O
reactivity O
of O
the O
unusual O
oxyaryl B
dianionic O
ligand O
, O
( B
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
2 I
- O
, O
in O
the O
Bi3 B
+ I
NCN I
pincer O
complex O
Ar B
' I
Bi I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
O I
- I
4 I
) I
, O
1 O
, O
[ O
Ar O
' O
= O
2 B
, I
6 I
- I
( I
Me2NCH2 I
) I
2C6H3 I
] O
has O
been O
explored O
with O
small O
molecule O
substrates O
and O
electrophiles O
. O

The O
oxyarylcarboxy B
and O
oxyarylthiocarboxy B
dianionic O
ligands O
were O
identified O
by O
X O
- O
ray O
crystallography O
in O
Ar B
' I
Bi I
[ I
O2C I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
O I
' I
] I
, O
2 O
and O
Ar B
' I
Bi I
[ I
OSC I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
S I
] I
, O
3 O
, O
respectively O
. O

The O
oxyarylcarboxy B
and O
oxyarylthiocarboxy B
dianionic O
ligands O
were O
identified O
by O
X O
- O
ray O
crystallography O
in O
Ar B
' I
Bi I
[ I
O2C I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
O I
' I
] I
, O
2 O
and O
Ar B
' I
Bi I
[ I
OSC I
( I
C6H2tBu2 I
- I
3 I
- I
5 I
- I
O I
- I
4 I
) I
- I
kappa I
2O I
, I
S I
] I
, O
3 O
, O
respectively O
. O

Silyl B
halides I
and O
pseudohalides B
, O
R3SiX B
( O
X O
= O
Cl B
, O
CN B
, O
N3 B
; O
R O
= O
Me B
, O
Ph B
) O
, O
react O
with O
1 O
by O
attaching O
X O
to O
bismuth B
and O
R3Si B
to O
the O
oxyaryl B
oxygen B
to O
form O
Ar B
' I
Bi I
( I
X I
) I
( I
C6H2tBu2 I
- I
3 I
, I
5 I
- I
OSiR3 I
- I
4 I
) I
complexes O
, O
a O
formal O
addition O
across O
five O
bonds O
. O

The O
reaction O
of O
1 O
with O
I2 B
forms O
Ar B
' I
BiI2 I
and O
the O
coupled O
quinone B
, O
3 B
, I
3 I
' I
, I
5 I
, I
5 I
' I
- I
tetra I
- I
tert I
- I
butyl I
- I
4 I
, I
4 I
' I
- I
diphenoquinone I
, O
by O
oxidative O
coupling O
. O

Using O
cross O
- O
sectional O
scanning O
tunneling O
microscope O
( O
XSTM O
) O
with O
samples O
cleaved O
in O
situ O
in O
an O
ultrahigh O
vacuum O
( O
UHV O
) O
chamber O
, O
this O
study O
demonstrates O
the O
direct O
visualization O
of O
high O
- O
resolution O
interfacial O
band O
mapping O
images O
across O
the O
film O
thickness O
in O
an O
optimized O
bulk O
heterojunction O
polymer O
solar O
cell O
consisting O
of O
nanoscale O
phase O
segregated O
blends O
of O
poly B
( I
3 I
- I
hexylthiophene I
) I
( O
P3HT B
) O
and O
[ B
6 I
, I
6 I
] I
- I
phenyl I
C61 I
butyric I
acid I
methyl I
ester I
( O
PCBM B
) O
. O

We O
were O
able O
to O
achieve O
the O
direct O
observation O
of O
the O
interfacial O
band O
alignments O
at O
the O
donor O
( O
P3HT B
) O
- O
acceptor O
( O
PCBM B
) O
interfaces O
and O
at O
the O
interfaces O
between O
the O
photoactive O
P3HT B
: O
PCBM B
blends O
and O
the O
poly B
( I
3 I
, I
4 I
- I
ethylenedioxythiophe I
) I
poly B
( I
styrenesulfonate I
) I
( O
PEDOT B
: O
PSS B
) O
anode O
modification O
layer O
with O
an O
atomic O
- O
scale O
spatial O
resolution O
. O

Nine O
new O
triterpene B
derivatives O
, O
yunnanterpenes B
A I
- I
F I
( O
1 O
- O
6 O
) O
, O
15 B
, I
16 I
- I
seco I
- I
cimiterpenes I
A I
and I
B I
( O
7 O
, O
8 O
) O
, O
and O
cimilactone B
C I
( O
9 O
) O
, O
and O
15 O
known O
analogues O
( O
10 O
- O
24 O
) O
were O
isolated O
from O
the O
aerial O
parts O
of O
Cimicifuga O
yunnanensis O
. O

Synthesis O
of O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
linked O
aminobenzothiazole B
conjugates O
as O
potential O
anticancer O
agents O
. O

A O
series O
of O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
linked O
2 B
- I
aminobenzothizole I
conjugates O
( O
6a O
- O
t O
) O
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
activity O
against O
five O
human O
cancer O
cell O
lines O
. O

The O
action O
of O
piperine B
( O
the O
pungent O
component O
of O
pepper O
) O
and O
its O
derivative O
SCT B
- I
66 I
( B
( I
2E I
, I
4E I
) I
- I
5 I
- I
( I
1 I
, I
3 I
- I
benzodioxol I
- I
5 I
- I
yl I
) I
) I
- I
N I
, I
N I
- I
diisobutyl I
- I
2 I
, I
4 I
- I
pentadienamide I
) I
on O
different O
gamma B
- I
aminobutyric I
acid I
( O
GABA B
) O
type O
A O
( O
GABAA O
) O
receptors O
, O
transient O
- O
receptor O
- O
potential O
- O
vanilloid O
- O
1 O
( O
TRPV1 O
) O
receptors O
and O
behavioral O
effects O
were O
investigated O
. O

Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly B
( I
L I
- I
lactide I
) I
( O
PLLA B
) O
or O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA B
) O
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone B
acetonide I
( O
selected O
as O
model O
drug O
) O
from O
nanoparticles O
. O

Design O
, O
synthesis O
and O
molecular O
modeling O
of O
novel O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidine I
analogs O
as O
antifolates O
: O
Application O
of O
Buchwald O
- O
Hartwig O
aminations O
of O
heterocycles O
. O

A O
novel O
series O
of O
pyrido B
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidines I
as O
selective O
and O
potent O
DHFR O
inhibitors O
against O
these O
opportunistic O
infections O
are O
presented O
. O

Buchwald O
- O
Hartwig O
coupling O
reaction O
of O
substituted O
anilines O
with O
pivaloyl B
protected O
2 B
, I
4 I
- I
diamino I
- I
6 I
- I
bromo I
- I
pyrido I
[ I
2 I
, I
3 I
- I
d I
] I
pyrimidine I
was O
successfully O
explored O
to O
synthesize O
these O
analogs O
. O

The O
OTMS B
- O
functionalized O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanorods O
and O
nanospheres O
were O
then O
incorporated O
into O
the O
active O
layers O
of O
two O
OPV O
polymer O
systems O
: O
a O
poly B
( I
3 I
- I
hexylthiophene I
) I
: O
[ B
6 I
, I
6 I
] I
- I
phenyl I
- I
C61 I
- I
butyric I
acid I
methyl I
ester I
( O
P3HT B
: O
PCB60M B
) O
OPV O
device O
and O
a O
poly B
[ I
2 I
, I
6 I
- I
4 I
, I
8 I
- I
di I
( I
5 I
- I
ethylhexylthienyl I
) I
benzo I
[ I
1 I
, I
2 I
- I
b I
; I
3 I
, I
4 I

- I
b I
] I
dithiophene I
- I
alt I
- I
5 I
- I
dibutyloctyl I
- I
3 I
, I
6 I
- I
bis I
( I
5 I
- I
bromothiophen I
- I
2 I
- I
yl I
) I
pyrrolo I
[ I
3 I
, I
4 I
- I
c I
] I
pyrrole I
- I
1 I
, I
4 I
- I
dione I
] I
( O
PBDTT B
- I
DPP I
: O
PC60BM B
) O
OPV O
device O
. O

New O
series O
of O
pyrrolidine B
mercaptosulfide I
, O
2 B
- I
mercaptocyclopentane I
arylsulfonamide I
, O
and O
3 B
- I
mercapto I
- I
4 I
- I
arylsulfonamido I
pyrrolidine I
matrix O
metalloproteinase O
inhibitors O
( O
MMPIs O
) O
were O
designed O
, O
synthesized O
, O
and O
evaluated O
. O

Among O
the O
formulations O
investigated O
, O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
- O
poly B
( I
ethylene I
glycol I
) I
- O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
triblock O
copolymer O
systems O
provided O
the O
longest O
sustained O
drug O
delivery O
, O
probably O
due O
to O
their O
rigid O
gel O
structures O
and O
/ O
or O
polymer O
- O
to O
- O
cidofovir B
interactions O
. O

Among O
the O
formulations O
investigated O
, O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
- O
poly B
( I
ethylene I
glycol I
) I
- O
poly B
( I
lactic I
- I
co I
- I
glycolic I
acid I
) I
triblock O
copolymer O
systems O
provided O
the O
longest O
sustained O
drug O
delivery O
, O
probably O
due O
to O
their O
rigid O
gel O
structures O
and O
/ O
or O
polymer O
- O
to O
- O
cidofovir B
interactions O
. O

Aminoalkenes B
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis B
( I
oxazolinyl I
) I
borato I
group O
4 O
complexes O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
R I
) I
) I
2 I
} I
M I
( I
NMe2 I
) I
2 I
( O
M O
= O
Ti B
, O
Zr B
, O
Hf B
; O
Ox B
( I
R I
) I
= O
4 B
, I
4 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I
isopropyl I
- I
5 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I

Aminoalkenes B
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis B
( I
oxazolinyl I
) I
borato I
group O
4 O
complexes O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
R I
) I
) I
2 I
} I
M I
( I
NMe2 I
) I
2 I
( O
M O
= O
Ti B
, O
Zr B
, O
Hf B
; O
Ox B
( I
R I
) I
= O
4 B
, I
4 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I
isopropyl I
- I
5 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I

Aminoalkenes B
are O
catalytically O
cyclized O
in O
the O
presence O
of O
cyclopentadienylbis B
( I
oxazolinyl I
) I
borato I
group O
4 O
complexes O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
R I
) I
) I
2 I
} I
M I
( I
NMe2 I
) I
2 I
( O
M O
= O
Ti B
, O
Zr B
, O
Hf B
; O
Ox B
( I
R I
) I
= O
4 B
, I
4 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I
isopropyl I
- I
5 I
, I
5 I
- I
dimethyl I
- I
2 I
- I
oxazoline I
, O
4S B
- I

Aminoalkenes B
are O
unchanged O
in O
the O
presence O
of O
a O
zirconium B
monoamido I
complex O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
2 I
} I
Zr I
( I
NMe2 I
) I
Cl I
or O
a O
cyclopentadienylmono B
( I
oxazolinyl I
) I
borato I
zirconium I
diamide I
{ B
Ph2B I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
} I
Zr I
( I
NMe2 I
) I
2 I
. O

Aminoalkenes B
are O
unchanged O
in O
the O
presence O
of O
a O
zirconium B
monoamido I
complex O
{ B
PhB I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
2 I
} I
Zr I
( I
NMe2 I
) I
Cl I
or O
a O
cyclopentadienylmono B
( I
oxazolinyl I
) I
borato I
zirconium I
diamide I
{ B
Ph2B I
( I
C5H4 I
) I
( I
Ox I
( I
4S I
- I
iPr I
, I
Me2 I
) I
) I
} I
Zr I
( I
NMe2 I
) I
2 I
. O

Elucidation O
of O
the O
biochemical O
basis O
for O
a O
clinical O
drug O
- O
drug O
interaction O
between O
atorvastatin B
and O
5 B
- I
( I
N I
- I
( I
4 I
- I
( I
( I
4 I
- I
ethylbenzyl I
) I
thio I
) I
phenyl I
) I
sulfamoyl I
) I
- I
2 I
- I
methyl I
benzoic I
acid I
( O
CP B
- I
778 I
875 I
) O
, O
a O
subtype O
selective O
agonist O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
. O

Abstract O
1 O
. O
5 B
- I
( I
N I
- I
( I
4 I
- I
( I
( I
4 I
- I
ethylbenzyl I
) I
thio I
) I
phenyl I
) I
sulfamoyl I
) I
- I
2 I
- I
methyl I
benzoic I
acid I
( O
CP B
- I
778 I
875 I
) O
, O
an O
agonist O
of O
the O
peroxisome O
proliferator O
- O
activated O
receptor O
alpha O
, O
has O
been O
evaluated O
in O
the O
clinic O
to O
treat O
dyslipidemia O
and O
type O
2 O
diabetes O
mellitus O
. O

Simultaneous O
determination O
by O
LC O
- O
MS O
/ O
MS O
of O
25 B
- I
methoxydammarane I
- I
3 I
beta I
, I
12 I
beta I
, I
20 I
- I
triol I
epimers O
and O
active O
metabolites O
in O
rat O
plasma O
after O
intravenous O
administration O
. O

The O
quantification O
was O
performed O
with O
the O
transitions O
of O
m O
/ O
z O
493 O
. O
5 O
- O
- O
> O
475 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
m O
/ O
z O
479 O
. O
5 O
- O
- O
> O
461 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

The O
quantification O
was O
performed O
with O
the O
transitions O
of O
m O
/ O
z O
493 O
. O
5 O
- O
- O
> O
475 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
m O
/ O
z O
479 O
. O
5 O
- O
- O
> O
461 O
. O
5 O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

The O
Lower O
Limit O
Of O
Quantitation O
( O
LLOQ O
) O
was O
20 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
2 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
in O
the O
plasma O
samples O
assay O
. O

The O
Lower O
Limit O
Of O
Quantitation O
( O
LLOQ O
) O
was O
20 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
2 O
. O
0 O
ng O
mL O
( O
- O
1 O
) O
for O
20 B
( I
R I
, I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
in O
the O
plasma O
samples O
assay O
. O

The O
pharmacokinetic O
parameters O
of O
AUC O
, O
t1 O
/ O
2 O
and O
MRT O
had O
no O
difference O
between O
20 B
( I
R I
) I
- I
and I
( I
S I
) I
- I
25 I
- I
OCH3 I
- I
PPD I
, O
but O
S O
- O
epimer O
has O
a O
lower O
plasma O
clearance O
compared O
to O
the O
R O
- O
isomer O
. O

The O
active O
metabolite O
20 B
( I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
showed O
significantly O
higher O
AUC O
, O
MRT O
and O
a O
longer O
half O
- O
life O
than O
that O
of O
20 B
( I
R I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

The O
active O
metabolite O
20 B
( I
S I
) I
- I
25 I
- I
OH I
- I
PPD I
showed O
significantly O
higher O
AUC O
, O
MRT O
and O
a O
longer O
half O
- O
life O
than O
that O
of O
20 B
( I
R I
) I
- I
25 I
- I
OH I
- I
PPD I
. O

These O
assay O
results O
are O
necessary O
for O
the O
evaluation O
of O
the O
pharmacokinetic O
behavior O
of O
25 B
- I
methoxydammarane I
- I
3 I
beta I
, I
12 I
beta I
, I
20 I
- I
triol I
in O
vivo O
. O

The O
structure O
revealed O
a O
conformation O
intermediate O
to O
that O
of O
the O
recently O
solved O
complex O
with O
amlodipine B
and O
of O
the O
more O
compact O
complex O
with O
4 B
- I
( I
4 I
- I
chlorophenyl I
) I
imidazole I
in O
terms O
of O
the O
placement O
of O
the O
F O
- O
G O
cassette O
. O

In O
an O
effort O
to O
seek O
Co B
( I
II I
) I
- O
independent O
inhibitors O
, O
a O
novel O
structural O
class O
containing O
a O
2 B
- I
( I
pyridin I
- I
2 I
- I
yl I
) I
quinazoline I
core O
has O
been O
discovered O
. O

Synthesis O
and O
biological O
evaluation O
of O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
- O
3 B
, I
3 I
' I
- I
( I
benzylidene I
) I
- I
bis I
- I
( I
1H I
- I
indole I
- I
2 I
- I
carbohydrazide I
) I
as O
a O
PET O
tracer O
for O
in O
vivo O
visualization O
of O
necrosis O
. O

Synthesis O
and O
biological O
evaluation O
of O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
- O
3 B
, I
3 I
' I
- I
( I
benzylidene I
) I
- I
bis I
- I
( I
1H I
- I
indole I
- I
2 I
- I
carbohydrazide I
) I
as O
a O
PET O
tracer O
for O
in O
vivo O
visualization O
of O
necrosis O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
develop O
a O
( B
68 I
) I
Ga I
labeled I
bis I
- I
DOTA I
derivative O
of O
benzylidene B
- I
bis I
- I
indole I
and O
compare O
the O
in O
vivo O
stability O
and O
biodistribution O
with O
that O
of O
the O
previously O
reported O
bis B
- I
DTPA I
derivate O
for O
in O
vivo O
imaging O
of O
necrosis O
using O
PET O
. O

We O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
study O
the O
dose O
- O
dependent O
change O
in O
conformational O
and O
mechanical O
properties O
of O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
( B
[ I
PtCl I
( I
en I
) I
( I
ACRAMTU I
- I
S I
) I
] I
( I
NO3 I
) I
2 I
, O
( O
en O
= O
ethane B
- I
1 I
, I
2 I
- I
diamine I
, O
ACRAMTU B
= O
1 B
- I
[ I
2 I
- I
( I
acridin I
- I
9 I
- I
ylamino I
) I
ethyl I
] I
- I
1 I
, I
3 I
- I
dimethylthiourea I
. O

We O
used O
atomic O
force O
microscopy O
( O
AFM O
) O
to O
study O
the O
dose O
- O
dependent O
change O
in O
conformational O
and O
mechanical O
properties O
of O
DNA O
treated O
with O
PT B
- I
ACRAMTU I
( B
[ I
PtCl I
( I
en I
) I
( I
ACRAMTU I
- I
S I
) I
] I
( I
NO3 I
) I
2 I
, O
( O
en O
= O
ethane B
- I
1 I
, I
2 I
- I
diamine I
, O
ACRAMTU B
= O
1 B
- I
[ I
2 I
- I
( I
acridin I
- I
9 I
- I
ylamino I
) I
ethyl I
] I
- I
1 I
, I
3 I
- I
dimethylthiourea I
. O

I3S B
increased O
expression O
of O
ROR O
gamma O
t O
, O
the O
master O
transcription O
factor O
for O
Th17 O
differentiation O
, O
and O
stimulated O
Th17 O
differentiation O
, O
in O
a O
comparative O
manner O
as O
2 B
, I
3 I
, I
7 I
, I
8 I
- I
tetrachlorodibenzo I
- I
p I
- I
dioxin I
( O
TCDD B
) O
, O
a O
prototypical O
AhR O
ligand O
. O

Phosphorylation O
of O
c O
- O
Src O
, O
which O
was O
shown O
to O
be O
activated O
by O
AhR O
ligands O
, O
was O
also O
increased O
by O
I3S B
and O
TCDD B
, O
and O
blocking O
of O
c O
- O
Src O
activity O
by O
4 B
- I
amino I
- I
5 I
- I
( I
4 I
- I
chlorophenyl I
) I
- I
7 I
- I
( I
t I
- I
butyl I
) I
pyrazolo I
[ I
3 I
, I
4 I
- I
d I
] I
pyrimidine I
( O
PP2 O
) O
inhibited O
phosphorylation O
of O
both O
c O
- O
Src O
and O
STAT3 O
, O
raising O
a O
possibility O
that O
stimulatory O
activities O
of O
I3S B
and O
TCDD B

Specifically O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
- I
methyl I
- I
8 I
- I
methoxyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
1 O
) O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
, I
8 I
- I
dimethyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
2 O
) O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
- I
methyl I
- I
3 I
- I

Specifically O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
- I
methyl I
- I
8 I
- I
methoxyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
1 O
) O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
, I
8 I
- I
dimethyl I
- I
3 I
- I
( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
2 O
) O
, O
( B
3R I
) I
- I
5 I
, I
7 I
- I
dihydroxyl I
- I
6 I
- I
methyl I
- I
3 I
- I

( I
4 I
' I
- I
hydroxylbenzyl I
) I
- I
chroman I
- I
4 I
- I
one I
( O
3 O
) O
, O
and O
polygonatone B
D I
( O
7 O
) O
exhibited O
significant O
activation O
effects O
. O

Synthesis O
and O
structure O
- O
activity O
relationships O
of O
a O
novel O
and O
selective O
bone O
morphogenetic O
protein O
receptor O
( O
BMP O
) O
inhibitor O
derived O
from O
the O
pyrazolo B
[ I
1 I
. I
5 I
- I
a I
] I
pyrimidine I
scaffold O
of O
Dorsomorphin O
: O
The O
discovery O
of O
ML347 B
as O
an O
ALK2 O
versus O
ALK3 O
selective O
MLPCN O
probe O
. O

A O
structure O
- O
activity O
relationship O
of O
the O
3 O
- O
and O
6 O
- O
positions O
of O
the O
pyrazolo B
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidine I
scaffold O
of O
the O
known O
BMP O
inhibitors O
dorsomorphin B
, O
1 O
, O
LDN B
- I
193189 I
, O
2 O
, O
and O
DMH1 B
, O
3 O
, O
led O
to O
the O
identification O
of O
a O
potent O
and O
selective O
compound O
for O
ALK2 O
versus O
ALK3 O
. O

2 B
, I
2 I
' I
, I
3 I
, I
3 I
' I
, I
4 I
, I
4 I
' I
, I
5 I
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
decabromodiphenyl I
ether I
( O
BDE209 B
) O
is O
commercially O
most O
important O
both O
in O
the O
production O
and O
in O
the O
use O
of O
polybrominated B
diphenyl I
ethers I
( O
PBDEs B
) O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA B
and O
protein O
- O
adsorbing O
SS O
- O
PPFS B
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide B
- O
functionalized O
poly B
( I
poly I
( I
ethylene I
glycol I
) I
methyl I
ether I
methacrylate I
) I
( O
azido B
- I
PPEGMA I
) O
and O
poly B
( I
2 I
, I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
pentafluorostyrene I
) I
( O
azido B
- I
PPFS I
) O
polymer O
brushes O
in O
azide B
- O
alkyne B
' O
click O
' O
reaction O
. O

Protein O
- O
resistant O
SS O
- O
PPEGMA B
and O
protein O
- O
adsorbing O
SS O
- O
PPFS B
surfaces O
were O
prepared O
by O
coupling O
of O
the O
respective O
azide B
- O
functionalized O
poly B
( I
poly I
( I
ethylene I
glycol I
) I
methyl I
ether I
methacrylate I
) I
( O
azido B
- I
PPEGMA I
) O
and O
poly B
( I
2 I
, I
3 I
, I
4 I
, I
5 I
, I
6 I
- I
pentafluorostyrene I
) I
( O
azido B
- I
PPFS I
) O
polymer O
brushes O
in O
azide B
- O
alkyne B
' O
click O
' O
reaction O
. O

Antifouling O
alkyne B
- O
functionalized O
poly B
( I
N I
- I
hydroxyethyl I
acrylamide I
) I
( O
alkynyl B
- I
PHEAA I
) O
and O
antibacterial O
alkyne B
- O
functionalized O
poly B
( I
2 I
- I
( I
methacryloyloxy I
) I
ethyl I
trimethylammonium I
chloride I
) I
( O
alkynyl B
- I
PMETA I
) O
polymer O
brushes O
were O
clicked O
on O
the O
SS O
- O
azide B
surface O
. O

The O
compound O
with O
the O
most O
potent O
neuroprotective O
action O
was O
N B
- I
{ I
3 I
- I
[ I
2 I
- I
( I
4 I
- I
phenyl I
- I
piperazin I
- I
1 I
- I
yl I
) I
- I
ethyl I
] I
- I
phenyl I
} I
- I
picolinamide I
( O
6b O
) O
, O
which O
reduced O
6 B
- I
OHDA I
- O
induced O
apoptotic O
death O
through O
stabilization O
of O
mitochondrial O
membrane O
and O
subsequent O
prevention O
of O
superoxide B
production O
, O
caspase O
activation O
and O
DNA O
fragmentation O
. O

In O
addition O
, O
pretreatment O
with O
Z B
- I
Val I
- I
Ala I
- I
Asp I
- I
fluoromethylketone I
( O
Z B
- I
VAD I
- I
fmk I
) O
, O
a O
broad O
spectrum O
of O
caspase O
inhibitor O
, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP O
toxicity O
. O

Design O
, O
synthesis O
and O
antiproliferative O
activity O
studies O
of O
novel O
1 B
, I
2 I
, I
3 I
- I
triazole I
- I
dithiocarbamate I
- I
urea I
hybrids O
. O

A O
series O
of O
novel O
1 B
, I
2 I
, I
3 I
- I
triazole I
- I
dithiocarbamate I
- I
urea I
hybrids O
were O
designed O
, O
synthesized O
and O
their O
antiproliferative O
activities O
against O
four O
selected O
human O
cancer O
cell O
lines O
were O
evaluated O
. O

A O
set O
of O
substituted O
- O
[ O
N B
' I
- I
( I
benzofuroxan I
- I
5 I
- I
yl I
) I
methylene I
] I
benzohydrazides I
( O
4a O
- O
t O
) O
, O
previously O
designed O
and O
synthesized O
, O
was O
experimentally O
assayed O
against O
Trypanosoma O
cruzi O
, O
the O
etiological O
agent O
of O
Chagas O
' O
disease O
, O
one O
of O
the O
most O
neglected O
tropical O
diseases O
. O

N B
- I
Alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
. O

The O
synthesis O
of O
a O
variety O
of O
N B
- I
alkylated I
2 I
, I
3 I
, I
3 I
- I
trimethylindolenines I
and O
2 B
- I
methylbenzothiazoles I
is O
reported O
herein O
. O

Synthesis O
and O
biological O
characterization O
of O
spiro B
[ I
2H I
- I
( I
1 I
, I
3 I
) I
- I
benzoxazine I
- I
2 I
, I
4 I
' I
- I
piperidine I
] I
based O
histone O
deacetylase O
inhibitors O
. O

Herein O
, O
we O
report O
further O
explorations O
, O
which O
resulted O
in O
the O
discovery O
of O
a O
new O
class O
of O
spiro B
[ I
2H I
- I
( I
1 I
, I
3 I
) I
- I
benzoxazine I
- I
2 I
, I
4 I
' I
- I
piperidine I
] I
derivatives O
. O

The O
Claisen O
- O
Schmidt O
reaction O
of O
22 B
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
with O
requisite O
aldehydes B
afforded O
2 B
- I
arylidene I
- I
22 I
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acids I
( O
7 O
- O
16 O
) O
. O

The O
Claisen O
- O
Schmidt O
reaction O
of O
22 B
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acid I
( O
5 O
) O
with O
requisite O
aldehydes B
afforded O
2 B
- I
arylidene I
- I
22 I
beta I
- I
hydroxy I
- I
3 I
- I
oxoolean I
- I
12 I
- I
en I
- I
28 I
- I
oic I
acids I
( O
7 O
- O
16 O
) O
. O

Resulting O
from O
this O
study O
, O
a O
structurally O
novel O
class O
of O
submicromolar O
fibrinogen O
GPIIb O
/ O
IIIa O
binding O
inhibitor O
bearing O
1 B
, I
2 I
, I
4 I
- I
oxadiazol I
- I
5 I
( I
4H I
) I
- I
one I
moiety O
is O
also O
described O
. O

Synthesis O
and O
biological O
evaluation O
of O
N B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
mercaptonaphthalen I
- I
1 I
- I
yl I
) I
amides I
as O
inhibitors O
of O
angiogenesis O
and O
tumor O
growth O
. O

A O
series O
of O
N B
- I
( I
4 I
- I
hydroxy I
- I
3 I
- I
mercaptonaphthalen I
- I
1 I
- I
yl I
) I
amides I
were O
synthesized O
and O
investigated O
for O
their O
in O
vitro O
antiangiogenic O
activity O
. O

The O
neuritogenic O
and O
neuroprotective O
activities O
of O
six O
starfish O
polar O
steroids B
, O
asterosaponin B
P I
1 I
, O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
4 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
octaol I
, O
and O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
heptaol I
( O
1 O
- O
3 O
) O
from O
the O
starfish O
Patiria O
pectinifera O
and O

The O
neuritogenic O
and O
neuroprotective O
activities O
of O
six O
starfish O
polar O
steroids B
, O
asterosaponin B
P I
1 I
, O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
4 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
octaol I
, O
and O
( B
25S I
) I
- I
5 I
alpha I
- I
cholestane I
- I
3 I
beta I
, I
6 I
alpha I
, I
7 I
alpha I
, I
8 I
, I
15 I
alpha I
, I
16 I
beta I
, I
26 I
- I
heptaol I
( O
1 O
- O
3 O
) O
from O
the O
starfish O
Patiria O
pectinifera O
and O

